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ABSTRACT 
The eye lens protein aS-crystallin plays an important role in maintaining the 
refractive index of the lens, however is also found in many non-lenticular tissues suggest 
that it has general cellular functions over and above its role in light refraction. The role of 
the C-terminal extension of aS-crystallin upon solubility, structure and function and the 
relationship with disease has not been investigated. In this study, the systematic analysis of 
the role of the C-terminal extension of aS-crystallin aimed to investigate the hypothesis 
that the C-terminal region in aS-crystallin is important for solubility, structure and function 
of the protein. This study also aimed to fmd a link between the role of the C-terminal and 
the symptoms of disease, thus providing a potential explanation of whether the three 
congenital mutations (450delA, Q151X and 464delCT), which alter the C-terminal 
extension of aS-crystallin, cause the various diseases via the loss of chaperone function or 
perhaps by a different mechanism. Further more this study aimed to elucidate the 
mechanism of phenotypic heterogeneity associated with these aS-crystallin mutations. 
I compared the three C-terminal aS-crystallin mutants (450delA, Ql51X and 
464delCT) to a series of C-terminal truncations (E164X, El65X, Kl74X and Al71X) and 
found that the C-terminal extension was essential for oligomerisation but not chaperone 
function, infact the removal of the entire C-terminal extension actually enhanced chaperone 
activity, however significantly destabilized aS-crystallin causing it to self-aggregate. This 
instability was supported by refolding analysis, where the 450delA and 464delCT mutants 
could only be refolded and assayed as a complex with wild type aS-crystallin, however the 
Q151X aS-crystallin could be refolded alone. From these studies, I conclude that all three 
disease-causing mutations (450delA, 464delCT and Q151X) in the C-terminal extension 
destabilise aS-crystallin and increase its tendency to self-aggregate. I propose that it is this, 
rather than a catastrophic loss of chaperone activity, that is a major factor in disease 
development. 
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CHAPTER I 
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1.1. THE LENS 
The function of the eye lens fulfils two requirements; it has to provide 
transparency and a high refractive index, i.e. low light scattering and high solubility of its 
cytoplasmic proteins (Bloemendal et al., 2004). The lens is an encapsulated structure 
consisting almost entirely of a large number of rigid, elongated cells known as lens fibres 
or fibre cells (Jacob et al., 2000). These cells are produced via the terminal differentiation 
of a monolayer of epithelial cells, located just beneath the anterior lens capsule (Rafferty, 
1985}, and include the programmed removal of cytoplasmic organelles (Piatigorsky, 
1981 ). This is accompanied by the expression of an extensive range of lens fibre cell-
specific proteins including a-, ~ and y-crystallins and membrane-associated proteins 
(Jacob et al., 2000; M<>mer, 1894; Pemg and Quinlan, 2005). Despite these alterations, 
the differentiated lens fibre cells maintain a well-organised lenticular cytoskeleton 
comprising actin-containing microfilaments, microtubules and at least two different 
Intermediate Filament networks (Merlin et al., 1998), one based on vimentin and the other 
based on a copolymer of lens-specific intermediate filament proteins (Merlin et al., 1998; 
Sandilands et al., 1995). 
In the mature lens, hexagonally packed, long ribbon-like fibre cells, which in man 
are up to 1 0 mm long, are arranged in concentric shells, with the oldest cells at the centre 
and the youngest on the outside (Maisel, 1985) (see Figure 1). This process begins early 
in embryogenesis and continues throughout life (Grainger, 1992}, resulting in the 
deposition of one layer of fibre cells upon another (Bron et al., 2000). As new layers of 
fibre cells are produced, existing layers are displaced toward the centre of the lens (Jacob 
et al., 2000). The absence of cell nuclei, of deoxyribonucleic acid (DNA) and ribonucleic 
acid (RNA) means that the fibre cells are unable to renew or replace their proteins or 
replace damaged proteins (Harding, 1991 ). Successful organogenesis results in a 
transparent biconvex lens suspended in the eye by zonular ligaments, between the aqueous 
humour and the vitreous body. Exchange of waste products and nutrients occurs with the 
aqueous humour across the semi-permeable lens capsule (Rafferty, 1985). 
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Figure 1. Schematic view of the eye lens showing the main features and regions. The lens 
of the eye is enclosed by lens capsule (A) and the anterior surface of the lens is covered 
with a single layer of epithelial cells (B). The lens fibre cells are formed from epithelial 
cells at the lens equator (C) as part of their differentiation pathway. The epithelia elongate 
until their ends reach the two lens poles and are joined at the lens sutures. One of the 
striking features of the lens differentiation process at this stage is the removal of 
membrane-bound organelles (D) including nuclei, as indicated here as black dots. A cross 
section of the lens reveals the elongated fibre cells with characteristic hexagonal shape 
(E). The bulk of the lens thus consists of long, ribbon-like fibre cells arranged as 
concentric layer with the primary fibre cells at the centre of the lens (F). (Reprinted from 
(Pemg et al., 2007) Copyright 2007, with permission from Elsevier). 
The shape of the fibre cells is determined and maintained by an extensive 
cytoskeleton (Alizadeh et al., 2002) consisting of the type III IFs. IFs are ubiquitous 
cytoskeletal elements generally considered as one of the most insoluble and resilient 
structures of the eukaryotic cell (Nicholl and Quinlan, 1994). The cells of the eye lens 
contain type III IF vimentin (present in both differentiated and undifferentiated lens 
epithelium) (Geisler and Weber, 1981; Ramaekers et al., 1982; Ramaekers et al., 1980) as 
well as two other IF proteins phakinin and filensin (Maisel and Perry, 1972). 
Interestingly, vimentin appeared to be absent from older fibre cells (Bradley et al., 1979; 
Ramaekers et al., 1980) and phakinin and filensin appear to be unique to the differentiated 
lens fibre cell (Gounari et al., 1993; Hess et al., 1993; Hess et al., 1996; Hess et al., 1998; 
Masaki and Watanabe, 1992; Orii et al., 1993; Sandilands et al., 1995). 
Thus, secondary lens fibre elongation and compaction are accompanied by 
alterations in the expression of several components of the cytoskeletal architecture. In the 
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mature lens fibre cell, keratin and vimentin are not expressed but instead, phakinin and 
ftlensin assemble to form a novel cytoskeletal structure referred to as the beaded filament 
(Maisel and Perry, 1972; Pemg et al., 2007). The critical role played by the exact 
architecture of the cytoskeleton is indicated by the fact that a lens lacking the lens-specific 
intermediate ftlament proteins phakinin and filensin is opaque even though the overall 
fibre cell morphology is normal (Alizadeh et al., 2002; Sandilands et al., 1995; Sandilands 
et al., 2003 ). The beaded filament appears to have the ability to interact with the 
chaperone protein a-crystallin (Iwaki et al., 1989; Kato et al., 1992; Lowe et al., 1992) and 
implicates chaperones in the remodelling of IF during development and cell differentiation 
(Nicholl and Quinlan, 1994). 
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1.2. a-CRYSTALLIN 
The human lens fibre cells have an unusually high protein concentration of 
approx. 0.32 g/ml (Bloemendal et al., 2004), and consist mostly of abundant water-soluble 
crystallins (Augusteyn, 2004), which account for 90% of total lens proteins (Thampi et al., 
2002). The lens crystallins play a crucial role in maintaining the clarity of the lens and its 
refractive properties (Thampi et al., 2002). For the lens to be able to retain life-long 
transparency in the absence of protein turnover, the crystallins must meet not only the 
requirement of solubility associated with high cellular concentration but that of longevity 
as well. For proteins, longevity is commonly assumed to be correlated with long-term 
retention of native structure, which in turn can be due to inherent thermodynamic stability, 
efficient capture and refolding of non-native protein by chaperones, or a combination of 
both (Bloemendal et al., 2004). 
The crystallins were first identified as the major proteins of the eye lens and their 
subsequent classification into a-, ~- and y-crystallins (Momer, 1894), allowed different 
functional properties to be assigned to the a- and the ~y-crystallin groups. The a-
crystallin functions as a molecular chaperone (Horwitz, 1992) as well as a structural 
protein (Nicholl and Quinlan, 1994) and ~- and y-crystallins are structural proteins 
(Bloemendal et al., 2004; Bloemendal and de Jong, 1991 ). 
In its native state, a-crystallin is a large water-soluble aggregate, with an average 
molecular weight (Mwt) of approximately 800 kDa (Groenen et al., 1994) and is 
comprised of two polypeptides, aA-crystallins and aB-crystallins each encoded by a 
different gene, which share 60% sequence homology (Bloemendal and de Jong, 1991 ). In 
humans, the aA-crystallin gene (CRY AA), which is located on chromosome 21, encodes a 
polypeptide of 173 residues. The aS-crystallin gene (CRY AB), which is located on 
chromosome 11, encodes a 175-residue polypeptide (Horwitz, 1992). Urea denaturation 
studies showed a-crystallin to be 50% unfolded at about 2.9 M urea, whilst the C-terminal 
domain of aB-crystallin, started unfolding at 2.5 M urea and the N-terminal domain at 4.0 
M urea. For unfolding of the C-terminal domain of aA-crystallin 4 M urea (at pH 3.9) is 
required indicating that aS-crystallin is less stable than aA-crystallin and is stabilized in 
the a-crystallin assembly by its interaction with aA-crystallin (Slin et al., 1998). 
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These two homologous subunits constitute about 30% of the proteins in young 
human lenses and in the outer cortex of the adult human lens (Bhat and Nagineni, 1989; 
Dubin et al., 1989). These proteins share a common central domain of about 90 residues 
(the 'a-crystallin domain') with variable N- and C-terminal extensions (Augusteyn, 2004). 
In its native state in the lens, a-crystallin is always found as a heterogeneous oligomeric 
assembly consisting of a 3: 1 ratio of aA to aS-crystallin subunits (Siezen et al., 1978) 
(2: 1 in the foetal lens (Ma et al., 1998)), that self-associate to form polydisperse 
assemblies with a wide Mwt distribution of 300000 to over one million (Horwitz, 1993). 
With a similar Mwt of 19909Da and 20159Da for aA- and aS-crystallin respectively, the 
native complex with an average Mwt of 800kDa (Groenen et al., 1994) may consist of 
between 15-50 subunits (Groenen et al., 1994; Horwitz, 2003). 
Sequence comparisons of a-crystallin with other proteins found homologies 
between small heat shock proteins (sHSPs) and a-crystallins, suggesting that a-crystallin 
is a member of the heat shock protein family (de Jong et al., 1988; Ingolia and Craig, 
1982; Nene et al., 1986) and functions as a molecular chaperone (Horwitz et al., 1992; 
Klemenz et al., 1991). 
Until about 1985, it was generally accepted that the a-crystallins were lens 
specific, however since that time, evidence has accumulated that show a-crystallins exist 
in many non-lenticular tissues (lnaguma et al., 1995; Lewis et al., 1988; Moscona et al., 
1985). The expression of aS-crystallin has been found in non-lenticular tissues with high 
oxidative activity such as heart, striated muscle, lung, spinal cord, brain, retina and kidney 
(Bhat and Nagineni, 1989; Dubin et al., 1989; Iwaki et al., 1989), but also in degenerative 
disorders of the nervous system. Reports show an over expression of aS-crystallin in the 
development of benign tumours associated with tuberous sclerosis, neuromuscular 
disorders, and other neurological diseases, such as Alexander disease (Head et al., 1993; 
Johnson and Bettica, 1989; Tomokane et al., 1991), Alzheimer's (Renkawek et al., 1994; 
Shinohara et al., 1993), Parkinson's diseases (Lowe et al., 1992; Renkawek et al., 1999), 
and multiple sclerosis (Lowe et al., 1992; Renkawek et al., 1999; van Noort et al., 1995; 
Van Noort et al., 1998). aS-crystallin is frequently found co-localised with amyloid 
plaques in vivo (Sun and MacRae, 2005) and amyloid has been connected with a wide 
range of disorders including Alzhemiers, Creutzfeld-Jakob disease and type II diabetes 
(Raso, 2000; Selkoe, 2003a; Selkoe, 2003b ). A recent study suggested that a fine balance 
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may be at play in vivo between a natively aggregated functional aB-crystallin and a 
misfolded aggregate in the form of amyloid fibrils (Meehan et al., 2007). Naturally 
occurring mutations of aS-crystallin have been associated with the onset of diseases such 
as cataract (Berry et al., 2001; Liu et al., 2006b; Vicart et al., 1998), desmin related 
myopathy (DRM) (Selcen and Engel, 2003; Vicart et al., 1998) and dilated 
cardiomyopathy (DCM) (Inagaki et al., 2006) (see Section 1.6). 
The extra lenticular expression of aS-crystallin has been reported in many tissues 
but aA-crystallin is mainly lenticular and divergence in the promoter region of aA-
crystallin means it is not stress induced (Derham and Harding, 1999). The protein aA-
crystallin however, has been found in non-lenticular tissues such as the rat spleen and the 
thymus in trace amounts (Jimenez-Asensio et al., 1999; Kato et al., 1991). Deretic et al. 
(1994) directly demonstrated aA-crystallin is synthesized outside of the lens in retinal 
cells of frogs (Deretic et al., 1994), and has more recently been found in the mouse retina 
(Xi et al., 2003). Reports show an over expression of aA-crystallin in transgenic mice 
resulted in myelin degradation and axonal dystrophy and developed hind limb paralysis 
after 8 weeks of age with large aA-crystallin deposits in the astrocytes of the spinal cord 
and Schwann cells of the sciatic nerve (De Rijk et al., 2000; Van Rijk et al., 2003). The 
naturally occurring mutation R116C was associated with autosomal dominant congenital 
cataract associated with a missense mutation in the human aA-crystallin gene CRYAA 
(Litt et al., 1998). 
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1.3. THE STRUCTURE OF a-CRYSTALLIN 
The polydisperse nature of a-crystallin is thought to have been the main obstacle 
to acquisition of high resolution X-ray crystallographic data to determine its structure. 
Over many years several models for the tertiary and quaternary structure of a-crystallin 
have been proposed using a variety of analytical techniques (Peterson et al., 2004). 
Kim et al. (1998) reported the crystal structure of sHSP 16.5 from 
Methanococcus jannaschii, a hyperthermophilic archaeon (Kim et al., 1998), which 
provided some insight into the structure of sHSPs assembly (van Montfort et al., 2001). 
Van Montfort et al. (200 1 ), presented the first crystal structure of a eukaryotic sHSP, 
cytosolic class I HSP16.9 from wheat, (see Figure 1.2), whose homology to aA- and aS-
crystallin via the highly conserved a-domain, allowed some insight into the structure of a-
crystallin. 
c 
Figure 1.2. Secondary structure of the HSP 16.9 subunit with an ordered N-terminus. 
Ribbon diagram of the monomer with the ordered N-terminal arm shown in green and the 
a-crystallin domain and the C-terminal extension shown in red. (Reprinted by permission 
from Macmillan Publishers Ltd: Nature Structural and Molecular Biology ((van Montfort 
et al., 2001), copyright 2001). 
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The N-tenninal domain contains three helical segments, in half of the subunits. 
The remaining subunits in HSP16.9 and all subunits in HSP16.5 have unstructured N-
termini. The a-crystallin domain consists of a seven-stranded ~}-sandwich, an interdomain 
loop containing one ~}-strand and a C-terminal extension (at the bottom), which is largely 
unstructured except for the short 1}10 strand (Augusteyn, 2004). 
The 2.7 A structure of wheat HSP16.9 indicates how its a-crystallin domain and 
flanking extensions assemble into a dodecameric double disk. The folding of the 
monomer and assembly of the oligomer are mutually interdependent involving strand 
exchange, helix swapping, loose knots and hinged extensions. In support of the chaperone 
mechanism, the substrate bound dimers in temperature dependant equilibrium with higher 
assembly forms have unfolded N-terminal arms and exposed conserved hydrophobic 
binding sites on the a-crystallin domain (van Montfort et al., 2001). 
Boelens et al. found that the N-terminal domain of aS-crystallin does not 
detectably bind to aB crystallin or with one of its two domains. The N terminus is 
involved in the formation of larger complexes but can only do so in the presence of the C-
terminal domain. It would seem that the highly conserved C-terminal domain forms the 
building blocks, which associate into large complexes through interactions between theN-
terminal domains (Boelens et al., 1998). 
The C terminal extensions of aA- and aS-crystallin are 34 and 32 residues, 
respectively. Both aA- and aS-crystallin have polar, flexible C-terminal extensions that 
have been implicated in the chaperone-like activity of these crystallins and are thought to 
contribute to the solubility of these crystallins (Carver and Lindner), because of a 
preponderance of charged amino acids .. Harrington et al. (2004), suggests that both N-
and C-terminal regions are important for proper folding of a-crystallin, subunit 
interactions between aA- and aS-crystallin, and chaperone activity. 
While aS-crystallin contains the same three structural domains found in 
Mjannaschii HSP16.5 and wheat HSP16.9, the complex assembly of human aS-crystallin 
is larger and more polydisperse than the two sHSPs that have been crystallised and cryo-
electron microscopy studies showed that aS-crystallin has an asymmetric variable 
quaternary structure consisting of 32 subunits with a central cavity (Feil et al., 2001; 
Haley et al., 1998). An alternative model consisting of a tetramer of tetramers is 
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consistent with many observations of the protein (Augusteyn, 2004; Augusteyn, 1998). A 
similar model has been suggested for the murine HSP 25 (Ehrnsperger et al., 1999). 
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1.4. a-CRYSTALLIN AS A MOLECULAR CHAPERONE 
While its lenticular function is also structural, both aB- and aA-crystallin and the 
hetero-oligomer a-crystallin have been shown to display molecular chaperone activity in 
vitro (Horwitz, 1992). Fundamental cellular processes such as protein synthesis, transport 
and turnover involve unfolded or partially denatured proteins. These processes and stress 
expose hydrophobic regions, which may interact incorrectly even at low concentration, 
thus molecular chaperones sequester unfolded polypeptides to prevent aggregation and 
allow for refolding (Derham and Harding, 1999). Molecular chaperones assist the correct 
non-covalent assembly of other polypeptide containing structures in vivo, but are not 
components of these assembled structures when they are performing their normal 
biological function. The predominant function of molecular chaperones is the prevention 
of incorrect associations and aggregation of unfolded polypeptides (Dahlman et al., 2005), 
by suppressing the unfolding of proteins or by mediating in the refolding of unfolded 
proteins (Thampi et al., 2002). a-crystallin can recognize and bind unfolded proteins over 
a range of temperatures and hence its chaperone function is maintained over a range of 
conformations (including sizes) (Bloemendal et al., 2004), however, unlike adenosine 
triphosphate (A TP)-dependent chaperones, the a-crystallins and other sHSPs are not 
thought to actively refold non-native proteins but rather to incorporate them into large 
complexes, thereby preventing their nonspecific aggregation (Aquilina et al., 2004). The 
function of a-crystallin as a chaperone protein has been linked to the dynamics of 
mammalian cytoskeleton assembly because correct folding of cytoskeletal proteins is 
dependent upon its presence (Nicholl and Quinlan, 1994). 
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1.5. THE FUNCTIONS OF aD-CRYSTALLIN 
The expression of aS-crystallin in a variety of tissues outside the lens and its 
ability to prevent thermal aggregation of proteins in a manner similar to molecular 
chaperones (Horwitz. 1992; Klemenz et al., 1991), suggest that it has general cellular 
functions over and above its role in light refraction (Andley et al., 2002). A number of 
physiological functions have been identified. 
1.5.1. MODULATORS OF IF ASSEMBLY 
Within the lens, the a-crystallins are intimately associated with the lens 
cytoskeleton (Nicholl and Quinlan, 1994). The function of this association is not clear, 
but it may be important in facilitating the chaperone activity of a-crystallins by providing 
a solid phase support in the form of IFs (Perng and Quinlan, 2005). Previous studies on 
the lens cytoskeleton have demonstrated that a-crystallins associate with and directly 
inhibit vimentin IF assembly in vitro and induce filament disassembly (Nicholl and 
Quinlan, 1994). These observations provide the first evidence that a-crystallins have the 
potential to influence IF assembly, which may participate in modulating the dynamic 
aspect of IF organisation and structure (Nicholl and Quinlan, 1994). During lens 
maturation, such a mechanism may also contribute to the selective removal of vimentin IF 
networks and rearrangement of the phakinin/filensin IF networks. Pemg et al. (1999) 
suggested that one of the functions of aS-crystallin is to help manage IF network by 
controlling filament-filament interactions (Pemg et al., 1999) and recently demonstrated 
the ability of aS-crystallin to assist the formation of IF networks in living cells (Pemg and 
Quinlan, 2005). 
Thus, aS-crystallin participates in the dynamic assembly, disassembly 
reorganisation and stabilisation of the filamentous cytoskeleton. In normal tissues a-
crystallin interacts directly with a number of filamentous proteins including phakinin, 
filensin (CP119), desmin, glial fibrillary acidic protein (OF AP) and vimentin where it 
functions in the organisation and stabilisation of the filament networks formed by these 
proteins (Bennardini et al., 1992; Ghosh et al., 2007; Vicart et al., 2006). One of the 
major functions of the association of sHSPs with IFs is to help manage the interactions 
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that occur between filaments in their cellular networks and a link was found suggesting 
that aS-crystallin regulates cell division through the stabilization of cytoskeleton 
filaments (Andley et al., 2001; Andley et al., 2000; Fujita et al., 2004). This is achieved 
by protecting filaments against those non covalent interactions that result when they come 
into close proximity and which have the potential to induce IF aggregation as seen in 
some disease pathologies (Perng et al., 1999). Other functions suggested have been 
protection of tubulin subunits of microtubules (Arai and Atomi, 1997}, and association 
with actin in ischemic cardiac cells, where it may prevent aggregation of filaments (Chiesi 
et al., 1990). aS-crystallin regulates actin filament dynamics, stabilises them in a 
phosphorylation dependant manner and protects the integrity of IFs against extracellular 
stress. Disturbance of the cytoskeleton leads by converging signalling pathways to the 
phosphorylation of aS-crystallin, which probably acts as a protective effecter of the 
cytoskeleton (Launay et al., 2006). 
Disruption of cytoskeletal assembly is one of the early effects of any stress that 
can ultimately lead to cell death. Singh et al. (2007) demonstrated that aS-crystallin can 
prevent stress-induced aggregation of actin in vitro and regulate actin filament dynamics 
and protects cells from stress-induced death in vivo. Association of aS-crystallin with 
actin helps maintenance of pinocytosis, a physiological function essential for survival of 
cells (Singh et al., 2007). aS-crystallin also associates with the tubulin cytoskeleton as 
shown by Xi et al., (2006) where the mitotic spindle is abnormally assembled in a number 
of aA- and aS-crystallin knockout lens epithelial cells {Xi, 2006). The study suggested 
that the aS-crystallin interacts with microtubule associated proteins (MAPs) to inhibit 
aggregation of microtubules in lens epithelial cells therefore affecting microtubule 
assembly by maintaining the pool of unassembled tubulin (Xi, 2006). 
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1.5.2. REGULATORS OF APOP'I'OSIS 
The ability of aS-crystallin to inhibit apoptosis was demonstrated by Kamradt et 
al. They showed that aS-crystallin is a novel negative regulator of myogenic apoptosis 
whose expression is selectively induced in surviving myoblasts during an early stage of 
their differentiation in vitro, and provided a direct and previously unrecognized link 
between the myogenic differentiation program and the acquisition of apoptosis resistance 
(Kamradt et al., 2002). aS-crystallin also antagonizes myogenic apoptosis by inhibiting 
the activation of caspase-3, which is consistent with previous fmdings in cancer cells that 
aS-crystallin inhibits caspase-3 activation by disrupting its proteolytic maturation 
(Kamradt et al., 2002). As caspase-3 plays a central role in the execution of apoptosis 
(Cryns and Yuan, 1998) aS-crystallin may participate broadly in the regulation of muscle 
cell death (Kamradt et al., 2002). 
1.5.3. TRANSCRIPTIONAL REGULATORS 
Both aS-crystallin and HSP27, are identified as nuclear speckle components in 
unstressed cells in tissue culture (van den IJssel et al., 2003). This new fmding suggests a 
constitutive function for these sHSP chaperones in the nucleus and suggests a new 
perspective on the cardiomyopathy-causing mutation for aS-crystallin (R120G) that could 
involve transcriptional splicing effects. Both aS-crystallin and HSP27 were 
immunolocalised to nuclear speckles (interchromatin granule clusters), whilst HSP27 was 
also seen associated with the nucleolar compartment, indicating a subtle difference 
between these closely related sHSPs. Phosphorylation was not required for nuclear 
localisation of aS-crystallin. This was confirmed by the transient transfection of HeLa 
cells with a phosphorylation-defective aS-crystallin (van den IJssel et al., 2003). 
Mutations of aS-crystallin would potentially have nuclear as well as cytoplasmic 
consequences. 
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1.5.4. GENOME STAB.IIL11TY AND HYPERPROL:n:FERATilON 
Preservation of genomic stability encompasses many factors, such as the 
maintenance of primary DNA sequence and the preservation of chromosomal ploidy and 
structure (Hartwell et al., 1994). Primary cultures of CRYAB knockout (-/-) lens 
epithelial cells show genome instability and hyperproliferation, suggesting that aS-
crystallin regulates cell division through the stabilization of cytoskeleton ftlaments 
(Andley et al., 2001; Andley et al., 2000; Fujita et al., 2004). 
Genomic instability is a hallmark of cancer cells, the over expression of aS-
crystallin during oncogene expression and in tumours of neuroectodermal origin suggests 
that the protein may accumulate as a stress response to maintain chromosomal integrity 
during cellular evolution from a normal to a cancer cell. This notion is consistent with the 
current finding that CRY AB-1- cells demonstrate genomic instability. The mechanism by 
which the loss of aS-crystallin enhances genomic instability needs further investigation 
(Andley et al., 2001). 
1.5.5. PROTEOSOME FUNCT][ON 
The aS-crystallin protein plays a role in the proteosome-mediated degradation of 
selected proteins (Parcellier et al., 2005). Degradation of a protein by the ubiquitin system 
involves two distinct and successive steps. Firstly, multiple ubiquitin molecules 
covalently attach to the target protein then the tagged protein is degraded by the 26S 
proteosome (Ciechanover, 1998). The ubiquitin-protein isopeptide ligase SCF 
~KPl/CULl/E-box) complex captures the target protein via the F-box protein (Cenciarelli 
et al., 1999). Den Engelsman et al, (2003) identified the F-box protein FBX4 as an 
interactor with aS-crystallin (den Engelsman et al., 2003). The interaction with FBX4 
seems to depend on the phosphorylation status of aS-crystallin, but is also enhanced by 
the mutation R120G aS-crystallin. Binding of FBX4 to aS-crystallin stimulates the 
ubiquitination of a detergent-insoluble protein, which probably destines this protein for 
ubiquitin-dependent degradation (den Engelsman et al., 2003). 
Cytoplasmic inclusions containing aS-crystallin found in various neurological 
_ disorders, suchas--Alzheimer!s,-"Pa:tkinson's~Hillltington's~ -Alexander'S,. and -diffuSe Lewr 
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body disease (Head and Goldman, 2000; Kato et al., 2001; Tamaoka et al., 1995), have 
been shown to consistently contain ubiquitin-positive proteins (Rideout et al., 200 I) 
suggesting that the proteins responsible for aggregate formation may have a role in 
ubiquitin-dependent degradation (Ciechanover, 2001). 
Other functions suggested included the regulation of platelet function. 
Aggregation of human platelets were dose-dependently inhibited by aS-crystallin and 
induced by thrombin or botrocetin. aS-crystallin can act intercellularly to regulate 
platelet functions. These results may provide the basis for a novel defence system against 
thrombus formation in vivo (Matsuno and Kozawa, 2003). 
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1.6. aD-CRYSTALLIN AND CATARACT 
Cataract, or opacification of all or part of the lens of the eye reduces optical 
performance most commonly manifested by decreased visual acuity, glare and decreased 
contrast sensitivity. While age-related cataract is the commonest cause of visual 
impairment worldwide, most advances have been made in understanding the genetic basis 
of its congenital counterpart (Francis et al., 1999). Cataract is a pathological opacity 
interfering with transparency caused either by disturbances to the regular cytoplasm-
membrane lattice repeat of the lens, or by perturbations of the local short-range order of 
the crystallins in the interior of the fibre cells (Bloemendal et al., 2004). 
There are three primary causes of cataract including age related, exposure to 
certain risk factors and congenital cataracts as detailed below. The consequences of the 
three primary causes of cataract suggest that cataractogenesis could be considered as a 
protein folding disease; due to unfolding of lens proteins, or be the consequence of a loss 
of solubility due to altered interaction of native proteins (Bloemendal et al., 2004). 
1.6.1. AGE RELATED CATARACT 
The incidence of three kinds of cataract increase with age and include nuclear, 
cortical and posterior subcapsular cataract (Klein et al., 2002). The theories of aging 
include firstly, the evolutionary theory, which regards aging as a result of natural selection 
becoming weaker with age (Medawar, 1952) and secondly the disposable soma theory of 
aging suggesting that ageing is a consequence of the progressive accumulation of 
molecular and cellular damage (Kirkwood and Austad, 2000). 
The exceptionally long lifetime of lenticular proteins means that the a-crystallins 
are susceptible to the accumulation of a variety of posttranslational modifications that are 
thought to disrupt their structure and include disulfide bonding, oxidation, backbone 
cleavage, proteolysis, aggregation, cross-linking, deamidation, methylation and 
glycosylation (Bloemendal et al., 2004). For aS-crystallin in the lens, the major 
modification has been identified as phosphorylation at serine residues 19, 45, and 59 
(Aquilina et al., 2004). Another ~oQiM~lltjgnj~_~d~datiQn, whichintroduces'a'"negative 
---- ~~ ~-~- -- ---------
charge, and is believed to cause alterations in protein tertiary structure, affecting their 
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structural and functional properties (Gupta and Srivastava, 2004). Therefore, the 
posttra.nslational modifications inhibit potential chaperone capabilities and lead to protein 
insolubilization and consequently cataract development. 
Age-related cataract derives from two distinct molecular routes: protein unfolding 
resulting in protein aggregation and/or altered interaction and association between native 
crystallins resulting in lesser solubility. With increasing age the incidence of lens 
opacities increases and visual acuity lessens. Ultimately, the only way to restore sight is 
cataract surgery, however post surgery cataract can occur if the lens epithelial cells remain 
in the capsular bag following surgery (Lois et al., 2003). Four types of post surgery 
cataract have been recorded and include Fibrous posterior capsular opacification (PCO) 
Soemmering's ring (Apple et al., 2000), Elschnig pearls (Cheng et al., 2001) and liquefied 
PCO (Miyake et al., 1998). 
1.6.2. DISEASE RELATED CATARACT: THE RISK FACTORS OF 
CATARACTOGENESIS 
Cataract can be one of the symptoms of systemic disease (Shinohara et al., 2007). 
Data from epidemiological and case control studies have suggested various risk factors 
(Shah et al., 2007; Virgolici and Popescu, 2006). These risk factors include diabetes 
(Iwamoto et al., 2004; Jacob, 1999; Thampi et al., 2002), steroid use (Dickerson et al., 
1997; Hamamichi et al., 2003; Kojima et al., 2002; Nakamura et al., 2003; Patteau et al., 
2003; Shibata et al., 2003), smoking (Hiller et al., 1997; Kelly et al., 2005; Klein et al., 
1993; Krishnaiah et al., 2005; Raju et al., 2006; Shalini et al., 1994; Sulochana et al., 
2002; West and Valmadrid, 1995), UV radiation (Hayashi, 1998; McCarty and Taylor, 
2002; Pastor-Valero et al., 2007), nutrition and oxidative stress (Christen et al., 2007; 
Delcourt et al., 2005; Fain, 2004; Reddy et al., 2002; Taylor et al., 1989; Valero et al., 
2002), diarrhoea (Minassian et al., 1984; Zodpey et al., 1999) and alcohol consumption 
(Lindblad et al., 2007). 
Chapter /-Introduction 19 
1.6.3. CONGENITAL CATARACT 
Congenital cataract is a result of a mutation in one of the lenticular proteins and is 
usually already present at birth or develops shortly thereafter. It is responsible for 10% of 
childhood blindness worldwide (Francis et al., 2000) and if left untreated permanent visual 
loss usually occurs (Zhang et al., 2007). 
Congenital cataract shows wide phenotypic variation reflecting its genetic 
heterogeneity (Francis et al., 1999). Current literature recognises several classifications of 
congenital cataract phenotypes taking into account the location and appearance of the 
opacity within the lens. The classifications include anterior polar, posterior polar, nuclear, 
lamellar (zonular), coralliform (coral-like appearance), blue-dot (cerulean), cortical, 
pulverulent (opacities have a 'pulverized' dust-like appearance) and total cataract (Francis 
et al., 1999). Posterior polar cataract is located at the back of the lens and is proximal to 
the optical centre of the eye, therefore can result in a marked effect on visual acuity (Berry 
et al., 2001 ). 
Inherited cataracts account for up to half of all congenital cataracts and are 
clinically heterogeneous, with the most common mode of inheritance being autosomal 
dominant congenital cataract (ADCC). The less common autosomal recessive and X-
linked forms are also observed (Berry et al., 2001 ). Thus far seventeen functionally 
diversified genes have been identified to cause isolated ADCC (Zhang et al., 2007). A 
study by Vi cart et al, ( 1998) reported the first defect in the aS-crystallin gene (CRY AB) 
at locus 11q22.3-q23.1, which caused the human muscle disorder of desmin related 
myopathy (DRM) (Vicart et al., 1998). Similarly in the aA-crystallin gene (CRY AA) an 
ADCC gene was mapped to chromosome 21q22.3 and sequencing identified a missense 
mutation R116C associated with ADCC (Litt et al., 1998). 
The observation has been made that clinical phenotypes might be caused by 
mutations in different genes, in contrast, mutations in the same gene do not necessarily 
lead to the same phenotype (Graw, 2003). This indicated the impo~ce of_ t\S _}'~t 
-untmown -modulators-of. gene-expression or-fut~ti~n. For example, mutations of the 
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CRY AB gene cause ADCC (Liu et al., 2006b; Vicart et al., 1998) as well as DRM (Selcen 
and Engel, 2003; Vicart et al., 1998) and DCM (lnagaki et al., 2006). Graw (2003) 
suggested that the detailed molecular analysis of allelic series of mutations will allow 
detailed genotype-phenotype correlations to be made, which should help understand the 
function of particular domains of the mutated proteins (Graw, 2003). 
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1.7. NATURALLY OCClURRliNG MlUTATION§ 01F 
aD-CRYSTALLIN 
21 
Naturally occurring mutations have been found in both aA- and aS-crystallin. 
The regions affected by these specific mutations helped to identify single amino acid 
substitutions that would drastically alter protein structure and eliminate chaperone like 
activity (Bova et al., 1999; Pras et al., 2000; Shroff et al., 2000). Mutations found in aA-
crystallin result only in cataract, however the mutations associated with aS-crystallin 
specifically are of more interest as high expression levels of aS-crystallin in non lenticular 
tissues and the lens leads to a variety of tissues displaying a phenotype associated with the 
aS-crystallin mutation (see Table 1.1). 
Table 1.1. Mutations of the CRYAB gene 
~lr~~~~~Y!ii~, liii~,~~t,~·:;,·· 
R120G Desmin Related Myopathy (DRM), (Vicart et al., 1998) 
Cardiomyopathy, cataracts 
450delA Isolated congenital cataract (Berry et al., 2001) 
Q151X Myofibrillar myopathy (MM) (Selcen and Engel, 2003) 
464delCT Myofibrillar myopathy (Selcen and Engel, 2003) 
D140N ADCC (Liu et al., 2006b) 
R157H* Dilated Cardiomyopathy (DCM) (lnagaki et al., 2006) 
P20S ADCC (Liu et al., 2006a) 
*-The R157H mutation was not analysed in this study. Although the C-terminal region 
was affected, the mutation was reported late into the study and as the mutation caused a 
base substitution without altering the length of the C-terminal extension it was deemed 
indirectly comparable to the remainder of the mutants studied. 
Mutations found in the aS-crystallin CRY AB gene result in a modified/truncated 
C-terminal region with the exception of the P20S, R120G and D140N mutation. Previous 
reports show that the removal of C-terminal extensions of 32 residues from aB-crystallins 
lead to improper folding, reduced chaperone activity, and formation of trimers or tetramers 
(Gupta and Srivastava, 2004), therefore the discovery of the CRYAB mutations willh~lp 
. furth~~ und~,;~dth;r;,}; ~;~;~ifi~';;d;~; ~~:e~~~-of ;;iii~ :~i~:·"i~ ~e-c~~~~ 
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region of the aS-crystallin on function, in terms of chaperone capability and solubility, 
and relationship between the mutant aS-crystallin and the expressed phenotypes. The 
known CRY AB mutations are discussed below. 
1.7.1. R120G aD-CRYSTALLIN 
The R120G missense mutation was the first case where a defect in a molecular 
chaperone was identified as a cause for an inherited human muscle disorder (Vicart et al., 
1998). The patients affected by the R120G mutation had proximal and distal weakness 
with desmin accumulation in skeletal muscle, cardiomyopathy and cataracts, (Selcen, 
2003 #31 ). Perng et al 2004 showed that the mutation alters the in vitro binding 
characteristics of aS-crystallin for desmin filaments (Perng et al., 2004) resulting in 
desmin aggregation. Desmin-related myopathies (DRM) are inherited neuromuscular 
disorders characterized by adult onset and delayed accumulation of aggregates of desmin, 
a protein belonging to the type III intermediate filament family, in the sarcoplasma of 
skeletal and cardiac muscles (Vicart et al., 1998). The adult onset of aB-crystallinopathy 
indicates that in the real physiological situation, the formation of the aggregates by Rl20G 
aS-Crystallin is a tightly regulated process. The delayed onset of the disease in vivo may 
be explained by co-polymerization with family members, assisted folding and targeted 
degradation (Chavez Zobel et al., 2003). 
The R120G mutation occurs within the highly conserved a-crystallin domain 
(residues 68-151 ), which is believed to be engaged in the subunit-subunit interactions, but 
the individual amino acids in subunit interactions and chaperone activity have not been 
fully identified (Gupta and Srivastava, 2004). Studies have shown that patients with DRM 
display heterozygous expression of wild type and R120G aS-crystallin and that misfolded 
Rl20G aB-Crystallin could be rescued by wild-type aS-Crystallin (Chavez Zobel et al., 
2003). The R120G mutation alters affected the secondary and tertiary structure of the aS-
crystallin (Perng et al., 1999), causing a decreased fl-sheet secondary structure and an 
altered aromatic residue environment compared with wild-type aS-crystallin (Bova et al., 
1999), and leads to the appearance of intracellular aggregates containing both aBg 
crystallin and desmin in the muscles of affected individuals (Barral et al., 2004). Treweek 
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et al. (2005) indicated that R120G aS-crystallin exists as a larger oligomer than wild-type 
aS-crystallin, and its size increases with time. It is likely that removal of the positive 
charge from R120 of aS-crystallin causes partial unfolding, increased exposure of 
hydrophobic regions, and enhances its susceptibility to proteolysis, thus reducing its 
solubility and promoting its aggregation and complexation with other proteins. These 
characteristics may explain the involvement of R120G aS-crystallin with human disease 
states (Treweek et al., 2005). The appearance of similar aggregates in another form of 
DRM, caused by missense mutations in desmin itself, lends support to the notion that 
failure of and also to assist in folding and assembly of desmin into the intermediate 
filament cytoskeleton leads to the disease (Barral et al., 2004). 
1. 7.2. 450DELA aB-CRYST ALLIN 
Berry et al. (200 1) reported the first mutation to cause isolated congenital cataract 
in the CRY AB gene. Sequence analysis of the CRY AB gene revealed a deletion mutation 
450delA in exon 3. This mutation co-segregated in a family with autosomal dominant 
posterior polar cataract who displayed a single well-defined plaque that was present at 
birth or developed during the first few months of life not progressing, with age to other 
regions of the lens. The mutation was not found in a panel of 100 normal unrelated 
individuals, excluding the possibility that it is a rare polymorphism. 
The result of the mutation is the production of an extended protein of 184 
residues with 35 novel amino acids at the C-terminus, starting at codon 154 of the protein, 
replacing several highly conserved residues. The C-terminal extension region is thought 
to be important for the chaperone function and solubility of aS-crystallin (Smulders et al., 
1996). Since the 450delA mutation in CRY AB leads to the replacement of the C-terminal 
extension by novel residues, it is very likely to compromise the chaperone-like activity of 
aS-crystallin (Berry et al., 2001). 
The constitutive expression of aS-crystallin in the lens and non-lenticular tissues 
raises the question, why the mutation results in isolated congenital cataract and shows no 
non lenticular symptoms like the R120G mutation, which displayed DRM and cataract. 
The major difference is the region in aS-crystallin where the mutation has occurred, 
resulting in a larger protein with significant alteration to the C-terminal residues. It is yet 
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to be understood the effect the 450delA mutant protein has on its interaction with substrate 
proteins relative to the wild type, to give rise to the isolated cataract. 
1.7.3. Q151X aD-CRYSTALLIN AND 464DELCT aD-CRYSTALLIN 
Selcen & Engel, (2003) reported further mutations of the CRYAB gene, which 
resulted in myofibrillar myopathy. Additional symptoms included adult onset proximal 
and distal leg muscle weakness, myopathic electromyogram with abnormal electrical 
irritability and muscle biopsy findings of myofibrillar myopathy and mild denervation 
(Selcen and Engel, 2003), however no cataracts were identified. The term myofibrillar 
myopathy was proposed in 1996 as a non-committal term for a pathological pattern of 
myofibrillar dissolution associated with the accumulation of myofibrillar degradation 
products and ectopic expression of multiple proteins that include desmin, aS-crystallin, 
dystrophin and congophilic amyloid material (Selcen et al., 2004). 
1.7.3.1. Q151X aD-crystallin 
The second mutation showed a C-to-T transition at position 451 ( 451 C-T) that 
generates a stop codon (Q151X) and predicts a protein consisting of 150 residues with a 
molecular mass of 17 .5kDa. This mutation results in the removal of the C-terminal 
extension, which consists of residues 149-175 (Selcen and Engel, 2003). 
1. 7 .3.2. 464delCT aD-crystallin 
The third mutation showed a 2bp deletion at position 464 ( 464delCT) that 
generates eight missense codons (RAHHSHHP) followed by a stop codon. This mutation 
predicts a protein consisting of 162 instead of 175 residues with a molecular mass of 
18.8kDa (Selcen and Engel, 2003). 
Although the phenotype of the Ql51X- and 464delCT aS-crystallin mutant 
affects non-lenticular tissues, the expression of the aS-crystallin protein is at its highest 
levels in the lens, but no evidence of cataract has been reported in patients with these 
mutations in aS-crystallin. Both wild type and mutant proteins are present in muscle, but 
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expression of the mutant moieties is less than of wild type. The decreased expression of 
the mutant protein could be a consequence of its relative instability, due to the truncation 
of the C-terminal region responsible for stabilisation of the aS-crystallin. Despite its 
reduced expression, the truncated proteins still result in pathological changes in skeletal 
muscle, consistent with a dominant negative effect (Selcen and Engel, 2003). Patients 
with the R120G missense mutation in aS-crystallin had cardiomyopathy, 
palatopharyngeal weakness, and cataracts (Vicart et al., 1998), all features not detected in 
patients with the Q 151 X or 464delCT mutations, and patients with 450delA mutation 
show isolated cataract and no neuromuscular degeneration. The differences in the 
expressed phenotype of the different CRY AB mutations may be related to functionally 
different regions of aB-crystallin itself, to single nucleotide polymorphisms in 
functionally related genes in the different patients (Selcen and Engel, 2003), or the 
presence of other chaperones in the eye lens, which associate with the mutant and prevent 
aggregation and thus cataractogenesis. 
1. 7.4. POST TRANSLATIONAL MODIFICATIONS (PTM) 
Recent studies have identified a number of PTMs occurring in aS-crystallin, 
which result in a truncated C-terminal region by proteolytic digestion and lead to cataract 
formation. Comparisons can be made between the affect of these PTMs and the congenital 
mutations on the function and stability of the specific aS-crystallin. 
Several post-translationally modified forms of aS-crystallin have been identified. 
Two degradation products, aS-crystallin (1-170) and aS-crystallin (1-174) (Jimenez-
Asensio et al., 1999; Plater et al., 1996) each make up between 9.5-27% of the total aS-
crystallin in Soemmerring's ring form of cataract and less than 1% in the normal lenses 
(Colvis et al., 2000). Other modified forms of aS-crystallin such as 1-163 are aberrant in 
the fibre cells of the Soemmerring's rings relative to normal lens. Soemmerring's ring is 
one form of secondary cataract that can occur following cataract surgery. The ring 
structure is formed by adherence of the anterior lens capsule to the posterior lens capsule. 
Epithelial cells, remaining after surgery, differentiate into lens fibre cells, but the resulting 
tissue mass does not remain transparent (Col vis et al., 2000; Ueda et al., 2002b ). 
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1.7.4.1. aD-crystallin 1-174 
An aS-crystallin fragment was detected in the cataract of a human lens and was 
preferentially phosphorylated over the wild type (Jimenez-Asensio et al., 1999). The 
fragment was identified as aS-crystallin minus the terminal lysine by Matrix-assisted laser 
desorption/ ionisation-Time of Flight-mass spectrometry (MALDI-TOF-MS) in 
Soemmerring's ring cataract (Colvis et al., 2000). The mechanism involved in generating 
truncated aS-crystallin is not known, but a premature termination of the aS-crystallin 
gene was ruled out by sequencing the polymerase chain reaction products of the last exon 
for the aS-crystallin gene from lenses containing the fragment (Jimenez-Asensio et al., 
1999). Recombinant truncated aS-crystallin was primarily soluble and the chaperone 
activity was comparable to that of the wild type aS-crystallin. 
Plater et al. (1996) showed the effect of substituting the two terminallysines of 
aS-crystallin with Leucine (L) or Glycine (G) residues. Plater et al. (1996) suggested that 
the effect of substituting the two terminal lysines resulted in a largely intact but less 
mobile C terminus. The absence of a strong hydrophilic positive charge at the end of the 
highly flexible C-terminal extension may result in the C terminus folding back on itself, 
losing its flexibility, and sterically hindering protein binding (Plater et al., 1996), thus 
explaining the significant reduction in chaperone activity. 
1.7.4.2. aD-crystallin 1-170 and 1-163 
The induction of diabetes resulted in a C-terminal truncated form of aS-crystallin 
1-170 in rat lenses, however, not observed in the human lenses of diabetic sufferers 
(Thampi et al., 2002). Another study also showed the presence of the aS-crystallin 1-170 
in vitro from rat lens nucleus using LP82 and M-calpain proteolysis and a second 
truncation 1-163, thus with 12 residues removed from the C-terminal (Veda et al., 2002a). 
The 1-170 and 1-163 modified forms of aS-crystallin were observed in patients who 
display Soemmerring's ring cataract (Colvis et al., 2000; Ueda et al., 2002a). Proteolytic 
removal of the Thr171- Lys175 region did not affect aS-crystallin chaperone activity 
(Carver et al., 1995), which again supports the theory that there would be sufficient 
charge-charge interactions with the remainder of the C-terminal arm to ensure efficient 
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chaperone-like activity (Plater et al., 1996). This also suggests that the terminal five amino 
acids do not affect the solubility of the aS-crystallin and the complexes formed during 
chaperone activities. The effect of the removal of the 12 amino acid residues on chaperone 
activity and solubility is unknown. 
The age related post-translational modifications of the C- terminal region, like the 
congenital mutations 450delA, 464delCT and QISIX show a relationship between the C-
terminal structures of aS-crystallin and its subsequent solubility and function as a 
molecular chaperone, which ultimately lead to the onset of disease. 
1.7.5. R157H aD-CRYSTALLIN 
Dilated Cardiomyopathy (DCM) is a disease characterised by cardiac 
enlargement accompanied by systolic dysfunction and associated congestive heart failure 
(Richardson, 1996). A novel missense CRYAB mutation Rl57H was found in a familial 
DCM patient and affected one of the evolutionary conserved amino acid residues amongst 
a-crystallin (Inagaki et al., 2006). Mutations in the sarcomeric proteins such as titin/ 
connectin are known to cause DCM (Gerull et al., 2002; Itoh-Satoh et al., 2002) and 
functional analysis revealed that the Rl57H mutation decreased the binding of aS-
crystallin to titinlconnectin heart specific N2B domain without affecting distribution of the 
mutant aB-crystallin in cardiomyocytes. In contrast the Rl20G mutation decreased the 
binding to both N2B and striated muscle-specific 126/27 domains and showed intracellular 
aggregates of the mutant protein. These observations by lnagaki et al. (2006) suggest that 
the Rl57H mutation disease causing mechanism is different from the Rl20G (Inagaki et 
al., 2006). This Rl57H mutation, which affects the C-terminal of aS-crystallin, alters the 
structural and functional integrity of aS-crystallin by hindering the ability of aS-
crystallin to bind to client proteins. 
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1.7.6. D140N aD-CRYSTALLIN 
Liu et al. (2006) reported a novel Dl40N mutation in the third exon of the 
CRY AB gene. The mutation was found to co-segregate with disease phenotype in a five 
generation ADCC family with isolated lamellar cataract, where opacity is limited to the 
layers of the lens external to the nucleus (Liu et al., 2006b ). Characterisation of the 
mutant aS-crystallin, which affects the highly conserved a-domain of sHSPs, indicated 
that although the mutation had no effect upon secondary structure, alterations to the 
tertiary and/or quaternary structure were observed with changes in surface hydrophobicity. 
The D 140N aS-crystallin aggregated into a larger complex than the wild type aS-
crystallin, was more susceptible to thermal denaturation and not only lost its chaperone 
activity but displayed a dominant negative effect by inhibiting the chaperone activity of 
wild type aS-crystallin (Liu et al., 2006b). The Dl40N mutation results in similar 
structural changes to Rl20G yet the Rl20G causes myopathy as well as cataract 
phenotype. Liu et al. (2006) proposed that the altered tertiary and/or quaternary structure 
and the dominant negative effect of the D 140N mutation underlie the molecular 
mechanism ofcataractogenesis ofthis nature (Liu et al., 2006b). 
1.7.7. P20S aD-CRYSTALLIN 
The CRY AB mutation first associated with isolated congenital cataract was 
450delA, however, Liu et al., (2006) identified a mutation, P20S, in the CRYAB gene in a 
large four-generation Chinese family with nonsyndromic posterior polar cataract (Liu et 
al., 2006a). 
The disease gene of this Chinese family was mapped to chromosome 11 in region 
q22-22.3, where two small heat shock proteins CRYAB and HSPS2 are harboured. The 
expression of HSPS2 is not detectable in the lens so it is unlikely to be the candidate gene 
for ADCC (Iwaki A, 1997). Instead, mutation analysis of CRY AB identified a novel 
mutation P20S that cosegregated with all affected individuals, but was not present in 
unaffected members of the family or the 200 normal control subjects. The mutation occurs 
at an evolutionarily conserved residue P20 in the aS-crystallin. Although this is the 
second novel mutation in CRY AB that has been linked to isolated cataract, it is interesting 
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to note that the P20S mutation is located at theN terminus of CRYAB, whereas the 
previously identified 450delA mutation associated with cataract and other CRYAB 
mutations associated with myopathy are all located at the C terminus. 
The relative effects of the aS-crystallin mutations upon the amino acid sequence 
of aS-crystallin are detailed in Figure 1.3. The sequence alignment shows the effect of 
congenital mutations 450delA, 464delCT, Q151X, D140N, R157H, P20S and R120G 
upon the C-terminal extension of aS-crystallin. Also shown are the PTM products 
E164X, K175X and A171X plus mutations of interest K174X and E165X that complete a 
series of C-terminal truncated mutants, which sequentially remove important regions of 
the C-terminal extension. 
It is clear from the structural alignment that with the exception of P20S, R120G 
and D140N, all the disease causing mutations of aS-crystallin, are associated with an 
altered C-terminal extension. The 450delA, 464de1Ct and Q151X mutations resulted in a 
C-terminal extension that was altered from residue 150 onwards ( 450delA) (Berry et al., 
2001), 155 onward (464delcn or completely removed (Q151X) (Selcen and Engel, 
2003). The deletion of a known substrate interaction site (157-164; (Ghosh, 2005 #157)) 
and a region important in the oligomerisation of aB-crystallin itself (155-166; (Ghosh, 
2005 #157)) support the hypothesis that this region in aS-crystallin is important to the 
solubility, the structure and function of the protein. The pathology of the R157H mutation 
lends further support to this conclusion. Thus far, the effect of such extensive deletions 
(Q151X) combined with altered C-terminal sequences (450delA, 464Cn upon aB-
crystallin solubility, structure and function have not been investigated. In aB-crystallin, 
there has not been any systematic analysis of the role of the C-terminal extension and 
therefore no potential explanation of whether the three mutations (450delA, Q151X and 
464delcn cause the various diseases via the loss of chaperone function or perhaps by a 
different mechanism. 
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R120G MD IAIHHPWI RRPFFPFHSPSRLFDQFFGEHLLESDLFPTSTS LS PFYLRPPSFLRAPSW 
D140N MD IAIHHPWI RRPFFPFHSPSRLFDQFFGEHLLESDLFPTSTS LSPFYLRPPS FLRAPSW 
~ud~ MDIAIHHPWIRRPFFPFHSPSRLFDQFFGEHLLESDLFPTSTS LS PFYLRPPS FLRAPSW 
K175X MD IAIHHPWI RR PFFPFHS PSRLFDQFFGEHLLESDLFPTSTS LSPFYLRPPSFLRAPSW 
K174X MD IAIHHPWI RRPFFPFHSPSRLFDQFFGEHLLESDLFPTSTS LS PFYLRPPSFLRAPSW 
A171X MD IAIHHPWI RRPFFPFHSPSRLFDQFFGEHLLESDLFPTSTS LS PFYLRPPS FLRAPSW 
R157H MD IAIHHPWI RRPFFP FHSPSRLFDQFFGEHLLESDLFPTSTS LSPFYLRPPS FLRAPSW 
E165X MD IAIHHPWI RRPFFPFHSPSRLFDQFFGEHLLESDLFPTSTS LSPFYLRPPS FLRAPSW 
E164X MD IAIHHPWI RRPFFPFHSPSRLFDQFFGEHLLESDLFPTSTS LSPFYLRPPS FLRAPSW 
464delCT MD IAIHHPWIRRPFFPFHS PSRLFDQFFGEHLLES DLFPTSTS LS PFYLRPPS FLRAPSW 
Q151X MD IAIHHPWI RRPFFPFHSPSRLFDQFFGEHLLESDLFPTSTS LSPFYLRPPSFLRAPSW 
450delA MD IAIHHPWI RRPFFPFHSPSRLFDQFFGEHLLESDLFPTSTS LSPFYLRPPSFLRAPSW 
P.WS MDIAIHHPWI RRPFFPFHS~SRLFDQFFGEHLLESDLFPTSTSLS PFYLRPPS FLRAPSW 
R120G FDTGLSEMRLEKDRFSVNLDVKHFSPEELKVKVLGDVIEVHGKHEERQDEHGFISREFH~ 
Dl40N FDTGLSEMRLEKDRFSVNLDVKHFSPEELKVKVLGDVI EVHGKHEERQDEHGFISRE FHR 
~udJY~ FDTGLSEMRLEKDRFSVNLDVKHFSPEELKVKVLGDVIEVHGKHEERQDEHGFI SRE FHR 
K175X FDTGLSEMRLEKDRFSVNLDVKHFSPEELKVKVLGDVI EVHGKHEERQDEHGFISRE FHR 
K174X FDTGLSEMRLEKDRFSVNLDVKHFSPEELKVKVLGDVI EVHGKHEERQDEHGFISREFHR 
Al71X FDTGLSEMRLEKDRFSVNLDVKHFSPEELKVKVLGDVI EVHGKHEERQDEHGFI SRE FHR 
R157H FDTGLSEMRLEKDRFSVNLDVKHFSPEELKVKVLGDVI EVHGKHEERQDEHGFISREFHR 
E165X FDTGLSEMRLEKDRFSVNLDVKHFSPEELKVKVLGDVI EVHGKHEERQDEHGFISRE FHR 
El64X FDTGLSEMRLEKDRFSVNLDVKHFSPEELKVKVLGDVI EVHGKHEERQDEHGFISRE FHR 
464delCT FDTGLSEMRLEKDRFSVNLDVKHFSPEELKVKVLGDVI EVHGKHEERQDEHGFISRE FHR 
Q151X FDTGLSEMRLEKDRFSVNLDVKHFSPEELKVKVLGDVI EVHGKHEERQDEHGFISREFHR 
450delA FDTGLSEMRLEKDRFSVNLDVKHFSPEELKVKVLGDVI EVHGKHEERQDEHGFI SREFHR 
P20S FDTGLSEMRLEKDRFSVNLDVKHFSPEELKVKVLGDVIEVHGKHEERQDEHGFISRE FHR 
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Rl20G KYRIPADVDPLTI TSS LSSDGVLTVNGPRKQVSGPERTIPITREEKPAVTAAPKK---- - ---- 175 
D140N KYRIPADVDPLT ITSSLSS~GVLTVNGPRKQVSGPERTIPI TREEKPAVTAAPKK--------- 175 
~udJY~ KYRIPADVDPLTI TSS LSSDGVLTVNGPRKQVSGPERTIPITREEKPAVTAAPKK--------- 175 
K175X KYRIPADVDPLTI TSS LSSDGVLTVNGPRKQVSGPERTIPITREEKPAVTAAPK---------- 174 
Kl74X KYRIPADVDPLTI TSS LSSDGVLTVNGPRKQVSGPERTIPI TREEKPAVTAAP------- - --- 173 
Al71X KYRIPADVDPLTI TSS LSSDGVLTVNGPRKQVSGPERTIPI TREEKPAVT---------- - --- 170 
Rl57H KYRIPADVDPLT ITSSLSSDGVLTVNGPRKQVSGPE~TIPI TREEKPAVTAAPKK-------- - 175 
E165X KYRIPADVDPLTI TSS LSSDGVLTVNGPRKQVSGPERTIPI TRE---------------- - -- - 164 
El64X KYRIPADVDPLTI TSS LSSDGVLTVNGPRKQVSGPERTIPI TR- - ------------------- 163 
464delCT KYRIPADVDPLTI TSS LSSDGVLTVNGPRKQVSG----- -- ----RAHHSHHP----------- 162 
Ql51X KYRIPADVDPLTI TSSLSSDGVLTVNGPRK----------------------------- ----- 150 
450delA KYRIPADVDPLTI TSS LSSDGVLTVNGPRNRS LAL SAPFPSPVKRSLLSPQPPRNRCPFLNC IF 184 
P.WS KYRIPADVDPLTI TSS LSSDGVLTVNGPRKQVSGPERTIPITREEKPAVTAAPKK--------- 175 
Figure 1.3. Structural alignment of the naturally occurring aS-crystallin mutations and 
specific mutations of interest. The structural alignment shows the effect of congenital 
mutations 450delA, 464delCT, Ql51X, D140N, Rl57H, P20S and Rl20G upon the 
structure of aS-crystallin. Details are also shown of the PTM products E164X, K175X 
and A171X and for comparison a series of C-terminal truncated mutants, which 
sequentially remove important regions of the C-terminal extension. Small and 
hydrophobic amino acids (including aromatic -Y) are indicated in red, acidic (blue), basic 
(magenta), Hydroxyl +amine+basic-Q, (green) and other amino acids are indicated in 
grey. Novel amino acid sequences are underlined. (Alignment produced using ClustalW 
multiple sequence alignment programme at www.ebi.ac.uk/clustalw). 
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1.8. HYPOTHESIS AND AIMS OF THE STUDY 
The systematic analysis of the role of the C-terminal extension aims to investigate 
the hypothesis that, the C-terminal region in aS-crystallin is important for solubility, 
structure and function of the protein, thus providing a potential explanation of whether the 
three mutations (450delA, Q151X and 464delCT) cause the various diseases via the loss 
of chaperone function or perhaps by a different mechanism. 
In this study, I aim to analyse the effects of the Q151X, 464delCT and 
450delA mutations upon the oligomerisation and chaperone activity of aB-crystallin. For 
comparison, I will also assess the activity of a series of aB-crystallin constructs truncated 
at residues K 17 4, E 165, A 171 and E 164 to sequentially remove important regions of the 
C-terminal extension and therefore help us understand the role it plays in the functional 
and structural integrity of aS-crystallin. The characterisation of these mutants also aims 
to provide understanding of the mechanism that allows mutations such as Q151X and 
464delCT to express the phenotype of myofibrillar myopathy without any evidence of 
cataractogenesis, where as 450delA shows isolated congenital cataract with no muscular 
degeneration. 
In Chapter 3, I have investigated the relationship between the C-terminal extension 
and the solubility of aB-crystallin, and its potential role in the mechanism that causes 
various disease states. This Chapter involved the cloning, expression and purification of 
the sequentially truncated C-terminal aS-crystallin mutants (K174X and El65X) along 
with the three naturally occurring disease causing mutants (450delA, Ql51X and 
464delCT) and the PTM truncations (El64X and Al71X). The nature of expression and 
purification helped understand the role of specific regions of the C-terminal extension 
important in solubilisation of aS-crystallin oligomers, and provided the basis for further 
characterisation that was performed in Chapter 4. 
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In Chapter 4, I investigated the role of the C-terminal extension upon 
oligomerisation and chaperone activity by characterising the effects of these C-terminal 
extension mutants upon the structure and function of aB-crystallin. This further 
characterisation of the C-terminal extension aimed to elucidate the mechanism that links 
the C-terminal extension with the chaperone function, oligomerisation and solubility and 
how the three naturally occurring mutations of this C-terminal extension not only cause 
disease but also result in the varying pathology of isolated polar posterior cataract 
(450delA) and myofibrillar myopathy (464delCT and Q151X). 
In Chapter 5, I wanted to focus on the mechanism that links chaperone activity 
with oligomerisation by investigating the relationship between the subunit dynamics of 
wild type aS-crystallin and oligomerisation, hoping to provide further understanding of 
the role this plays in efficient chaperoning of client proteins by wild type aB-crystallin. In 
this chapter, I analysed the effect of protein concentration of wild type aS-crystallin upon 
oligomerisation and also identified a low Mwt species of wild type aS-crystallin, which 
could potentially be an active unit of chaperone activity however further analysis is 
required. 
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CHAPTER2 
MATERIALS AND METHODS 
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2.1. CHEMICALS 
All chemicals and reagents used were purchased from Merck Ltd (Poole, UK) or 
Sigma Aldrich (Poole, UK) and were of analytical grade unless otherwise stated. All 
restriction endonucleases were from New England Siolabs (Herts, UK) unless otherwise 
stated. 
2.2. CONSTRUCTION OF aB-CRYSTALL:U:N MUTANTS 
2.2.1. PRIMER DESIGN 
Primers for aS-crystallin mutants (see Table 2.1) were designed based on the 
messenger RNA (mRNA) sequence for wild type human aS-crystallin 
(DDSJ/EMSL/GenBank entry NM_001885) (Sigma Genosys, UK). Unique restriction 
enzyme sites were incorporated into the primers to assist screening, using the software 
available at: http://www.dwalab.com/DNAProject/bin/DNA _Analysis _Frame.html and 
products amplified using wild type aS-crystallin as a template for PCR mutagenesis. With 
the exception of the Q 151 X and the E 165X mutations, the amplified products were cloned 
into the vector pGEM®-T Easy (Promega, UK). After verification of the sequences the 
mutant aS-crystallin constructs were subcloned into the Nco! and EcoRI sites of the 
expression vector pET23d (New England Siolabs). The Ql51X and El65X mutations 
were introduced into pET23d by Site Directed mutagenesis (SDM) (Stratagene, UK) using 
complementary primers, (see Table 2.1). Constructs were sequenced and compared for 
fidelity to the GenSank data base entry (accession no. NM001885). 
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Table 2.1. Oligonucleotide primer sequence details used for introduction of the aS-
crystallin mutatiOns 
Ql51X Stu! 
El65X Hindi!! 
464delCT n/a 
Kl74X Sac! I 
Al71X Sac! 
El64X Pstl 
.· .· 
Forward primer 
gtgaatggaccaaggaaataggcctctggccctgagcgcacc 
Reverse Primer 
ggtgcgctcagggccagaggcctatttccttggtccattcac 
Forward primer 
attcccatcacccgtgaatagaagcttgctgtcaccgcagccccc 
Reverse Primer 
gggggctgcggtgacagcaagcttctattcacgggtgatgggaat 
Forward primer 
Taccatggacatcgccatccaccacc 
Reverse Primer 
tcacgggtgatgggaatggtgcgctcggccagagacctgtttcc 
Forward primer 
Taccatggacatcgccatccaccacc 
Reverse Primer 
Ctagggggccgcggtgacagcaggcttc 
Forward primer 
Taccatggacatcgccatccaccacc 
Reverse Primer 
gggcatctatttcttgggagctcaggtgacagcaggcttctc 
Forward primer 
Taccatggacatcgccatccaccacc 
Reverse Primer 
cttgggagctgcggtgactgcaggcttctcttaacgggtgatgggaatggt 
35 
The unique restriction enzyme sites incorporated into the pnmer design are 
highlighted in bold text. Q151X and E165X were introduced using SDM requiring 
complementary forward (5'-3') and reverse (3'-5) primers. The 464delCT, K174X, 
~Al]lXam:l E16_4XmutantmRNA were amplified using a forward primer~overlapping the 
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pET23d insertion site and the 5' end of the template wild type aS-crystallin. Reverse 
primers were complementary to the 3' end of the template wild type aS-crystallin and 
incorporated the mutation and the unique restriction site. A suitable restriction enzyme 
site was not available for the 464delCT mutation. 
2.2.2. CONSTRUCTION OF Ql51X aD-CRYSTALLIN MUTANT USING SDM 
2.2.2.1. Polymerase Chain Reaction (PCR) 
Initial attempts to incorporate the Q 151 X mutation into wild type aS-crystallin 
using SDM required optimisation of the magnesium chloride (MgCh) concentration and 
extension time during the PCR. The pfu Turbo polymerase supplied with the Stratagene 
kit utilised a proofreading function, however, comparison for fidelity to the GenBank data 
base entry (accession no. NM001885) identified random base changes, although the 
mutant sequence had been successfully cloned. Therefore, SDM was performed using 
Taq polymerase and a T7 Terminator primer. Table 2.2 details the reaction mixture and 
Table 2.3 details the cycling parameters utilised during the PCR stage of the SDM 
process. 
Table 2.2. Q151X aD-crystallin mutant reaction mixture for PCR 
Reagent Volume 
T7 terminator primer 1 Of!M 1 f!l 
Q151X forward primer lOf!M 1 f!l 
pET 23d vector with wild type aD-crystallin insert lOOng 
lOX buffer (Roche Diagnostics, Lewes, UK) 5f!l 
dNTP mix 1 OmM 1 f!l 
DEPC Water (Invitrogen, Paisley, UK) To final volume 50!!1 
25mMMgCh 3f!l 
Taq polymerase (Dioline, London, UK) 0.5f!l 
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Table 2.3. Q151X aB-crystallin mutant PCR cycling condition 
Stage Temp (°C) Time (min) Nn cycles 
1 94 1 I 
2 94 1 25 
60 1 
72 4* 
3 72 2 I 
4 4 Hold 1 
*The extension time is representative of 1min/kb plasmid 
The PCR product was digested for 1 h at 37°C with Dpn I (Stratagene, UK) to 
remove parental DNA from the product DNA. An agarose gel (0.6% w/v) was performed 
to confirm the product was of the required size (see 2.2.2.2). 
2.2.2.2. Agarose gel electrophoresis 
For a 0.6% (w/v) agarose gel, 0.3g of agarose was reconstituted in 50ml of 40mM 
Tris(hydroxymethyl)methylamine (Tris)-acetate, 1mM EDTA pH 8.0, (TAE), buffer and 
heated in the microwave until the agarose had completely melted. Once cooled to 50°C, a 
2.5[!1 aliquot of 10 mg/ml ethidium Bromide was added and the gel cast. The gel was 
allowed to set for 30 min prior to sample loading. DNA samples for gel analysis require 
addition of 0.25% (w/v) Bromophenol blue, 0.25% (w/v) xylene cyanol, 30% (w/v) 
glycerol, (6X DNA running buffer) (Maniatis, 1989)). The gels were calibrated using 
DNA ladders, the first, 4 [!l of a GeneRuler® 100 bp DNA ladder (Fermentas, York, UK) 
consisting of 14 fragments ranging from 100-3000 bp. The second, 12 [!1 of a 1000 bp 
marker (A. Pst I) consisting of fragments of Lambda DNA (New England BioLabs, UK) 
digested by Pst I (New England BioLabs, UK) ranging from 15- 11501 bp. The DNA is 
resolved by 50V constant voltage and DNA products visualised using a Biorad Gel Doc 
2000 and Quantity one v4.0.3 software (Biorad Laboratories, UK). 
Chapter 2-Materia/s and Methods 38 
2.2.2.3. Transformation of mutant DNA 
Confirmation of the correctly sized PCR product prompted transformation of the 
PCR product into DH5a competent cells for proliferation, (see Section 2.3). The PCR 
product consists of the pET23d( +) vector containing the mutant aB-crystallin mRNA 
insert. 
2.2.2.4. Cultivation and purification of plasmid DNA 
A selection of suitable colonies were picked and placed into 5ml of Luria-Bertani 
(LB) media with 50~-tg/ml Carbenicillin and incubated overnight at 37°C at 225rpm. The 
plasmid DNA was purified using plasmid mini prep Kit (Sigma, Gillingham, UK) 
following the recommended protocol. Each 5ml culture was centrifuged for 15 min at 
4000rpm at 4 °C, and the supernatant discarded. The resulting pellet was resuspended in 
400~-tl of resuspension buffer and separated into two 200~-tl volumes for further 
purification in 1.5ml eppendorf tubes. The cells were lysed by the addition of 200~-tl lysis 
buffer and gently inverted 6-8 times ensuring the neutralisation buffer was added (350~-tl) 
within 5 min of the Lysis buffer. The tubes were inverted 4-6 times and centrifuged in the 
microcentrifuge for 10 min at 12500rpm. The supernatant was added to a spin column, 
which was prepared by the addition of 500~-tl of column preparation buffer and centrifuged 
for 1 min at 12500 rpm and the flow through was discarded. With the plasmid DNA 
applied the spin column was centrifuged for 1 min at 12500 rpm and the flow through 
discarded. The 750~-tl of wash solution was added to the spin column and centrifuged for 
1 min at 12500 rpm and flow through discarded. The column was spun for a further 2 min 
without any additional buffer, to ensure maximum removal of ethanol from the column 
membrane. The purified plasmid DNA was eluted with 50~-tl of sterile water, and the two 
aliquots per 5ml culture were recombined and stored at -20°C. 
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2.2.2.5. Screening for transformants 
Purified plasmid DNA was digested with Nco I I Stu I. To 10 fl.l of DNA, 0.5 fl.l of 
each restriction enzyme was added with 1 fl.l of 1 mg/rnl DSA (New England DioLabs, 
UK), 1 f1.l Buffer B digestion buffer (provided with the restriction enzyme) and 7 f1.l of 
sterile purified water. The mixture was incubated at 37°C for 1-2 h then analysed by 
agarose gel (see Section 2.2.22) to identify the constructs with fragments of the correct 
insert size. Constructs were sequenced and compared for sequence fidelity to the 
GenBank data base entry (accession no. NM001885). 
2.2.3. CONSTRUCTION OF E165X aD-CRYSTALLIN MUTANT USING SDM 
The pfu Turbo polymerase supplied with the Stratagene kit utilised a proof reading 
function, which failed to prevent the introduction of random base changes, however the 
mutant sequence had been successfully cloned. SDM was performed using Taq 
polymerase with an optimised annealing temperature and cycle number. Table 2.4 details 
the reaction mixture and Table 2.5 details the cycling parameters utilised during the PCR 
stage of the SDM process. 
Table 2.4. E 165X aD-crystallin mutant reaction mixture for PCR 
Reagent Volume (fl.l) 
E165X Reverse primer 1 Ofl.M 1 fl.l 
E 165X forward primer 1 Ofl.M 1 fl.l 
pET 23d vector with wild type aD-crystallin 100ng 
insert 
1 OX buffer (Roche Diagnostics, Lewes, UK) 5 fl. I 
dNTP mix 1 OmM 1 fl.l 
DEPC Water (Invitrogen, Paisley, UK) To final volume 50f1.l 
25rnrn MgCb 3fl.l 
Taq polymerase (Dioline, London, UK) 0.5f1.l 
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Table 2.5 El65X aB-crystallin mutant PCR cycling conditions 
Stage Temp Time (min) N2 cycles 
(oC) 
1 94 1 1 
2 94 1 5 
55 1 
72 4 
3 94 1 20 
60 1 
72 4 
4 72 2 1 
5 4 Hold 1 
The PCR product was digested for 1 hat 37°C with Dpnl to remove parental DNA 
from the product DNA. An agarose gel (0.6% w/v) was performed to confirm the product 
was of the required size (see Section 2.2.2.2). 
Digested PCR product was transformed into DH5a competent cells for proliferation, (see 
Section 2.3), resulting colonies picked, cultured overnight and plasmid DNA purified 
using plasmid mini prep Kit (Sigma, Gillingham, UK) (see Section 2.2.2.4). The purified 
plasmid DNA was digested with Nco!/ Hindlll (see Section 2.2.2.5) and analysed by 
agarose gel (see Section 2.2.22) to identify the constructs with fragments of the correct 
insert size. Constructs were sequenced to confirm mutagenesis. 
2.2.4. CONSTRUCTION OF 464DELCT, E164X, K174X AND A171X 
aD-CRYSTALLIN MUTANTS 
Initial SDM experiments failed to produce PCR products of the correct size for the 
464delCT, El64X, K174X and A171X aB-crystallin constructs. A different approach 
used primers for the amplification of PCR products using wild type aS-crystallin as a 
template for PCR mutagenesis. The amplified products were cloned into the vector 
pGEM®-T Easy (Promega, UK). After verification of the sequences the mutant aB-
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crystallin constructs were subcloned into the Nco! and EcoRI sites of the expression 
vector pET23d (New England Diolabs). 
2.2.4.1. Primer design 
Primers for aD-crystallin mutants (Table 2.1; sigma Genosys, UK) were designed 
based on the mRNA sequence for wild type human aD-crystallin (DDDJ/EMBL/GenBank 
entry NM _ 00 1885). The first 4 bases of the forward primers consisted of pET23d( +) 
sequence, in which the wild type aD-crystallin gene was inserted. Unique restriction 
enzyme sites were incorporated into the primers to assist screening, using the software 
available at: http://www.dwalab.com/DNAProjectlbin!DNA Analysis Frame. 
2.2.4.2. PCR 
The pGEM®-T Easy system required a PCR product with a 3' A overhang, which 
was generated using the EasyA high fidelity polymerase (Stratagene, UK). Table 2.6 
details the reaction mixture and Table 2.7 details the cycling parameters utilised during the 
PCR mutagenesis. 
T bl 2 6 E A PCR a e .. asy reac ton m1 ure f •xt 
Reagent Volume 
Reverse primer 1 Of.tM 1 fll 
Forward primer 1 Of.tM 1 fll 
pET 23d vector with wild type aD-crystallin 100ng 
insert 
1 OX buffer (Stratagene, UK) 5f.tl 
d.NTP mix 1 OmM 1 fll 
DEPC Water (Invitrogen, paisley, UK) To final volume 50!-tl 
Easy A polymerase (Stratagene, UK) 0.5f.tl 
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T bl 2 7 E A PCR a e asy r eye mg con d". 1t10ns 
stag~ Tewp{°C}. Time ··NoCycles 
1 95 2min 1 
2 95 40 sec 25 
72 30 sec 
72 1 min 
4 72 7min 1 
5 4 Hold 1 
2.2.4.3. PCR product Gel Extraction (QIAquick - Qiagen) 
The PCR product of interest was resolved from other non-specific bands by 0.6% 
(w/v) agarose gel electrophoresis, (see Section 2.2.2.2). The DNA fragment was excised 
from the agarose gel with a clean sharp scalpel and it was ensured that exposure to UV 
was minimal in order to prevent mutation of the DNA. The size of the gel slice was 
minimised by removal of excess agarose. The gel slice was weighed and then solubilised 
by the addition of 3 volumes of buffer QG (Qiagen, Crawley, UK) to 1 volume of gel. To 
aid dissolution, heating at 50°C was utilised with intermittent vortexing. The sample was 
applied to a QIAquick spin column in a 2ml collection tube centrifuged for I min at 12500 
rpm and the flow though discarded. The column was washed with 0.75 ml Buffer PE 
(Qiagen, Crawley, UK), centrifuged for I min at 12500 rpm and the flow though 
discarded. To ensure complete ethanol removal the column was centrifuged for a further 1 
min at 12500 rpm and the QIAquick spin column placed into a clean tube. The DNA was 
eluted by application of 50 ~-tl of sterile water onto the membrane and after being allowed 
to stand for 1 min, was centrifuged for I min at I2500 rpm. The purified DNA was 
ligated immediately. 
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2.2.4.4. Ligation into pGEM-T Easy vector system 
Ligation reactions utilised the Promega pGEM-T Easy ligation kit (Promega WI, 
USA). The ligation reactions were performed using the reaction mixture detailed in Table 
2.8. 
T able 2.8. Ligation reactions using the pGEM-T Easy (Promega) li gation kit. 
.Reagent.· 
stariaaril Positive 'Ba¢kgrcn1nd 
.. 
reaction Control contiof 
2X rapid ligation buffer 10!!1 10!!1 10!!1 
pGEM-T Easy vector I 111 1 !!l 1 !!1 
PCRproduct 5!!1 - -
Control insert - 5!!1 -
T4 DNA ligase 1 !!l 1 !!l 1 !!l 
Sterile water 3!!1 3!!1 8!!1 
The ligation reaction mixtures were incubated for 3 h at room temperature or 
overnight at 4 °C. 
2.2.4.5. Transformation, cultivation and purification of plasmid DNA 
The entire 20!!1 ligation reaction was transformed into DH5a competent cells 
performed as detailed in Section 2.3. 
A selection of white colonies were picked and placed into 5ml of LB media with 
50!-lg/ml carbenicillin and incubated overnight at 37°C at 225rpm. The DNA was purified 
using the plasmid mini prep Kit (Sigma, Gillingham, UK) and the recommended protocol 
(see 2.2.2.4). 
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2.2.4.6. Screening for transformants 
Purified plasmid DNA was digested (see Section 2.2.2.5) with the appropriate 
restriction enzymes as shown in Table 2.9 
Table 2.9. Mixture for restriction enzyme digestion 
· c6iistfd2t :'Restticti()D.:~nzyln.es 
:--_,_-;;. 
464delCT Ncoll EcoRI 
E164X Nco// Pstl 
Kl74X Nco!! Sac!! 
Al71X Ncol/Sacl 
The mixture was incubated at 37°C for 1 - 2 h then analysed by agarose gel (see 
Section 2.2.2.2) to identify constructs ofthe correct size for sequencing analysis. 
2.2.4.7. Sub cloning of mutant DNA into bacterial expression vector pET23d(+). 
The mutant aB-crystallin sequence was cleaved from the pGEM-T easy vector 
using a double digest with Nco!/ EcoRJ restriction enzymes (see Section 2.2.2.5). A 
second double digest was performed with the empty pET23d(+) expression vector with the 
same restriction for insertion of the excised fragment. The mixture was incubated at 3 7°C 
for I - 2 h then separated by Agarose gel electrophoresis (see Section 2.7.2.2). The 
pET23d(+) vector minus fragment and the cleaved aB-crystallin sequence cleaved from 
pGEM-T Easy are excised from the gel and undergo gel extraction purification, see 
2.2.4.3. Once purified, the vector and fragment are ligated as detailed in Table 2.1 0. 
_-___ :-__ _: __ .::_ 
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Table 2.1 0. Ligation reaction for sub cloning into pET23d( +) 
·· ..  ... ~~~t·• ... ·····••· ~t~j1·:r~~rtr~1~d 
1 OX rapid ligation buffer 2JA.l 2JA.l 2JA.l 
PCRproduct 
Control insert 
T4 DNA ligase 
Sterile water 
The ligation reaction mixtures were incubated for 3 h at room temperature or 
overnight at 4 °C, then either stored at 4 OC or -20°C until further use. The entire 20JA.l 
ligation reaction was transformed into DH5a competent cells performed as detailed in 
Section 2.3. A selection of 12 colonies were picked and placed into 5ml ofLB media with 
50J.tg/ml Carbenicillin and incubated overnight at 37°C at 225rpm. 
The DNA was purified using the plasmid mini prep Kit (Sigma, Gillingham, UK) 
and the recommended protocol (see Section 2.2.2.4). Purified plasmid DNA was digested 
with the appropriate restriction enzymes (Table 2.9) and screened as detailed in Section 
2.2.4.6. Constructs with confirmation of the correct mutant sequence in pET23d(+), are 
suitable for expression in BL-21(pLysS) competent cells. 
2.2.5. SUB-CLONING OF MUTANT DNA INTO MAMMALIAN EXPRESSION 
VECTOR PCDNA3.1(-) FROM PET23D (+) 
The sub-cloning of mutant DNA from pET23d(+) to pcDNA3.1(-) follows the 
protocol detailed in Section 2.2.4. 7 with restriction enzymes appropriate for ligation into 
pcDNA3.1(-). The enzymes required are specific to the vector pcDNA3.1(-) not the insert 
(Table 2.11 ). 
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Table 2.11. Mixture for restriction enzyme digestion 
Reagep.t VolU1Ile 
Hind//! 1 !!I 
Xba/ 1!!1 
Yellow Tango Buffer 2!!1 
Mutant DNA I pcDNA3.1(-) 17!!l/500ng 
The resulting digest fragments undergo gel extraction (see Section 2.2.4.3), 
ligation (see Section 2.2.4.7), transformation (see Section 2.3), cultivation, purification of 
plasmid DNA (see Section 2.2.2.4) and finally screening for transformants using 
restriction enzymes Apa/1 Hind///. This digest allows confirmation of the presence of a 
mutant fragment and transfer into the pcDNA3 .1 (-) vector as pET23d( +) has no Apa/ site. 
Confirmation of the presence of the required mutant DNA by sequencing preceded 
transient transfection of mutant aB-crystallin DNA in pcDNA3.1(-) into mammalian cells. 
2.3. TRANSFORMATION OF PLASMID DNA AND 
PREPARATION OF INOCULUM FOR BATCH CULTURE. 
Competent cells (BL-21/DH5a) were thawed on ice and divided into pre cooled 
eppendorf tubes in 50!!1 aliquots, (50!!1 per transformation). A 2!!1 volume of plasmid 
DNA, ( aB-crystallin insert in pET23d( + ), was added to the 50!!1 aliquot and mixed by 
gentle swirling. The transformation mixture was incubated on ice for 30 min, followed by 
incubation at 42°C for 45 sec, then incubation on ice for 2 min. A 500!!1 volume of LB 
media was added to the tube contents, and the transformation reaction was incubated at 
3rC for 60 min at 225rpm. The reaction mixture was plated onto LB agar plates with 
50!-tg/ml carbenicillin for growth of DH5a colonies and 50!-tg/ml carbenicillin with 
34~-tg/ml Chloramphenicol, for growth of BL-21 colonies. Plates were incubated 
overnight at 3rC. One colony was picked and placed into lOml of LB media with 
suitable antibiotics (plus 0.05% (w/v) glucose for BL-21 cultures) and incubated overnight 
at 37°C at 225rpm. 
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2.4. BATCH FERMENTATION OF E.COL/BL-21 (PLYSS) CELLS 
A 500ml flask of LB media containing 34~-tg/ml chloramphenicol, 50~-tg/ml 
carbenicillin and 0.05% (w/v) glucose was inoculated with a 1 Oml of a fresh overnight 
culture. The flask was mixed at 225rpm at 37°C and the optical density was monitored at 
00600 until a value of 0.6 ± O.IAU was observed, at which time protein expression was 
induced by adding 0.5mM Isopropyl-beta-D-Thiogalactopyranoside (IPTG) and the cells 
were cultured for a further 3 h. 
2.5. CELL HARVESTING, HOMOGENISATION AND RECOVERY 
OF THE aB-CRYSTALLIN PROTEIN FRACTION 
Following a 3 h post induction growth period, the cells were removed from the 
3 rc incubator and centrifuged at 4 oc for 15 min at 4000 rpm. The supernatant was 
decanted and discarded. The pelleted material was resuspended in 20ml of 50mM Tris-
hydrochloric acid (HCl), pH8.0, 1mM EDTA, lOOmM sodium chloride (NaCl), lOmM 
MgCh 0.2mM Phenylmethylsulphonylfluoride (PMSF) with the addition of a Complete™ 
protease inhibitor cocktail tablet (Roche Diagnostics, Lewes, UK). Cell lysis was initiated 
by 3 freeze thaw cycles at -20°C, after which, the cell resuspension was homogenised 
using a Dounce glass homogeniser, on ice, in order to prevent proteolysis. The cell lysate 
was centrifuged at 15000rpm for 30 min at 4°C. For soluble protein expression such as 
wild type aB-crystallin, the supernatant is retained and further purified. Expression of 
mutant aB-crystallin as inclusion bodies results in further purification of the pelleted 
material. 
----
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2.6. PURIFICATION OF SOLUBLE PROTEIN WILD TYPE 
aD-CRYSTALLIN 
48 
2.6.1. REMOVAL OF DNA FROM THE WILD TYPE aD-CRYSTALLIN 
SOLUBLE PROTEIN FRACTION 
Benzonase® nuclease, (Novagen, Nottingham, UK) was added to a final cone. of 
10 u/ml to the soluble protein fraction (SPF) to degrade endogenous nucleic acids that 
may have interfered with purification due to high viscosity. The SPF was mixed gently at 
ambient temperature for 30 min. The DNA material present in the SPF was precipitated by 
the addition of 0.1 %(v/v) Polyethylimine (PEl) and was incubated on ice for 5min. 
Precipitated DNA material was removed by centrifugation at 15000rpm for 1 Omin at 4 oc. 
To remove the PEl, the supernatant was dialysed, overnight at 4°C against 20mM Tris 
HCl pH 7.4, lmM MgCh, lmM EDTA, lmM Dithiothreitol (OTT), 0.2M PMSF, using 
12K-14K molecular weight cut off, (MWCO) dialysis tubing (Medicell International Ltd, 
London, UK). The dialysate was concentrated to ~ 5ml using a 15ml Amicon spin 
concentrator, (Millipore UK, Watford, UK). The concentrated material was filtered using 
a 32mm Acrodisc® polyethersulphone (PES) syringe filter (Pall, Portsmouth, UK). 
Clarified SPF was stored at 4 oc until further purification. 
-·--
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2.6.2. ION EXCHANGE CHROMATOGRAPHY 
Further purification of the wild type aS-crystallin was performed using Fractogel 
® Trimethylarnrnoniumethyl group (TMAE) (Merck Biosciences, West Drayton, UK) ion 
exchange chromatography (lEX) resin, (binding capacity for BSA I OOmg/ml resin). A I 0 
ml column was poured with a packed bed height, (PBH) of I 0 em and underwent a 
cleaning in place, (CIP) and equilibration protocol using the Merck Hitachi 
Biochromatography High performance liquid chromatography (HPLC) system (Merck 
Hitachi Ltd, Tokyo, Japan). 
• 2 h sanitisation with 0.5M sodium hydroxide, (NaOH). 
o 3 column volumes (CV) of milliQ water 
o 2 CV of 20mM Tris HCl pH 7.4, lmM MgCh, IM NaCl, lmM EDTA, lmM 
DTT, 0.2M PMSF, (Buffer B). 
o 3 CV of 20mM Tris HCl pH 7.4, lmM MgCh, lmM EDTA, lmM DTT, 0.2M 
PMSF, (Buffer A) or until oo2so reaches a stable baseline. 
All HPLC buffers were degassed and vacuum filtered to 0.2!--tm using a Whatman 
Cellulose nitrate membrane disc filter (Whatman, Maidstone, UK). The load material was 
applied at lml/min to the column in 10 ml of Buffer A and was eluted with a 50 mllinear 
gradient of 0 - 0.5M NaCl (Buffer B). Residual bound protein was eluted over a 30 ml 
linear gradient of 0.5 - 1M NaCl (Buffer B). Eluted material was collected as lml 
fractions using a Biorad Model 2110 fraction collector (Biorad Laboratories, UK) and 
assayed by sodium dodecyl (lauryl) sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) (see Section 2.10), using 12% (w/v) acrylamide gels. Fractions enriched with wild 
type aS-crystallin were pooled. The column was sanitised by a 2 h contact time with 
0.5M NaOH followed by 30 ml of milliQ water. The column was stored in 20 ml of 
20mM Tris HCl, 1M NaCl, 0.02% (v/v) sodium azide, pH 7.4. The data was analysed 
using Chromeleon 6.30 software (Sunnyvale, CA, USA). 
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2.6.3. SIZE EXCLUSION CHROMATOGRAPHY 
Further purification of the wild type aS-crystallin pool was performed using, a 
120 ml size exclusion (SEC) Fractogel EMD BioSEC Superperformance® column (60 x 
1.6cm) (Merck, Darmstadt, Germany), which underwent the following CIP and 
equilibration protocol. 
• 2 h sanitisation with 0.5M NaOH. 
• 3 CV ofmilliQ water 
• 2 CV of 20mM Tris HCl pH 7 .4, 500mM NaCl 
• 3 CV of 20mM Tris HCl pH 7 .4, 1 OOmM NaCl, (Buffer A) or until oo2so reaches 
a stable baseline. 
All HPLC buffers were degassed and vacuum filtered to 0.2~M using a Whatman 
Cellulose nitrate membrane disc filter (Whatman, Maidstone, UK). The wild type aS-
crystallin lEX pool (see Section 2.6.2) was dialysed for 16 hat 4°C into Buffer A using 
12-14kDa MWCO dialysis tubing (Medicell International Ltd, London, UK) then 
concentrated to 0.5ml using an Amicon Ultra Centrifugal filter device 1 OK MWCO 
(Millipore, Watford, UK) and 0.2~M filtered using a 32mm Acrodisc® PES syringe filter 
(Pall, Portsmouth, UK). The concentrated pool was applied at 1ml/min to the column in 
Buffer A and was collected in the flow through as lml fractions. Fractions were assayed 
by SDS-PAGE, using 12% (w/v) acrylamide gels and those fractions enriched with wild 
type aS-crystallin were pooled, aliquoted and stored at -20°C. The column was sanitised 
by a 2 h contact time with 0.5M NaOH followed by 3 CV of milliQ water. The column 
was stored in 2 CV of20mM Tris HCl, 1M NaCl, 0.02% (v/v) sodium azide, pH 7.4. 
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2.6.4. LARGE SCALE (6L) aD-CRYSTALLIN PURIFICATION 
Large scale purification was performed as detailed in sections 2.5 and 2.6 with 
the appropriate 6x increase in process volumes. The lEX chromatography was performed 
using a 68 ml the strong anion exchange resin Fractogel ® TMAE EMD (s) column (13cm 
x 2.6cm) (Merck, Darmstadt, Germany). Sample application was performed via three 5ml 
injections and eluate was collected in 6 ml fractions. SEC purification was performed 
using a 415 ml HW55s (Tosoh, Japan) (78cm x 2.6cm) column with a Gilson Minipuls 2 
peristaltic pump (Gilson, France) at 0.6 ml/min (7.5cmlh linear flowrate). The sample (5 
ml ~ 1% CV) was applied directly to the top of the column bed and eluate collected in 6 
ml fractions using a Biorad Model 2110 fraction collector (Biorad laboratories, UK). 
2.7. PURIFICATION OF MUTANT aB-CRYSTALLIN AS 
INCLUSION BODIES 
2.7.1. INCLUSION BODY EXTRACTION AND SOLUBILISATION 
The inclusion body pellet was resuspended in 20ml of20Mm Tris, 1% (v/v) Triton 
X-100, 150mM NaCl, 5mM EDTA, lmM ethylene glycol tetraacetic acid (EGTA) 0.5mM 
DTT 0.2mM PMSF, pH 7.5 (Extract buffer 1). Benzonase® nuclease, was added to a 
final cone. of 10 u/ml to the resuspension, to degrades all forms of DNA and RNA, that 
may have interfered with purification due to high viscosity, while having no proteolytic 
activity, and was mixed gently at ambient temperature for 30 min. The inclusion body 
solution was centrifuged at 15000rpm for 30 min at 4 °C, and the supernatant containing 
cell debris was discarded. The inclusion body pellet was resuspended in 20ml of 20mM 
Tris, 0.5% (v/v) Triton X-100, 600mM NaCl, 5mM EDTA, lmM EGTA 0.5mM DTT 
0.2mM PMSF, pH 7.5 (Extract buffer 2), and was mixed gently at ambient temperature for 
30 min. The inclusion body solution was centrifuged at 15000rpm for 30 min at 4°C, and 
the supernatant containing cell debris was discarded. The inclusion body pellet was 
resuspended in 20ml of IOmM Tris pH 7.5, 150mM NaCl, 5mM EDTA, lmM EGTA 
0.5mM DTT 0.2mM PMSF (E_xtract_ huffer,_3), and was_mixed~gently-at- -ambient 
~----~--~~--2.....-==--- -
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temperature for 30 min. The inclusion body solution was centrifuged at 15000 rpm for 30 
min at 4 oc, and the supernatant containing cell debris was discarded. The resulting pellet 
was solubilised in 10 volumes of IOmM Tris, 6M urea, pH 8.0 lmM EDTA, lmM DTT 
0.2mM PMSF and incubated at 4°C with mixing for 4 h. The solubilised material was 
clarified by centrifugation at 15000 rpm for 30 min at 4°C, and the supernatant was 
decanted and dialysed against lOmM Tris, 6M urea, lmM EDTA, pH 8.0, lmM DTT 
0.2mM PMSF overnight at 4°C using 12-14kDa MWCO dialysis tubing (Medicell 
International Ltd, London, UK) then concentrated to 0.5 ml 
The dialysate was concentrated to :S 5 ml using a 15 ml Amicon Ultra Centrifugal filter 
device lOK MWCO (Millipore, Watford, UK). The concentrated material was 0.2~-tM 
filtered using 32 mm Acrodisc® PES syringe filter (Pall, Portsmouth, UK) and stored at 
4 oc until further purification. 
2.7.2. lEX 
Further purification of the mutant aB-crystallin was performed using the lEX 
column detailed in Section 2.6.2. and underwent the following CIP protocol and 
equilibration. 
• 2 h sanitisation with 0.5M NaOH. 
• 3 CV ofmilliQ water 
• 2 CV of lOmM Tris HCl, lmM EDTA, 6M urea, pH 8.0, IM NaCl, lmM 
DTT, 0.2M PMSF, (Buffer B). 
• 3 CV of IOmM Tris HCl, lmM EDTA, 6M urea, pH 8.0, lmM DTT, 0.2M 
PMSF, (Buffer A) or until o0280 reaches a stable baseline. 
All HPLC buffers were degassed and vacuum filtered to 0.2~-tm using a Whatman 
cellulose nitrate membrane disc filter (Whatman, Maidstone, UK). The mutant aB-
crystallin was applied at I ml/min to the column in 1 0 ml of Buffer A and was eluted with 
a 50 ml linear gradient of 0-0.5M NaCl (Buffer B). Residual bound protein was eluted 
over 3 CV linear gradient of 0.5-lM NaCl, (Buffer B). Elut~fl mat~J.:Htl w~~J:oll~~~e_d_as~ _ 
----------------~~rir~cti;~s~-illcr~s~y~d -by SDS-I,-AGE ~~~-g -~;:;~(;;~)-a~ryl~mide gels and those 
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fractions, which were wild type aB-crystallin enriched were pooled. The column was 
sanitised by a 2 h contact time with 0.5M NaOH followed by 3 CV ofmilliQ water. The 
column was stored in 2CV of 20mM Tris HCl, 1M NaCI, 0.02% (v/v) sodium azide, pH 
7.4. 
2.7.3. REFOLDING OF THE MUTANTaB-CRYSTALLIN 
Aggregation prone mutant aB-crystallins (450delA, 464delCT and Q151X) 
required the presence of wild type aB-crystallin in order achieve a soluble refold product 
(see Section 2. 7.3 .1. ). Further refolding was dependant upon the solubility characteristics 
of each specific mutant, where the 450delA/- and Q151X/ wild type aB-crystallin 
mixtures required a diluted refold for aggregation prone mutants (see Section 2.7.3.2) and 
the 464delCT/ wild type aB-crystallin required an undiluted refold for non aggregating 
mutants (see Section 2.7.3.3). 
2.7.3.1. Association with wild type aD-crystallin 
Mutants requiring association with the wild type aB-crystallin ( 450delA, 
464delCT and Q151X aB-crystallin) are combined with the wild type aB-crystallin prior 
to refolding. Firstly, the wild type aB-crystallin was dialysed into the mutant aB-
crystallin denaturing buffer conditions (lOmM Tris, 6M urea, pH 8.0, 1mM DTT) for 16 h 
at 4 °C. Protein concentrations of the denatured wild type and mutant aB-crystallin were 
determined by optical density (OD) OD280. Extinction Coefficients were determined using 
the Emboss Pepstats programme (www.ebi.ac.uk/emboss/pepinfo/) and then the wild type 
and mutant aB-crystallin were mixed in a 1: 1 molar ratio. The Extinction Coefficients for 
each mutant aB-crystallin are detailed in Table 2.12 and are derived from the quotient of 
the molar extinction coefficient for aB-crystallin of 13940 over the Mwt of the specific 
mutant. 
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Table 2.12. Extinction Coefficients of a.B-crystallin mutants used for concentration 
determinations. 
wild type 0.69 
450delA 0.66 
464delCT 0.74 
Ql51X 0.8 
E164X 0.74 
El65X 0.73 
Kl74X 0.70 
Al71X 0.71 
450delA/ wild type 0.675 
464delCT/ wild type 0.715 
Q151X/ wild type 0.745 
2. 7.3.2. Diluted refolding protocol for aggregation prone mutants 
The diluted protocol was required for the refolding of 450delA/ wild type, Q151X/ 
wild type, Ql51X and El64X aS-crystallin. 
The protein was diluted to 0.25mg/ml (by OD280 using extinction coefficient 
specific to the mutant aS-crystallin (see Table 2.12)) with lOmM Tris, 6M-urea, pH 8.0 
1 mM EDT A, 1 mM DTT and mixed gently at ambient temperature for 2 min. The 
addition of 1M-cystamine dihydrochloride to a final concentration of lmM was followed 
by a 10 min mixing at ambient temperature. The urea concentration in the pooled material 
was diluted by an additional6 fold dilution to 1M urea in refold buffer (lOmM Tris-HCl, 
5mM EDT A, I mM EGTA, 150mM NaCl pH 7 .5) and mixed gently at ambient 
temperature for 10 min. The mutant a.B-crystallin was dialysed, for 4 h at l6°C against 
the refold buffer, using 12-14K MWCO dialysis tubing (Medicell lntemational, Ltd, 
London, UK). The dialysate was partially concentrated using a 15rnl Amicon Ultra 
Centrifugal filter device IOK MWCO (Millipore, Watford, UK) in a Jouan CR422 
centrifuge at l6°C at 4000 rpm then centrifuged for 2 h at 4°C at 250000 (g) in the 
Beckman Optima MAX Ultracentrifuge, MLA-80 rotor (Beckman Instruments Inc, 
Fullerton, CA, USA). The supernatant was further concentrated at 4°C tQ .'! suital:>l~---
-voliune~ The concentrated~ateri;i;~ss~~;~d-~ -S0°C.~-.-'h'-' -~---._, __ ----···-----~--· 
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2.7.3.3. Undiluted refolding protocol for non aggregating mutants 
The undiluted protocol was required for the refolding of 464delCT/ wild type and 
E 165X aB-crystallin. 
The protein mixture was dialysed into refold buffer for 4 h at l6°C and the 
resulting dialysate was centrifuged 2 h at 4 oc at 2500000 (g) Beckman Optima MAX 
Ultracentrifuge, MLA-80 rotor and the supernatant concentrated using the Amicon Ultra 
Centrifugal filter device 1 OK MWCO (Mi11ipore, Watford, UK) to a suitable volume in a 
Jouan CR422 centrifuge at 4°C. 
Chapter 2-Materia/s and Methods 56 
2.8. CHARACTERISATION OF aD-CRYSTALLIN MUTANTS 
2.8.1. IN VITRO PROTEIN CHAPERONE ASSAYS 
2.8.1.1. Citrate Synthase chaperone activity assays 
A 200 J..tl aliquot of citrate synthase from porcine heart was dialysed for 16 h 
against 50mM Tris HCI, 2mM EDTA, pH 8.0 at 4°C, using 12-14 K MWCO dialysis 
tubing (Medicell International, Ltd, London, UK). Following dialysis the protein 
concentration was determined by Bicinchoninic acid (BCA) assay, (Pierce, UK), and the 
citrate synthase was diluted to achieve a stock concentration of 0.49 mg/ml. The assay 
mixture contained citrate synthase at a concentration of 0.196 mg/ml (88 J..Ll of a 0.49 
mglml stock solution) and chaperone to produce varying citrate synthase: chaperone ratios 
in a final test volumes of 220 j..tl. The time dependant light scattering was measured at 360 
nm every 15 sec over a 30 min period using Beckman Tm cuvette (14mm high) for kinetic 
assays and a Beckman DU640 spectrophotometer (Beckman instruments Inc, CA, USA). 
2.8.1.2. Insulin assay chaperone activity assays 
A 20 mg aliquot of insulin from bovine pancreas was reconstituted in 5 ml of 
1 OOmM sodium sulphate (NaS04), 20mM sodium phosphate (NaP04) pH6.9 (Insulin 
buffer) and solubilised by the addition of 1 ml of acetic acid 30% (v/v) and gentle mixing 
for 15 min. The insulin solution was dialysed for 16 h against the Insulin buffer at 4 °C, 
using 12-14K MWCO dialysis tubing (Medicell International, Ltd, London, UK). The 
dialysate was centrifuged for 1 min at 13000 rpm in an Eppendorf bench top centrifuge 
(5417R; Eppendorf, Hamburg, Germany). The insulin concentration was determined from 
the measured OD2so using its extinction coefficient, ((A280/5840) x 5600 = mg/ml). The 
assay mixture contained, 20mM DTT, insulin at a concentration of 0.35mg/ml and 
chaperone to produce varying insulin: chaperone ratios in a final test volumes of 220J..LL 
The time dependant light scattering was measured using a Beckman Tm cuvette (14mm 
high) at 360 nm every 15 sec over a 15 n1in_l'~zi.()d at 37°C !!sJnga Beckman_D_U6AO _ 
-, -- --- --"-----=----~-=-------· --- -- ----
spectrophotometer for (Beckman instruments Inc, CA, USA). 
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2.8.2. ANALYTICAL SEC 
Purified and refolded aD-crystallin proteins were analysed using a Superose 6 
column (290 x 1 Omm) with a maximum pressure limit of I 0 bar at a flow rate of 
0.2ml/min at room temperature using a Merck-Hitachi Biochromatography system (Merck 
Hitachi Ltd, Tokyo, Japan). The data was analysed using Chromeleon 6.30 software, 
(Sunnyvale, CA, USA). All HPLC buffers were degassed and vacuum filtered to 0.2~-tM 
using a Whatman Cellulose nitrate membrane disc filter (Whatman, Maidstone, UK). 
2.8.2.1. Column preparation 
The Superose 6 SEC column was sanitised at 0.2 ml/min using a 2 hr contact time 
with O.SM NaOH. During periods of increased back pressure the flow rate was reduced 
accordingly. A 2 CV wash with purified water was followed by 2 CV of lOmM Tris, 
lmM EGTA, SmM EDTA, IM NaCl, pH 7.5 (Buffer B). The column was equilibrated 
overnight at 0.2 mJ!min in lOmM Tris, lmM EGTA, SmM EDTA, 150mM NaCI, pH 7.5 
(Buffer A). 
2.8.2.2. Mwt calibration of Superose 6 column 
Mwt determination used a High MW calibration kit (Amersham Biosciences, UK). 
The components of this kit included a MW range from 2000 kDa (Blue Dextran 2000) to 
150 kDa (Aldolase) with intermediate calibrators 440 kDa (Ferritin) and 232 kDa 
(Catalase). Additional low MW calibrators were included for a full range of calibration 
and included 66 kDa bovine serum albumin (BSA), 29 kDa Carbonic Anhydrase from 
Bovine erythrocytes (Sigma Aldrich, UK), and 12.4 kDa Cytochrome C from equine heart 
(Sigma Aldrich, UK). All high Mwt calibrators were reconstituted in Buffer A to a stock 
solution concentration of lO mg/ml. To determine the void volume (V0 ) of the column, 
Blue Dextran was loaded onto the column 1% of the geometrical column volume of23 ml, 
(250 ~-tl of a 1 mg/ml solution). The high Mwt calibrators were analysed as mixtures 
recommended by the manufacturer to allow resolution of individual peaks. The mixtures 
and individual calibrators are detailed in Table 2.12. A 250 ~-tl blank injection (Buffer A) 
-·-·-· ---~-· was performedirebetween-each~calioratorrun:- --- -- · 
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T bl 2 13 D '1 f h C l'b a e etm so t e a 1 ratwn o f h s t e uperose 6SEC coumn 
Mwt Concentration Load volume 
Run Calibrator 
(kDa) (mg/ml) (fA, I) 
1 Aldolase 158 5 
100 
Ferritin 440 1 
2 Catalase 232 5 
100 
Thyroglobulin 669 5 
3 BSA 66 5 100 
4 Carbonic anhydrase 29 5 100 
5 Cytochrome C 12.4 5 100 
The data was analysed using Chromeleon 6.30 software, (Sunnyvale, CA, USA) 
and a calibration curve of Kav versus log molecular weight was prepared using the 
following equation: 
K av = 
Where V e = elution volume as retention time, V 0 == column void volume, V c = 
geometric column volume. 
Two calibration curves were prepared, one for the high Mwt calibrators and one 
for low Mwt calibrators due to the large separation range covered. 
2.8.2.3. SEC of wild type and mutant aD-crystallin 
Wild type aB-crystallin was dialysed into Buffer A for 16 hat 4°C using 12-14 
kDa dialysis tubing (Medicell International Ltd~ London, UK). The protein concentrations 
of the wild type and mutant aB-crystallin were determined using BCA protein assay kit 
(Pierce, UK) and the samples diluted accordingly in Buffer A to 0.2 mg/ml. The samples 
were injected in a 250 f.tl volume to provide 0.2 % of the geometric column volume. The 
corresponding K av for the aB-crystallin wild type and mutants were calculated and their 
molecular weight determined from the appropriate calibration curve prepared in Section 
2.8.2.2. 
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2.8.2.4. Large scale (6L) analytical SEC 
The chromatography conditions were as those detailed in section 2.6.4. The buffer 
used was 200mM ammonium Acetate and fractions were collected in 8 ml volumes using 
a Biorad Model 2110 fraction collector (Biorad Laboratories~ UK). 
2.8.3. MASS SPECTROMETRY FOR MOLECULAR WEIGHT 
DETERMINATION 
The aS-crystallin mutants used for molecular weight determination was provided 
either refolded (wild type, K174X and A171X) or unfolded in lOmM Tris, lmM EDTA, 
6M urea, pH 8.0. Unfolded mutants were provided in this fmm due to their instability in 
aqueous buffer. The protein was loaded onto a MassPREP desalting cartridge (Waters, 
Elstree, Herts, UK) to remove buffer contaminants. The protein was eluted with 70% 
(v/v) acetonitrile, 0.5% (v/v) formic acid at 0.2 ml/min and introduced into a Waters Q-
TOF Premier mass spectrometer operating in positive electrospray mode, with a cone 
voltage of 40V. Spectra were externally calibrated using sodium formate then corrected 
for drift using a leucine enkephalin lockspray. Multiply-charged protein ions were 
deconvoluted using the manufacturer-supplied, MaxEntl software, to determine protein 
mass. 
2.8.4. CIRCULAR DICHROISM SPECTROSCOPY 
Wild type aS-crystallin was dialysed into 1 OmM Tris, 1 mM EGT A, 5mM EDTA, 
150mM NaCl, pH 7.5 (CD buffer) for 16 h at 4°C using 12-14 kDa dialysis tubing 
(Medicell International Ltd, London, UK). Mutant aB-crystallins were thawed from 
storage at - 80°C and kept on ice prior to analysis. The Wild type and mutant aB-
crystallins were centrifuged at 18000 x g for 1 min in a Bench Top centrifuge ( 541 7R; 
Eppendort: Hamburg, Germany) at room temperature. The protein concentrations of the 
wild type and mutant a.B-crystallin were determined using BCA protein assay kit (Pierce, 
UK) and the samples diluted accordingly using circular dichroistp (<;:D) ~uff~l'_tQ Q.2_- D.3_ 
- - -----
~- ------- rng'lmr1n'l.medfately-prior to accumulation of spectra. Far ultra violet (UV) and near UV 
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circular dichroism spectra of wild type and mutant aB-crystallin were recorded in a 
cuvette with O.lcm path length at room temperature using a Jasco J-810 
spectropolarimeter. The optimised assay parameters are detailed in Table 2.13. 
Data pitch 0.5 run 
Response 4 sec 
Band width 2 
Sensitivity lOOmdeg 
Speed 100 run/min 
Accumulations 4 
Scruming mode Continuous 
Wavelength 350-195 nm 
The UVCD spectra were baseline corrected using spectra for CD buffer. The CD 
spectra were normalised and expressed as molar ellipticity using the following equation: 
Molar 
Ellipticity 
(8) 
0.1 X 8 obs 
cxl 
Where c =concentration (M), l =path length (em) and 8 obs =CD mdeg 
The near UVCD is represented by data collected between wavelengths 195 - 250 
nm and far UVCD by data collected between wavelengths 250-350 nm. 
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2.8.5. THERMAL STABILITY ASSAY 
Wild type aS-crystallin was dialysed into 1 OmM Tris, 1 mM EGT A, 5mM EDT A, 
150mM NaCl, pH 7.5 (assay buffer) for 16 h at 4°C using 12-14 kDa dialysis tubing 
(Medicell International Ltd, London, UK). Mutant aB-crystallins were thawed from 
storage at -80°C and kept on ice prior to analysis. The Wild type and mutant aB-
crystallins were centrifuged at 18000 (g) for 1 min in a Bench Top centrifuge ( 5417R; 
Eppendorf, Hamburg, Germany) at room temperature. The protein concentrations of the 
wild type and mutant aS-crystallin were determined using BCA protein assay kit (Pierce, 
UK) and the samples diluted accordingly using assay Buffer to 0.1 mg/ml immediately 
prior to the assay. A 200 ~~volume of each sample was dispensed into a Beckman Tm 
cuvette for kinetic assays and the thermal stability monitored by observing changes in 
absorption at 360nm over a temperature gradient of 25-86°C at 1 °C/min ramp rate using 
the Beckman DU640 spectrophotometer. Data were corrected for the assay buffer. 
2.8.6. IN VITRO DES MIN FILAMENT ASSEMBLY AND 
CO-SEDIMENTATION ASSAY 
In vitro assembly and cosedimentation assay were carried out using the technique 
developed by Dr Ming Der Perng (Durham, UK) (Pemg et al., 1999; Pemg et al., 2004). 
2.8.6.1. Preparation of samples 
Purified recombinant wild type desmin (a kind gift from Dr Ming Der Pemg 
(Durham, UK) in 20mM Tris-HCI, pH 8.0, lmMEDTA, lmM EGTA, lmM DTT, 0.2mM 
PMSF (Buffer A) was dialysed by step wise lowering of the urea concentration firstly to 
IOmM Tris-HCI, 3M urea, pH 8.0 (Buffer B) over 4 h at 4°C. Finally the desmin is 
dialysed into lOmM Tris-HCl, pH 8.0 (Buffer C) over 16 hat 4°C in parallel with wild 
type and mutant aB-crystallins in separate vessels using 12-14 kDa MWCO dialysis 
tubing (Medicell International Ltd, London, UK). Post dialysis, the desmin and Wild type 
and mutant aB-crystallins were .centrifuged~~tJBJ)OOce,.(g), for J min in-a-'Bcnch--"Top 
-~·~----~~:~ ;:_-~~-=---'=~~---~--". ---=..:...______:_·_...::,..:--·· ~----==' ~--------
centrifuge ( 541 7R; Eppendorf, Hamburg, Germany) at room temperature. The protein 
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concentrations were determined using BCA protein assay kit (Pierce, UK) and the samples 
diluted accordingly using Buffer C. 
2.8.6.2. Desmin Filament assembly 
Wild type or mutant aS-crystallin was mixed with desmin at pH 8.0 in Buffer C 
at a 1:1 mass ratio at 0.2 mg/ml into thick walled 2 ml centrifuge tubes for the TLS-55 
rotor of the Beckman Optima MAX Ultracentrifuge, (Beckman Instruments Inc., 
Fullerton, CA, USA). Due to the limitations of the low refold yield, assays involving 
Q 151 X aS-crystallin were performed at concentrations of 0.1 mg/ml. The assembly of 
desmin filament was initiated by the addition of a 20X concentrated assembly buffer at pH 
6.8 to give a final concentration of 1 OOmM Imidazole-HCL A typical sample consisted of 
95 !Jl (desmin: aS-crystallin) plus 5 !Jl assembly buffer. The appropriate control of95 !Jl 
of aS-crystallin plus 5 f.ll assembly buffer was also prepared. The samples were mixed by 
gentle tapping avoiding liquid being displaced onto the wall of the centrifuge tube. The 
tubes were sealed with parafilm to avoid evaporation during the 1 h incubation at the 
required temperature of20, 37 or 44°C. 
2.8.6.3. Sedimentation Assays 
After filament assembly an equal volume (100 !Jl) of 0.85 M sucrose in assembly 
buffer was layered onto the protein samples. On addition of the sucrose cushion, care was 
taken to ensure the pipette tip was not immersed into the sample mixture to avoid contact 
with desmin filaments. Each sample was centrifuged at 80000 (g) for 30 min at 20°C in a 
Beckman Optima MAX Ultracentrifuge, TLS-55 rotor, (Beckman Instruments Inc., 
Fullerton, CA, USA) to pellet assembled desmin filament and associated aS-crystallin. 
To investigate the effect of aS-crystallin mutations upon aggregate formation in vitro, 
duplicate samples were prepared and subjected to a low-speed centrifugation at 2500 x g 
for 15 min in a Bench Top centrifuge ( 5417R; Eppendorf, Hamburg, Germany). The 
pellet and supernatant fraction volumes were solubilised in equal volumes of SDS-PAGE 
sample buffer (see Section 2.1 0). Pellet fractions were thoroughly resuspenqed _ill_ 25J) Jtl _2 
----- ----Ix SDS~PAGE sample-buffer ~d ;~p~~~tartt fr~ctio~~ dilu;~d-~th -5-0 ~;-;~-S~S-PAGE 
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sample buffer. Great care was taken to ensure all material was solubilised in the SDS-
PAGE sample buffer in order to achieve an accurate account of the distribution of protein 
between the pellet and the supernatant fraction. The samples were separated on 12% 
(w/v) SDS-PAGE and protein bands visualized by Coomassie Blue staining (see Section 
2.1 0). The amount of protein in the supernatant and pellet fractions were analyzed by a 
luminescent image analyser (LAS-I OOOplus; Fuji Film, Tokyo, Japan) and quantified 
using the Image Gauge software (version 4.0; Fuji Film). 
2.8.7. CROSS-LINKING OF aD-CRYSTALLIN 
The optimised cross-linking of aS-crystallin was performed using 
gluteraldehyde at a final concentration of 0.0 I%. For best results, a 0.1% gluteraldehyde 
solution was added to the aS-crystallin solution to give a fmal concentration of 0.01% 
gluteraldehyde and a sample volume of l35f.Ll. The mixture was incubated at room 
temperature for 1 h after which, 15J,tl stop solution (0.5M glycine) was added. The 
samples were concentrated by methanol chloroform precipitation (see Section 2.9.1.1 ), 
resuspended in 25J,tl SDS-PAGE sample buffer and analysed by SDS-PAGE (see Section 
2.10). 
2.8.8. DYNAMIC LIGHT SCATTERING 
Dynamic light scattering (DLS) experiments were performed at 20°C using a 
Zetosizer Nano ZS (Malvern Instruments, Worcs. UK). The aS-crystallin samples (0.2 
mg/ml) were 0.2f.LM filtered using a 32mm Acrodisc® PES syringe filter (Pall, 
Portsmouth, UK) and sealed with parafilm, into a lml disposable cuvette, (Fisher 
scientific, UK) blown out with nitrogen. Data collection utilised three data sets, each 
containing 5 accumulations, averaged using the Zetosizer Nano ZS software. 
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2.8.9. BIS-ANS FLUORESCENCE MEASUREMENTS 
aB-crystallin variant proteins were incubated in lOmM Tris, 150mM NaCI, 5mM 
EDTA, lmM EGTA, pH 7.5 at a protein concentration of lt.tM and in the presence of a 
10-fold molar excess of bis-ANS ( 4,4'-dianilino-1, 1'-binaphthyl-5,5'-disulfonic acid, 
purchased from Invitrogen, Paisley, UK). Samples were allowed to equilibrate for I hour 
at room temperature prior to the acquisition of fluorescence spectra on a Varian Cary 
Eclipse fluorescence spectrophotometer. The excitation wavelength was 410 nm and 
emission was collected between 420 - 700 nm with excitation and emission slit-widths of 
5 nm and a scan speed of 600 nm/min. All spectra are the average of I 0 individual scans. 
2.9. CELL CULTURES AND TRANSIENT TRANSFECTION 
ASSAYS 
MCF7 cells, which contain no endogenous aB-crystallin thus avoiding the need to 
tag the protein for subsequent detection, were obtained from the European animal Cell 
Culture Collection (EACC, Portan Down, UK) and grown in Dulbeccos's minimum 
eagle's medium (DMEM) (Sigma-Aldrich, Poole, UK)), supplemented with 10% (v/v) 
fetal calf serum (FCS) (Sigma-Aldrich, Poole, UK) 2 mM L-glutamine, and antibiotics 
(100 U of penicillin and 0.1 mg of streptomycin). All cells were maintained at 37°C in a 
humidified incubator of 95% (v/v) air and 5% (v/v) C02. For transfection experiments, 
plasmid DNA containing wild type and mutant aB-crystallin in pcDNA3.1 (Invitrogen) 
(see 2.2.5) was prepared using MidiPrep kits (QIAGEN, Dorking, Surrey, United 
Kingdom). Cells were grown in 75 cm2 flasks and seeded on 13-mm coverslips and 1 Ocm 
petri dishes. The cells at a density of 50-60% confluence were transiently transfected 
with wild type or mutant aB-crystallin by GeneJuice transfection reagent (Novagen) 
according to manufacturer's protocol. Cells were incubated for 24 h before processing for 
cell fractionation (see Section 2.9.1), immunofluorescence microscopy (see Section 2.9.2), 
and immunoblotting (see Section 2.11) 
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2.9.1. PROTEIN EXTRACTION AND CELL FRACTIONATION 
Cells grown on I Ocm dishes were washed twice with phosphate buffered saline 
(PBS) (Sigma-Aldrich, Poole, UK) before being trypsinised for 5 min in 1 ml trypsin-
ethylene diamine tetra acetate (EDT A) (Sigma-Aldrich, Poole, UK) and resuspended in 
10ml DMEM for cell counting. Cultures were divided into aliquots containing 1x106 cells 
prior to protein extraction. The cells were washed twice with PBS before being lysed with 
0.5ml of extraction buffer (PBS, 0.5% (v/v) Triton-X (Sigma-Aldrich, Poole, UK)) by ten 
times passage through a 25-guage needle. Following incubation on ice for 15 min, the 
lysates were clarified by centrifugation 18000 x g for 10 min at 4 oc in a precooled Bench 
Top centrifuge (5417R; Eppendorf, Hamburg, Germany). The resulting supernatant and 
pellet fractions were further processed using separate techniques. This allowed the 
fraction volumes to be equalised before SDS-PAGE (see Section 2.11) and 
immunoblotting analysis (see Section 2.11 ). 
2.9.1.1. Supernatant treatment 
The supernatant fraction was concentrated by chloroform methanol precipitation 
(Wessel and Flugge, 1984), which involved the addition of 4 parts methanol: 1 part 
chloroform: 3 parts purified water, and sedimented by bench top centrifugation at room 
temperature for 2 min at 12500 rpm. The top layer of liquid was removed and a further 3 
parts methanol added. The mixture was well mixed and centrifugation repeated. The 
pelleted soluble protein fraction was resuspended with 1x SDS-PAGE sample buffer in 
50mM Tris-HCI, pH 6.8, 1% (w/v) SDS, lmM EDTA to a 100 !!l volume. 
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2.9.1.2. Pellet treatment 
The pellet fraction was washed twice by resuspension in 1 ml PBS followed by 
centrifugation at room temperature for 1 min at 12500 rpm and disposal of the 
supernatant. The pellet was resuspended in a 200 f.Al volume of 20mM Tris-HCI, pH 8.0, 
1 OmM MgCh containing SOU Benzonase® nuclease, and incubated at room temperature 
whilst mixing gently for 30 min. The pellet was recovered by centrifugation at 4 °C for 5 
min at 12500 rpm and resuspended in 100 f.Allx SDS-PAGE sample buffer. 
2.9.1.3. Primary and secondary antibodies 
Primary antibodies included purified mouse monoclonal anti-aD-crystallin 
2D2B6, (Inoue, 1994; Sawada et al., I 993) (see Section 2.12.1 ), poly clonal anti-aD-
crystallin antibody (Sandilands, 1995; van den IJssel et al., 2003) (see Section 2.12.2) and 
monoclonal anti-HSP27 antibody, ER-D5, (King et al., 1987) diluted 1:1000. Secondary 
antibodies were horseradish Peroxidase (HRP) conjugated Goat anti-mouse 
Immunoglobulins (DakoCytomation) diluted 1:1000. 
2.9.2. IMMUNOFLUORESCENCE MICROSCOPY 
For immunofluorescence studies, cells grown on I 3mm coverslips were washed 
twice with PBS and fixed with ice-cold methanol/acetone [1: 1 (v/v)] for 20 min at room 
temperature, and washed three times with PBS containing 0.02% (w/v) BSA. Cells were 
then preblocked with 10% (v/v) goat serum in PBS/BSA for 30 min, washed three times in 
PBS/BSA, and then incubated with primary antibodies at room temperature for 1 h. The 
primary antibodies used in this study were, rabbit polyclonal anti-aD-crystallin (1 :200; 
Chernicon Ab1546) (Sandilands, 1995; van den IJssel et al., 2003) and monoclonal mouse 
anti-keratin LE41, (1: 1; CRUK). After washing three times with PBS/BSA, the primary 
antibodies were detected using Alexa 488 or Alexa 594 (1 :500; Molecular Probes) HRP 
conjugated secondary antibodies. All antibodies were diluted in PBS/BSA buffer. 
Nuclear detection was achieved using 4 '-6-diamidino-2-phenylindole DAPI (1 :2000; 
Sigma). The glass coverslips were mounted on slides with the fluorescent protecting 
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agent Citifluor, (Citifluor Labs, London, United Kingdom) and observed with an Axioplan 
fluorescence microscope (Carl Zeiss, Jena, Germany) by using a 63X Plan-Apochromat 
1.4 numerical aperture objective. Images were obtained through a cooled charge-coupled 
device camera (Digital Pixel, Brighton, United Kingdom) running IP Lab software. 
Alternatively, images were collected using a 63X oil immersion lens of the confocal 
Axiovert 200M microscope and LSM 510 META software (both Zeiss, Germany). Optical 
sections were set to ~1.0 ~m. Images were processed and prepared for figures using 
Adobe Photoshop 8.0 (Adobe Systems). Quantitation of the aS-crystallin phenotypes was 
by visual assessment of the cells. 
2.10. ONE-DIMENSIONAL SDS-PAGE ANALYSIS 
One-dimensional SDS-PAGE analysis was performed essentially according to 
Laemmli (Laemmli, 1970), under reducing conditions. Slab gels of 12% (w/v) were used 
as a resolving gel and the concentrating gel was 3% (w/v). A pre-mixed acrylamide 
solution containing bis-acrylamide (33% (Biorad Laboratories, UK)) was used as a stock 
solution for One-dimensional SDS-PAGE analysis. A layer of water-saturated butanol 
was applied to ensure the concentrating gel interface was flat. The gels were calibrated 
using a PageRuler™ Prestained protein ladders (Fermentas, UK) containing a mixture of 
proteins with molecular weights of 11, 17, 24, 33, 40, 55, 72, 100, 130 and 170 kDa. 
Samples for analysis were diluted in Laemelli's sample buffer, (50mM Tris-HCI 
pH 6.8, 1 OOmM DTT, 2% (w/v) SDS, 0.1% (wN) Bromophenol Blue, 10% (v/v) 
glycerol) (Laemmli, 1970) to the target concentration required for specific gel loading. 
Samples not containing urea were boiled for 5 min and allowed to cool before 
centrifugation for 3 sec at 12500 rpm in a microcentrifuge to concentrate the sample at the 
bottom ofthe tube. Gels were run at 200V constant voltage in running buffer (25mM Tris 
HCl, 200mM glycine, 0.1% SDS) (Kyhse-Andersen, 1984) 
After electrophoresis, gels were fixed in 50% (v/v) methanol and 10% acetic acid 
then stained with 0.5% (w/v) Coomassie® brilliant blue R-250 (Merck-BDH, UK), 
solubilised in 50% (v/v) methanol and 10% (v/v) acetic acid for 15 min, and destained 
with several changes of 10% (v/v) methanol and 5% acetic acid. The gels were kept in 
7% acetic acid. 
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2.11. IMMUNOBLOTTING 
Immunoblotting was performed usmg the semidry blotting method (Kyhse-
Andersen, 1984) according to the manufacturer's specifications (Bio-Rad Laboratories, 
UK). Following one-dimensional SDS-PAGE, proteins were transferred onto NitroBind 
0.45r.tM nitrocellulose membrane, (VWR, UK). After blotting, protein transfer was 
assessed by Ponceau S (Sigma Aldrich, UK) staining of the nitrocellulose membrane 
followed by destaining in Tris-buffered saline (TBS) (20 mM Tris-HCI, pH 7.4, 150 mM 
NaCl). After incubation with blocking solution consisting of 5% (w/v) dried milk powder 
(Marvel, Tesco Ltd., UK) in TBS containing 0.2% (v/v) Tween 20 (TBST) for 1 hat room 
temperature with agitation, (or overnight, static at 4 °C) the membranes were probed with a 
panel of primary antibodies in antibody buffer (1 part block solution: 2 parts TBS) for 2 h 
at room temperature with agitation. The nitrocellulose membrane was washed 3 times 
with TBST and once with TBS over a 30 min period then incubated with the appropriate 
horseradish peroxidase-conjugated secondary antibodies (DakoCytomation) diluted 
1 : 1000 in antibody buffer for 1 h at room temperature with agitation. Antibody labelling 
was detected by enhanced chemilluminescence (Walker et al., 1995) using a luminescent 
image analyser (LAS-lOOOplus; Fuji Photo Film (UK), London, United Kingdom). 
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2.12. ANTIBODY PURIFICATION 
2.12.1. MONOCLONAL aB~CRYSTALLIN ANTIBODY FROM CELL 
CULTURE SUPERNATANT 
Hybridoma cells expressing aB~rystallin mouse monoclonal antibody (MAb) 
2D2B6 clone generated to chicken aB-crystallin (Inoue, 1994) were cultured in DMEM 
with 10% FCS and 1% GPS until 50% cell death. The cell supernatant was centrifuged at 
4°C for lOmin at 3000r.p.m using a Sorvall RT 6000D centrifuge with HIOOOB rotor, 
followed by a 0.45f!M filtration using a 32mm Acrodisc® PES syringe filter (Pall, 
Portsmouth, UK) The supernatant was left to achieve ambient temperature. 
Purification of the aB-crystallin MAb was performed with a 5ml PROSEP® G 
(Millipore, Watford, UK) Affinity chromatography column (10 x IOOmm Omnifit) on a 
Pharmacia fast performance liquid chromatography (FPLC) system comprising a 
Pharmacia high precision pump (P-500), a Pharmacia Fraction collector (Frac-100), UV-1 
UV detector and a Labdata chart recorder (Amersham Biosciences, NJ, USA). AH FPLC 
buffers were vacuum filtered to 0.2f!M using PROPOR PES (proportional 
polyethersulphone) membrane discs (Domnick Hunter, UK). The column was 
equilibrated in 10 CV PBS to remove the storage buffer PBS 0.05% sodium azide (w/v). 
The aB-crystallin MAb was loaded via the sample load pump at 3mllmin and chased 
through with PBS. The column flow through was retained in order to reapply any 
unbound aB-crystallin MAb onto the PROSEP® G column. 
The aB-crystallin MAb was eluted using the following gradient: 
• 
• 
• 
• 
5 CV 1 OOmM Citrate pH 7.0 at 5ml/min 
10 CV 0-100% IOOmM Citrate pH 3.0 at 3ml/min 
10 CV lOOmM Citrate pH 3.0 
3 CV IOOmM Citrate pH 7.0 
Fractions were collected in 3ml volumes, neutralised by adding 0.8ml 0.5M di-
sodium hydrogen phosphate (Na2HP04), and pooled corresponding to the major peak 
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(eluted after approx 84% lOOmM Citrate pH 3.0). The column was regenerated using 
1 OCV PBS, 5-l 0 CV 30mM HCI and 5-l 0 CV PBS via the load pump at 3 ml/min. The 
purification was repeated using the unbound flow through as load material and fractions 
pooled as stated previously. The column was stored following sanitisation as detailed 
below and stored at 4 °C. 
• In upflow via the load pump at 3 ml/min 
• 5 CV PBS 
• 8 CV 6M Guanidine HCl 
• 20 CV PBS 0.05% (w/v) sodium azide 
An appropriate dilution of aS-crystallin MAb in PBS was performed and the 
absorbance read at 280nm. The extinction coefficient of 1.4mg/ml/cm was used to 
determine the amount of purified aS-crystallin MAb recovered from the purification. The 
aS-crystallin MAb pool was concentrated to 1 mg/ml using a 1 OOkDa MWCO Vivaspin 
centrifugal concentrator (Vivascience, Epsom, UK), rinsed in PBS prior to application of 
aS-crystallin MAb using a Sorvall RT 6000D centrifuge with HlOOOB rotor, and dialysed 
against 50 diavolumes of PBS for at least 6 hours or overnight at 4°C. The dialysis was 
repeated with fresh PBS. 
The aS-crystallin MAb final yield was calculated using the extinction coefficient 
following a 0.2 J.!M filtration using a 32mm Acrodisc® PES syringe filter (Pall, 
Portsmouth, UK) into a pre-weighed bottle and diluted to lmg/ml in PBS prior to storage 
at -20°C in 1 ml aliquots. 
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2.12.2. POLYCLONAL aD-CRYSTALLIN ANTIBODY FROM RABBIT SERUM 
The aS-crystallin poly clonal antibody (P Ab) was a rabbit polyclonal antibody 
3148 generated to the decapeptide KP A VT AAPKK and coupled to keyhole limpet 
haemocyanin, by gluteraldehyde prior to immunisation (Sandilands, 1995; van den IJssel 
et al., 2003). 
The ammomum sulphate technique for rabbit serum immunoglobulins (IgG) 
followed by rabbit antiserum purification was performed to isolate the aS-crystallin P A b. 
The aS-crystallin PAb serum was diluted 1:1 in PBS (IOmM potassium phosphate 0.9% 
NaCl (w/v) pH 7.0- 7.6) by gradual addition of PBS. The solution was mixed gently to 
avoid foaming and centrifuged if precipitate was present using Sorvall® RT 6000D 
centrifuge with HlOOOB rotor. For each lml of diluted serum, 0.67ml of saturated 
ammonium sulphate (70g of ammonium sulphate to lml of 1M NaOH in 75ml of 
deionised water) was added in four portions, vortexing gently after each addition. The 
mixture was incubated at 4°C for 30min and centrifuged at 4°C for 30min at 3000r.p.m 
using a Sorvall® RT 6000D centrifuge with HIOOOB rotor, (Sorva1l®, USA). The 
supernatant was carefully decanted to waste. 
The pellet was washed by resuspension with 40% saturated ammonium sulphate (lml PBS 
to 0.67ml of saturated ammonium sulphate) to the same total volume achieved by addition 
of saturated ammonium sulphate. The centrifugation was repeated and the pellet was 
resuspended in two portions of deionised water to the original aS-crystallin P Ab serum. 
'The ammonium sulphate was removed from the aS-crystallin P Ab resuspension 
using a PD-1 0 Desalting column (Sephadex G-25 Medium, GE Healthcare, UK). An 
8.3ml PD-10 desalting column was equilibrated with 5-IOCV of PBS and aS-crystallin 
PAb was absorbed into the media following application to the top of the column. PBS 
was flowed by gravity through the column for 2.3ml (void volume) and the following 2ml 
containing the aS-crystallin P Ab was collected in a separate tube. The aS-crystallin P Ab 
yield was determined by extinction coefficient (see Section 2.12.1) and the aS-crystallin 
PAb was diluted to lmg/ml in PBS for storage at -20°C in lml aliquots. 
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2.13. ANTIBODY CONJUGATION 
2.13.1. HRP CONJUGATION 
2.13.1.1. Benzoquinone-HRP antibody coupling 
Benzoquinont>-HRP (BQ-HRP) has a low level of activation, which avoids 
antibody cross-linking, as the BQ-HRP does not have multiple conjugation sites. A large 
excess of HRP was required to force the coupling process. For a MAb BQ-HRP 
conjugation lmg MAb was added to 10mg BQ-HRP. This reaction ratio of 1:10 was 
suggested as a starting point for new MAb coupling as it gives a moderate level of HRP 
incorporation. Higher incorporation levels can usually be achieved by process 
optimisation. For a polyclonal BQ-HRP conjugation 0.5mg PAb was added to IOmg BQ-
HRP. A I :20 reaction ratio will usually provide high activity conjugate (approx 1:1 
Ab:HRP), however high reaction ratios may inactivate the antibody. 
The purified antibody solution (see Section 2.12) was added to the freeze dried 
BQ-HRP (IDS Ltd, Boldon, UK) allowed to reconstitute for 2-3 min prior to gentle 
vortexing. The antibody: BQ-HRP (Ab: BQ-HRP) coupling mixture was diluted with 
IOOmM Sodium Bicarbonate (Coupling Buffer) to 0.5 mg/ml and incubated for 16-20 hat 
2-8°C. The coupled antibody was precipitated by I :I addition of saturated ammonium 
sulphate (see Section 2.I2.2) slowly in four portions, which was gently vortexed after each 
addition. The mixture was incubated at 4°C for 60 min and centrifuged at 4°C for 30 min 
at 3000r.p.m. The supernatant was carefully decanted to waste and the pellet was drained 
for I 0-20 sec before addition of a minimum number of 100 ~-tl portions of PBS. 
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2.13.1.2. Gel Filtration Chromatography to remove excess HRP 
Purification of the Ab: BQ-HRP was performed using a 35ml Sephacryl S-lOOHR 
(Sigma-Aldrich, Poole, UK) Gel Filtration Chromatography (GFC) column (10 x 450mm 
Omnifit) on a Pharmacia FPLC system (Amersham Biosciences, NJ, USA). All FPLC 
buffers were vacuum filtered to 0.2flM using PROPOR PES membrane discs (Domnick 
Hunter, UK). The column was equilibrated in 1 OCV PBS to remove the storage buffer 
PBS 0.05% sodium azide (w/v) and the Ab: BQ-HRP was loaded directly onto the column 
bed and eluted in PBS at 0.5ml/min. The column was sanitised by equilibration with PBS 
0.05% (w/v) sodium azide. Fractions were collected in lml volumes and fractions 
containing Ab: HRP were identified using an anti-(rabbit/mouse lgG) coated plate, (IDS 
Ltd, Boldon, UK). From each fraction, 1 Ofll was diluted with 2ml of (1 OmM potassium 
phosphate, 0.9% NaCI, 0.05% Tween 20 (w/v), 0.5% BSA (w/v), 0.1% Proclin (v/v), 1% 
HRP stabilisers, (IDS Ltd, Boldon, UK) pH 7.0 - 7.6, (HRP basic buffer) and mixed 
thoroughly. A 20fll volume of each diluted fraction was combined with 1 OOfll of basic 
HRP buffer in the well. The plate was covered and incubated for 30 min at ambient 
temperature, followed by a 3x wash with lOmM phosphate, 1.8% NaCl (w/v), 0.05% 
Tween 20 (w/v), 0.025% Proclin (v/v), pH 7.0 - 7.6, (AC wash) using a Thermo 
Wellwash® 4 MK2 plate washer (Thermo Electron Corporation, Vantaa, Finland). 
3,3',5,5'-Tetramethylbenzidine (TMB) substrate reagent (BioFX Laboratories Inc., MD, 
USA) was added (I OOfll/well) and the plate incubated for 5-10 min before adding 0.5M 
HCI (Stop solution). The plate was read at 450nm using an Anthos Lucy microplate 
luminometer (Anthos Labtec Instruments, Salzburg, Austria) and fractions pooled with the 
highest absorbance readings. Fractions were excluded that had high 280nm absorbance 
(from GFC) but lower Ab-HRP activity as these fractions would contain the resolved 
excess HRP. 
The Ab: HRP solution was 0.2!-lM filtered using Acrodisc 32mm syringe filters 
(Pall, Portsmouth, UK) into a pre-weighed container and the Ab: HRP concentration was 
determined (see Section 2.12.1). The Ab: HRP solution was diluted to 25 flg/ml in Basic 
HRP buffer and the 0.2f.A.M filtration was repeated prior to storage at -20°C in l.Sml 
aliquots. 
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2.13.2. ANTIBODY-BIOTIN CONJUGATION 
A 0.5mg aliquot of purified antibody solution (1 mg/ml) (see Section 2.12) was 
diluted to 0.5 mg/ml in 100mM sodium bicarbonate (pH 8.0-8.4) with care taken to ensure 
that the antibody solution was equilibrated to 20°C-23°C before the coupling reaction was 
initiated. Per 1 ml of the purified antibody solution, 50 f!l succinimidyl-(biotinamido) 
hexanoate-biotin (Biotin LC NHS) was added during continuous mixing and the coupling 
mixture was incubated at 20°C - 23°C for 15 min. The biotin LC NHS solution (Sigma-
Aldrich, Poole, UK) was prepared by reconstitution in dry Dimethyl Formamide (DMF) 
(Sigma-Aldrich, Poole, UK) to achieve 9.1mg/ml and used within 10 min. The coupling 
reaction was stopped on addition of 50f!Vml of 1M Ethanolamine pH 8.0 and the excess 
biotin was removed using a PD-1 0 Desalting column (see Section 2.12.2). The Ab: Biotin 
concentration was determined (see Section 2.12.1) and diluted to 25 f!g/ml in IOmM 
potassium phosphate, 0.9% NaCl, 0.05% Tween 20 (w/v), 0.5% BSA (w/v), 0.09% 
sodium azide (w/v), pH 7.0 - 7.6 (Ab: Biotin Buffer). The Ab: Biotin solution 0.2f!M 
filtered using a 32mm Acrodisc® PES syringe filter (Pall, Portsmouth, UK) prior to 
storage at -20°C in 1.5ml aliquots. 
2.14. PLATE COATING WITH MAB AND PAB ANTIBODIES 
The 96 well F8 Maxisorp plates (Nunc, Denmark) were coated at a 2 mg/L 
concentration of antibody. The purified antibody solution (1 mg/ml) (see Section 2.12) was 
diluted 500x in PBS and a 1 :4000 volume of Yoko yellow dye (IDS Ltd, Boldon, UK) was 
added. The coating solution was mixed for 15 min at ambient temperature then dispensed 
into the 96 well plates (200f!l/well) for overnight incubation at room temperature. Post 
incubation the plates were washed 3x with AC wash (see Section 2.13.1.2), followed by 
the addition of 300f!l of glaze solution/wen (IDS Ltd, Boldon, UK). The plates were 
incubated for 30min at room temperature then aspirated to remove the glaze buffer, before 
overnight drying at 35°C. Plates are sealed in foil bags with silica gel and stored at 4°C. 
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2.15. ENZYME LINKED IMMUNOSORBANT ASSAY FOR 
DETECTION AND QUANTITATION OF aD-CRYSTALLIN 
2.15.1. CALIBRATORS AND SAMPLE PREPARATION USING AB: HRP 
CONJUGATE 
The Ab: HRP conjugate was used for detection of significant levels (> 0.1 mg/ml 
or 100000 ng/ml) of aS-crystallin by enzyme linked immunosorbant assay (ELISA). For 
greater sensitivity the Ab: Biotin conjugate was more appropriate. A five point calibration 
curve ranging from 1 OOng/ml to 1.27ng/ml was prepared by serial dilution of calibrator 
stock solution (CSS). The CSS consisted ofpurified wild type aS-crystallin (see Section 
2.6) diluted to a concentration of 1 !J.g/ml in 1 OmM potassium phosphate, 0.9% NaCI, 
0.05% Tween 20 (w/v), 0.5% BSA (w/v), 0.1% Proclin (v/v), pH 7.0 - 7.6, filtered to 
0.211M and stored at 4°C (Assay Buffer). A typical dilution series used for calibrator 
preparation is shown below: 
• Calibrator 5- 0.2 ml CSS to 1.8 ml Assay Buffer (100 ng/ml) 
• Calibrator 4- 0.5 ml Calibrator 5 to 1 ml of Assay Buffer (33.3 ng/ml) 
• Calibrator 3 - 0.5 ml Calibrator 4 to 1 ml of Assay Buffer (11.1 ng/ml) 
• Calibrator 2- 0.5 ml Calibrator 3 to 1 ml of Assay Buffer (3.7 ng/ml) 
• Calibrator 1 - 0.5 ml Calibrator 2 to 1 ml of Assay Buffer (1.27 ng/ml) 
Samples were diluted in Assay Buffer to fit the standard curve. The Ab: HRP 
conjugate (see Section 2.13 .1.2) was diluted 1 OOx to a concentration of 250 ng/ml in Basic 
HRP buffer (see Section 2.13.1.2) by adding 0.5 ml Ab: HRP conjugate (25 !J.glml) to 49.5 
ml Basic HRP buffer. 
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2.15.2. CALIBRATORS AND SAMPLE PREPARATION USING AB: BIOTIN 
CONJUGATE 
The Ab: Biotin conjugate was used for detection ( < 0.1 rng/rnl or 1 x 108 pg/rnl) 
of aS-crystallin by ELISA as it delivered greater sensitivity than the Ab: HRP conjugate. 
A five-point calibration curve ranging from 5000 pg/rnl to 128 pg/ml was prepared 
by serial dilution of CSS (see Section 2.15.1 ). A typical dilution series used for calibrator 
preparation is shown below: 
Prepare a dilution series of wild type aB-crystallin to achieve a 5 point calibration 
curve ranging from 5000pg/ml to 128pg/ml as follows: 
• Calibrator 5 - 0.025 ml CSS to 4.975 rnl Assay Buffer (5000 pg/ml) 
• Calibrator 4 - 0.8 rnl Calibrator 5 to 1.2 rnl of Assay Buffer (2000 pg/rnl) 
• Calibrator 3 - 0.4 rnl Calibrator 4 to 0.6 rnl of Assay Buffer (800 pg/ml) 
• Calibrator 2 - 0.4 rnl Calibrator 3 to 0.6 rnl of Assay Buffer (320 pg/ml) 
• Calibrator 1 - 0.4 ml Calibrator 2 to 0.6 ml of Assay Buffer (128 pg/ml) 
Samples were diluted in Assay Buffer to fit the standard curve. The Ab: Biotin 
conjugate (see Section 2.13.2) was diluted 1 OOx to a concentration of 250 ng/ml in Ab: 
Biotin buffer (see Section 2.13.2) by adding 0.5 rnl Ab: Biotin conjugate (25 !J.g/ml) to 
49.5 ml Ab: Biotin buffer. 
Assays utilising the Ab: Biotin conjugate, require an additional step, to allow 
binding of Avidin-HRP to Biotin prior to addition of substrate. The Avidin-HRP buffer 
consisted of equal amounts of labelled Avidin HRP (25 !J.g/ml) (IDS Ltd, Boldon, UK) to 
unlabelled A vi din (25~-tg/rnl) (IDS Ltd, Boldon, UK). 
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2.15.3. SIMULTANEOUS ELISA FOR aBPCRYSTALLIN DETECTION AND 
QUANTITATION 
A simultaneous assay operates at moderate sensitivity. Figure 2.1. shows a typical 
plate map. 
Figure. 2.1 Simultaneous aB-crystallin ELISA plate map 
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Each calibrator (Cal) was assayed in duplicate. A dilution resulting in a high and 
low concentration (cone.) (see Figure 2.1) of each sample (nwnbered cell) was prepared 
and assayed in duplicate to cover the range of the calibration curve, ensuring accurate 
quantitation. The calibrators and samples (100 ~-tl) were added to the appropriate wells 
(see Figure 2.1 ), to which 1 00~-tl of Ab: conjugate was added. The plates were covered 
and incubated for 2 h at room temperature followed by a 3x wash with AC wash buffer 
(see Section 2.13.1.2). At this point, separate protocols were followed depending on the 
Ab: conjugate in operation 
For assays utilising Ab: HRP conjugates, TMB substrate solution (IDS Ltd, 
Boldon, UK) was added (200 ~-tllwell) to detect aB-crystallin and plates were incubated 
for 30 min at room temperature before 100 ~-tl 0.5M HCl (Stop solution) was added. 
For assays utilising Ab: Biotin conjugates, 250 ng/ml Avidin/Avidin HRP (see 
Section 2.15.2) was added (200 J..tl/well) and plates incubated for 30 min at room 
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temperature followed by a 3x wash with AC wash buffer. To detect the aB-crystallin, 
TMB substrate solution (IDS Ltd, Boldon, UK) was added (200 J.tl/well) and plates were 
incubated for 30 min at room temperature before 100 J.tl 0.5M HCl (Stop solution) was 
added. 
The aB-crystallin signal produced by the TMB substrate was read at 450nm using 
an Anthos Lucy microplate luminometer (Anthos Labtec Instruments, Salzburg, Austria) 
and the amount of aB-crystallin quantified using a calibration curve of Mean absorbance 
versus log concentration. 
2.15.4. SPLIT ELISA FOR aD-CRYSTALLIN DETECTION AND 
QUANTITATION 
A split assay achieves greater sensitivity than the simultaneous assay, as twice the 
amount of analyte is present in the assay. The same sample and calibrator plate map was 
utilised for split assays (see Figure 2.1 ). The calibrators and samples (200 J.tl) were added 
to the appropriate wells (see Figure 2.1). The plates were covered and incubated for 1.5 h 
at room temperature followed by a 3x wash with AC wash buffer (see Section 2.13.1.2). 
A 200J!l volume of Ab: conjugate was added and the incubation and wash step was 
repeated. At this point, separate protocols detailed in Section 2.15.3 were followed 
depending on the Ab: conjugate in operation. 
----- --~--___:_ 
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CHAPTER3 
THE FLEXIBLE C-TERMINAL 'TAIL' PLAYS AN 
IMPORTANT ROLE IN MAINTAINING THE SOLUBILITY 
OF THE aD-CRYSTALLIN OLIGOMER 
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3.1. AIMS 
The flexible C-terminal 'tail' has been suggested to play an important role in 
solubilising the hydrophobic complexes formed between a-crystallin particles and 
denatured proteins (Smulders et al., 1996). 
In this Chapter, I wanted to investigate the relationship between the C-terminal 
extension and the solubility of aB-crystallin, and its potential role in the mechanism that 
causes various disease states. This chapter, therefore aimed to clone, express and purify 
the sequentially truncated C-terminal aB-crystallin mutants (K174X and E165X) along 
with the three naturally occurring disease causing mutants (450delA, Q151X and 
464delCT) and the post translational modification truncations (E 164X and A 171 X). The 
nature of expression and purification will help further understand the role of specific 
regions of the C-terminal extension important in solubilisation of aB-crystallin oligomers, 
and will provide the basis for further characterisation aiming to understand the 
relationship between the C-terminal extension, the chaperone function, oligomerisation 
and the relationship with disease. 
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3.2. INTRODUCTION 
The C-terminal extension is conserved amongst aA-and aB-crystallin and the 
family of sHSPs. Similar to the N-terminal domain, its sequence is of variable length and 
composition as shown by structural alignment (see Figure 3.1A) and according to nuclear 
magnetic resonance (NMR) analyses, the C-terminal 9 and 11 residues of aA- and aS-
crystallin, respectively, appear to adopt the conformation of a flexible solvent-exposed 
random coil (Carver et al., 1992; Carver and Lindner, 1998) 
The exposed nature of this random coil was in accord with the observation that the 
last 20 or so residues of the a-crystallin are especially liable to truncations and 
modifications (Jimenez-Asensio et al., 1999; Lin et al., 1997). For example, enzymatic 
truncation of the C terminal with cal pain II or trypsin results in a decreased chaperone-like 
activity (Takemoto et al., 1992) 
The solvent exposed random coil has been defined as a highly mobile 'tail' with 
regions of flexibility being pinpointed to the terminal 9 and 11 residues of Bovine aA and 
aB-crystallin as well as the terminal 16 residues of Human HSP27, the terminal 10 
residues of Rat HSP20 and the terminal 18 residues of mouse HSP 25 (see Figure 3.1 B) 
(Carver, 1999). The C-terminal flexibility is a common feature of mammalian sHSPs, and 
despite sharing little sequence similarity, they are characterised by being polar. 
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figure 3.1. Structural alig1m1ent of the C-tenninal extensions a-crystallins and sHSPs. 
(A) Structural alignment of the C-terminal extensions of metazoan (red) and non-
metazoan (green) sHSPs. Conserved and conservatively substituted residues are indicated 
in grey, except for the C-terminal motif (purple). The C-terminal extensions are indicated 
Reprinted from (Stamler et al. , 2005) Copyright (2005) with permission from Elsevier. 
(B) shows a sequence alignment including mammalian sHSPs and their regions of C-
terminal flexibility (underlined). Reprinted from (Carver, 1999) Copyright ( 1999) with 
permission from Elsevier. 
In a -crystallin, the primary role of the flexible C-terminal extension 'tail' is to 
offset the large degree of hydrophobicity exposed to the solution by the a-crystallin i.e the 
'tail' acts as a solubilising agent for the relatively hydrophobic protein and any subsequent 
sHSP-client complexes, which form upon chaperone action (Lindner et al., 2000). Each 
sHSP subunit possesses this short, polar, highly flexible, hydrophilic and solvent-exposed 
C-tcrminal ' tail', whose composition is dominated by polar and charged amino acid 
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residues (Caspers et al., 1995). Interestingly, a mutant of aA-crystallin in which 
hydrophobicity was introduced into the C-terminal 'tail' had significantly reduced 
flexibility within this 'tail' and a corresponding reduction in solubility, heat stability and 
chaperone activity, compared with the wild type protein and supports the argument that 
the extensions may have a role in solubilising the hydrophobic complexes formed between 
a-crystallin particles and denatured proteins via electrostatic interactions (Smulders et al., 
1996). 
Lindner et al., (2000) suggested that the C-terminal 'tails' might serve as 'spacers' 
in preventing sHSP---client complexes from approaching one another (Lindner et al., 
2000). Without their presence, hydrophobic interactions between the proteins would 
result in aggregation and precipitation, thus if the polarity and flexibility of the 'tails' are 
disrupted the stability and chaperone activity of the protein are reduced significantly 
(Lindner et al., 2000). 
The role of the C-terminal as a 'solubiliser' has been well studied for aA-
crystallin. As discussed earlier, the introduction of hydrophobic residues such as 
tryptophan in the C-terminal 'tail' of aA-crystallin affected structural and functional 
integrity, reducing chaperone activity, thermostability, and flexibility (Smulders et al., 
1996). 
Further evidence to suggest the role of the 'tail' as a solubiliser of the a-crystallin 
complex, was shown when its deletion from Caenorhabditis elegans HSP16.2 caused 
precipitation of the complex upon freeze-thawing (Leroux et al., 1997). Deletion of 17 
residues from the C terminal of aA-crystallin (R157STOP), despite having spectroscopic 
properties similar to wild type protein, formed large insoluble aggregates with a marked 
reduction in chaperone-like activity (Andley et al., 1996). Similar results were observed 
for Xenopus HSP30C (Fernando, 2000). Complete removal of the flexible 'tail' was 
observed in a study, which investigated the influence of the 163REEK166 region on aA-
crystallin structure and function by the sequential removal of the 163REEK166 residues. 
This resulted in a reduction in chaperone activity and oligomerisation without affecting 
the solubility. The study showed that the charged residues in the 163REEK166 motif 
provide the electrostatic interactions in the C-terminal extension needed to form 
oligomeric complexes. In addition, the R163 residue was found to provide a positive 
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charge for intersubunit electrostatic interactions in the C-terminal extension (Rajan et al., 
2006). Similar truncations in aA-crystallin have also shown no affect on the solubility, 
when recombinantly produced, but have been found in rat lenses (aA1-15" aA1-1 57, aA1-162, 
aAI-163 and aA1-168) (Thampi and Abraham, 2003), in human lenses (aAI-162 and aAI-168) 
(Colvis et al., 2000) and diabetic human lenses (aA1_172) (Thampi et al., 2002). 
Interestingly, the removal of the terminal serine resulted in aggregation of aA-crystallin 
(Aziz et al., 2007). 
A study investigating the C-terminal 'tail' of aB-crystallin, looked at the 
proteolytic removal of the C-terminal Thr171 - Lys175 region. There was no significant 
affect on the solubility of the aB-crystallin complex (Carver et al., 1995) as there would 
be sufficient charge-charge interactions with the remainder of the C-terminal 'tail' to 
ensure efficient solubility and chaperone-like activity. Similarly, the removal (Liao et al., 
2002) and substitution (Plater et al., 1996) of the terminallysines of aB-crystallin resulted 
in a stable complex. It may be that the mutations resulted in a largely intact but less 
mobile C terminal. The absence of a strong hydrophilic positive charge at the end of the 
highly flexible C-terminal 'tail' may result in the C terminal folding back on itself, losing 
its flexibility, and sterically hindering protein binding (Plater et al., 1996). The formation 
oflarge insoluble aggregates observed with the aA-crystallin truncation (R157X) (Andley 
et al., 1996) would tend to suggest that a similar modification to the aB-crystallin C-
terminal would also result in aggregatior1 of the truncated aB-crystallin protein. 
Interestingly, a recent study by Ghosh et.al, 2006 saw the removal of the polar C-
terminal sequence (155PERTIPITREE165), which, resulted in poor solubility despite the 
retention of 10 of the 11 C-terminal 'tail' residues, plus limited or no chaperone activity. 
This study demonstrated the importance of C-terminal residues aB15s-165 in maintaining 
the solubility of unfolded substrates in a manner independent of the amount of substrate 
protein unfolding (Ghosh et al., 2006). It also suggested an additional influence on the 
solubilisation of aB-crystallin by the 163REEK166 motif and the highly conserved IX/(IN) 
motif (159IPI161), both of which are important in intersubunit interactions and chaperone 
function (Pasta et al., 2004; Rajan et al., 2006). Mutations in the C-terminal lysines and 
glutamic acid residues resulted in altered oligomerisation and chaperone activity 
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Further investigation of the role of the C-terrninal 'tail' in the solubility of aB-
crystallin would require the creation of a series of sequentially truncated C-terminal 
mutants to help further characterise the effect of specific regions of the C-terminal 
extension 'tail' on the solubilisation function. 
In addition, the discovery of three naturally occurring mutations, which affect the 
C-terminal extension of aB-crystallin are of interest firstly, due to their disease causing 
nature in both the lens and extra lenticular tissues. Secondly by their phenotypic 
heterogeneity, where the mutations result in either isolated posterior polar cataract 
(450delA) with no muscle phenotype, or Myofibrillar myopathy (464delCT and Q151X) 
with no cataract. Two post translation modifications have also been identified, which 
result in a truncated C-terrninal extension and include aB1_11o and aBI-163· The aBI-170 
was found in diabetic rat lenses (Thampi et al., 2002) and was observed in patients who 
display Soemmerring's ring cataract (Colvis et al., 2000). The aB1_163 was found in 
human lens fiber cells growing in lens capsules following cataract surgery (Colvis et al., 
2000) and was identified as a fragment from LP82 and M-calpain proteolysis of the rat 
lens nucleus (Ueda et al., 2002). These observations further strengthen the argument 
suggesting the C-terminal extension plays an important role in the solubilisation of the 
aB-crystallin oligomer. 
In aB-crystallin, there has been no systematic analysis of the role of the C-terminal 
extension and therefore no potential explanation of whether the three mutations ( 450delA, 
Ql51X and 464delCT) cause the various diseases via a loss in solubility or perhaps a loss 
in chaperone function and oligomerisation or even by a completely different mechanism. 
Cloning, expression and purification of these aB-crystallin mutations along with 
sequential truncations of the C-terminal extension, will help further understand the role of 
specific amino acids important in the solubilisation of aB-crystallin oligomers. This study 
will provide the basis for further characterisation aiming to understand the relationship 
between the C-terminal extension and the chaperone function, oligomerisation and the 
relationship with disease. 
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3.3. RESULTS 
The role of the C-terminal extension of aS-crystallin upon solubility has been 
characterised in this section. The relative solubility of expressed mutant aS-crystallin 
protein in both a bacterial and mammalian cell environment are shown in Section 3.3.2 
TI1e assembly of the C-terminal aB-crystallin mutant constructs are detailed in Section 
3.3.1 and the subsequent purification of the bacterial recombinant aS-crystallin mutants 
are discussed in Section 3.3.3. 
3.3.1. ASSEMBLY OF MUTANT aB-CRYST ALLIN CONSTRUCTS 
The construction of all aB-crystallin mutants detailed in Section 2.2 involved a 
basic PCR mutagenesis system with the exception of Q 151 X and E 165X aB-crystallin, 
which utilised SDM. All mutagenesis utilised specific mutagenic primers with unique 
restriction sites for digest screening (see Table 2.1). The 450delA construct in pET23d(+) 
was a kind gift from Dr Ming der Perng. 
3.3.1.1. Ql51X aD-crystallin mutant construct 
The QISIX aB-crystallin construct was assembled by SDM using a mutagenic 
reverse primer in combination with a Taq promoter to incorporate the QlSlX mutation 
into the wild type aB-crystallin template, present in the pET23d(+) vector. ProJiferation 
of the PCR product allowed screening for the QlSIX mutant using a unique restriction 
site incorporated in the primer (Stu!). Constructs which produced a fragment of 455bp 
were sequenced by the departmental sequencing facility, after which, the sequence 
obtained was checked by the nucleotide-nucleotide option of the Basic Local Alignment 
Search Tool (BLAST) software. The sequencing and BLAST analysis confirmed the 
presence of the mutant Q 151 X insert when compared to the GenBank data base entry 
(accession no. NM001885) for human aS-crystallin. (For further details of the cloning 
procedure and BLAST sequence, see Appendix 1, Section Al.2) 
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3.3.1.2. Assembly ofE165X aD-crystallin mutant by SDM 
The El65X aS-crystallin construct was assembled by SDM using 
complementary mutagenic primers to incorporate the E 165X mutation. Subsequent 
screening for the E 165X mutant utilised the unique Hind/If restriction site. Constructs~ 
which produced a fragment of 497bp were sequenced and checked by the BLAST 
software and confirmed the presence of the mutant E165X insert. (For further details of 
the cloning procedure and BLAST sequences see Appendix I~ Section A1.3) 
3.3.1.3. Assembly of 464deiCT aD-crystallin construds 
PCR mutagenesis utilised a mutagenic primer to generate the 464delCT aS-
crystallin mutant insert ( 492bp) with 3 'A overhangs for subsequent ligation into the 
pGEM®-T Easy vector. The presence of the 464deiCT mutation was assessed using the 
Ncol!EcoRI digest on purified constructs to screen for fragments of expected size of 
498bp. Following confirmation by sequencing~ the construct was subcloned into 
pET23d( +) using Ncol/EcoRJ digest. The multiple cloning region of pET23d( +) is shown 
in Appendix I~ Figure A8.2B. Further Ncol!EcoRJ screening~ sequencing and BLAST 
analysis confirmed the 464delCT insert had successfully been subcloned into the 
pET23d(+) vector and was viable for protein expression. (For further details of the cloning 
procedure and BLAST sequences see Appendix 1, Section Al.4). 
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3.3.1.4. Assembly of E164X aD-crystallin mutant 
The E164X aS-crystallin construct was generated by PCR. using a mutagenic 
primer to generate a 528bp fragment, which was ligated into the pOEM®-T Easy vector. 
The E 164X mutant contains a unique Psrf restriction site downstream from the stop 
codon. DNA from selected transformants was purified and the presence of the E164X 
mutation was assessed using Nco//Pst/ digest to screen for fragments of expected size of 
506bp. The construct containing the El64X mutation was subcloned into pET23d(+) 
using Nco/!EcoRI digest. Further screening, sequencing and BLAST analysis confirmed 
the El64X insert had successfully been subcloned into the pET23d(+) vector. (For further 
details of the cloning procedure and BLAST sequences see Appendix 1, Section A 1.5) 
3.3.1.5. Assembly of A171X aD-crystallin mutant 
The Al71X aS-crystallin construct was assembled by PCR, using a mutagenic 
primer to generate a 540bp fragment. Ligation of the fragment into the pOEM®-T Easy 
vector was assessed using Ncol/Sacl digest to screen for fragments of expected size 512bp 
and confirmed by sequencing. The construct containing the A 171 X mutation was 
subcloned into pET23d(+) using Ncol!EcoRI digest and confirmation was achieved by 
screening, sequencing and BLAST analysis. (For further details of the cloning procedure 
and BLAST sequences see Appendix 1, Section Al.6) 
3.3.1.6. Assembly of K174X aD-crystallin mutant 
The Kl74X aS-crystallin construct was generated by PCR, using a 
mutagenic primer to generate a 528bp fragment, which was ligated into the pOEM®-T 
Easy vector and assessed using Nco//Sacl/ digest to screen for fragments of expected size 
514bp and confirmed by sequencing. The construct containing the K174X mutation was 
subc1oned into pET23d( +) using Ncol/EcoR/ digest and confirmation was achieved by 
screening, sequencing and BLAST analysis. (For further details of the cloning procedure 
and BLAST sequences see Appendix 1, Section A I. 7) 
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3.3.1.7. Subcloning of aD-crystallin constructs into pcDNA3.1(-) 
In order to express the a.B-crystallin mutants in mammalian cells by transient 
transfection, the inserts were subcloned from the pET23d( +) bacterial expression vector 
into pcDNA3. 1 (-) using Xbai/Hindlll digest. Subsequent screening utilised Apal!Hind!JJ 
digest, where Apal is unique to the pcDNA3.1(-) vector, thus confirming the efficient 
ligation of the mutant insert~ but also the presence of the target vector pcDNA3.1 (-). The 
multiple cloning region ofpcDNA3.1(-) is shown in Appendix 1, Figure A8.3. The wild 
type aB-crystallin insert in pcDNA3.1(-) was a kind gift from Dr Ming der Pemg. (For 
fuH details of the subcloning process and BLAST sequences, see Appendix 1, Section 
Al.8) 
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3.3.2. THE EFFECT OF THE C-TERMINAL MUTATIONS ON THE 
SOLUBILITY OF aD-CRYSTALLIN MUTANT PROTEINS EXPRESSED 
IN BACTERIAL AND MAMMALIAN CELLS 
The C-terminal extension has been reported to be important for the solubility of 
aB-crystallin and its associated complexes, thus the sequential removal of the C-terminal 
arm should increase the insolubility of the a.B-crystallin mutants. 
The effect of the C-terminal mutations on the solubility of the various a.B-
crystallin mutants was assessed firstly, in bacterial E.coli strain BL-21 (pLysS) cells by 
transformation of the mutant a.B-crysta11in constructs cloned into the pET23d( +) vector 
and secondly, in mammalian epithelial breast carcinoma MCF7 cells by transient 
transfection of the constructs cloned into the pCDNA3.1 (-)vector. 
3.3.2.1. The solubility of aD-crystallin mutant constructs expressed in E.coli strain 
BL-21 
The disease causing nature of the naturally occurring mutations 450delA, 
464delCT and Q151X aS-crystallin and the age related cataract causing E164X a.B-
crystallin would tend to lead us to the conclusion that the mutants would be expressed as 
inclusion bodies (Berry et al., 2001; Col vis et al., 2000; Selcen and Engel, 2003; Ueda et 
al., 2002). 
The mutant a.B-crystallin constructs cloned into the pET23d( +) vector were 
transformed into E.coli strain BL-21 (pLysS) cells tor protein expression and cultured. 
The level of expression and the solubility of the expressed mutant proteins were assessed 
initially by investigating whether the protein produced remained soluble when expressed 
recombinantly in E. coli (see Figure 3.2). 
These mutants also are those where the C-terminal extension is the most 
modified. The four mutants are all expressed as inclusion bodies (see Figure 3.2A-D, lane 
4) with the entire mutant protein present in the pellet fraction (P). 
The predicted Mwts calculated from the amino acid sequences using Emboss 
Pepstats software are confirmed by the mobility of the mutant a.B-crystallins in 
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comparison to the protein ladders (lane 1 ). The E 165X aS-crystallin, being only one 
amino acid longer than El64XaB-crystallin is also expressed and present in inclusion 
bodies (see Figure 3.2E). 
The remaining aS-crystallin mutants A171X and K174X (truncated by 5 and 2 
amino acids respectively) are expressed as soluble protein similar to the wild type aS-
crystallin (see Figure 3.2 (F-H) respectively, lane 3). The SDS-PAGE also suggests the 
expression of these mutants and the wild type aS-crystallin as inclusion bodies as there 
are significant levels of the respective proteins in the pellet fractions (lane 4). Inclusion 
bodies are condensed particles of protein that are formed within the bacterial cell when the 
cell is forced to make large amounts of protein and are the result of 'off pathway' 
aggregation or folding which could explain the presence of inclusions alongside soluble 
mutant protein. It is more likely, however that the pellet material is indicative of an 
inefficient lysis, where the whole cells, which have not been efficiently homogenised, 
continue to be sedimented by the centrifugation process required for fractionation. 
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Figure 3.2. Solubility of aS-crystallin mutants expressed in BL-21 E.co/i cells. The 
whole cells for each mutant and the wild type are shown in lane 2 (A-H). The soluble 
fractions (S) in lane 3 (A-H), and insoluble fractions (P) in lane 4 (A-H), from lysis show 
the dishibution of the mutant protein. The predicted Mwt is shown as calculated from the 
amino acid sequence using the Emboss Pepstats software 
www.ebi.ac.uk/emboss/pepstats). 
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3.3.2.2. The Solubility of aD-crystallin mutants expressed in mammalian MCF7 
Cells 
Transient transfection of aS-crystallin mutants into breast epithelial MCF7 cells 
was performed to investigate the relative solubility of the mutants in a mammalian cell 
environment. MCF7 celJs have no endogenous aS-crystallin thus avoiding the need to tag 
the protein for subsequent detection but high levels of endogenous HSP27, a small heat 
shock protein chaperone that is known to form heterogeneous oligomers with aS-
crystallin (Zantema et al., 1992) 
Figure 3.3 illustrates the solubility and distribution of the specific mutants. Cells 
expressing wild type aS-crystallin (Figure 3.3.A; green channel), showed a homogenous 
cytoplasmic distribution. A similar distribution was observed for the El65X, A171X and 
Kl74X (Figure 3.3.F-H respectively) 
In contrast, cells expressing Ql51X, 464delCT, E164X and 450delA aS-crystallin 
were obvious by the presence of cytoplasmic aggregates that were immunopositive for 
aS-crystallin (Figure 3.3.B-E respectively), all of which have been shown to be extremely 
insoluble in E. Coli SL-21 expressions (see Section 3.3.2.1, Figure 3.3). The distribution 
of the 450delA and 464delCT aggregates were scattered throughout the cytoplasm 
whereas the Ql51X and E164X aS-crystallin aggregates were perinuclear in distribution. 
This data has been complemented by a recent paper, which found that both the QISIX 
aS-crystallin and 464delCT aS-crystallin formed aggregates in transfected cells (Simon 
et al., 2007). 
In order to provide an assessment of the solubility of the different aS-crystallin 
constructs in populations of transiently transfected MCF7 cells, cells were extracted and 
the presence of aS-crystallin in supernatant and pellet fractions was measured by 
sedimentation assay followed by SDS-PAGE and immunoblotting with monoclonal anti-
aS-crystallin (see Figure 3.4). A second antibody, monoclonal anti-HSP27 antibody 
(ERD-5) was used as a control to detect the endogenous levels ofHSP27. 
Transfected wild type aS-crystallin was found almost entirely in the soluble 
fraction (see Figure 3.4, lane 1). Transfected Q151X, 464delCT and E164X aS-
crystallin, however, were detected almost entirely in the pellet fractions, (see Figure 3.4, 
lanes 8, 4 and 1 0 respectively) with only a small proportion left in the supernatant 
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fractions (see Figure 3.4, lanes?, 3 and 9 respectively). The K174X, Al71X and E165X 
whose mutations involve the least truncation of the C-terminal extension, are all entirely 
present in the supernatant fractions similarly to the wild type aB-crystallin (see Figure 
3.4, lane 11, 13 and 15 respectively). Interestingly, the El65X aB-crystallin was shown 
to be entirely insoluble in E. Coli BL-21 expressions (see Section 3.3.2.1, Figure 3.3.E). 
The 450delA aB-crystallin, which was expected to be present entirely in the pellet 
fraction, seems to show only a trace amount in the supernatant fraction (see Figure 3.4, 
lane 3). This could be a problem with the transfection conditions or the nature of the 
mutant in preventing efficient recovery of the 450delA aB-crystallin protein either during 
the transfection or the protein extraction stage. 
The endogenous HSP27 was unable to prevent the formation of aggregates by the 
various mutant aB-crystallins and the presence of these aggregates did not cause a 
significant shift in the solubility of the endogenous HSP27 to the pellet fraction. These 
data support the hypothesis that the sequential loss of the C-terminal extension also results 
in a sequential loss of solubility even in a cellular environment. 
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Figure 3.3. Formation of cytoplasmic aggregates by selected aS-crystallin mutants in 
MCF7 cells. MCF7 cells (A-D) transiently transfected with wild-type (A), Q151X (B), 
464delCT (C) or E164X (D) aS-crystallin were fixed at 24 h post transfection and 
processed for immunofluorescence microscopy. The subcellular distribution of aS-
crystallin and keratin were visualized by double labeling with monoclonal anti-keratin (red 
channel) and polyclonal anti-aS-crystallin antibodies (green channel). A-D are merged 
images showing the superimposition of the green, red and blue (DAPI staining) channels 
with areas of re and green overlap in yellow. Images are individual optical sections 
acquired using a confocal laser scanning microscope (Zeiss 51 0). Cells expressing wild 
type aS-crystallin (A). showed the expected cytoplasmic distribution of aS-crystallin. In 
contrast, cells expressing mutant aS-crystallin resulted in the formation of cytoplasmic 
aggregates of aS-crystallin (B-D). Notice that 464delCT and 450delA aggregates are 
scattered throughout the cytoplasm whereas the Ql51X and El64X aggregates locate to 
the peripnuclear region of the cell. Bars, 10 J..tm. Immunoblotting analysis (E), of aS-
crystallin expressed in MCF7 cells, illustrating the insolubility of the mutant aB-
crystallins. At 24 h posttransfection, cells were extracted with detergent buffer followed 
by centrifugation at 18,000 x g for 10 min at 4°C. The resulting supernatant (S) and pellet 
(P) fractions were separated by SDS-PAGE followed by immunoblotting analysis by 
using anti-HSP27 and aS-crystallin antibodies as detailed in the Materials and Methods. 
The blot was developed using the enhanced chemiluminescence system. Whereas wild-
type aS-crystallin was present almost entirely in the soluble fraction (E, lane 1, labeled S), 
Ql51X (lane 4), 464delCT (lane 6) and El64X (lane 8) was found mostly in the pellet 
fraction, (labeled P). Mutant aS-crystallin bands are denoted by the arrow head ( ..,_ ). 
HSP27 Immuno-positive signals were detected mostly in the supernatant fractions (E 
lanes 2, 4, and 6, labeled P). These data are representative of three experiments. 
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Figure 3.4. The solubility of a.B-crystallin mutants in populations of transiently 
transfected MCF7 cells. This data illustrates the insolubility of the mutant aB-crystallins. 
At 24 h post transfection, cells were extracted with detergent buffer followed by 
centrifugation at 18,000 x g for 10 min at 4 °C. The resulting supernatant (S) and pellet (P) 
fractions were separated by SDS-PAGE followed by immunoblotting analysis by using 
anti-HSP27 and aS-crystallin antibodies. The blot was developed by enhanced 
chemilluminescence system. Whereas wild type a.B-crystallin was present almost entirely 
in the soluble fraction (lane 1, labelled S), Q 151 X (lane 8), 464delCT (lane 6) and E164X 
(lane 10) was found mostly in the pellet fraction, (labelled P). The K174X (lane 11) 
A 171 X (lane 1 3) and E 165X (lane 15) are present entirely in the supernatant fraction 
similar to the wild type a.B-crystallin. The 450delA was expected to be completely 
insoluble, however the only band visible is in the supernatant (lane 3) and is very faint. 
Mutant a.B-crystallin bands are denoted by the arrow head ( • ). HSP27 Immuno-positive 
signals were detected mostly in the supernatant fractions These data are representative of 
three experiments. 
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3.3.3. PURIFICATION OF RECOMBINANT aD-CRYSTALLIN MUTANTS 
The various mutant aB~crystallins expressed in E.coli strain BL~21 (pLysS) cells 
were purified to allow further characterisation of the effect of a modified C-terminal 
extension on the structure and function of aS-crystallin. 
The solubility of the expressed protein dictated the purification protocol utilised. 
Expression data shown in Section 3.3.2 confirmed that the disease mutants 450delA, 
464deiCT, QISIX and E164X were present as inclusion bodies along with the EI65X 
mutant, therefore solubilisation in 6M urea was required to allow purification of the 
protein. The expression of soluble protein shown for the Al71X and the Kl74X meant 
they would be purified using the wild type aB-crystallin purification protocol. 
3.3.3.1. Wild type aD-crystallin 
The wild type protein expressed (see Figure 3.2H) was purified following the 
protocol detailed in Section 2.6. The first chromatography step used Ion Exchange 
chromatography (lEX) to remove contaminating proteins and allow the isolation of the 
wild type protein. A typical lEX purification is shown in Figure 3.5A. Following SDS-
PAGE analysis (see Figure 3.58), fractions 3-23 inclusive were pooled. The pooling 
criteria excluded those fractions with additional contaminating proteins despite the 
presence of the wild type aS-crystallin. 
The second stage of the purification was Size Exclusion Chromatography (SEC), 
which would further resolve wild type aS-crystallin from any contaminating proteins 
carried forward in the lEX pool. The lEX pool was concentrated from 21 ml to 0.5 ml 
prior to SEC. The SEC purification resulted in the recovery of 27mg of wild type aS-
crystallin (see FigW'e 3.6A). The aS-crystallin was the major species present in the SEC 
profile, and SDS-PAGE analysis of these fractions (see Figure 3.6S) confirmed that 
fractions 35-49 were enriched and were subsequently pooled to give a total pool volume 
of 15ml. The SEC pool material was divided into 0.5ml aliquots and stored at -80°C. 
A number of additional species were identified at 40 kDa, 28 kDa and several 
below the wild type band at approx. 17 kDa. These may be contaminatiJ!g_proteif!S_ or 
-~--- -- -~-·- - ·- -- - ----- -- -- - -- ---
could potentially be a dimer (40 kDa) and breakdown products. The nature of these 
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additional bands was investigated by immunoblotting with aB-crystallin mouse 
monoclonal 2D2B6 clone generated to chicken all-crystallin, (see Figure 3. 7). The 
immunoblotting confirms that the bands at 28 kDa and 40 kDa are wild type nR-
<.:rystallin, A number of the low Mwt hands thHi were observed between the wild typ~ 
band and 17 kDa in Figure 3.6B may be masked in Figure 3.7, by the large wild type hand 
at 20 kDa. A very low intensity band at approx. 17 kDa shown in the Ponceau stain (sec 
Figure 3. 7) was not detected by the wild type ai3-crystallin monoclonal antibody, 
suggesting that the band was a contaminant. The amount of the low Mwt band present in 
the 1.8 mg/ml SEC pool was negligible and would not be visible in SDS-PAGE analysis 
of wild type aS-crystallin under typical experimental conditions of 0.1-0.2 mg/ml. 
D)'namic Light Scattering (DLS) was used to confirm the quality of the purified 
wild type aB-crystallin because it is a non-invasive, well-established technique for 
measuring the size of molecules and size distribution of particles typically in the sub 
micron region. Therefore DLS can confirm the purity of the wild type aB-crystallin SEC 
pool material and the data shows that the aB-crystallin is the only species present (see 
Figure 3.8). 
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Figure 3.5. lEX Chromatography of wild type aB*crystallin and fraction analysis. The 
wild type aS-crystallin was initially purified by lEX (A), and the appropriate fractions for 
pooling were identified by reducing SDS*PAGE (B). Fractions 3-23 inclusive were 
enriched with aD-crystallin and were pooled to give a 2lml pool volume. The pool 
excluded contaminating proteins, which co-eluted with aS-crystallin in fractions 27 
onwards under higher NaCl concentrations. 
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Figure 3.6. SEC Chromatography of wild type a.B-crystallin and fraction analysis. The 
wild type aB-crystallin was further purified by SEC (A), and the appropriate fractions for 
pooling were identified by reducing SDS-PAGE (B). Fractions 35-49 inclusive were 
enriched with aB-crystallin and were poo]ed to give a 1 5ml pool volume of 1.82 mg/ml. 
A number of low intensity bands were present in the pooled material at low and high Mwt, 
which may be dimer (40 kDa) and breakdown products of the pool material . 
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Figure 3.7. Analysis of additional species in the wild type aS-crystallin SEC pool. The 
Ponceau stain of the SEC pool identifies the wild type band at 20 kDa, showing the 
greatest intensity. Two additional bands are also evident at 28 k.Da and 40 kDa. There is 
a trace amount of the lower Mwt proteins at 17 kDa, however is masked due to the large 
wild type band. The immunoblotting confirms that the bands at 28 kDa and 40 kDa are 
wild type aS-crystallin by showing a signal when probed with aS-crystallin mouse 
monoclonal 2D2B6 clone generated to chicken aS-crystallin. The bands at 17 kDa are 
not detected by the immunoblotting suggestive of a contaminant. 
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Figure 3.8. Dynamic Light Scattering analyses of aS-crystallin wild type. The data 
shown represents the average of 3 rw1s, each of which consisted of 5 data accumulations. 
Figure 3.8A shows the 3 data sets overlayed and confirms that the wild type oligomer 
accounts for 100% of the protein in the SEC pool. Figure 3.88 shows the corresponding 
histogram and (C) represents the intensity or level of light scattering produced by the aD-
crystallin wild type. 
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3.3.3.2. K174X aD-crystallin 
The Kl74X protein expressed (see Figure 3.2F) was purified following the 
protocol detailed in Section 2.6. The first chromatography step used lEX chromatography 
to remove contaminating proteins and allow the isolation of the K174X aS-crystallin. A 
typical lEX purification is shown in Figure 3.9. The K174X protein was co-eluted under 
higher NaCI concentrations with a range of contaminating proteins. This was identified 
by SDS-PAGE analysis of the appropriate fractions (see Figure 3.98) and subsequently 
fractions 35·43 inclusive were pooled giving a 15ml pool volume. The pool criteria 
excluded those fractions (F44 onwards) with additional contaminating proteins despite the 
presence ofthe K174X aB-crysta1Iin. 
The second stage of the purification was SEC, which would further resolve K174X 
aS-crystallin from the contaminating proteins carried forward in the lEX pool. The lEX 
pool was concentrated to 0.5ml prior to SEC. The SEC purification resulted in the 
recovery of 4mg of K174X aS-crystallin (see Figure 3.1 OA). The Kl74X aS-crystallin 
was well resolved as a single species as shown in the SEC profile (see Figure 3.1 OA), and 
SDS-PAGE analysis of these fractions identified fractions 34-42 to be enriched and were 
subsequently pooled to give a total pool volume of 9ml at 0.4 mg/ml (see Figure 3.10S). 
The yield was compromised by the exclusion of fTactions from the SEC pool 
where the Kl74X was co eluted with a low level of contaminating bands (see Figure 
3.108, Fraction 44 and 46). The SEC was successful in resolving the majority of 
contaminating proteins that were carried forward from the lEX (see Figure 3.9). SEC pool 
material was divided into 0.5ml aliquots and stored at -80°C. 
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Figure 3.9. lEX Chromatography of K174X a.B-crystallin and fraction analysis. The 
K174X aB~crystallin was initially purified by lEX (A), and the appropriate fractions for 
pooling were identified by reducing SDS-PAGE (B). Fractions 35-43 inclusive were 
enriched with all-crystallin and were pooled to give a 9 ml pool volume. The pool 
excluded contaminating proteins, which co-eluted with all-crystallin in fractions 45 
onwards. 
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Figure 3.1 0. SEC Chromatography of K174X a.B-crystallin and fraction analysis. The 
K174X a.B-crystallin was further purified by SEC (A), and the appropriate fractions for 
pooling were identified by reducing SDS-PAGE (B). Fractions 34·42 inclusive were 
enriched with aS-crystallin and were pooled to give a 9ml pool volume of 0.4 mg/ml. 
Although fraction 44 and 46 contained K174X aB-crystallin, they were discarded due to 
the presence of high molecular weight contaminating proteins. The contaminating 
proteins carried forward in the lEX pool are removed subsequently in the latter stages of 
the SEC. 
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3.3.3.3. Al71X aD-crystallin 
The A171X protein expressed (see Figure 3.20) was purified following the 
protocol for soluble protein detailed in Section 2.6. A typical lEX purification is shown in 
Figure 3.11A. The Al71X protein was co-eluted under high NaCl concentrations with a 
range of contaminating proteins as shown by SDS-PAGE analysis of the appropriate 
fractions (see Figure 3.11 B). Fractions 31-45 inclusive were pooled giving a ISm I pool 
volume. The pool criteria excluded those fractions (F46 onwards) with additional 
contaminating proteins despite the presence of the A 171 X aS-crystallin. 
The SEC purification resulted in the recovery of 36mg of A171X uS-crystallin 
(see Figure 3.12A). The A171X uS-crystallin was resolved as a single species up to 
fraction 44, after which, the A171X was co-eluted with a nwnber of contaminating 
proteins (see Figure 3.128). Fractions 33-44 were enriched with A171X uS-crystallin 
and pooled to give a volume of 12ml at 3.0 mg/ml. The SEC was successful in resolving 
the majority of contaminating proteins that were carried forward from the lEX (see Figure 
3.11 ). SEC pool material was divided into 0.5ml aliquots and stored at -80°C. 
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Figure 3 .11. lEX Chromatography of A 171 X aB-crystallin and fraction analysis. The 
A171X aB-crystallin was initially purified by lEX (A), and the appropriate fractions for 
pooling were identified by reducing SDS-PAGE (B). Fractions 31-45 inclusive were 
enriched with aS-crystallin and were pooled to give a 15ml pool volume despite 
containing contaminating proteins. The pool excluded additional contaminating proteins, 
which co-eluted with aS-crystallin in fractions 46 onwards. 
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Figure 3.12. SEC Chromatography of A171X aS-crystallin and fraction analysis. The 
Al71X aB-crystallin was further purified by SEC (A), and the appropriate fractions for 
pooling were identified by reducing SDS-PAGE (B). Fractions 33-44 inclusive were 
enriched wjth aB-crystallin and were pooled to give a 12m I pool volume of 3.0 mg/ml. 
Although fraction 45-49 contained significant levels of A171X aB*crystallin, 
they were discarded due to the presence of high molecular weight contaminating proteins. 
The contaminating proteins carried forward in the lEX pool are removed subsequently in 
the latter stages of the SEC. 
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3.3.3.4. 450deiA aD-crystallin 
The 450delA aB-crystallin was expressed as inclusion bodies (see Figure 3.2A) 
and required solubilisation with 6M urea to facilitate further purification by lEX. Prior to 
urea solubilisation, the inclusion bodies were initial1y purified by washes using detergent 
Triton-X and NaCI to remove cell debris, an advantage of inclusion body expression. The 
washes resulted in white inclusion bodies, which are indicative of inclusions of high purity 
(see Section 2.7). The solubilisation of 450delA inclusion bodies in 6M urea required 4 h 
incubation whilst gently mixing. This insolubility supports the literature stating that the 
mutant is highly insoluble and is found in large plaques in the disease state, (Berry et al., 
2001). 
The solubilised 450delA aB~crystallin was purified by lEX, (see Figure 3.13A). 
The advantage of inclusion body purification is the ability to remove the majority of cell 
debris prior to the lEX, highlighted by the relatively low number of contaminating bands 
shown in the SDS-PAGE analysis of the lEX load (see Figure 3.13.B, lEX load). 
Fractions 3-19 inclusive were enriched with 450delA aS-crystallin and were subsequently 
pooled, giving a 17 ml pool volume containing 60mg of the mutant in 6M urea. The SDS-
p AGE analysis revealed a higher Mwt protein migrating to approx. 42 kDa and a number 
oflower Mwt bands (see Figure 3.13.B). 
The nature of these proteins was analysed by immunoblotting to assess whether 
they were of 450delA aS-crystallin origin or contaminants (see Figure 3.14). The 
450delA aS-crystallin lEX pool was probed with the 2D2S6 monoclonal aS-crystallin 
antibody in parallel with the wild type SEC pool, which in previous analyses by 
immunoblotting confirmed bands at 40 kDa and 28 kDa were of wild type aB-crystallin 
origin (see Figure 3.7). Figure 3.14 clearly shows that the band migrating to approx. 42 
kDa was immunopositive for 450delA aS-crystallin, thus suggesting a dimer. The lower 
Mwt bands were not detected therefore it was likely that these bands represented 
contaminating proteins. The proportion of the 3.5 mg/ml lEX pool represented by these 
low Mwt proteins was negligible and would not be visible in SDS-PAGE analysis of 
450delA aS-crystallin under typical experimental conditions of 0.1-0.2 mg/ml. 
One of the disadvantages of protein expression in inclusio~_~o~ie~_is ~he_11:eeg to ___ .. 
------ -denantre-tlie-protein to allow- solubilisation and subsequent purification with 6 M urea. 
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The 450delA aB-crystallin lEX purified material was in a denatured form and needed 
refolding in order to obtain a functional protein that could be subsequently characterised. 
The refolding required buffer exchange into aqueous buffer and is detailed in Section 
3.3.4. 
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Figure 3.13. lEX Chromatography of 450deJA aB-crystallin and fraction analysis. The 
450delA aB-crystallin was initially purified by lEX (A), and the appropriate fractions for 
pooling were identified by reducing SDS-PAGE (B). Fractions 3-19 inclusive were 
enriched with aB-crystallin and were pooled to give a 17m1 pool. The load material was 
relatively pure after detergent washes. 
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Figure 3.14. Analysis of additional proteins present in the 450delA aS-crystallin IEX 
pool by Immunoblotting. A higher Mwt band (approx. 42 kDa) in the 450delA aB-
crystallin lEX pool was suggestive of a dimer. Confirmation that the protein was of 
450delA aB-crystallin origin was achieved by immunoblotting with monoclonal wild type 
aS-crystallin antibody 2D2B6, which resulted in a signal for the monomer at 21 kDa and 
also the high Mwt band at 42 k.Da. The wild type a.B-crystallin SEC pool was also 
analysed in parallel as a marker, where dimer (40 kDa), a band at 28kDa and monomer 
(20 kDa) have been identified previously (see Figure 3.7). 
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3.3.3.5. 464deiCT aD-crystallin 
The 464delCT aS-crystallin like the 450delA aS-crystallin construct was 
expressed as inclusion bodies (see Figure 3.2S) therefore, subsequent purification also 
required the use of 6M urea to solubilise the inclusion bodies, thus facilitating further 
purification by lEX (see Section 2.7). The washes resulted in white inclusion bodies, 
which are indicative of inclusions of high purity (see Section 2. 7). The solubilisation of 
464delCT inclusion bodies in 6M urea required a 4 h incubation whilst gently mixing. 
This insolubility was similar to that experienced with the 450delA aS-crystallin and again 
supports the literature where the 464delCT mutant was found to accumulate as aggregates 
in muscle tissue of patients suffering from myofibrillar myopathy (MM) (Selcen and 
Engel, 2003). lEX chromatography was used to remove contaminating proteins and allow 
the isolation of the 464delCT protein. A typical lEX purification is shown in Figure 
3.15.A. The 464delCT aB-crystallin was eluted at the start of the NaCl gradient however, 
the yield of 464delCT aS-crystallin was compromised by co elution with a protein of 
approx 26 kDa shown in fractions 19-22. SDS-PAGE analysis of the appropriate 
fractions (see Figure 3.15.B) identified fractions 23-32 inclusive to be enriched with 
464delCT aB-crystallin and were subsequently pooled, giving a 10 ml pool volume 
containing 20mg of the mutant in 6M urea. Refolding of the 464delCT aS-crystallin is 
detailed in Section 3.3.4. 
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Figure 3.15. lEX Chromatography of 464delCT aB-crystallin and fraction analysis. The 
464delCT aS-crystallin was initially purified by lEX (A), and the appropriate fractions 
for pooling were identified by reducing SDS·PAGE (B). Fractions 23-32 inclusive were 
enriched with aB-crystallin and were pooled to give a 1 Oml pool. Fractions 19-22 were 
excluded despite significant levels of 464delCT, due to the presence of a contaminating 
band at approx. 26 kDa. 
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3.3.3.6. El64X aD-crystallin 
The E164X aB-crystallin was expressed as inclusion bodies (see Figure 3.2D) 
therefore, subsequent purification utilised the same protocol as the 450delA and 464delCT 
aB-crystallin (see Section 2. 7). The detergent washes resulted in white inclusion bodies, 
which are indicative of inclusions ofhigh purity (see Section 2.7). The El64X inclusion 
bodies were solubilised in 6 M urea more readily than the 450de1A and 464de1CT aD-
crystallin inclusion bodies. The El64X mutation results in a 12 amino acid residue 
truncation, where as the 450delA and 464delCT aB-crystallin mutations produce more 
extreme alterations to the C-terminal extension by the introduction of novel peptides, 
therefore the increased solubility observed for the E164X aS-crystallin inclusion bodies is 
representative of the severity of the C-terminal extension modifications and suggests an 
important role of the C-terminal extension in maintaining solubility. lEX chromatography 
was used to remove contaminating proteins and allow the isolation of the El64X protein. 
A typical lEX purification is shown in Figure 3.16.A. The El64X aB-crystallin was 
eluted at the start of the NaCl gradient followed by very low levels of contaminating 
protein, which peaked at 37, 56 and 78 min (see Figure 3.16.A). SDS-PAGE analysis (see 
Figure 3.16.B) shows that the lEX load was almost entirely pure except for a trace amount 
of a band at approx 27 k.Da. SDS-PAGE analysis identified fractions 11-26 inclusive to 
be enriched with El64X aS-crystallin and were subsequently pooled (see Figure 3.22B), 
giving a 16 ml pool volume yielding 70 mg of the mutant in 6M urea. Refolding of the 
E164X aB-crystallin is investigated in Section 3.3.4. 
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Figure 3.16. lEX Chromatography of E164X aS-crystallin and fraction analysis. The 
E164X aS-crystallin was initially purified by lEX (A), and the appropriate fractions for 
pooling were identified by reducing SDS-PAGE (B). Fractions 11-26 inclusive were 
enriched with aS-crystallin and were pooled to give a 1 Oml pool. The lEX load was 
almost entirely pure following the detergent washes. 
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3.3.3.7. E165X aB-crystallin 
The E165X aS-crystallin was, like the El64X all-crystallin construct, expressed 
as inclusion bodies (see Figure 3.2E) and was purified using the 6 M urea solubilisation. 
The E 165X inclusion bodies were solubilised immediately when treated with 6M urea 
suggesting that extension ofthe El64X aS-crystallin C-terminal by just one glutamic acid 
can improve the solubility of aS-crystallin. This enhanced solubility correlates with the 
literature, where the E164X aS-crystallin mutation has been observed in the rat lens 
nucleus following proteolysis with LP82 and M-calpain (Ueda et al., 2002) and in human 
lens fiber cells growing in lens capsules following cataract surgery (Colvis et al., 2000), 
however removal of the terminal 11 amino acids is not disease causing for aS-crystallin 
but is observed for aA-crystallin in human diabetic lenses (Thampi et al., 2002). 
A typical lEX purification is shown in Figure 3.17.A. SDS-PAGE analysis (see 
Figure 3.17.S) shows that the El65X aS-crystallin was co eluted with a band ofapprox 
30kDa. Fractions 7-16 inclusive were enriched with El65X aS-crystallin and were 
subsequently pooled (see Figure 3.17.S), giving a 10 ml pool volume yielding 30 mg of 
the mutant in 6M urea. The pooling criteria excluded fractions 2-6 due to the presence of 
the contaminant band at 30 kDa. Refolding of the E 165X aS-crystallin is investigated in 
Section 3.3.4. 
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Figure 3.17. lEX Chromatography of E 165X aS-crystallin and fraction analysis. The 
E165X aB-crystallin was purified initially by lEX (A), and the appropriate fractions for 
pooling were identified by SDS-PAGE (B). Fractions 7-16 inclusive were enriched with 
E 165X aS-crystallin and were pooled to give a 1 Oml pool. Fractions 2-6 were excluded 
despite significant levels of E 165X, due to the presence of a contaminating band at 
approx. 30kDa. Additional contaminant bands were resolved under high NaCl conditions 
shown in fractions 26 onwards. 
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3.3.3.8. Q151X aD-crystallin 
The Q151X aS-crystallin is a naturally occurring mutation causing Myofibrillar 
myopathy (MM), like the 464delCT aS-crystallin, and was also expressed as inclusion 
bodies (see Figure 3.2C) therefore, subsequent purification also required the use of 6 M 
urea to solubilise the inclusion bodies, thus facilitating further purification by lEX (see 
Section 2.7). The Ql51X aS-crystallin mutation involved a 25 amino acid truncation of 
the whole C-terminal extension so theoretically should be more insoluble than the El64X, 
however the Q 151 X inclusion bodies surprisingly were almost immediately solubilised in 
6M urea compared to the 464delCT and 450delA aS-crystallin, which both required a 4h 
incubation to achieve solubilisation. 
A typical lEX purification is shown in Figure 3.18.A and shows that the Q151X 
aS-crystallin was eluted under low NaC1 conditions. SDS-PAGE analysis identified a 
very low intensity 30 kDa protein, which is difficult to visualise in Figure 3.18.B, however 
the protein co eluted with Q 151 X aS-crystallin over the leading edge of the Q 151 X peak 
and was represented by a shoulder (see Figure 3.18.A). The 30 kDa protein was resolved 
from fractions 14 onwards allowing fractions 14-24 inclusive to be pooled (see Figure 
3.18.S), giving an 11 ml pool volume yielding 18 mg of the mutant in 6M urea. 
Refolding of the Q 151 X aB-crystallin is investigated in Section 3.3.4. 
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Figure 3.18. lEX Chromatography of Q151X aS-crystallin and fraction analysis. The 
Q 151 X aB-crystallin was purified initially by lEX (A), and the appropriate fractions for 
pooling were identified by reducing SDS-PAGE (B). Fractions 14-24 inclusive were 
enriched with aB-crystallin and were pooled to give a llml pool. Fractions 3-13 were 
excluded despite significant levels of Q 151 X, due to the presence of a contaminating band 
at approx. 30 kDa shown as a shoulder on the leading edge of the peak lEX. Additional 
contaminant bands were resolved under high NaCI conditions shown in fractions 45 
onwards. 
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3.3.4. THE EFFECT OF THE C-TERMINAL MUTATIONS ON THE 
ABILITY OF THE aD-CRYSTALLIN MUTANTS TO REFOLD 
The C-terminal mutations of wild type aS-crystallin have been suggested to be 
necessary for proper folding of aS-crystallin, subunit interactions and chaperone activity, 
(Harrington et al., 2004) and its solubility, (Carver et al., 1995). This suggested that the 
refolding ofthe 450delA, 464delCT, Q151X, E164X and El65X aS-crystallin, whose C-
terminal were significantly altered and expression was in the form of inclusion bodies, 
may result in protein aggregation and precipitation. 
Initial refolding analysis using 450delA aS-crystallin (see Section 3.3.4.1), was 
unsuccessful due to the extreme insolubility of the mutant. The refolding analysis, 
therefore was continued and finally optimised using Q 151 X aS-crystallin (see Section 
3.3.4.2), after which the optimised conditions were applied to the 450delA aS-crystallin 
(see Section 3.3.4.3) and the other remaining aS-crystallin mutants (see Sections 3.3.4.4-
3.3.4.6) to achieve the recovery of a soluble aS-crystallin mutant. The 450delA and 
464delCT aS-crystallin could only be refolded successfully when associated with wild 
type aS-crystallin, highlighting their extreme propensity to aggregate. The refolding 
efficiency for each mutant aS-crystallin is summarised in Section 3.3.4.7. 
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3.3.4.1. Initial refold analysis using 450delA aD-crystallin 
The basic refolding protocol required a one step dialysis of the lEX pool material 
into aqueous buffer (IOmM Tris-HCl, 150mM NaCJ, lmM EGTA, 5mM EDTA, pH 7.5) 
over a 4 h period. This dialysis resulted in complete precipitation of the mutant a.B-
crystallins, with the exception of the E 165X a.B-crystallin, which yielded 54% soluble 
protein following the one-step dialysis procedure (see Section 3.3.4.4). Figure 3.19 shows 
an example of this complete precipitation observed for the 450delA a.B-crystallin. 
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Figure 3.19. The 450delA a.B-crystallin refolding procedure using a one step dialysis. 
The recovery of 450delA a.B-crystallin is entirely in the insoluble pellet fraction, with no 
evidence of any 450delA in the supernatant fraction. 
Optimisation of the refolding process was required in order to obtain soluble 
mutant a.B-crystallin, thus allowing the characterisation of the 450delA, Q 151 X, 
464delCT and E164X a.B-crystallin. 
Initial optimisation of the 450delA a.B-crystallin refold, included varying the 
number of dialysis steps, dialysis temperature and duration of steps, but all failed to 
recover soluble 450delA a.B-crystallin. Therefore, the chaperone capabilities of the wild 
type a.B-crystallin were utilised to stabilise the 450delA a.B-crystallin during the dialysis 
process. 
The wild type and 450delA aB-crystallin were combined at a 1:1 molar ratio ( 10:1 
ratio of wild type to 450delA a.B-crystallin was investigated, but showed no improvement 
over the 1:1 combination). Initial combination experiments investigated the number and 
duration of dialysis steps. A dialysis utilising a 6-4-3-2-1-0M urea concentration step 
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reduction with a 12 h step interval duration at 4 °C, yielded a 23% recovery of soluble 
450delA aB-crystallin, (see Figure 3.20, post dialysis supernatant), however, the length of 
the procedure carried out to achieve the yield was not practical (60 h) and the amount of 
mutant was not sufficient to perform any characterisation work. Incorporating the 
450delA/ wild type aB-crystallin into the one step dialysis ( 4 h duration) even resulted in 
the complete precipitation of the complex. 
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Figure 3.20. Refolding 450delA aB-crystallin in association with the wild type aB-
crystallin. The step dialysis with 450delA combined with wild type, yields 23% recovery 
of soluble 450deW wild type. 
This data confirmed that despite the presence of wild type aB-crystallin, it was 
actually the gradual reduction in urea concentration, which was successful in yielding 
soluble protein. Further optimisation looked to develop a refolding protocol, which would 
utilise an intermediate urea concentration, whilst maintaining a relatively short dialysis 
duration. 
This optimisation was carried out with Q151X aB-crystallin due to the extreme 
insolubility of 450delA aB-crystallin as a homogenous solution. The recovery of a 
homogenous protein solution rather than a combination with wild type aB-crystallin 
would be preferred in order to achieve optimum characterisation of the aB-crystallin 
mutants. 
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3.3.4.2. Further refold optimisation using Q151X aB·crystallin: Analysis of the urea 
and protein concentration prior to dialysis 
In section 3.3.4.1, I discussed how a gradual reduction of the urea concentration 
resulted in a more efficient refolding process. The C-terminal domain of aS-crystallin 
begins to fold at.:; 2.5M concentration of urea, (SW1 et al., 1998). Therefore, the reduction 
of the urea concentration from 6M-1M would allow partial refolding to occur prior to 
dialysis, thus resulting in a relatively more stable protein being exposed to the aqueous 
buffer. 
The relatively high protein concentrations of the mutant aS-crystallin prior to 
refolding (3-5 mg/ml) could be influential on the ability of the precipitation prone mutants 
to refold efficiently. High protein concentrations are known to affect reactions including 
folding and association of proteins resulting in irreversible aggregation, (Ellis and Minton, 
2003), therefore, lowering the protein concentration prior to the reduction of the urea 
concentration may further improve the solubility during refolding, by reducing the 
frequency of collisions. The conditions investigated are detailed in Table 3.1 and looked 
to optimise both the protein concentration and the urea concentration prior to dialysis. 
The mutant used for the experiment was Q 151 X aS-crystallin. 
Table 3.1. Optimisation of the urea and mutant concentration for successful refolding 
Q 151 X aS-crystallin Urea Cone. 
Sample No. 
Cone. in 6M Urea (mg/ml) (M) 
1 1.6 6 
2 1.0 6 
3 0.5 6 
4 0.25 6 
5 1.6 1 
6 1.0 1 
7 0.5 1 
8 0.25 1 
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The samples were dialysed for 4 hat ambient temperature (l6°C) and the dialysate 
clarified by centrifugation for 30 min at 4 °C at 255000 x g. The OD280 was measured for 
the soluble and insoluble fractions, from which the protein concentration was determined 
using the extinction coefficient for the Q151X aS-crystallin of 0.8mg" 1ml" 1cm·'. 
Extinction Coefficients were determined from the amino acid sequence using the Emboss 
Pepstats programme (www.ebi.ac.uk/emboss/pepinfoD. 
The yields of soluble Q 151 X aB~crystallin are shown in Figure 3.21 and represent 
the amount of soluble protein recovered in the centrifugation supernatant, as a percentage 
ofthe amount ofQ151X aS-crystallin dialysed. 
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Figure 3 .21. The effect of protein and urea concentration on soluble Q 151 X aS-crystallin 
yield. The optimisation of sample conditions required for successful refolding involved 
varying the urea concentration and the Q 151 X concentration in urea prior to refold 
dialysis. 
Figure 3.21 shows that reducing the protein concentration results in an increased 
yield of soluble Q 151 X aB~crystallin, which is further increased by the dilution of urea 
from 6M to 1M prior to dialysis. For example, Q151X was diluted to 0.25mg/ml using 
6M urea buffer, followed by a 6X dilution of urea to 1M, which produced a protein 
concentration of0.04 mg/ml. These refolding conditions resulted in a soluble Q151X aS-
crystallin yield of24%. 
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This is significant as it allows characterisation of the mutant without the presence 
of other stabilising chaperones, however the resulting protein concentration of 0.013 
mg/ml was too low to enable any characterisation of mutant aB-crystallin. 
The refold was performed for a larger 1.2 mg scale with the aim to increase the 
amount of recovered soluble Q 151 X aB-crystallin. The refolding utilised the optimised 
conditions, where the Ql51X aS-crystallin was diluted to 0.25 mg/ml using 6 M urea 
buffer, followed by a 6X dilution of the urea concentration to 1M prior to dialysis. The 
duration of the centrifugation step was increased to 2 h from 30 min to ensure all the 
aggregated Q 151 X aB-c1ystallin was sedimented. The soluble Q 151 X aB-crystallin was 
concentrated from 0.024 mg/ml using an Amicon spin concentrator (Millipore, Watford, 
UK) to 0.255 mg/ml, resulting in a 20-fold concentration factor. The yield of soluble 
Q151X aB-c1ystallin over the spin concentration was 66% resulting in an overall 17% 
yield. The resulting yields are summarised in Table 3.2. 
Table 3.2. Yield ofQ151X aB-crystallin over the diluted refolding process from 1.2 mg 
Stage Q151X Volume Total Q151X Yield Step Yield 
cone. mg/ml ml Mg 
Protein dilution 0.25 4.853 1.2 100 100 
Urea dilution 0.04 29.01 1.2 100 100 
Post dialysis 0.013 24 0.31 25 25 
and clarification 
Post concentration 0.26 0.17 0.20 17 66 
The yield and concentration of the Q 151 X was sufficient for characterisation, 
however, with only 0.17 ml of the refolded mutant, the final volume is not sufficient for 
any subsequent experiments. 
The refold was performed for a larger 12 mg scale with the aim to provide both 
the required concentration and volume of Q 151 X aB-crystallin. The scale up of the refold 
procedure was limiting due the large process volumes encountered upon dilution to 0.25 
mg/ml and 1M urea. A starting amount of Q151X of 12 mg (7.3 mg/ml) resulted in a 
dialysis volume of approx. 300m I, therefore after the dialysis, a preliminary concentration 
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was required using an Amicon spin concentrator (Millipore, Watford, UK) to 48ml to 
accommodate the volumes held by the centrifuge. Following a 2 h centrifugation a final 
concentration was performed to a volume of 1ml. The yield of soluble Q151X aS-
crystallin over the spin concentration was 4.6% resulting in an overall 0.91% yield. 
Despite this fall in yield compared to the 1.2 mg refold (see Table 3.4), the resulting 
Ql51X aS-crystallin was at 0.11 mg/ml in lml volume, which was sufficient for further 
characterisation work. The resulting yields are summarised in Table 3.3. 
Table 3.3. Yield ofQ151X aS-crystallin over the diluted refolding process from 12mg 
Stage Q151X Volume Total Q151X Yield Step Yield 
cone. mg/ml ml mg 
Protein dilution 0.25 46.72 12 100 100 
Urea dilution 0.04 280.32 12 100 100 
Post dialysis 0.035 48 1.7 14.2 14.2 
and clarification 
Post concentration 0.11 1.0 0.11 0.91 4.6 
The yield of 0.91% was very low and subsequently, an experiment combining the 
Q151X with wild type aS-crystallin at a 1:1 molar ratio was carried out to assess whether 
a greater yield of Q 151 X aB-crystallin could be achieved. Although the product would 
not be homogenous it would still be very useful to investigate the effect of the Ql51X 
mutation upon the function of aS-crystallin. 
Initially the refold of Q151X/ wild type was performed without any dilutions prior 
to dialysis (direct dialysis protocol), however resulted in compete precipitation of the 
Q 151 XI wild type aS-crystallin. The optimised refolding conditions, which involved 
modification to the urea and protein concentration prior to dialysis (diluted protocol), were 
applied to the Q 151 X/ wild type aS-crystallin and the resulting yield data are shown in 
Table 3.4. The refolded complex ofQ151X/ wild type aS-crystallin was shown by SDS-
PAGE to maintain the 1:1 molar ratio throughout the refolding (data not shown), thus the 
yield data represents a 1:1 complex of wild type to Q 151X aS-crystallin. 
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Table 3.4. Refolding efficiency ofQ151X/ wild type using the diluted protocol. 
Stage Ql51X/ wt Volume Total Ql5lX/ Yield 
cone. (ml) wt (%) 
(mglml) (mg) 
Pre dialysis 5.2 2.4 12.4 100 
Protein dilution 0.25 50.0 12.4 100 
Urea dilution 0.042 300 12.4 100 
Post concentration 0.45 3.0 1.35 11 
The refolding of Q 151 X associated with the wild type aS-crystallin, following the 
diluted protocol, resulted in a 10-fold increase of the yield of soluble Ql51X/ wild type 
aS-crystallin (11 %) compared to the homogenous QISIX aS-crystallin (0.91 %) as 
shown in Table 3.5. 
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3.3.4.3. Refolding of 450delA aD-crystallin 
The recovery of soluble homogeneous Q 151 X aS-crystallin using the diluted 
protocol (see Section 3.3.4.2, Figure 3.7) suggested the possibility that soluble 
homogeneous 450delA aB-crystallin may be obtained utilising this method. The 
optimised refolding conditions resulted in complete precipitation of the 450delA aS-
crystallin as a homogeneous solution, however, yielded soluble 450delA aS-crystallin 
when combined with wild type aB-crystallin at a 1:1 molar ratio (see Figure 3.22). 
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Figure 3.22. Refold of 450delA/ wild type aS-crystallin using diluted protocol. The 
centrifugation step was developed from 30 min to 2 h to ensure entire sedimentation of 
aggregated protein. The resulting 2 h supernatant was concentrated to 0.48 ml to achieve 
a sufficient protein concentration. 
The soluble 450deW wild type aS-crystallin, (see Figure 3.26, post concentration 
supernatant), was concentrated using an Amicon spin concentrator (Millipore, Watford, 
UK) to achieve the required protein concentration. The yield of soluble 450delA/ wild 
type aS-crystallin is detailed in Table 3.5. 
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Table 3.5. Yield of 450delA: wild type a.B-crystallin mixture ( 1:1 molar ratio) over a 1.2 
mg diluted refolding process 
Stage 450delA: WT Volume Total Yield Step Yield 
cone. (ml) 450delA/ wt (%) (%) 
(mg/ml) (mg) 
Pre dialysis 1.62 0.75 1.2 100 100 
Protein dilution 0.25 4.83 1.2 100 100 
Urea dilution 0.042 29.16 1.2 100 100 
Post centrifugation 0.024 27.5 0.66 55 55 
Post concentration 0.361 0.48 0.159 13 24 
The diluted protocol for refolding resulted in a 13% yield soluble 450deW wild 
type aS-crystallin, (0.361 mg/rnl), similar to the 17% yield of Q 151 X a.B-crystallin, 
(0.255mg/ml). The significant difference however, is that the Q151X aS-crystallin could 
be refolded as a single protein solution, whereas the 450delA aS-crystallin required 
combination with the wild type aB-crystallin for soluble recovery. 
3.3.4.4. Refolding of E165X aD-crystallin 
Refolding of the E 165X aS-crystallin was successful without any modifications to 
the urea and protein concentrations prior to dialysis. The dialysis showed no visible 
precipitate, typically seen with 450delA and Q151X aB-crystallin at this stage. 
Clarification by centrifugation at 4°C for 2h at 255000 x g produced a clear pellet. The 
yield of soluble El65X aS.crystallin was quantified by OD2so measurements (see Table 
3.6.) 
Table 3.6. Yield ofE165X aS-crystallin from direct one step dialysis 
Stage El65X cone. Volume Total Yield Step 
(mg/ml) (ml) E165X (%) Yield 
(mg) (%) 
' 
Pre dialysis 1.6 6 9.7 100 100 
Post centrifugation 0.90 6 5.3 54 54 
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The yield of E165X aB-crystallin was 54% at a protein concentration of 0.9 
mg/ml. The refolding data suggests that the modifications to the C-terminal extension 
introduced by the Ql51X and 450delA mutations produced mutant aB-crystallin lmable to 
refold by direct dialysis due to their extreme insolubility under aqueous conditions. In 
contrast, the E 165X mutation produced a mutant aB-crystallin whose solubility was 
significantly greater thus was able to refold to achieve a 54 % yield of soluble E 165X aB-
crystallin. 
3.3.4.5. Refolding of 464delCT aD-crystallin 
Based on the refolding optimisation performed with Q 151 X aB-crystallin (see 
Section 3.3.4.2), an initial experiment was performed looking at the refolding efficiency of 
the 464delCT aB-crystallin as a homogeneous protein solution, using both the direct 
dialysis and diluted protocol. Both protocols resulted in complete aggregation of the 
464delCT aB-crystallin, thus yielding no soluble protein. Therefore, the dialysis 
experiments were repeated with the 464delCT aB-crystallin in combination with the wild 
type aS-crystallin at a 1:1 molar ratio (see Figure 3.23). 
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Figure 3.23 . Optimisation of the 464deJCT aB-crystallin refold process. The experiment 
investigated refolding in association with wild type aB-crystallin using both the diluted 
and the direct dialysis protocol. The association with wild type was successful in 
refolding 464delCT aB-crystallin using both dialysis protocols. 
Chapter 3-Results 132 
Figure 3.23 illustrates that the 464delCT aBMcrystallin when associated with the 
wild type aBMcrystallin can be successfully refolded to yield soluble protein without the 
need for dilution. The refold yields are detailed in Table 3.7 and 3.8. 
Table 3.7. Refolding efficiency of 464delCT/ wild type aB~crystallin using the diluted 
protocol 
Stage 464delCT/ Wt Volume Total Yield Step 
cone. (rnl) 464delCT/ Wt (%) Yield 
(mg/ml) (mg) (%) 
Pre dialysis 2.0 1.0 2.0 100 100 
Protein dilution 0.25 8.0 2.0 100 100 
Urea dilution 0.042 48.0 2.0 100 100 
Post centrifugation 0.024 48.0 1.2 60 60 
Post concentration 0.72 0.1 0.07 3.6 6 
Table 3.8. Refolding efficiency of 464delCT/ wild type aS-crystallin using the direct 
dialysis protocol 
Stage 464delCT/ Wt cone. Volume Total Yield 
(mg/ml) (ml) 464delCT/ Wt (mg) (%) 
Pre dialysis 2.0 1 2.0 100 
Post centrifugation 0.25 1 0.25 12.5 
The refold yield data clearly illustrates that although the diluted protocol yields a 
0.72 mg/ml solution, the volume was only 0.1 ml, which was not sufficient for any 
subsequent experiments. The direct dialysis refold protocol with no dilution however, 
resulted in a relatively lower concentration of 0.25 mg/ml but in a 1 ml volume, which 
therefore achieves both objectives of sufficient concentration and volume to allow 
characterisation to be performed. 
The 464delCT, can be successfully refolded without the need for dilution, however 
requires the presence of a 1:1 molar ratio of wild type aS-crystallin. This suggests 
although very unstable, the 464delCT mutation has a less severe effect on the olubility 
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than the 450delA (whose refold requires both dilution and combination with wild type) 
and a more severe effect than the Q 151 X, which can be successfully refolded as a 
homogenous protein solution using the diluted protocol. 
3.3.4.6. Refolding of E164X aD-crystallin 
As seen previously in Section 3.3.4.4, the E165X was successfully refolded as a 
homogenous solution without the need for dilution, therefore we should expect the 
El64X, with only one less amino acid, to have similar solubility characteristics. An 
experiment investigated the refolding efficiency ofE164X aB-crystallin under the diluted 
and direct dialysis protocol as a homogenous protein (see, Figure 3.24). 
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Figure 3.24. Refolding efficiency of E164X using the diluted and direct dialysis 
protocols. The El64X aS-crystallin was found entirely in the pellet fraction when using 
the direct dialysis protocol however, with the diluted protocol, El64X aS-crystallin was 
observed in the soluble fraction. 
Figure 3.24 illustrates that the El64X aS-crystallin can be successfully refolded to 
yield soluble protein, but requires dilution of both the protein and urea concentration prior 
to dialysis. The refold yields are detailed in Table 3.9 and 3.10. 
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Table 3.9. Refolding efficiency ofE164X using the diluted protocol 
Stage E164X cone. Volume Total Yield 
(mg/ml) (ml) E164X (%) 
(mg) 
Pre dialysis 4.5 0.4 1.8 100 
Protein dilution 0.25 7.2 1.8 100 
Urea dilution 0.042 43.2 1.8 100 
Post centrifugation 0.021 43 .2 0.87 48 
Post concentration 0.21 0.5 0.11 13 
Table 3.10. Refolding efficiency ofE164X using the direct dialysis protocol 
Stage E164X cone. Volume Total Yield 
(mg/ml) (rnl) E164X (%) 
(mg) 
Pre dialysis 4.5 1 4.5 100 
Post centrifugation 0.08 1 0.08 1.8 
Both Figure 3.24 and Tables 3.9 and 3.10 clearly illustrate that the refolding yield 
of homogenous E 164 X aS-crystallin was optimal when using the diluted protocol and 
resulted in a 0.5 ml volume at 0.21 mg/ml. Despite the E164X aS-crystallin being only 
one glutamic acid shorter than the E l 65X aS-crystallin, it showed refolding requirements 
similar to the highly insoluble Ql51X aS-crystallin. This data strengthens the argument 
that the C-terminal extension is important for maintaining the solubility of aS-crystallin 
and those mutants, which, display extreme insolubility have been associated with various 
disease states. 
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3.3.4. 7. Summary of refold optimisation for aD-crystallin mutants 
The analysis of the refolding efficiency of the aB-crystallin mutants achieved 
optimised refolding protocols for each mutant aB-crystallin. These protocols were used 
for all future refolding as a means to provide material for characterisation experiments. 
Sunm1aries of subsequent refolding procedures are detailed in Table 3. 11 and show data 
from three separate refolds for each mutant aB-crystallin. 
Table 3 .11 . Summary of refold efficiency of aB-crystallin mutants 
Pre Yield Yield Standard Average 
aB-crystallin 
dialysis (mg) (%) Deviation Yield 
(Refold protocol) 
(mg) (±) (%) 
7.7 0.4 4.8 
450de iA/ wi ld type 
12.4 1.0 7.9 1.8% 6.8 
(Diluted) 
12.4 1.0 7.8 
12.3 1.2 9.6 
464deiCT/ wi ld type 
2.0 0.2 9.6 1.6% 10.5 
(Direct) 
2.0 0.2 12.4 
12.4 1.4 10.9 
Ql5lX/ wi ld type 
5.0 0.4 7.4 2.6% 10.2 
(Diluted) 
1.6 0.1 6.4 
12.0 0.2 1.7 
QJ5 1X 
11.7 0.2 1.7 0.4% 1.4 
(Diluted) 
11.7 0.1 0.9 
12.0 1.2 10.2 
E164X 
12.0 1.3 10.9 2.5% 12.0 
(Diluted) 
12.0 1.8 14.8 
6.3 0.7 10.6 
El65X 
1.2 0.1 8.9 1.6% 10.5 
(Direct) 
6.3 0.8 12.0 
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The purified and refolded a.B-crystallin mutants are illustrated in Figure 3.25. 
The SDS-PAGE analysis highlights the relative changes in Mwt conferred by the 
mutations. The 450delA and 464delCT a.B-crystallin are the only mutants whose 
insolubility required refolding in association with a.B-crystallin wild type. 
The Q151X was also refolded with the wild type to allow a direct comparison 
with the other disease mutants, however could be refolded as a homogenous complex. 
The 450delA mutation has a unique characteristic in that it is does not fonn a 1: I molar 
ratio with the wild type a.B-crystallin similar to the 464delCT and the Q 151 X aB-
crystallin. The SDS-PAGE analysis revealed that the wild type aB-crystalJin is present in 
excess compared to the 450delA aS-crystallin. 
In fact, this proved to be the maximum ratio compatible with protein solubility 
for the 450delA/ wild type a.B-crystallin complex and is in stark contrast to 464delCT a.B-
crystallin, where a 1 :I mixture with wild type aB-crystallin resulted in a refolded protein 
mixture with a 1: 1 molar ratio of wild type/ 464delCT a.B-crystalliu as shown by the equal 
intensity of the wild type and 464de1CT a.B-crystallin protein bands depicted in Figure 
3.25. 
The 450deiA a.B-crystallin is also unique in that the mutation introduces a novel 
extended C-terminal extension, which could potentially hinder the associations required to 
achieve a 1 : 1 ratio by physically masking the necessary binding sites. 
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Figure 3.25. Characterisation of the bacterially expressed and purified mutants used in 
this study by SDS-PAGE. The 450delA (arrow) and 464delCT (arrowhead) mutants 
could not be produced as individual soluble proteins and therefore were refolded in the 
presence of wild type aB-crystallin. 
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3.4. DISCUSSION 
The principal role of the C-terminal 'tail' had been identified as a polar 
solubilizing agent for the relatively hydrophobic sHSPs and the sHSP-client complex, 
which forms upon chaperone action, but are not involved in binding directly to the 
substrate (Smulders et aJ., 1996). They may also serve as 'spacers' in preventing subunits 
from approaching too close to one another which, without their presence, would result in 
aggregation and precipitation due to hydrophobic interactions between sHSP-dient 
complexes. lfthe polarity and flexibility of the extensions are disrupted, the solubility and 
chaperone activity of the protein are reduced significantly (Lindner et al., 2000). 
In aB-crystaJlin, there had not been any systematic analysis of the role of the C-
terminal extension and therefore no potential explanation of how alterations to the C-
temiinal extension disrupt the solubility of the protein. In this Chapter, I have investigated 
a series of mutations including two truncated C·terminal aB·crystallin mutants of interest 
(Kl74X and E165X), along with the three naturally occurring disease causing mutants 
(450delA, Ql51X and 464delCT) and the PTMs (E164X and A171X). This study 
investigated the role of specific regions of the C-terminal extension important in 
solubilisation of aB-crystallin oligomers, thus providing the basis for further 
characterisation of the relationship between the C-terminal extension, the chaperone 
function, oligomerisation and the relationship with disease. 
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3.4.1. The role of the C-terminal 'tail' in the solubilisation of 
a.B-crystallin 
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The role played by the C-terminal 'tail' in solubilising the aB-crystallin complex, 
would suggest that the naturally occurring mutations 450delA, 464delCT and Q151X aS-
crystallin, the post translational modification El64X and the truncation E165X aB-
crystallin, would be expressed as insoluble inclusion bodies with the post translational 
modification A171X and truncation K174X being expressed as soluble protein similar to 
the wild type aB-crystallin. The nature of the disease mutants is to form aggregates 
within the lens (450delA, E164X) and muscle tissue (464delCT and Q151X) thus, 
providing a link between the effect of a severely altered C-terminal and the solubility of 
the expressed protein. 
Expression of the aB-crystallin mutants in both bacterial and mammalian cells 
revealed an influence of the altered C-terminal on the solubility of aB-crystallin. In E. coli 
cells the 450de1A, 464delCT, Q151X, El64X and E165X aB-crystallin were expressed as 
inclusion bodies with soluble expression being observed for K174X and A171X aS-
crystallin. Similar effects were seen in mammalian MCF7 cells, where for the 450delA, 
464delCT, Q151X and the El64X aB-crystallin clear cytoplasmic aggregates were 
observed. In contrast, however the E165X aB-crystallin displayed a homogenous 
cytoplasmic distribution of aB-crystallin similar to the K174X, A171X and wild type aB-
crystallin. 
Further effects of the C-terminal mutations were evident in the varying ability of 
the recombinant aB-crystallin mutants to refold efficiently without aggregation. 
Refolding directly from 6 M urea to aqueous buffer resulted in rapid and complete 
aggregation of the 450delA, 464delCT, Q151X and E164X aB-crystallin, all of which 
were expressed in E. coli as inclusion bodies. In contrast, however the E 165X aS-
crystallin remained soluble resulting in a refolded, soluble protein showing similar 
solubility characteristics to E165X aB-crystallin expressed in MCF7 cells. 
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The highly insoluble a.B-crystallin mutants (the 450delA, 464delCT, Ql51X and 
E164X) were successfully refolded by lowering of the urea and protein concentrations 
prior to dialysis, thus allowing the protein to partially refold before exposure to the 
aqueous buffer and preventing immediate aggregation. 
It was evident that the C-terminal extension was playing a role in the solubility of 
these mutants and despite the expression of E 165X aS-crystallin as inclusion bodies, once 
refolded it was a relatively soluble protein. Despite its inherent insolubility, the El64X 
aB-crystallin was successfully refolded as a homogenous complex by partial refolding 
before dialysis to remove the denaturing buffer, showing a greater propensity to aggregate 
than the E165X aB-crystallin despite being only one glutamic acid shorter. 
The removal of the entire C-terminal extension by the Q 151 X mutation did not 
prevent the refolding and recovery of a soluble homogenous complex of the Q 151 X aS-
crystallin. The yield however, was significantly lower than the E164X aS-crystallin, 
highlighting the important role of both the flexible and the non-flexible C-terminal in 
maintaining solubility. Combination of the Q 151 X with the wild type aB-crystallin 
resulted in a 1 OX increase in the refold yield. 
Both the 450delA and 464delCT a.B-crystallin could only be refolded in the 
presence of the wild type a.B-crystallin, with the 464delCT aB-c.rystallin refolding by 
direct dialysis. The 450delA a.B-crystallin proved the most difficult to refold from 6M 
urea and keep soluble as both a combination with the wild type and prior lowering of the 
urea and protein concentration was required in order to produce refolded 450delA aS-
crystallin of a similar yield to the 464deiCT aB-crystallin. 
Expression and purification of the a.B-crystallin mutants has revealed that a 
sequentially modified C-terminal extension results in an equally sequential loss of 
solubility of the respective mutants. 
The data presented in this Chapter support the literature, which has shown that the 
tenninal 11 residues of aS-crystallin are highly mobile and the maintenance of its polarity 
and flexibilty facilitates solubilisation of the complex (Carver, 1999; Carver et al., 1992). 
Therefore, the 'tail' is present to offset the large degree of hydrophobicity exposed to 
solution by the aB crystallin. 
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The data in this Chapter identify specific regions of the C-terminal extension 
important in the solubilisation of aS-crystallin complex. All the aS-crystallin mutants 
whose C-terminal 'tail' had been removed or modified were highly insoluble but to 
varying degrees. The E164X, E165X and Q151X aS-crystallins are simple truncations 
removing the 'tail' region, whereas the 464delCT aS-crystallin incorporates an 8 codon 
missense mutation and a premature stop codon resulting in a 162 residue mutant. The 
450delA aS-crystallin shows the greatest modification by the introduction of a novel 35 
amino acid sequence producing a 184 residue protein. The relative solubility of the 
mutants is reflected by the nature of the specific mutation, with solubility diminishing as 
the C-tem1inal mutations become more severe. The A171X and Kl74X aS-crystallin 
mutants were soluble and were similar to the wild type suggesting that despite the 
truncations there were sufficient charge-charge interactions with the remainder of the C-
terminal 'tail' to ensure sufficient solubility. 
Most surprising are the differences in solubility between the E 165X and the 
E164X aS-crystallin, where both are expressed as inclusions in E.coli but during 
refolding the E 165X aB-crystallin proves to have a higher level of solubility. In a 
mammalian cell environment the E 165X aS-crystallin shows homogeneous cytoplasmic 
distribution similar to the wild type aS-crystallin~ however, the E164X aS-crystallin is 
highly insoluble and forms perinuclear aggregates similar to the Q 151 X aS-crystallin. 
The E165X and El64X mutations both involve the removal of the entire flexible 
'tail' (I6sEKP A VTAAPKKm) exposing the t63REEKt66 motif and the interface between 
the non-flexible and flexible part of the C-terminal extension. In addition, the removal of 
the entire 163REEK166 motif (Rl63X) also resulted in highly insoluble protein aggregates 
(Treweek et al., 2007). 
In contrast studies have shown that for aA-crystallin the sequential removal of this 
I63REEKt66 motif does not affect the solubility of the resulting aA-crystallin protein 
(Rajan et al., 2006) but does reduce the chaperone activity and oligomerisation. In 
contrast, other studies have shown the truncation of the terminal amino acid residue 
caused insolubilty of aA-crystallin (Aziz et al., 2007) and complete removal of the 
I63REEKt66 motif by the R157X mutation (aAts6) resulted in the formation of la!gc 
insoluble aggregates (Andley, U~ 1996). 
Chapter 3-Results 142 
The Raj an, 2006 study identified an important role for the 163REEKw, motif in the 
oligomerisation of aA-crystallin, especially the Arg163 which provides a positive charge 
for intersubunit electrostatic interactions in the C-terminal extension needed to form 
oligomeric complexes. (R4jan et al., 2006). 
A recent study of aD-crystallin by Ghosh et.al, 2006 saw the removal of the polar 
C-terminal sequence (155PERTIPITREE165) (Ghosh et al., 2006), which involved the 
disturbance of the I6JREEK166 motif and saw removal of the highly conserved IX/(IN) 
motif(159IPI 161 ). The removal ofthese two motifs, both ofwhich are found to participate 
in inter subunit interactions (Pasta et al., 2004; Rajan et al., 2006) resulted in poor 
solubility despite the retention of 1 0 of the tenninal 11 'tail' residues and little or no 
chaperone activity. A very recent study, which involved mutations of the Cwtenninal 
lysines and glutamic acid residues, resulted in proteins with altered oligomerisation and 
enhanced chaperone activity against amyloid fibril formation (Treweek et al., 2007). 
Therefore, the insolubility of El64X and E 165X aS-crystallin during refolding is 
primarily caused by the deletion of the C-terminal 'tail' region, however additional 
insolubility of the El64X may be caused by the further disturbance of the 163REEK166 
motif. The recent studies (Ghosh et al., 2006; Pasta et al., 2004; Rajan ct al., 2006) 
demonstrated the importance of both flexible and non-flexible C-tetminal residues, in 
maintaining solubility and highlight the potential influence of the 163REEK166 motif in the 
solubilisation of aD-crystallin, perhaps through a different mechanism involving the 
chaperone function and oligomerisation. 
The effect of the disease causing C-terminal mutations on aD-crystallin solubility 
was as expected with high levels of aggregation being observed in both a bacterial and 
mammalian cell environment. However the mechanism, which causes a variation in 
pathology between the myofibrillar myopathy mutants (Ql51X and 464delCT) and the 
posterior polar cataract mutant ( 450delA), remains unclear. The mutants display a varying 
level of insolubility during the refold process as a function of the severity of the 
alterations to the C-terminal extension, however this does not provide a link between the 
-mutation and the disease mechanism~ 
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3.5. CHAPTER'S CONCLUSIONS 
In this Chapter, I wanted to investigate the relationship between the solubility of 
aB-crystallin and the C-terminal extension with the aim to provide further understanding 
of the mechanism that causes the phenotypic variation experienced with the disease 
mutants of aB-crystallin. It was clear that the flexible C-terminal 'tail' was essential to 
produce a stable aB-crystallin complex and that perhaps additional regions in the non 
flexible region of the C-terminal extension also conferred an additional level of solubility 
to the complex, through a mechanism that also involved the oligomerisation and 
chaperone function (Ghosh et al., 2006). The C-terminal extension can influence the 
structure and function of aB-crystallin apart from the solubilising function that is 
generally attributed to this region. Attempting to gain understanding of the mechanism of 
phenotypic variation by only investigating the solubility perhaps gives a one-dimensional 
view of the system involved. Further understanding of the disease mechanism requires 
characterisation of the chaperone activity and oligomerisation properties of these C-
terminal mutations. This additional characterisation will help to provide a link between 
the structural and functional properties of the C-terminal mutants and the associated 
disease phenotypes. 
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CHAPTER4 
THE ROLE OF THE C-TERMINAL EXTENSION IN THE 
OLIGOMERISA TION AND CHAPERONE FUNCTION OF 
aB-CRYST ALLIN 
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4.1. AIMS 
In Chapter 3, I used the sequential truncations of the C-terminal extension (K174X 
and El65X), the PTM truncations (A171X and E164X) and the disease causing mutants 
(450delA, 464delCT and Q151X) to show how the flexible C-terminal 'tail' was essential 
to produce a stable aS-crystallin complex. The data suggested that perhaps additional 
regions in the non-flexible region of the C-terminal extension also conferred an additional 
level of solubility to the complex, through a mechanism that also involved the 
oligomerisation and chaperone activity. 
In this chapter, I wanted to investigate the role of the C-terminal extension in 
oligomerisation and chaperone activity, thus characterising the effects of these C-terminal 
extension mutants upon the structure and function of aS-crystallin. 
This further characterisation of the C-terminal extension aimed to elucidate the 
mechanism that links the C-terminal extension with the chaperone function, 
oligomerisation and solubility and how the three naturally occurring mutations of this C-
terminal extension not only cause disease, but also result in the varying pathology of 
isolated polar posterior cataract ( 450delA) and MM ( 464delCT and Q 151 X). 
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4.2. INTRODUCTION 
The C-terminal extension can influence the structure and function of aB-crystallin 
apart from the solubilising function that is generally attributed to this region. It appears 
that this region can have either inter- or intra-molecular tertiary interactions that contribute 
significantly to the chaperone function and oligomerisation characteristics (Pasta et al., 
2002). 
In its native state in the lens, a-crystallin is always found as a heterogeneous 
oligomeric assembly consisting of a 3: 1 ratio of aA to aB-crystallin subunits that self-
associate to form polydisperse assemblies with a wide Mwt distribution of 300000 to over 
one million Daltons (Horwitz, 1993). With a similar Mwt of 19909Da and 20159Da for 
aA- and aB-crystallin respectively, the native complex with an average molecular mass of 
800 kDa (Groenen et al., 1994) may consist of between 15-50 subunits (Groenen et al., 
1994; Horwitz, 2003). The a-crystallin oligomer shows self-interaction due to the 
interactions between the aA-crystallin subunits rather than the aB-crystallin subunits. On 
the other hand, the aB-crystallin had a stronger binding activity than aA-crystallin to 13-
and y-crystallin (Kamei and Matsuura, 2002). Therefore, aA- and aB-crystallin may play 
different roles when a-crystallin displays chaperone-like activity, and also that the 
decreased chaperone-like activity of a-crystallin finally results in cataract formation 
following aggregation and insolubilization of lens proteins (Kamei and Matsuura, 2002). 
The nature of the oligomers formed by aB-crystallin were determined by tandem 
mass spectrometry to reveal a distribution primarily of oligomers containing 24-33 
subunits with a dominant species composed of 28 subunits. Additionally low levels of 
oligomers as small as 10 and as large as 40 subunits were observed (Aquilina et al., 2003). 
In extra lenticular tissues aB-crystallin forms heterogeneous oligomers with the small heat 
shock protein HSP27 (Zantema et al., 1992). 
A number of interactive domains have been identified in human aB-crystallin and 
have been suggested to have a dual role in chaperone function and oligomerisation (see 
Table 4.1). These specific interactive domains are responsible for the recognition and 
selection mechanisms of aB-crystallin an~ other sHSPs for __ simil~ _s~b~its, unfolding __ 
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substrate proteins, or assembling filament proteins (Ghosh et al., 2006b; Ghosh et al., 
2006c). 
Seven interactive domains for chaperone activity (CS l-CS7) have been identified 
(see Table 4.1 and Figure 4.1) and overlap five previously identified sites required for 
subunit interaction (Ghosh et al., 2005). In addition, other studies have identified 
numerous peptides such as mini aBC, RS-1, RS-2 and ATPl (see Table 4.1), which are 
influential upon the chaperone activity and oligomerisation of aS-crystallin and represent 
partial regions of the seven interactive sites identified by Ghosh et al. (2005). These 
studies suggest that particular interactive regions of aS-crystallin have dual roles in 
oligomerisation and chaperone function. The location of these interactive regions in 
relation to the aS-crystallin C-terminal extension mutants (see Figure 4.1 B.) also 
highlight the potential effect the mutations may have upon the structure and function of 
aS-crystallin. 
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Table 4.1. Interactive sites of aB-crystallin and their numerous functions. The interactive 
sites involved in the chaperone function are denoted CS. The recognition sequences (RS) involved 
in association of aB-crystallin with aA-crystallin are denoted RS. Mini aBC is a peptide of aS-
crystallin found to display chaperone function. ATP1 is a sequence important in ATP binding. 
Site Interactive Secondary Overlapping Function(s) associated with the 
Reference chaperone structure subunit site interactive site 
Site 
CS1 9-20 None None Chaperone 
CS2 43-58 a3-turn-a4 37-54 Chaperone/subunit interaction 
motif 
RS-1 42-57 a3-turn-a4 37-54 aA-crystallin association/ subunit 
motif interaction/chaperone 
RS-2 60-71 a3-turn-a4 None aA-crystallin association 
motif 
Mini 73-92 133 strand 75-82 Mini aB-crystallin/ 
aBC chaperone/subunit interaction 
CS3 75-82 133 strand 75-82 Chaperone/subunit interaction 
ATP1 82-96 134-138 75-82 A TP binding/Chaperone/subunit 
groove interaction 
CS4 113-120 None None Chaperone 
CS5 131-138 138 strand 131-138 Chaperone/subunit interaction 
CS6 141-148 139 strand 141-148 Chaperone/subunit interaction 
CS7 157-164 None 155-166 Chaperone/subunit interaction 
The mini aB-crystallin peptide ( aB73_92), can still function as a molecular 
chaperone (Bhattacharyya et al., 2006), and overlaps the chaperone site CS-3 and subunit 
interaction site of aB7s-s2 (Ghosh et al., 2005). In contrast, the site RS-1 (aB42-s7), which 
is required for the association of aB- with aA-crystallin (Sreelakshrni and Sharma, 2006), 
overlaps CS-2 ( aB43-ss), but was shown to have no chaperone activity (Bhattacharyya et 
al., 2006). 
Whilst the dual function mechanisms of these specific regions are not yet clear, the 
subunit interaction sequence of the N-terminus (aB37•54) and the C-terminus (aB155-16S) 
have been linked with higher order assembly whilst sequences within the a-domain ( aB1s-
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s2, aBt3I-t38 and aBt4t-t4s) are involved in the formation of the dimer interface (Ghosh et 
al., 2005), which is the unit of subunit exchange between closely related oligomers and the 
structural determinant for dimerisation (Koteiche and McHaourab, 2002; McHaourab et 
al., 2002). A truncated form of a B-crystallin (aB57_157), which exists as a dimer, still 
displays chaperone activity, despite the loss of structure required for higher order 
assembly (Feil et al., 2001) as it is not dependant on 3D structure for binding unlike 
antibodies or enzymes (Ghosh and Clark, 2005) 
A C-terminal 
N-terminal 
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Figure 4.1. Interactive regions of aB crystallin important for chaperone function and 
oligomerisation. (A) Ribbon representation of the secondary and tertiary structure of 
human aB crystallin. Interactive chaperone sites of human aB-crystallin are coloured red, 
while non-interactive regions are coloured blue. The sequences CS 19-20, CS4113-I20, and 
CS7 157•164 did not have secondary structure. The sequence CS243.5s, formed the a3-turn-a4 
motif, while the sequences CS375.s2, CS5m-138, and CS6t4I-t48 formed f3 strand motifs [33, 
[38, and [39, respectively (Figure was modified from Ghosh et al. (2005) using Adobe 
Photoshop.CSv.8; Reprinted with permission from (Ghosh et al., 2005). Copyright 2005 
American Chemical Society). The structural alignment of the C-terminal extension aB-
crystallin mutants (B) shows the position of the interactive chaperone sites CS 1-CS7 in 
relation to the C-terminal extension and highlights the potential consequences of the C-
terminal mutations upon the chaperone and oligomerisation functions. The alignment 
includes a-helix-3 and a-helix-4 (wave) P-sheets and the IX(IN) motif are indicated by 
black boxes. Small and hydrophobic amino acids (including aromatic -Y) are indicated in 
red, acidic (blue), basic (magenta), Hydroxyl +arnine+basic-Q, (green) and other amino 
acids are indicated in grey. The f32 sequence spans residues 66SEMRL1o, f33-
74RFSVLNDso, f34-s9LKVKVL94. f35-97VIEVHGto2, P7-II8 FHRKYR123, P8-134 TSSLSns 
and the P9 sequence spans residues 142VLTVNGP 148 (Ghosh et al., 2005; Guruprasad and 
Kumari, 2003). The highly conserved IX(IN) motif spans residues ts9IPh6I· The C-
terminal extension consists of residues 149RKQVSGPERTIPITREEKPAVTAAPKKm 
, ...... \ 
Chapter 4-Results 151 
(Stamler et al., 2005). (Alignment produced using ClustalW multiple sequence alignment 
programme at www.ebi.ac.uk/clustalw). 
The discovery of an ATP binding site (ATPI) of aD-crystallin is contradictory to 
previous literature that identified sHSP's as chaperones who function independently of 
A TP, however a recent study by Ghosh et al. (2006), identified the f34-(38 groove as an 
int~raction site for ATP in aD-crystallin. The sequence aD82_96 has been identified as a 
W&lker D motif, (R/K-X2-10-0-X-O-ID in human aD-crystallin, which is similar to the 
conserved Asp96 in HSP90. The a and (3 phosphate groups of ATP are positioned to 
interact with side chains of residues of the (34 and (38 strand. The binding of ATP to 
residues of the (34 and (38 groove has an affect on sub unit dynamics by disrupting the 
interaction between the C-terminal and the (34-(38 groove, thus affecting complex size and 
exposure of the interactive chaperone sites on the surface of the aD-crystallin (Ghosh et 
al., 2006c ). The binding of ATP could potentially displace bound substrate protein 
releasing it to A TP dependant machinery allowing the subsequent disaggregation and 
refolding of the unfolded protein. 
The C-terminal extension plays a role in aD-crystallin subunit interaction but is 
not involved in the formation of the heterogeneous oligomer of a-crystallin, whose 
assembly requires interaction between the N-terminal regions of the aA- and aD-
crystallin subunits. 
The study of subunit interactions between aA- and aD-crystallin identified 
sequences RS-1 (aB42-s7) (Sreelakshmi et al., 2004) and RS-2 (aB60_71 ) (Sreelakshmi and 
Sharma, 2005) of aD-crystallin as the sites involved in association with aA-crystallin. 
Inversion of the aD-crystallin sequence aD54-6o, which overlaps both RS-1 ( aD42_ 
57) and the subunit interaction site aD37_54, led to a two-fold reduction in the subunit 
exchange rate with aA-crystallin and saw aD-crystallin oligomers 38% smaller than the 
wild type. This suggested that the correct orientation was important for the formation of 
aD-crystallin oligomers and for the optimal subunit interaction and oligomerisation with 
aA-crystallins (Sreelakshmi and Sharma, 2006). A slight increase in a-helical content was 
observed and chaperone activity was similar to the wild type. 
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Mutations in the RS-2 region, W60R and S66G increased the oligomeric size of 
aS-crystallin by 1.6- and 2.7-fold respectively whereas an F61N mutation had no effect 
(Sreelakshmi and Sharma, 2005). The mutant W60R mutation had no effect on subunit 
exchange between aB- and aA-crystallin, whereas F61N slowed subunit exchange by 
36%, and the S66G increased subunit exchange by 100%. Thus, the region RS-2 (aS60_71 ) 
is important in the o1igomerisation of aS-crysta11in, in addition to subunit interactions 
between aA- and aS-crystallins (Sreelakshmi and Sharma, 2005). An increase in 
oligomeric size may not be correlated with an increase in chaperone activity or subunit 
exchange as shown by the deletion of theN-terminal sequence 21SRLFDQFFG29, which 
lead to a reduction in the oligomeric size but an increase in subunit exchange and 
chaperone function (Sreelakshmi and Sharma, 2005). 
Thus, the interactive sequences in the N-terminal are important for the formation 
of the aB-crystallin oligomer, the associations between the aA- and aB-crystallins and 
also contain the interactive sites CS-1 and CS-2 required for chaperone activity ( aB9_20, 
and aS43-58 respectively). 
The focus and experimental goals of this chapter aim to establish the relationship 
between the structure and function of aS-crystallin and the C-terminal extension. The 
emergence of the interactive sites in aB-crystallin for subunit interactions, chaperone 
function, ATP binding and aA-crystallin associations, combined with the further 
characterisation of the C-terminal aB-crystallin mutants will help elucidate the 
mechanisms involved in substrate binding and oligomerisation. 
A number of recent studies by Ghosh et.al, (2006) looked further at the role of the 
a-domain ~3-~8-f39 surface as an interface for complex assembly and chaperone activity 
(Ghosh et al., 2006a) and theN-terminal region aS41_58 and C-terminal region aS 155_165 in 
the recognition selection and solubility of unfolding substrate proteins during the 
chaperone process (Ghosh et al., 2006d). The studies revealed that chaperone activity is 
dependant on composition of interactive sequences in the a-domain, independent to 
complex size (Ghosh et al., 2006a), and characterized the importance of the exposed side 
chains of the non conserved Glu-78, Lys-82, and His-83 in the interactive ~3 sequence for 
chaperone function, which was influence( by th~ amount of unfolding of the target 
---- - -
proteins and independent of complex size (Ghosh et al., 2006b). 
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Mutations or post-translational modifications of these interactive domains can shift 
the dynamic equilibrium to increase oligomerisation and reduce chaperone activity or lead 
to dissociation of the oligomeric assembly and formation of protective multimeric 
chaperone-substrate aggregates (Ghosh et al., 2006b; Ghosh et al., 2006c ). 
Complex assembly is the result of subunit-subunit interactions that involves an 
interaction of the C-terminal extension of one aB-crystallin molecule with the ~4-~8 
interface on the surface of the a-domain of a second a.B-crystallin molecule (see Figure 
4.2). Chaperone activity is the result of interactions between the ~3-~8-~9 interface on 
the surface of aB crystallin and the exposed residues of an unfolding target substrate 
protein (see Figure 4.2) (Ghosh et al., 2006a), however a more recent study also suggested 
that the polar C-terminal sequence aB 155• 165 interacted with unfolding proteins to maintain 
solubility, independent of the amount of substrate protein unfolding (Ghosh et al., 2006d). 
Figure 4.2 Interactive sites of aB-crystallin associated with functional and structural 
activity. A Ghosh (2006) 3-D computer model for the ~3-~8-~9 interface on the surface of 
the a crystallin core domain of human aB crystallin. In the space-filled model of human 
a.B crystallin (blue), the exposed side chains of the ~3-~8-~9 interface are shown as green 
(~3), orange (~8), and white (~9) surfaces. The exposed side chains of the ~4 strand are in 
red. Complex assembly is the result of subunit-subunit interactions that involves an 
interaction of the C-terminal extension of one aB crystallin molecule (tan) with the ~4-~8 
interface on the surface of the a crystallin core domain of a second a.B crystallin molecule 
(blue). Chaperone activity is the result of interactions between the ~3-~8-~9 interface on 
the surface of aB crystallin (blue) and the exposed residues of an unfolding target 
substrate protein (purple). The exposed residues, Asn-78, Lys-82, and His-83 of the ~3 
sequence, Leu-131, Thr-132, Thr-134, Ser-136, and Ser-138 ofthe ~8 sequence, and Gly-
141 and Thr-144 ofthe ~9 sequence together form the ~3-~8-~9 chaperone interface on 
the surface of the a crystallin core domain (Reprinted with permission from (Ghosh et al., 
2006a). Copyright 2006 American Chemical Society). 
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The role of the C-tem1inal and its relationship with chaperone activity and 
oligomerisation has been extensively studied by mutagenesis of selected residues in the 
interactive regions, which suggests that the C-terminal is not essential for chaperone 
activity, but has a primary role in subunit interaction and also interacts with unfolding 
proteins to maintain solubility (Ghosh and Clark, 2005; Ghosh et al., 2005; Ghosh et al., 
2006a; Ghosh et al., 2006b; Ghosh et al., 2006d). 
There has however, been no systematic analysis ofthe C-terminal extension and its 
role in chaperone function and oligomerisation or the relationship between the structural 
and functional relevance of the C-terminal extension and the pathology of C-terminal 
mutants 450delA, Ql51X and 464delCT. 
The aS-crystallin C-terminal mutants and their solubility have been discussed 
previously (see Chapter 3). It was concluded that in order to elucidate the mechanism 
responsible for the phenotypic heterogeneity observed with the C-tetminal disease 
mutants, further characterisation of an altered C-terminal extension upon chaperone 
activity and oligomerisation was essential. This additional characterisation will provide a 
link between the structural and functional properties of the C-terminal extension mutants 
and the associated disease phenotypes. It will also provide further insight into the role the 
C-terminal extension plays in the chaperone function and oligomerisation of aB-crystallin 
and other sHSPs. 
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4.3. RESULTS 
4.3.1. TRUNCATION OF THE C-TERMINAL EXTENSION REDUCES aB-
CRYST ALLIN OLIGOMERISATION 
The oligomerisation properties of aS-crystallin mutants were assessed using an 
analytical size exclusion column (see Figure 4.3A). Calibration curves covering a range 
of high and low Mwt calibrators allowed the Mwt determination of the mutants (see 
Appendix 2 Figure A2.1-2). Each mutant was analysed three times and the average 
retention time was used for Mwt determination (see Figure 4.3S). Wild type aS-
crystallin formed oligomers that were equivalent to 564 kDa, agreeing with previously 
published data (Horwitz et al., 2004). 
The sequential truncation of the C-terminal extension of aS-crystallin produces a 
steady decrease in oligomer size (see Figure 4.3A). The shortest construct, Ql51X aS-
crystallin produces a peak with a very significantly increased elution volume equivalent to 
19 kDa (Figure 4.3S) and represents the most dramatic reduction in oligomerisation 
observed for all the constructs studied. 
This effect on Q151X oligomerisation is obvious when the negative stained 
electron micrographs of wild type and Ql51X aS-crystallin are compared (Fig 4.3C, D 
respectively). Notice the absence of particles in the Ql51X sample (Figure 4.3D) relative 
to the wild type (Figure 4.3C). Deletion of the two C-terminal lysines (K174X) did not 
alter the oligomerisation of aS-crystallin, as previously reported (Plater et al., 1996), 
producing a 605 kDa complex. Removal of 5 C-terminal residues only reduced the 
apparent size of the main peak to 553 kDa, however the removal ofboth 11 (El65X) and 
12 (E164X) residues resulted in oligomers of 454 kDa and 413 kDa respectively. In the 
case of the latter two truncation mutants, there is evidence of increased polydispersity as 
indicated by the very noticeable shoulder on the main peak for the E 165X construct and 
the presence of an additional peak at the void volume of the column for the E 164X 
construct. The reduction of mean complex size for aS-crystallin oligomers suggests that 
residues El64/E165 also contribute to aS-crystallin oligomerisation. The two frame-shift 
disease causing mutants 450delA and 464delCT remained insoluble unless they were 
refolded in the presence of wild type aS-crystallin (see Section 3.3.4). As seen from the 
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elution profiles in Figure 4.3A, the presence of these mutant proteins decreased the 
oligomer size of the wild type aS-crystallin to 491 kDa and 434 kDa in the presence of 
450delA aS-crystallin and 464delCT aS-crystallin respectively. 
SDS-PAGE analysis (Section 3.3.4, Figure 3.29) revealed that the wild type aS-
crystallin is present in excess compared to 450delA aS-crystallin, yet this excess was not 
sufficient to retain the elution characteristics of the wild type protein. In fact, this proved 
to be the maximum ratio compatible with protein solubility for the 450delA/ wild type 
aS-crystallin complex and is in stark contrast to 464delCT aS-crystallin, where a 1:1 
mixture with wild type aS-crystallin was entirely soluble. The presence of the 450delA 
aS-crystallin also increased the polydispersity of the main peak, as seen by the shoulder 
and the additional small peak with a predicted Mwt equivalent to aS-crystallin dimers. 
The 450delA mutation, introduces a unique 33 residue polypeptide completely unrelated 
to the C-terminal extension of wild type aS-crystallin and quite clearly this frameshift 
sequence has a significant effect upon the oligomerisation of aS-crystallin. It is, however, 
the Q 151 X mutation that has the most dramatic effect, with the complete removal of the 
single peak equivalent to the 564 kDa oligomer and the appearance of a peak with elution 
characteristics predicted to be equivalent to a monomer. 
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Figure 4.3. Effect of the C-terminal mutations upon the oligomerisation of aB-crystallin. 
The elution profiles of the various aB-crystallins were determined on a 290 x 1 Ornm 
Superose 6 column (A). The elution characteristics of the various mutants are plotted 
relative to those obtained for wild type aB-crystallin (wild type), as highlighted by the 
vertical line indicating the retention time of the oligomeric complex, which is the major 
and only peak resolved in the wild type aB-crystallin sample. Additional minor species 
seen in El64X and 450delA/ wild type aB-crystallin are highlighted. A summary of the 
retention times and Mwt (B) is shown for the major peak resolved during SEC of the wild 
type aB-crystallin and other constructs. The retention times and Mwt of minor peaks are 
included in the figure as appropriate. The retention times(± SD) were calculated from the 
average of three cycles of SEC, from which the Mwt was determined. Negative stained 
images of wild type (C) and Q151X aB-crystallin (D) were obtained by transmission 
electron microscopy and illustrate the absence of characteristic particles in the Q 151 X aB-
crystallin sample, in agreement with the SEC data. Bar = 500nm 
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Non-denaturing gel electrophoresis also confirmed that the Q151X mutation 
dramatically altered its electrophoretic mobility under non-denaturing conditions (see 
Figure 4.4). Figure 4.4 shows the increased mobility of the wild type (lane 1) when 
associated with the Ql51X aB-crystallin (lane 2) and the mobility of the Q151X aB-
crystallin is increased further when analysed as a homogenous complex (lane 3) 
suggesting a significantly smaller oligomer, which supports the altered oligomerisation 
observed in Figure 4.3. 
Lane Sample Details Molecular Weight (kDa) 
I Wild TypeaB-crystallin 564 
2 Q I 5 I XI Wild TypeaB-crystallin 442 
3 Ql51X 18 
4 Thyroglobulin 725 
5 GroEL 700 
6 BSA 62 
7 Carbonic anhydrase 29 
Figure 4.4. Native gel electrophoresis of the Ql51X aB-crystallin oligomer. Analysis of 
Q151X aB-crystallin oligomer size, relative to wild type and QISIX/ wild type aB-
crystallin. High and low Mwt calibrators are shown in lanes 4-7. All lanes represent a 20 
1-lg loading with the exception of the Q151X aB-crystallin (1.0 ~-tg) where the nature ofthe 
Q 151 X aB-crystallin refolding limits the available level of protein for analysis. 
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4.3.2. EFFECT OF THE C-TERMINAL MUTATIONS UPON THE 
SECONDARY STRUCTURE AND OLIGOMERISATION OF aD-
CRYSTALLIN. 
Circular Dichroism (CD) spectroscopy was performed to identify Far UVCD 
spectra of the aB-crystallin mutants (see Figure 4.5). The Far UVCD of wild type aS-
crystallin showed a single broad minima, between 208 and 217nrn, indicative of a protein 
rich in P-sheet (Figure 4.5A), which is consistent with previously reported data (Bova et 
al., 1999; Ghosh et al., 2006a; Horwitz et al., 2004; Pasta et al., 2003; Sreelakshmi and 
Sharma, 2006). 
The Q151X mutation in aB-crystallin had the most significant effect upon the Far 
UVCD characteristics of aB-crystallin (Figure 4.5.A), due to a very significant red-shift 
of the minima to 217nrn and a ~50% reduction in magnitude, relative to the wild type aS-
crystallin, suggestive of a significant loss of secondary structure. Similar shifts have been 
seen for C-terminal truncation mutants of aA-crystallin (Raj an et al., 2006). A 1:1 molar 
mixture of Q 151 X with aB-crystallin wild type produced a spectrum that was clearly 
biased toward the Q151X aB-crystallin, indicative of the dominant nature of this 
mutation. Of the other mutants studied, the E164X and E165X mutants were intermediate 
in their effects upon negative ellipticity as compared to the Q 151 X mutant. This 
intermediate effect is likely associated with the extent of the C-terminal truncations of 
E 164X and E 165X aB-crystallin relative to Q 151 X aB-crystallin and suggests a less 
significant loss of secondary structure. 
Interestingly, the El64X mutant showed a red-shift in the minimum indicating that 
the deletion of the second of the two glutamic acid residues in the REEK-motif does 
introduce a detectable change in secondary structure as well as introducing increased 
insolubility as discussed in Section 3.3.4. The frame-shift mutation, 464delCT aS-
crystallin, introduced a small blue-shift of the minimum to 208nrn and the appearance of a 
shoulder at approximately 223 nrn, both of which are indicative of increased helicity. This 
increase may be the result of helix formation by the novel C-terminal sequence. 
Both the K174X and Al71X truncation mutants and the 450delA frameshift 
mutant have Far UVCD spectra very similar to the wild type ~B-cry~t~lin._ The _&l71X 
--- - --and K174X aB-crysiallin are similar in shape and magnitude and contained broad minima 
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between 208 and 217nm. The 450deW wild type aS-crystallin show increased negative 
ellipticity and a shift in minima to 208nm. 
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Figure 4.5. Circular dichroism of wild type aS-crystallin and the C-terminal extension 
mutants. The Far UVCD spectra (205-250nm) for each mutant protein were the average of 
four spectra. Protein concentrations were determined by Sicinchoninic Acid (BCA) 
assay. The Far UVCD signal was converted to molar ellipticity expressed as 
deg.cm2.dmor1 to normalise for slight differences in molecular mass between the wild 
type and the other aS-crystallin constructs. The Far UVCD spectra ofwild type, A171X 
and K 1 7 4 X aS-crystallin are similar in shape and magnitude and contained broad minima 
between 208 and 217nm. The 450delA/ wild type and 464delCT/ wild type aS-crystallin 
mixtures show increased negative ellipticity and a shift in minima to 208nm. Truncation 
of the C-terminal extension results in the loss of secondary structure reflected by a 
decrease in negative ellipticity and a shift in wavelength minima (E 164X, E 165X, Q 151 X, 
Q 151 XI wild type) with the most dramatic effects seen for Q 151 X aS-crystallin. 
The effects of the C-terminal extension mutants upon oligomerisation and 
secondary structure were further highlighted by investigating the changes in relative 
exposed hydrophobicity. The probe, bis-ANS, has a low fluorescence quar~tum yield in 
aqueous solution however, this increases dramatically upon binding to surface-exposed 
hydrophobic regions. As can be seen in Figure 4.6, all the aS-crystallin mutants bound 
more bis-ANS relative to the wild-type aS~crystallin, except for the Q151X mutant, 
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which bound substantially less. As all the mutants except Q 151 X aB-crystallin formed 
oligomers (see Figure 4.3A), it suggests that the increase in exposed hydrophobic surfaces 
arose from changes within their respective oligomeric structures. The reason why Q 151 X 
aB-crystallin binds so little bis-ANS was probably due the combined effects of decreased 
oligomerisation and loss of secondary structure. This was tested by examining the bis-
ANS binding properties of the wild-type protein under mildly denaturing conditions (2M 
guanidinium hydrocholoride (Gdn-HCl)), which had been shown previously to eject aB-
crystallin from native a-crystallin oligomers and to cause a significant loss of secondary 
structure (Doss-Pepe et al., 1998). The presence of the Gdn-HCl greatly reduced the bis-
ANS binding to wild-type aB-crystallin, with the fluorescence intensity dropping almost 
as low as that obtained for Ql51X aB-crystallin alone. 
110 
100 
90 
80 
,.-.. 70 ;::J 
< 
'-' 60 0 
·;; 
~ 50 
40 
30 
20 
10 
0 
420 460 500 540 580 
Wavelength (run) 
--+-- Blank 
~ WildType 
--*- 450deW Wild Type 
- 464de1Cf/ Wild '!ype 
-+-- Ql51X/ Wild '!ype 
- Ql51X 
-a- El64X 
El65X 
__....._ K174X 
- AI71X 
~ Wild Type plus 2M Gdn-HCI 
620 660 700 
Figure 4.6. Bis-ANS fluorescence binding properties of the aB-crystallin mutants. The 
effect of the C-Terminal mutations upon the relative exposed hydrophobicity was 
performed using bis-ANS to bind to surface exposed hydrophobic regions on the mutant 
and wild type aB-crystallin. Protein concentrations were determined by A280nm using 
extinction coefficients specific for each mutant aB-crystallin (see Table 2.12). Each 
protein was analysed at l!J.M in the presence of a 10-fold molar excess of bis-ANS. The 
excitation wavelength was 410 nm and emission spectra were collected between 420-700 
run. All spectra are the average of 10 individual scans. The resulting exposed 
hydrophobicity is increased for all mutants relative to the wild type aB-crystallin, with the 
exception of the Ql51X mutant. 
----
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4.3.3. LOSS IN HEAT STABILITY OF aD-CRYSTALLIN CORRELATES 
WITH CHANGES IN SECONDARY STRUCTURE. 
In order to understand further the consequences of an altered C-terminal extension 
of aS-crystallin upon structure and function, the stability under heat denaturing conditions 
was determined (see Figure 4.7). These data show that the two most unstable mutants are 
the El64X and E165X aS-crystallin because both the onset of aggregation and optical 
signal (OD36o) was very significantly increased compared to wild type aS-crystallin for 
these two mutants. The El64X mutant began to aggregate at 46°C, some 30°C lower than 
the wild type protein. The E 165X mutant was notable for the rapidity of aggregation when 
initiated at 57°C, whilst the Q 151X mutant was notable in its failure to develop a strong 
OD36o signal, despite the very significant decrease in stability indicated by the increased 
turbidity at 53°C. This signal reached a maximum at 55°C and remained constant until the 
conclusion of the assay. 
The absence of the stabilising C-terminal 'tail' and the partial removal the 
interaction site 155PERTIPITREE16s are a result of the El64X and El65X mutations. 
Deletion of this interactive site was shown to cause high levels of instability in aS-
crystallin (Ghosh et al., 2006d) and perhaps the exposure of this region had a detrimental 
effect on the heat stability of these mutants. Surprisingly, the complete removal of this 
sequence seemed to confer enhanced heat stability upon the Q 151 X aS-crystallin relative 
to the E 164X aS-crystallin. The significantly reduced oligomer size observed for the 
Q151X aS-crystallin (see Section 4.3.1, Figure 4.3) contributed towards the variation in 
OD360 signal observed, as the Q 151 X aS-crystallin oligomer (19 kDa) was 22-24 times 
smaller than El64X aS-crystallin (413 kDa) and the El65X aS-crystallin (454 kDa) 
respectively (see Figure 4.3S), thus the aggregates formed are less prone to sedimentation. 
The two shorter C-terminal truncations (Kl74X, Al71X), showed decreased stability, but 
were the most stable of the mutants studied. 
These data suggest a correlation between altered secondary structure and 
decreased heat stability. This trend is also seen for the two frame-shift mutants, (450delA/ 
wild type and 464delCT/ wild type aS-crystallin) that were more stable than the three 
shortest mutants, but less stable than eit~e-~_th: A_!21~ or K174X aB_-:_c~stall_il_l trunc~ion __ 
--------
-----
constructs. These data also support the observations with regards to the changes in 
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ol igomerisation, where the Q 151 X aS-crystallin, despite being relatively unstable 
produces an optical signal that remains consistently low relative to the other mutants, 
highlighting the variations in light scatter, thus the size of aggregates formed under the 
assay conditions. 
These data correlate with more conservative changes in secondary structure as 
detected by Far UVCD spectroscopy for the two frame-shift mutants (Figure 4.5A) and 
the largely unchanged spectra for the Al71X and K174X mutants. 
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Figure 4.7. Thermal stability of wild type and C-terminal extension mutants of aS-
crystallin. The effect of the C-terminal extension mutations on the heat induced 
aggregation of aB-crystallin was measured at 360nm over the temperature range 25 °-
860C. The temperature was increased at a 1 °C/min over 1 h. Wild type and mutant aB-
crystallins were assayed at 0.1 mg/ml. Notice the significantly reduced stability of the 
E164X, Q151X and E165X aS-crystallin mutants. 
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4.3.4. EFFECT OF C-TERMINAL EXTENSION MUTATIONS UPON THE 
CHAPERONE ACTIVITY OF aD-CRYSTALLIN. 
164 
Citrate synthase and insulin chaperone assays were used to determine the effects 
of the aB-crystallin C-terminal extension mutations on the chaperone capabilities of the 
modified aB-crystallin mutants. Each assay was performed three times at a 4:1 mass ratio 
of substrate: aB-crystallin to produce an average chaperone activity for each substrate as 
shown for Citrate synthase (see Figure 4.8A) and Insulin (see Figure 4.9A). The 
percentage inhibition achieved was calculated from the end point level of aggregation 
(represented by AU at 360nm) of each mutant aB-crystallin as a percentage of the wild 
type aB-crystallin activity. The triplicates for Citrate Synthase are shown in Appendix 3, 
Figure AlO.l and Table AlO.l and for the Insulin assay Appendix 3, Figure Al0.2 and 
Table A10.2. 
Based on the effects of the mutations on protein secondary structure and heat 
stability it was predicted that E164X, E165X and Q151X aB-crystallin would exhibit the 
least activity in these assays. The chaperone activity achieved by these mutants in a 
citrate synthase aggregation assay (see Figure 4.8B) showed that whilst E164X aB-
crystallin was indeed the worst of all the aB-crystallin constructs, (-57% inhibition) none 
of the other C-terminal extension constructs performed worse that the wild type protein 
(100% inhibition). Indeed, the E165X aB-crystallin (313%) was slightly better than the 
wild type protein and Ql51X aB-crystallin (755%) was one of the best. In fact, the 
combination of Q151X and wild type aB-crystallin was the best chaperone in the citrate 
synthase assay (1263% inhibition). 
Another surprise from the citrate synthase chaperone assay was the relative 
performance of the two frame-shift mutants, 450delA and 464delCT aB-crystallin, both of 
which performed better in combination with wild type aB-crystallin than the wild type 
aB-crystallin alone, (625 %and 216% inhibition respectively). These data show that the 
disease causing mutations in aB-crystallin (Q 151 X, 450delA and 464delCT) all retain 
significant chaperone activity, surpassing the potential of the wild type protein alone for 
this client protein in this particular chaperone assay. 
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In contrast to the results with citrate synthase, all the C-terminal extension 
mutants performed worse than the wild type aB-crystallin in the insulin based chaperone 
assay (see Figure 4.9A). In this assay, the three most heat-sensitive aB-crystallin mutants, 
E 164 X, E 165X and Q 151 X aB-crystallin, increased protein aggregation compared to wild 
type aB-crystallin ( -138, -8 and -45% inhibition respectively (see Figure 4.9B)). An 
equimolar mixture of Q 151 X and wild type aB-crystallin ( 4 7% inhibition) retained 
significant chaperone activity of Q 151 X aB-crystallin, but it was still one of the poorer 
chaperones in this assay. The K174X (93%) and A171X (93%) mutants had chaperone 
activities that most closely resembled the wild type aB-crystallin (1 00%) and even the 
two frame-shift mutants 450delA and 464delCT aB-crystallin in their respective 
combinations with wild type aB-crystallin, still possessed credible activities, (68 % and 
78% inhibition respectively). 
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Wild Type 100%± 0 
450deW Wild Type 625%± 97 
464deiCT/ Wild Type 216%± 119 
Q151X/ Wild Type 1263%± 150 
Q151X 755%± 136 
E164X -57%±40 
E165X 313%± 123 
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Figure 4.8. Mean aggregation of Citrate Synthase in the presence ofwild type and mutant 
aB-crystallins. The effect of wild type and mutant aS-crystallin on the thermal 
aggregation of Citrate synthase, over a 30 min period at 42 oc was measured using OD360 
(A). A 4:1 molar ratio of substrate: chaperone was used. The relative inhibition of citrate 
synthase aggregation (B) by the C-terminal extension mutants was calculated from the end 
point level of aggregation of each mutant as a % of that observed for the wild type aS-
crystallin alone (1 00% inhibition). The data shown are the mean (± SD) values taken 
from three independent experiments (see Appendix 3, Figure A3.1 and Table A3.1 for 
details of the complete data sets). 
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Figure 4.9. Mean aggregation of insulin in the presence of wild type and mutant aB-
crystallins. The effect of wild type and mutant aB-crystallin on reduction-induced 
aggregation of insulin (C), over a 15min period at 37°C was measured using OD360. A 4:1 
molar ratio of substrate: chaperone was used. The relative inhibition of insulin aggregation 
(B) by the C-terminal extension mutants was calculated from the end point level of 
aggregation of each mutant as a % of that observed for the wild type aB-crystallin alone 
(I 00% inhibition). The data shown are the mean (± SD) values taken from three 
independent experiments (see Appendix 3, Figure A3.2 and Table A3.2 for details of the 
complete data sets). 
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4.3.5. ABILITY OF THE DISEASE CAUSING aB-CRYSTALLIN MUTANTS 
TO INHIBIT DESMIN FILAMENT AGGREGATION. 
One of the characteristic histopathological features of the human myopathies 
caused by some of the mutations in aB-crystallin under investigation in this study is the 
presence of aggregates of desmin filaments (Schroder et al., 2007; Vicart et al., 1998) It 
was therefore decided to analyse the ability of the aB-crystallin mutants in this study to 
prevent desmin filament-filament associations using an assay developed to investigate the 
cell biological effects of the R120G mutation in aB-crystallin (Perng et al., 2004). The 
assay takes advantage of the fact that IFs interact with each other in solution (Bousquet et 
al., 2001; Perng et al., 2004) and this can be measured by sedimentation assay. The 
presence of a mutant protein that interacts with desmin filaments, for example R120G aB-
crystallin, activity encourages more filament-filament associations and therefore increases 
the proportion of pelletable desmin. The assays were performed at the physiologically 
relevant temperature of 3rC and control conditions of 20°C (see Figure 4.12) and 44°C 
(see Figure 4.13). Initially all samples were analysed at 0.2 mg/ml with the exception of 
the Q 151 X aB-crystallin, whose limited yield only allowed an assay concentration of 0.1 
mg/ml. To eliminate any interactions that may have been caused by mass effects, the 
assay was repeated at the physiologically relevant temperature of 37°C with all samples at 
0.1 mg/ml (see Figure 4.1 0). This resulted in a small loss of binding and chaperone 
function, but did not affect the general pattern of interaction between the mutants. Thus, 
the control assay at 20°C and 44 oc show the relative effects of temperature on binding 
between the mutants at these temperatures and also the Q151X aB-crystallin at 37°C. The 
assay at 37°C shows the relative effects of the C-terminal mutations on binding at this 
physiologically relevant temperature, but is not a direct comparison between the mutants 
(with the exception ofthe Q151X aB-crystallin) at the various control assay temperatures. 
At the physiologically relevant temperature of 3rC, both the Q151X and 
464delCT aB-crystallin mixed with wild type displayed desmin filament associations 
similar to the wild type alone, whereas the 450delA-wild type protein mixture was 
significantly more effective than R120G aB-crystallin in inducing this filament 
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association, highlighting the dominant effect of the 450delA mutation over the wild type 
aS-crystallin (Figure 4.1 OA). 
In stark contrast to these results, the Q 151 X aS-crystallin was the most effective 
chaperone of all the disease causing mutants and was also better than wild type aS-
crystallin in reducing the proportion of pelletable desmin (Figure 4.1 OA). Most of the 
Q151X mutant (80%) co-sedimented with desmin in the pellet fraction (see Figure. 4.10S 
and C) and resulted in a 25% decrease in the amount of pelletable desmin, relative to the 
wild type aS-crystallin. The chaperone activity of the Q 151 X aS-crystallin was also 
evident at 20°C where more than half the Q151X aB-crystallin was bound to the desmin 
filaments (see Figure 4.12B and C) and the proportion of pelletable desmin was less than 
the wild type (see Figure 4.12A). 
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Figure 4.1 0. Sedimentation assay to investigate the prevention of desmin filament 
aggregation in the presence of various aS-crystallins at 37°C. (A-C) shows the% desmin 
pelleted (A), the % aS-crystallin wild type and mutants remaining soluble in the presence 
of desmin (B), and the% of the total aS-crystallin pelleted in the presence of desmin (C), 
following low speed centrifugation (2500 x g). These data were calculated from SDS-
p AGE data of the desmin binding assays. (D) An example of the data used to calculate 
these values for wild type and mutant aS-crystallin. those mutants associated with wild 
type are ( 450delA, 464delCT and Q 151 X) identified with arrowhead. These data illustrate 
the ability of the Q151X aS-crystallin to prevent desmin filament aggregation. 
To show that the effects of Q 151 X aS-crystallin were not due to an inhibition of 
desmin filament assembly per se, negatively stained samples were analysed by electron 
microscopy (see Figure 4.11) and the presence of abundant 10 run filaments confirmed 
When compared to desmin assembled in the presence of wild type aS-crystallin (see 
Chapter 4-Results 171 
Figure 4.11A), the absence of aB-crystallin particles in the Q151X containing sample was 
also immediately apparent (see Figure 4.11B), confmning independently the data in 
Figure 4.3A and D. 
Figure 4.11. Desmin Filament assembly in the presence of wild type and Q151X aB-
crystallin. Images obtained by electron microscopy of negatively stained samples of the 
assembled filaments for desrnin assembled in the presence of wild type (A) and Q151X 
(B) aB-crystallin are shown to show that the addition of both chaperones has not 
dramatically altered filament morphology or length. Notice the lack of crystallin particles 
in the Q 151 X sample. Bar = 1 OOnm. 
Mixing Q 151 X with wild type aB-crystallin in an equimolar ratio reduced this 
binding to desmin filaments at 3rc (see Figure 4.10B and C) and restored the levels of 
pelletable desmin to those obtained in the presence of wild type aS-crystallin (see Figure 
4.10A). In contrast, the 450delA mutant was clearly dominant over the wild type aB-
crystallin as there was not only increased binding to the filaments (see Figure 4.1 OB and 
C), hut also a significant increase in the proportion of pelletable desmin (Figure 4.1 OA). 
These data indicate that the increased binding of 450delA aB-crystallin induces more 
filament-filament interactions resulting in more desmin in the pellet. Interestingly all the 
mutant aB-crystallins exhibited elevated binding to desmin filaments (see Figure 4.1 OC) 
compared to the wild type aB-crystallin, but under these assay conditions (0.1mg/ml 
desmin @ 3TC), the Q151X and 450delA aB-crystallin had opposite effects upon the 
promotion of filament-filament interactions. 
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The chaperone activity of aS-crystallin is enhanced at elevated temperatures 
(Datta and Rao, 1999; Koretz et al., 1998; Raman and Rao, 1994; Raman and Rao, 1997). 
At temperatures greater than 37°C, chaperone activity is elevated by an increase in the 
subunit dynamics with elevated association and dissociation rate of subunits (Liu et al., 
2006a). This stress related signal causes a shift in the equilibrium constant and activates 
further binding of substrate to the chaperones (Shashidharamurthy et al., 2005), as 
observed from 20°C to 44°C, where we see an increased binding of the mutants to the 
desmin filaments (see Figure 4.12C and 4.13C respectively). This enhanced binding was 
accompanied by increased desmin filament-filament associations shown by increased 
levels of desmin in the pellet (see Figure 4.12A and 4.13A). The most significant increase 
in filament-filament associations was observed for the Q151 X aS-crystallin, where the 
amount of pelleted desmin at 37°C doubled at 44°C (see Figure 4.13A) despite only a 
slight increase in binding between the Q 151 X aS-crystallin and the des min filaments (see 
Figure 4.13 Sand C). 
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Figure 4.12. Sedimentation assay to investigate the prevention of desmin filament 
aggregation in the presence of various aB-crystallins at 20°C. (A-C) shows the% desmin 
pelleted (A), the % aB-crystallin wild type and mutants remaining soluble in the presence 
of desmin (B), and the % of the total aB-crystallin pelleted in the presence of desmin (C), 
following low speed centrifugation (2500 x g). These data were calculated from SDS-
p AGE data of the desmin binding assays. (D) An example of the data used to calculate 
these values for wild type and mutant aB-crystallin. Those mutants associated with wild 
type are (450delA, 464delCT and Q151X) identified with arrowhead. 
20 
10 
90 
80 
90 
80 
.s 70 
c:: ,...._ 
;.::=~ 60 ] '-' 
"'t) 50 ~ 40 ~ 30 
20 
10 
Chapter 4-Resu/ts 
• Wild'JYpe 
• 450dciA/ Wiki'JYpe 
• 464de!Cfl W~d Type 
• QISIXI Wild 'JYpe 
. QISIX 
• RI20G 
174 
D 
Wildl)'pe 450deiA/ Wild T)'pe 
+-Desmin 
S P _S __ P S P p 
+ Desmin • + 
464deiCT/ Wild l)'pe QL5LX/ Wild T)'pe 
-
... -
-, 
-
.-:=.........:.- ___ P S P 
+ Desmin • 
Q151X RJ20G 
- -
-
-"---"p- ____!.. ....;S::....-..:..P __ s__ P 
+ Desmin • + 
Figure 4.13 . Sedimentation assay to investigate the prevention of desmin filament 
aggregation in the presence of various aB-crystallins at 44°C. (A-C) shows the% desmin 
pelleted (A), the % aB-crystallin wild type and mutants remaining soluble in the presence 
of desmin (B), and the % of the total aB-crystallin pelleted in the presence of desrnin (C), 
following low speed centrifugation (2500 x g). These data were calculated from SDS-
p AGE data of the desmin binding assays. (D) An example of the data used to calculate 
these values for wild type and mutant aB-crystallin. Those mutants associated with wild 
type are (450delA, 464delCT and Q151X) identified with arrowhead. 
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4.4. DISCUSSION 
The C-terminal extension is proposed to play an important role in maintaining 
solubility and preventing aggregation of the aS-crystallin oligomer. Chapter 3 discussed 
how the sequential truncation of the C-terminal extension resulted in an equally sequential 
loss of solubility, with the greatest effect upon solubility being observed with the disease 
causing mutants. These disease mutants produced the most extreme modifications, where 
either the whole C-terminal extension was removed (Ql51X) or completely altered by 
frame shift mutation (450delA and 464delCT), thus affecting both the flexible 'tail' and 
the non-flexible region of the C-terminal extension. The data suggest that perhaps 
additional regions in the non-flexible C-terminal extension also conferred an additional 
level of solubility to the complex through a different mechanism. 
In order to gain understanding of this mechanism, I wanted to investigate the effect 
of the C-terminal mutations upon structure and function, which included the 
characterisation of the relative chaperone function, oligomerisation properties, secondary 
structure, exposed hydrophobicity and thermal stability. This characterisation aimed to 
not only provide understanding of the mechanism that links the C-terminal extension with 
the chaperone function, oligomeric properties and solubility, but to also explain how 
mutations of this C-terminal, not only cause disease, but result in phenotypic variation. 
The consensus view that has emerged from recent studies on mammalian sHSPs is 
that the C-terminal extension is important for oligomerisation and chaperone function 
(Andley et al., 1996; Ghosh et al., 2005; Rajan et al., 2006; Thampi and Abraham, 2003). 
Characterisation of the disease causing mutants and the series of C-terminal 
truncation constructs of aS-crystallin in this Chapter has shown that, whilst the C-
terminal extension was essential for subunit interactions involved in oligomerisation, it 
showed a surprising inhibitory effect upon the chaperone function. Infact, for the QI51X 
aS-crystallin, the removal of the entire C-terminal extension significantly enhanced the 
chaperone function of aS-crystallin for some client proteins suggesting it is not essential 
for chaperone activity. 
These data, combined with the previous observations in Chapter 3, that all three 
disease-causing mutations (450delA, 464delCT and Q151X) in the C-terminal extension 
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destabilise aB-crystallin and increase its tendency to self-aggregate, suggest it is this 
destabilisation rather than a catastrophic loss of chaperone activity, that is a major factor 
in disease development. 
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4.4.1. REMOVAL OF THE C-TERMINAL EXTENSION REDUCES aD-
CRYSTALLIN OLIGOMERISATION, BUT NOT CHAPERONE 
ACTIVITY. 
The data presented in this Chapter shows the effects of sequentially truncating 
this domain (K174, A171, E165, E164 and Q151X), upon both aspects for aB-crystallin. 
It shows that deletion of the last 5 residues can improve chaperone activity in the citrate 
synthase assay without dramatically changing the secondary structure or oligomerisation 
ofaB-crystallin. Truncations (E164X, E165X) in the conserved REEK-motif(Rajan et al., 
2006) decreased chaperone activity and oligomerisation, although this coincided with 
more polydispersity for the oligomer as judged by SEC (see Figure 4.3A). The removal of 
the C-terminal extension by the Ql51X mutation produced a construct with the best 
chaperone activity profile of all the individual proteins investigated (see Figures 4.8 and 
4.11) despite the most significant changes in secondary structure (see Figure 4.5) exposed 
hydrophobicity (see Figure 4.6) and altered oligomerisation (see Figure 4.3 and 4.4). 
Whilst these results are in broad agreement with the consensus for other mammalian 
sHSPs, they demonstrate that the removal of the C-terminal extension from residue 151 
prevents oligomerisation (at concentrations less than O.lmg/ml), but not at the expense of 
chaperone function for aB-crystallin. Indeed the citroconylation of full length aB-
crystallin achieves similar results and together with these data strongly support the 
conclusion that oligomerisation is not required for aB-crystallin chaperone activity 
(Horwitz et al., 2004). 
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4.4.2. THE C-TERMINAL EXTENSION IS NOT ESSENTIAL FOR 
CHAPERONE ACTIVITY AND IS INHIBITORY FOR SOME CLIENT 
PROTEINS 
The chaperone activity of aB-crystallin mutants for client protein citrate synthase 
illustrated that even the removal of only the terminal two lysines was sufficient to 
significantly increase the chaperone activity of aB-crystallin above the level of the wild 
type. The Q 151 X most surprisingly was not only an efficient chaperone despite its' 
extreme truncation and inherent instability, but was seen to actually improve chaperone 
activity for citrate synthase and also desmin, in stark contrast to the effect of removing a 
similar region from aA-crystallin where chaperone activity was lost (Andley et al., 1996; 
Thampi and Abraham, 2003). The C-terminal extension deleted by the Q151X mutation 
includes the IX (IN) motif (de Jong et al., 1998), which is part of P-strand 10 (Kim et al., 
1998a; van Montfort et al., 2001) that has been shown to be both part of a client protein 
binding site aB157-I64 (Ghosh et al., 2005) and an oligomerisation sequence aB 155_165 
(Ghosh and Clark, 2005) in aB-crystallin (see Figure 4.1 ). This is removed by all three 
disease causing mutations, including Q 151 X, but retained in the other aB-crystallin 
mutants. Glycine substitutions in the IX(IN) motif not only increased oligomerisation and 
polydispersity of aB-crystallin, but also significantly increased chaperone activity (Pasta 
et al., 2004). The data presented for Q151X aB-crystallin and the other truncation 
constructs suggest that the client protein binding site that embraces the IX(IN) motif 
sequence (Ghosh and Clark, 2005; Pasta et al., 2004) is not only dispensable for activity, 
but that it could actually inhibit chaperone function as its removal actually increased 
activity for Q151X (citrate synthase, ~7.5 fold; desmin, ~2 fold). Partial removal ofthis 
site in E164X significantly inhibits chaperone activity for citrate synthase and insulin 
(citrate synthase, ~-0.5 fold; Insulin, ~-1.4 fold) and is slightly improved by extension of 
the site in the E165X (citrate synthase,~ 3.1 fold; Insulin, ~-0.1 fold). A 3D model of 
aB-crystallin (see Figure 4.2) has suggested that the C-terminal extension potentially acts 
as a 'cap' on an important oligomerisation and client protein binding site, namely the P3-
P8-P9 interface (Ghosh et al., 2006a). This region also interacts with the P4 strand, which 
is important in sHSP oligomerisation as seen from the crystal structure of sHSP16.9 (van 
Montfort et al., 2001), but it is also critical for chaperone activity (Ghosh et al., 2006a). In 
Chapter 4-Results 179 
fact reducing aS-crystallin to just its a-crystallin domain spanning residues 57-157, 
which still includes the ~3-~8-~9 surface, retained significant chaperone activity, but this 
construct only formed dimers and could not oligomerise (Feil et al., 2001) due to the 
absence of the subunit interaction sequences of the N-Terminal (aB37_54) and the C-
terminal (aB 155_165), which have been linked with higher order assembly (Ghosh et al., 
2005). 
It is easy to explain these observations and also data for the Q 151 X aD-crystallin 
mutant, in terms of how the removal of this C-terminal extension 'cap' as proposed in the 
model (Ghosh et al., 2006a) could allow substrate to bind more readily and thus enhance 
chaperone function, whilst also decreasing oligomer size. The data presented supports this 
model and also add an interesting new dimension, suggesting that the C-terminal 
extension actually limits the full potential of aS-crystallin chaperone activity. 
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4.4.3. AGGREGATION OF aD-CRYSTALLIN IS ENCOURAGED BY THE 
REMOVAL OF THE C-TERMINAL EXTENSION. 
In Chapter 3, I discussed the role of the C-terminal extension as a solubiliser of 
the aB-crystallin complex. The strong tendency of Q151X to aggregate at protein 
concentrations greater than 0.1 mg/ml and its very low refolding yield, along with the 
other aggregation prone disease mutants and E164X and E165X, which saw the removal 
of the flexible 'tail' supported the idea that the C-tenninal extension played an important 
role in preventing the uncontrolled self-aggregation of aB-crystallin (Aquilina et al., 
2004 ). The conclusion was that the flexible C-terminal 'tail' was essential to produce a 
stable aB-crystallin complex and that perhaps additional regions in the non flexible region 
of the C-tenninal extension also conferred an additional level of solubility to the complex, 
through a mechanism that also involved the oligomerisation and chaperone function 
(Ghosh et al., 2006d). The C-terminal extension can influence the structure and function 
of aB-crystallin apart from the solubilising function that is generally attributed to this 
region. It appears that this region can have either inter- or intramolecular tertiary 
interactions that contribute significantly to the function (Pasta et al., 2002). In sHSP16.9, 
the IX(IIV) motif from one subunit lays in a hydrophobic groove between P4 and P8 
strands of the other interacting monomer. Although aB-crystallin has similar structural 
features, including the conserved IX(IN) motif in its C-terminal extension, the oligomers 
it forms are more polydisperse (Aquilina et al., 2004; Haley et al., 2000; Kim et al., 
1998b) compared to either sHSP16.5 or sHSP16.9, suggesting that the precise detail for 
the interactions of the C-terminal extension in aB-crystallin will vary, not least due to the 
different hinge sequences between P-strands 9 and 10 (van Montfort et al., 2001). The 
strong tendency of Q 151 X aB-crystallin to aggregate suggests that the C-terminal 
extension actually prevents such errant subunit associations to favour instead 
oligomerisation. Therefore, the non-flexible C-terminal extension confers a level of 
stability to the aB-crystallin in addition to the solubilising 'tail' through a mechanism, 
which provides an interactive arm for oligomerisation and acts as a 'cap' over the 
interactive substrate binding P3-P6-P9 region. 
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4.4.4. REDUCED PROTEIN STABILITY AND UNCONTROLLED SELF-
AGGREGATION UNDERLIES THE MOLECULAR BASIS OF THE 
Q151X, 450DELA AND 464DELCT MUTATIONS. 
To fully understand the role of C-terminal extension in the disease mechanisms 
causing phenotypic variation required characterisation of not only the solubility (see 
Chapter 3), but also of the chaperone activity and oligomerisation properties of these C-
terminal mutations. This additional characterisation helped to provide a link between the 
structural and functional properties of the C-tem1inal mutants and the potential molecular 
basis of associated disease phenotypes. 
The partial loss of the C-terminal extension due to the E164X and E165X and the 
complete loss due to the Q 151 X mutation in aS-crystallin dramatically altered the 
secondary (see Figure 4.5) and tertiary structure of the protein (see Figure 4.3). These 
truncations significantly destabilised the protein as seen from the heat stability assay (see 
where the E164X and E165X rapidly formed substantially larger aggregates than Q151X 
Figure 4.7) as supported by the variations in complex size and oligomeric characteristics 
(see Figure 4.3). This truncation ofthe C-terminal extension, which removes the flexible 
solubilising 'tail', showed a dramatic increase in the tendency to self-aggregate in vitro 
(see Chapter 3, Section 3.3.4) and in vivo (see Chapter 3, Section 3.3.5). However, the 
Q 151 X aS-crystallin, even in the presence of equimolar wild type, had significantly 
altered secondary structure (see Figure 4.5) which affected aS-crystallin oligomerisation 
(see Figure 4.3) and reduced refold yields (see Chapter 3, Section 3.3.4). 
The Q151X mutation was dominant over the wild type protein in its effects upon 
heat stability, solubility and secondary structure. These data suggest that the strong 
tendency to self-aggregate as a result of reduced stability is potentially an important factor 
in disease development. Data for both 450delA and 464delCT also suggest that it is a 
similar loss in protein stability that causes cataract and myofibrillar myopathy 
respectively. Both mutants can only be refolded in the presence of wild type aS-crystallin 
and even then the temperature stabilities of the mixtures are reduced by some 20 °C 
compared to the wild type protein alone. Both the 450delA and 464delCT mutations 
introduced novel C-terminal peptides that have no homology to the existing C-terminal 
extension of aB-crystallin (see Figure 4.18). Both mutations changed the oligomerisation 
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of wild type aS-crystallin and neither mutant/wild type mixture was an effective 
chaperone in either the desmin (see Figure 4.12) or insulin (see Figure 4.9) assays. 
Therefore loss of chaperone activity could also potentially contribute to the development 
of disease for these two mutants, as suggested in the case of amyloidogenesis, the 
chaperone ability is crucial for preventing fibril formation. The aggregation of aS-
crystallin has been shown to have all the characteristics of fibrils associated with the 
family of amyloid diseases and that under destabilising conditions conversion of aS-
crystallin into fibrils could contribute towards the disease pathology (Meehan et al., 2007). 
The data suggest that the mechanism of disease associated with C-terminal 
mutants is influenced by an effect upon solubility and chaperone activity, however it is 
still not possible to draw a link between structure and function of the all-crystallin and its 
phenotypic heterogeneity. The three disease-causing mutations in the C-terminal 
extension of aS-crystallin (Q 151 X, 450delA and 464delCT) are restricted in their 
pathology to either the lens (450delA (Berry et al., 2001)) or muscle (Q151X, 464delCT; 
(Selcen and Engel, 2003) and yet all-crystallin is very highly expressed in both tissues 
(Kato et al., 1991 ). This is a familiar trend for all-crystallin mutations and even the most 
recently published mutation, D140N, causes only lens cataract (Liu et al., 2006b). Thus 
far, R120G all-crystallin is the only mutation that has produced both lens and muscle 
pathologies (Vicart et al., 1998), but this is not to say that sub-clinical pathology can be 
totally excluded for the other mutations, including Q 151 X, as tissue biopsies from 
apparently unaffected tissues were not analysed. Aggregation is a key histopathological 
feature of the Q151X mutation (Selcen and Engel, 2003) concurring with the data from 
the transient transfection and cell fractionation studies (see Chapter 3, Section 3.3.5) and 
so, this provides a plausible mechanism to support a potential dominant negative effect of 
the mutation by inhibiting the chaperone function of wild type all-crystallin via co-
aggregation with mutant Q151X as implicated from the in vitro refolding studies in 
Chapter 3, Section 3.3.4. 
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4.5. CHAPTER'S CONCLUSIONS 
In Chapter 3 it was clear that the flexible C-terminal 'tail' was essential to 
produce a soluble aB-crystallin complex. A recent study however, showed how 
additional regions in the non-flexible region of the C-terminal extension conferred an 
additional level of solubility to the complex through a mechanism that also involved the 
oligomerisation and chaperone function (Ghosh et al., 2006d). 
Therefore, in this chapter I wanted to understand how the C-terminal extension 
influences the chaperone function, oligomeric properties and solubility, with the aim of 
finding a link to the mechanism that not only causes disease but also results in varying 
pathology. 
This Chapter has shown that the C-terminal extension influences both the 
structure and function of aB-crystallin in addition to the solubilising function that is 
generally attributed to this region. 
The C-tenninal extension is primarily involved in subunit-subunit interactions 
required for oligomerisation and is not essential for chaperone activity. The C-terminal 
extension can actually inhibit client substrate binding by 'capping' the 133-138-139 interface 
in the a-domain, which is the interactive site for substrate binding. I have also suggested 
that the potential molecular mechanism behind the pathology of the disease causing 
mutants is a function of the reduced protein stability and uncontrolled self-aggregation 
caused by the alterations to the C-terminal extensions. The link however, between these 
findings and the mechanism, which causes the observed variations in phenotype, remains 
unclear and requires further investigation. 
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CHAPTERS 
THE RELATIONSIDP BETWEEN SUBUNIT DYNAMICS 
AND THE OLIGOMERISATION OF WILD TYPE 
aD-CRYSTALLIN 
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5.1. AIMS 
In this Chapter, I have investigated the relationship between the subunit dynamics 
of wild type aD-crystallin and oligomerisation. hoping to provide further insight into the 
role played by this domain in the efficient chaperoning of client proteins. The 
poly disperse assembly of wild type aS-crystallin exists as part of a dynamic equilibrium 
with a constant exchange of subunits between the oligomer and a pool of subunits (Bova 
et al., 1997; Bova et aL, 2000; Van Den Oetelaar, 1990), which have been suggested as 
potential active units of chaperone activity (Aquilina, 2005; Aquilina et al., 2003; Bova et 
al., 2000). The subunit dynamics of aD-crystallin are affected by various factors such as 
temperature and pH, however one of the factors important in the rate of reactions is 
protein concentration, which determines the frequency of collision of subunits and 
subsequently the rate of subunit exchange. In this chapter, I wanted to analyse the effect 
of protein concentration of wild type aD-crystallin upon oligomerisation, with the aim to 
further understand the relationship between subunit dynamics and the mechanism of 
chaperone activity. 
In Chapter 4, l discussed how chaperone activity is reliant upon the presence of the 
a-domain f33-f38-f39 surface for client protein interaction, thus dissociation of aB-
crystallin subunits from the oligomer would increase exposure of this interface to client 
proteins. Similarly, the literature suggests that under conditions of stress there is an 
increased level of dissociation of aS-crystallin subunits from the oligomer to prevent the 
aggregation of unfolding or denatured proteins. The argument for this theory is not only 
supported by the data in Chapter 4 which observed an increase in chaperone activity for 
the Q 151 X aD-crystallin which appears monomeric, but would also be strengthened by 
the isolation and characterisation of an active pool of dissociated subunits. Thus far 
however, under normal physiological conditions it is impossible to isolate significant 
amount of monomers, dimers, or tetmmers of a-crystallin (Horwitz et al., 2004 ). 
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5.2. INTRODUCTION 
In the lens, a-crystallin subunits self-associate through subunit exchange to form 
polydisperse assemblies that function as chaperones, however the a.A- and aS-crystallin 
subunits may play different roles both in the a-crystallin heteroaggregate and as separate 
proteins under stress conditions (Datta and Rao, 1999; K.amei and Matsu~ 2002). 
Whilst the subunit dynamics that influence the complex assembly of human aA and aD-
crystallin are important in the regulation of chaperone activity (Bova et al., 1997; Liu et 
at, 2006; Shashidharamurthy et aL, 2005; Spinozzi et al., 2006; Studer and N~ 
2000) a study has shown the rate of subunit exchange is not the critical parameter in 
detennining efficient chaperone behaviour for mammalian «A-crystallin (Aq~ 2005). 
The polydisperse assemblies of both uA and aD-crystallin exist as part of a dynamic 
equilibrium with a constant exchange of subunits between the oligomer and a pool of 
subunits (Bova et aJ., 1997; Van Den Oetelaar, 1990). For aA-crystallin., a study revealed 
a quaternary structure of «A-crystallin consisting of small multimers of aA-crystallin 
subunits (trimer or tetramer) in a dynamic equilibrium with the oligomeric complex (Bova 
et at, 2000). Similarly for aD-crystallin, Aquilina et al. (2003) observed the formation of 
aS-crystallin oligomers that contained odd and even numbers of subunits implying both 
dimeric and non-dimeric quaternary interactions form the basic building block of 
oligomerisation and that these monomers or dimers may constitute the active units of 
chaperone activity in dynamic exchange with the oligomer (Aquilina et al., 2003; Aquilina 
et at, 2004). Thus far, under normal physiological conditions, however it is impossible to 
isolate significant amount of monom~ dim~ or tetramers of a.B-crystallin (Horwitz et 
at, 2004) to enable further investigation of these potential active units and their role in 
chaperone activity. 
The relationship between chaperone activity, subunit dynamics and oligomer 
assembly remain unresolved and the mechanism by which this chaperone function occurs 
is not fully understood, however, a number of theories exist to explain the relationship 
between oligomerisation state., chaperone activity and the influential factors which induce 
subunit exchange and regulate chaperone activity. 
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5.2.1. TIIEORIES FOR THE ROLE OF OLIGOMERISATION AND SUBUNIT 
DYNAMICS IN CHAPERONE ACTIVITY 
The theories for the role of oligomerisation and subunit dynamics in chaperone 
activity suggest that oligomerisation is essential for efficient chaperone activity and that 
dissociation of subunits from the oligomeric state is required for chaperone function., 
whilst others suggest that the oligomeric complex is the active unit of chaperone activity 
and that no dissociation is required. There have been a number of studies showing support 
for both the oligomerisation and the dissociation theory of chaperone function. 
5.2.1.1. Dissociation Theory 
The theory of dissociation suggests the oligomer dissociates into smaller subunits 
such as monomers, dimers or multimers exposing hydrophobic surfaces enabling binding 
(Haslbeck et al., 1999; Van Montfort et al., 2001a). Loosening of subunit organisation 
may lead to more dynamic properties enhancing the available chaperone sites for target 
proteins. (Pasta et al., 2003). Once substrate (client protein) binding has occurred the 
subunits may re-associate into large soluble complexes that interact with ATP-dependant 
refolding machinery such as HSP70 (van Montfort et al., 2001h). Liu et.al. (2006) 
proposed that the subunits act as a one way irreversible 'sink:' that traps the Wlfolded 
proteins (Liu et al., 2006). Another proposal suggests a different mechanism where aB-
crysUdlin molecules are assembled into large insoluble protein aggregates that enable the 
subsequent disaggregation and refolding by the A TP dependant refolding machinery 
(Haslbeck et al., 2005). 
Narberhaus states that oligomerisation is a pre-requisite for chaperone function and 
subunit exchange (Narberhaus, 2002) and acts as a supply of subunits, which dissociate to 
form the soluble pool of the active unit of chaperone activity. Some studies, however 
suggest this oligomerisation may not be necessary for chaperone function. The unit of 
subunit exchange between cJosely related oligomers is a dimer (Stamler et al., 2005) and 
interestingly, a truncated form of aB-crystallin (aB57•157), which exists as a dimer still 
shows activity as a chaperone (Feil et al., 2001), suggesting that that the native oligomeric 
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state of aB-crystalJin may not be essential for chaperone function and that muJtimerisation 
above a dimer is not required (Feil et al., 2001 ). 
Horwitz et al. (2004), used citroconylation to disrupt the oligomeric state of aA 
and aB-crystallin and induce the dissociation of subunits. After this treatment the a.B-
cry•stallin oligomerisation was shown to be concentration dependant with monomers and 
dimers forming at 0.01 mglml, while at concentrations > 0.5 mg!ml tetramers are the 
major species. aA-crystallin is mostly tetrameric at any concentration following 
citroconylation. This study observed similar chaperone activity for the tetramers and 
monomers to the wild type suggesting that oligomerisation was not essential for chaperone 
activity (Horwitz et al., 2004). 
5.2.1.2. Chaperone assisted stabilisation of aD-crystallin via subunit exdlange 
Some studies have identified another pre-requisite for efficient chaperone function. 
The binding of an alternative chaperone in conjunction with subunit dissociation acts to 
stabilise a.B-crystallin thus promoting its role as a chaperone. HSP27 interacts with aA 
and aS-crystallin in vivo, but to a greater extent with aB-crystallin. In non-lenticuJar 
tissues HSP27 is expressed with o.B-crystallin rather than «A-crystallin and may serve to 
stabilise o.B-crystallin in non-lenticular tissues by co-localisation with o.B-crystallin under 
both normal conditions and in a stressed or diseased state (Zantema et al., 1992). The 
likely mechanism of aB-crystallin protection by HSP27 is subunit exchange similar to the 
stabilising effect o.A-crystallin has with aB-crystallin in the lens (Horwitz et al., 1999; 
Sun et al., I 998). One study by Bova et al. (2000), discusses two mechanisms for the 
subunit exchange between o.A-crystallin and HSP27 including firstly, the continuous 
association and dissociation of subunits as a result of a collision between oligomers and 
secondly, the continuous dissociation and reassociation of the exchange unit (Bova et al., 
2000). 
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5.2.1.3. Oligomer Theory 
A number of studies have proposed that the oligomer is the active unit of 
chaperone activity. One study showed that the oligomer remains intact as it binds 
substrate on its surface and no subunit exchange is necessary (Kim et al., 2003). Initial 
cross-linking studies with a-crystallin have shown an oligomer a-crystallin is an efficient 
chaperone (Shanna and Ortwerth, 1995). Later studies which, involved preventing 
dissociation by cross-linking aB-crystallin, illustrated how the cross-linked aS-crystallin 
proved a more effective chaperone than native aB-crystallin. This study concluded that 
chaperone activity is a surface phenomenon and dissociation is not required for full 
activity (Augusteyn, 2004). 
Avilov et al. (2004) used surface plasmon resonance (SPR) to study the 
interactions between oligomeric a-crystallin and its individual subunits with unfolded 
proteins. Immobilization at the sensor chip allowed the study of isolated a-crystallin 
subunits under physiological conditions for the first time and showed that a-crystallin 
subunits, in contrast to a-crystaUin oligomers did not bind unfolded protein. These data 
indicated that quaternary structure of a-crystallin is necessary for its chaperone-like 
activity (Avilov et al., 2004). A recent contrasting SPR study was able to identify various 
influential factors, which affect aB-crystallin subunit interactions including pH and 
temperature. This utilised a layer of aB crystallin subunits adsorbed onto the surfuce of a 
sensor chip and a solution of aB crystallin was then flowed over the surface-bound 
subunits. The associations between individual subunits were analysed under varying 
conditions of acidity, temperature and oxidative stress and illustrated binding even at the 
monomeric level (Liu et al., 2006). 
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5.2.2. INFLUENTIAL FACTORS AFFECTING SUBUNIT DYNAMICS, 
OLIGOMERISATION AND CHAPERONE ACTIVITY 
lnterconversion of the oligomer between multiple states is the underlying 
mechanism of regulation of chaperone function, however, the relationship between 
chaperone activity, subunit dynamics and assembly remain unresolved. 
In order to understand the mechanism regulating subunit dynamics, 
oligomerisation and chaperone activity it is important to understand what factors activate 
the mechanisms of subunit exchange, oligomer dissociation and exposure of interactive 
regions, whilst considering how these changes relate to the theories of chaperone activity. 
We know that aB-crystallin interacts with a broad range of proteins, including 
itself and its homolog aA-crystallin, and is up regulated during conditions of stress 
including heat shock, low pH and oxidative stress (Datta and Rao, 1999; Liu et aJ., 2006; 
Pasta et al., 2003) . These stress conditions mediated by other factors have been shown to 
affect the subunit dynamics, oligomerisation and chaperone activity of aS-crystallin and 
include temperature, pH, phosphorylation and ATP. Divalent metal ions such as calcium, 
magnesium, copper and zinc have been found to influence chaperone activity but show no 
effect upon the subunit dynamics of aS-crystallin (del Vaile et al., 2002; Duncan and 
Jacob, 1984; Ganadu et al., 2004; Marini et al., 1995). 
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5.2.2.1. Phosphorylation 
Phosphorylation of a-crystallin has been reported variously to have no effect on 
chaperone activity (Carver et al., 1996; Nicholl and Quinlan. 1994 ). to reducing chaperone 
activity (Aquilina et al., 2004; Kamei et al., 2001) and to cause a decrease in oligomeric 
size (Moroni and Garland, 2001 ). 
Both aA- and aB-crystallin polypeptides are phosphorylated on serine 
residues 19, 45, and 59 by cAMP-dependent and cAMP-independent mechanisms. The 
cAMP-independent pathway is an autophosphorylation that has been demonstrated in 
vitro, depends on magnesium and requires cleavage of A TP (Kantorow and Piatigorsky, 
1998; Miesbauer et al., 1994). These phosphorylated forms are not only important 
because of their abundance in aging lenses and the implications for cataract but also 
because they have been identified in patients with degenerative brain disease (Kato et al., 
2001). A study by Aquilina et al. (2004) found that phosphorylation of Ser-45 increases 
polydispersity of aB-crystallin, which stems from disruption of the dimeric substructure 
and changes in the subunit dynamics within the polydisperse aB-crystallin assembly 
(Aquilina et al., 2004). 
In U373 MG human glioma cells. aB-crystallin was observed as large oligomers 
with apparent molecular masses about 500 kDa and the oligomerization size was reduced 
after phosphorylation of all three Ser sites (19, 45 and 59). Phosphorylation of aD-
crystallin caused dissociation of large oligomers to smaller sizes of molecules and 
reduction of chaperone-like activity (Ito et al., 2001 ). The a-crystallin polypeptides differ 
with respect to their abilities to undergo cAMP-dependent phosphorylation, with 
preference given to the aB-crystallin chain. These differences and complexities in a-
crystallin phosphorylations, coupled with the differences in expression patterns of the two 
a-crystallin polypeptides, are consistent with the idea that each polypeptide has distinctive 
structural and metabolic roles (Kantorow and Piatigorsky, 1998). 
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5.2.2.2. Temperature 
Studies have shown that temperature significantly influences subunit exchange of 
aB-crystallin subunits. The chaperone activity of aB crystallin was enhanced at elevated 
temperatures,(Datta and Rao, 1999; Koretz et al., 1998; Raman and Rao, 1994; Raman 
and Rao, 1997). Heat shock raised the demand for chaperone function and led to the 
exposure of hydrophobic chaperone sites by subunit exchange (Shashidharamurthy et al., 
2005). At temperatures greater than 3 7°C, chaperone activity was elevated and an 
increase in the subunit dynamics with elevated association and dissociation rate of 
subunits was observed (Liu et al., 2006). This stress-related signal causes a shift in the 
subunit exchange equilibrium constant and activates binding of substrate to the 
chaperones. (Shashidharamurthy et aL, 2005) 
Studies attempting to evaluate chaperone activity as a function of temperature 
showed that the polydispersity of the aB-crystallin oligomer increased at elevated 
temperatures in the presence of insulin, urea and thiocyanate (Spinozzi et al., 2006). The 
changes in polydispersity occurred in three stages, the first transition at temperatures 
greater than 3 7°C affects activity but size is not affected until the temperature has elevated 
above 42°C and above 60°C there is a large structural reorganisation (Spinozzi et al., 
2006). At elevated temperatures the demand for chaperone activity is increased and an 
increase in oligomer size may be explained by the reassociation of substrate bound 
subunits into the oligomer. 
Circular dichroism studies by Datta et al. (1999), showed some tertiary structural 
changes in aA-crystallin above 50°C, but aS-crystallin shows significant alteration of 
tertiary structure by 45°C. The study demonstrated that despite a high degree of sequence 
homology and their generally accepted structural similarity, a.B-crystallin is much more 
sensitive to temperature-dependent structural perturbation than aA-crystallin or a-
crystaJlin and shows differences in its chaperone-like properties. These differences appear 
to be relevant to temperature-dependent enhancement of chaperone-like activity of a-
crystallin and indicate different roles for the two proteins both in a-crystallin 
heteroaggregate and as separate proteins under stress conditions (Datta and Rao, 1999). 
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5~~.3. pH 
A recent study observed that under acidic conditions, the interaction between aB 
crystallin subunits increased with a higher association rate and a lower dissociation rate, 
suggesting that the formation of stable oligomeric assemblies of aS-crystallin was 
favoured under acidic pH conditions. At pH values lower than pH 7.0 chaperone activity 
was reduced but association was increased, however dissociation was decreased. These 
findings suggested that dynamic and rapid subunit exchange may regulate chaperone 
activity (Liu et al., 2006). The pH dependence of the subunit-subunit interactions of a.B 
Cl)"stallin was independent of temperatw-e. a.B-crystallin is more sensitive to changes in 
pH than is a.A~crystallin and is found in degenerating brain tissues where pH conditions 
are acidic (van Rijk and Bloemendal, 2000; Yun et al., 2002) and aB crystallin is found to 
be co-localized in high Mwt insoluble cytotoxic aggregates, neuritic plaques, amyloid-f3 
peptides and other aggregating proteins as observed in neurofibrillary tangles and plaques 
in brains of Alzheimer's patients as well as cataracts in the elderly (Cobb and Petrash, 
2002; Liang, 2000; Mao et al., 2001; Pan et al., 1993). In vitro studies have further shown 
that the binding affinity of aS-crystallin to actin and desmin filaments increases 
considerably at slightly acidic pH of pH 6.5, consistent with the findings of Liu et al., 
(2006) where increased associations resuJted in the formation of stable complexes at 
pH<7.0 and was found to effectively prevent the tendency of actin filaments to form 
aggregates at acidic pH. These in vitro data suggest a protective role of a.B-crystallin 
during stress conditions such as ischemia of the heart Crystallin couJd prevent the 
aggregation of filaments, which might occur during the acidification of the cytosol and 
lead eventually to irreversible structural damage (Bennardini et al., 1992; Cbiesi et al., 
1990). A study by Koretz et al. (1998), revealed CD spectra, which indicated that acidic 
conditions Jed to some degree of unfolding and that this unfolding correlates directly with 
functionality (Koretz et al., 1998). 
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5..2.2.4. ATP 
<ill-crystallin and other sHSP's have traditionally been thought of as A TP 
independent chaperones, however a recent study has identified the tw-tm groove in aB-
crystallin as an interaction site for ATP (Ghosh et al., 2006c). Upon binding of ATP there 
is an effect on the subunit dynamics caused by conformational changes via disruption of 
the interaction between the C-terminal and the normally buried fW-(i8 chaperone interface, 
leading to an increased association with unfolding substrates and enhancement of 
chaperone activity (Ghosh et al., 2006c). An earlier study demonstrated an ATP-
dependent structural modification in the core a-crystallin domain of aB-crystallin 
(Mucbowski et al., 1999). 
A functional relationship between ATP and chaperone-like activity for a-crystallin 
was suggested when an interaction between ATP and bovine a-crystallin was observed 
{Palmisano et al., 1995; Re-ddy et al., 1992) and some studies have shown the binding of 
A TP to a-crystallin and not its hydrolysis was required to enhance chaperone activity 
(Biswas and Das, 2004). 
A model for chaperone activity of small heat shock proteins by van Montfort et al. 
(2001) proposed that A TP causes sHSPs to release substrates, which are then renatured by 
other larger heat shock proteins. Once substrate binding has occurred the subunits may 
reassociate into large soluble complexes that interact with A TP-dependant refolding 
machinery such as HSP70 (van Montfort et al., 200lb). A similar role has been proposed 
for A TP in a-crystallin chaperone activity. A study implied that multiple ATP molecules 
bind to each subunit and/or ATP causes a more compact a-crystallin structure. Such a 
conformational change could release a boWld substrate via both direct displacement and a 
global conformational change (Hasan et al., 2002). 
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5.2.2.5. Affinity 
The collective response of the interactive domains of sHSPs determines selectivity 
for similar subunits, unfolding substrate proteins, or filaments in the dynamic equilibrium 
model for the function of sHSPs in vivo (Liu et al., 2006). The selective rather than 
specific nature of the interactions between sHSPs and unfolded substrate proteins appears 
to be a function of the amount of unfolding and exposed hydrophobic surface of the 
substrates in response to stress (Liu et al., 2006). Perhaps both dissociated subunits and 
oligomer have the ability to chaperone but it's the level of stress, which dictates the level 
of protein unfolding, thus the required oligomerisation state. 
~iatron affects the exposure of sites with varying levels of affinity for the 
substrate. Ghosh and Clarke (2005) suggested multiple domains of varying affinity of aS-
crystallin, giving the ability to adapt the exposure of surfaces depending on the severity of 
the demand for chaperone and level of stress, i.e. unfolded or partially unfolded proteins 
(Ghosh et al., 2005). Continuing investigation of the relative binding affinities of 
interactive domains in human aB crystallin will characterize the collective interactions 
used in molecular recognition and selection mechanisms of the sHSPs (Ghosh et al., 
2006d). 
~ng the relationships between oligomer assembly, subunit dynamics 
and chaperone activity will help gain further insight into the mechanism that induces and 
influences chaperone function. The existing oligomer theory (Augusteyn, 2004; Avilov et 
at, 2004; Kim et al., 2003; Sharma and Ortwerth, 1995) and dissociation theory (Feil et 
al., 2001; Haslbeck et al., 1999; Horwitz et al., 2004; Liu et al., 2006; Narberbaus, 2002; 
Pasta et al., 2003; Stamler et al., 2005) explaining the relationship between 
oligomerisation state, subunit dynamics and chaperone activity along with the extensive 
studies performed to characterise the interactive regions exposed during subunit 
dissociation (Bhattacharyya et al., 2006; Ghosh and Clark, 2005; Ghosh et al., 2005; 
Ghosh et al., 2006a; Ghosh et al., 2006b; Ghosh et al., 2006c; Ghosh et al., 2006d; 
Sreelakshmi et al., 2004; Sreelakshmi and Sharma, 2005; Sreelakshmi and Sharma, 2006), 
suggest that the dissociation and subunit exchange is a pre requisite for chaperone function 
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and is not consistent with the oligomer theory. This supports the theory that there may be 
a soluble pool in constant equilibrium and dynamic exchange with the oligomer (Bova et 
a1., 1997; Bova et al., 2000; Van Den Oetelaar, 1990), which have been suggested as 
potential active units of chaperone activity (Aquilina, 2005; Aquilina et al., 2003; Bova et 
al., 2000). 
The subunit dynamics and oligomerisation of aB-crystallin are affected by various 
factors such as phosphorylation, temperature, pH and ATP, however one of the factors 
important in the rate of reactions is protein concentration, which determines the frequency 
of collision of subunits and subsequently the rate of subunit exchange. In this chapter, I 
aim to analyse the effect of protein concentration of aD-crystallin upon oligomerisation, 
with the aim to further understand the relationship between subunit dynamics and the 
mechanism of chaperone activity, whilst investigating the existence of a soluble pool of 
aD--crystallin subunits and its potential as the active unit of chaperone activity. 
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5.3. RESULTS 
The investigation of the effect of aB-crystallin concentration upon 
oligomerisation involved the use of a Superose 6 SEC column with a Merck Hitachi 
HPLC system with injection valve. Initial experiments identified peak material, which 
appeared consistently at the end of the 93.3 min separation range of the column. Buffer 
blank SEC with various buffers including Tris, ammonium acetate and NaP04 all 
identified the peak material at approximately 93 min, as did conditions using I M NaCl, 
confirming it was not caused by a buffer component or by hydrophobic interactions with 
the column matrix. 
Further analysis of the system confirmed that the 93 min peak was an effect 
introduced by the injection valve, and interfered with the UV detection because of the low 
level of sensitivity at which, the experiments were performed. 
Immunoblotting analysis also revealed that separation of aB-crystallin wild type 
resolved an unknown aB-crystallin species past the separation range of the column 
independent to the 93 min peak. (For full details see Appendix 4). 
The results contained within this section focus upon (i) the effect of aS-crystallin 
concentration upon oligomerisation and (ii) the characterisation of an unknown aS-
crystallin species past the separation range of the column. 
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5.3.1. THE EFFECT OF aD-CRYSTALLIN CONCENTRATION UPON 
OLIGOMERISATION AND POLYDISPERSITY 
Horwitz et al. (2004), usmg citroconylation showed that aS-crystallin 
oligomerisation is concentration dependant with monomers and dimers forming at 0.01 
mg!ml while at concentrations > 0.5 mg/rnl tetramers are the major species. This study 
suggests that the increased concentration causes a shift in the equilibrium and activates 
association of subunits. Here I investigated the effect of aB-crystallin concentration upon 
oligomerisation by repeated separation (rechromatography) of the wild type aB-crystallin 
migomer by SEC (see Section 2.8.2). The first cycle involved the separation of 500 JLg of 
wild type aS-crystallin (2 mg/ml) and the resolved oligomer fraction was stored 
imennediately overnight at ambient temperature 20°C before the second cycle of 
separation. This was repeated for a total of 4 cycles to achieve appropriate falls in 
concentration and enable the subsequent effect upon oligomerisation. Based on 
absorbance data, cycle 2 represented a 0.25 mg/ml solution and cycles 3 and 4 represented 
a 0.1 mg/ml and 0.01 mg/mJ solution respectively (see Figure 5.1). 
Tire first cycle (see Figure 5.lA) shows the aS-crystallin oligomer as a 
symmetrical peak at 57.4 min. The four cycles of SEC showed a change in the 
oligomerisation of wild type aS-crystallin as the concentration decreases. The peak 
height of the Cycle 2 oligomer (see Figure 5.1B) suggests a dilution of approx 8X to a 
predicted dilution of 0.25 mg/ml, however there is no effect upon oligomerisation with the 
retention time being consistent with cycle 1 and the peak area for cycle 1 and 2 both being 
100%. Cycle 3 represented an approx 0.1 mg/ml solution and had the most interesting 
effect upon oligomerisation. Figure 5.1C shows the introduction of a shoulder on the 
leading edge of the oligomer peak at 49.8 min representing 10% of the total wild type 
mixture and the presence of 1.02 %of high Mwt material at 27 .6 min (see Table 5.1). 
The oligomer peak appears less symmetrical and represents 88.36 % of the wild type aS-
crystallin. The presence of these additional peaks and the asymmetry of the oligomer peak 
suggest that the fall in aS-crystallin wild type concentration has increased the 
po1ydispersity of the wild type oligomer. 
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Further dilution by recycling fraction 55-60 min from Cycle 3 results in a shift in 
retention time from 57.6 min in Cycle 3 to 60.2 min for Cycle 4 (see Figure 5.1D) and is 
suggestive of a smaller oligomer. The polydispersity appears more like that seen for 
Cycle 1 and 2 with the oligomer peak regaining its symmetry. Any additional peaks 
however, oflower or higher Mwt may not be observed due to the level of sensitivity. 
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Figure 5.1. The effect of decreasing concentration upon the oligomerisation of wild type 
a.B-crystallin at ambient temperature (20°C). Wild type a.B-crystallin was separated by 
analytical SEC using a 26 ml Superose 6 column in 1 OmM Tris-HCl, 1 OOmM NaCl, 
pH7.4 at 2 mg/ml (A) and the fraction collected between 55-60 min was recycled over the 
SEC column for a further 3 cycles (B-D) in order to see the effect of dilution upon the 
oligomerisation characteristics. Cycle 2 (B) represents an a.B-crystallin concentration 
equivalent to 0.5 mg/rnl, with Cycle 3 (C) and cycle 4 (D) representing 0.1 mg/ml and 
0.01 mg/ml respectively. Samples for rechromatography at 20°C were stored overnight at 
20°C. 
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Table 5 .l. Integration data for Figure 5.1 
Cycle Time(min} Height (mA.U) Peak ,Area (%) 
1 57.367 132.74 100 
2 57.881 16.94 100 
3 27.566 0.07 1.02 
49.797 1.87 10.62 
57.635 9.28 88.36 
4 60.273 0.62 100 
At ambient temperature, a fall in aB-crystallin concentration from 2 mg/ml to 
0.25 mg/m] had no effect upon oligomerisation or polydispersity. Subsequent dilutions to 
0.1 mg/rnl resulted in a significant increase in polydispersity and further dilution to 0.01 
mg!ml saw a decrease in the oligomer size represented by a shift in retention time. 
The four cycles in Figure 5.1 were repeated this time with incubation of aS-
crystallin at 4 oc prior to SEC analysis performed at ambient temperature with storage of 
samples at 4°C between cycles. The low temperature will reduce the rate of association 
and dissociation and perhaps amplify the effects of concentration on polydispersity at 0.1 
mglml. 
The aB-crystallin oligomer is consistent through cycles 1 and 2 (see Figure 5.2A 
and B) and not until the third cycle do we observe a change in the polydispersity. 
Additional peaks relatively small in height were observed at 19.2, 39.3 and 73.6 min (see 
Figure 5.2C) with peak areas of 12.36%, 1.93% and 6.04% respectively (see Table 5.2). It 
is worth noting however, that the void volume of the column is 30 min at which proteins 
of2000 kDa are observed (see Appendix 2). The oligomer peak remains symmetrical. At 
ambient temperature cycle 3 showed a greater effect upon polydispersity of the oligomer 
as well as the introduction of additional peaks (see Figure 5 .l C), also under conditions of 
high ionic strength at ambient temperature (performed to assess the interaction 
characteristics of the 93 min peak material with the column matrix), cycle 3 showed an 
additional peak at 81.6 min (see Appendix 4, Figure A4.1C). 
The data supports the theory that there is a critical concentration below which, 
there is a change in subunit equilibrium resulting in the formation of oligomers smaller in 
size with greater polydispersity. 
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Figure 5.2. The effect of decreasing concentration upon the oligomerisation of wild type 
aB-crystallin at 4 °C. Wild type aB-crystallin was separated by analytical SEC using a 26 
ml Superose 6 column in lOmM Tris-HCl, lOOmM NaCl, pH 7.4 at 2 mglml (A) and the 
fraction collected between 55-60 min was recycled over the SEC column for a further 3 
cycles (B-D) in order to see the effect of dilution upon the oligomerisation characteristics. 
Cycle 2 (B) represents an aB-crystallin concentration equivalent to 0.25 mglml, with 
Cycle 3 (C) and cycle 4 (D) representing 0.1 mg/ml and 0.01 mg/ml respectively. 
Samples for rechromatography at 20°C were stored overnight at 4 °C. 
Table 5.2. Integration data for Figure 5.2 
Cycle Tnne(min) Height (rnA. U) Peak Area(%) 
1 57.367 132.74 100 
2 57.479 22.87 100 
3 19.214 0.22 12.36 
39.289 0.08 1.93 
58.763 4.09 79.68 
73.643 0.15 6.04 
4 59.345 0.423 100 
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A series of SEC experiments were performed similar to previous runs, however, 
the oligomer will not be recycled to achieve the dilution, instead the wild type a.B-
crystallin sample at 2 mg/ml was diluted to achieve the range of concentrations prior to 
SEC separation~ with the aim to reproduce the changes in oligomerisation observed in 
figures 5.1 and 5.2. The samples were prepared immediately before loading and were at 
ambient temperature. Previous SEC experiments incubated the samples overnight at 
ambient (see Figure 5.1) or 4°C (see Figure 5.2) before rechromatography. The dilutions 
used were based upon the approx dilutions observed during rechromatography and 
included 2 mg/ml, 0.5 mg/ml, 0.1 mg/ml and 0.01 mg/ml (see Figure 5.3). 
At 2 mg!ml the oligomer is represented by a sharp symmetrical peak and 
subsequent dilution to:::; 0.5 mg/ml results in a broadening of the oligomer peak suggestive 
of increased polydispersity (see Figures 5.3A-D). Unlike previous SEC cycle 3 data at 
approx 0.1 mg/ml (see Figure 5.1C and Figure 5.2C) the SEC for the 0.1 mg/ml a.B-
crystallin shown in Figure 5.3C produced one species, being the wild type oligomer. At 
0.01 mg/ml the a.B-crystallin oligomer peak is similar in symmetry to the 2 mg/ml a.B-
crystallin, however, shows a shift in retention time from 58.8 min to 56.9 min (see Figure 
5.3 A and D respectively). The most significant shift in retention is the 0.5 mg/ml sample 
showing 56.6 min with the 0.1 mg/ml sample showing a slightly smaller shift to 57.2 min 
(see Table 5.3). 
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Figure 5.3. The effect of decreasing concentration upon the oligomerisation of wild type 
aS-crystallin at 20°C. Wild type aB-crystallin was separated by analytical SEC using a 
26 ml Superose 6 column in lOmM Tris-HCI, lOOmM NaCl, pH7.4 at 2 mg/ml (A). A 
second SEC separation using 0.5 mg/ml wild type aS-crystallin (B) was run without 
overnight incubation of the sample. Further concentrations at 0.1 mg/ml (C) and 0.01 
mg/ml were analysed. 
Taf>k 5.3. Integration data for Figure 5.3 
Cycle Ti.me(min} Height (rnA. U) Peak Area (%) 
1 58.820 151.46 100 
2 56.605 44.93 100 
3 57.179 7.15 100 
4 56.896 0.49 100 
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The all-crystallin concentration has an effect upon the oiigomerisation of wild 
type aB-crystallin shown by changes in oligomeric size and polydispersity with the most 
significant changes in polydispersity observed at aB-<.."l)'stallin concentrations of approx 
0.1 mglml. The storage temperatures of ambient and 4°C and time of incubation induced 
variations in the polydispersity between data sets proving that the oligomerisation of aS-
crystallin is in constant dynamic exchange, which can be influenced by external factors. 
205 
5.3.2. IDENTIFICATION OF AN UNKNOWN MWT aD-CRYSTALLIN 
SPECIES 
The nature of the 93 min peak was determined to be an artefact (for full details 
see Appendix 4 ), however the separation of aB-crystallin wild type by SEC resolved an 
unknown aB-crystallin species past the separation range of the column independent to the 
93 min peak by immunoblotting analysis (see Figure 5.4). 
The observation of an unknown aS-crystallin species combined with evidence of 
a dynamic exchange (see Section 5.3.1) posed the question whether there was a presence 
of Jow Mwt complexes that were actively dissociated as part of the mechanism of 
chaperone activity, activated by the changes in concentration and temperature. The 
species could however, also represent a denatured form of aB-crystallin that binds to the 
coJumn and is retained even in the presence of IM NaCl (see Appendix 4, Figure A4.1) 
and a range of running conditions. In contrast, it could represent an active form of aB-
crystaUin that binds to either the column or denatured protein attached to the column, thus 
changing its elution properties. The aB-crystalJin, whether in an active or denatured form 
may be displaced when more aB-crystallin is provided. 
ln this section 1 aimed to further investigate this species by isolating the material, 
which would enable the characterisation of the unknown aS-crystallin species. Firstly, I 
wanted to confirm the presence of this species at the end of the separating range of the 
column. 
I aimed to confirm that there was an unknown Mwt species, which may represent 
a low Mwt complex in equilibrium with the oligomer that may be active in the chaperone 
function of aB-crystallin. I wanted to exclude the possibilities that the species was due to 
additional binding to the column of active or denatured forms and confirm that it was not a 
function of the injection system. 
A series of experiments were performed, which compared the presence of the 
unknown Mwt species between a Superose 6 column with the Merck Hitachi HPLC 
system and a HW55S column of the same dimensions with manual injection using a 
peristaltic pump. This aimed to firstly confirm the presence of an unknown Mwt species 
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and secondly that the species was not a product of external factors such a~ the column 
matrix or injection systems. To strengthen the identification of the aS-crystallin species 
at such a low level of sensitivity, an aS-crystallin specific ELISA was utilised in 
conjunction with immunoblotting and UV detection (For development and optimisation of 
the aB-crystallin ELISA, see Appendix 5). 
A 2 mglml (500 J..tg) wild type solution was analysed by SEC using the original 
system as used in Section 5.3.1. Figure 5.4 illustrates the presence of a species in the tail 
of the aS-crystallin oligomer. The tail begins at 75 min (see Figure 5.4A) and focusing 
on the Absorbance signal in the region 88-120 min we can see two additional peaks at l 00 
min and 112 min (see Figure 5.4B). The immunoblotting data confirms the resolution of 
a.nother aB-crystallin species, peaking between 108-110 min (see Figure 5.4C), however, 
w1th a greater sensitivity, the ELISA identifies numerous species with the largest eluting 
between 102-116 min (see Figure 5.4D). 
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Figure 5.4. Characterisation of tail material from a 2 mg/ml aS-crystallin load onto a 
23ml Superose 6 column. The column was run at 15 cmlhr and fractions were collected in 
0.4 ml volume. (A) Shows the elution profile for the SEC separation. (B) Shows a 
zoomed in region of the elution from 86-120 min, which identifies resolution of two 
additional peaks at IOO min and 112 min. Western Blotting (C) and ELISA data (D) 
confirms that there is a definite rise in aS-crystallin signal during this region. 
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The outcome of this experiment with the additional analysis confirmed that there 
was an unknown aB-crystallin species in the tail of the aB-crystallin oligomer, which 
elutes past the separation range of the column (93 min). 
The identification of this unknown Mwt species using a different matrix of 
HW55S and a manual injection system and peristaltic pump with would further confirm 
that the peak was not a function of the injection system or specific to the column matrix. 
A 2 mg/ml wild type aB-crystalJin solution was loaded directly onto the bed of a 23 mJ 
HW55S column and eluted using a peristaltic pump (see Figure 5.5). Resulting analysis 
shows an oligomer peak of similar height and retention time to that seen in Figure 5.4A 
with a tail starting at 80 min (see Figure 5.5A). Magnification of the UV data for the tail 
region of 88-144 min suggests a slight increase in signal between approx. 116-128 min 
(see Figure 5.5B). Once again the UV data does not provide sufficient sensitivity to be 
able to confirm the resolution of another aB-crystallin species, however, the 
immunoblotting illustrates an increase in a.B-crystallin levels peaking at the 114 min 
:fraction, which encompasses eluant between 112-114 min. Increased assay sensitivity 
achieved with the aB-crystallin ELISA identifies additional species peaking at 108, 114 
and 120 min, similar to the Superose 6 run from Figure 5.4D, which saw peaks at 102, 108 
and 114 min. 
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Figure 5.5. Characterisation of tail material from a 2 mg!ml aB-crystallin load onto a 
HW55S 23ml column. The column was run at 15 cmlhr using a peristaltic pump and 
fractions were collected in 0.4 ml volume. (A) Shows the elution profile for the SEC 
separation. (B) Shows a zoomed in region of the elution from 88-144 min, which 
identifies resolution of additional peaks. Western Blotting (C) and ELJSA data (D) 
confirms that there is a definite rise in aB-crystallin signal during this region. 
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These data confinn that there is an unknown aB-crystallin species present in the 
tail region of the oligomer peak and the retention time is suggestive of a low Mwt 
multimer or potentially monomer. 
The current theories of chaperone activity are supportive of the dissociation and 
association of aB-crystallin subunits between the oligomer and the active pool of active 
chaperones. These data may identify the active pool of chaperone activity and it could 
potentially be a more effective chaperone than a wild type solution, which is 99.99/o 
oligomeric. The question remained whether this species was monomeric or multimeric 
and required characterisation. 
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5.3.3. CHARACTERISATION OF THE UNKNOWN aD-CRYSTALLIN 
SPECIES 
Small scale SEC analysis of wild type a.B-crystallin (see section 5.3.2) confirmed 
the presence of an unknown aS-crystallin species at the ng level. 
Previously, I posed the question. whether there was a presence of low Mwt 
complexes that were actively dissociated as part of the mechanism of chaperone activity or 
whether the unknown Mwt species could represent a denatured form of aS-crystallin that 
binds to the column. The unknown Mwt species may also represent an active form of a.B-
crystallin that binds to either the column or denatured protein attached to the column and 
this aB-crystallin, whether in an active or denatured form may be displaced when more 
aB-crystallin is provided. The unknown Mwt species, however, has been observed for 
both Superose 6 and HW55S matrices showing the effect is independent to the type of 
column matrix utilised (see Section 5.3.2). 
ln vnler to determine the size of this species, thus confirming whether the 
unknown Mwt species was a low Mwt complex, a scaled up analytical SEC was carried 
out using a load of 125 mg (see Section 5.3.3.2). (Purification of the wild type aS-
crystallin is detailed in Section 5.3.3.1 ). This separation should provide a sample of the 
unknown Mwt species at a higher concentration (see section 5.3.3.1), suitable for 
cbarncterisation by ELISA, UV and immunoblotting (see Section 5.3.3.2) and allow 
investigation of the potential of the unknown Mwt species as a chaperone. Previously, 
fractions from the small scale runs had been analysed by Tandem mass spectrometry, a 
two step procedure which involves the selection of specific assemblies in the gas phase 
and inducing their dissociation through collisions with argon atoms to produce fragment 
ions. The dislodging of individual subunits from the non covalent assemblies results in a 
redistribution of charge on the products, therefore the range and the relative populations of 
the different oligomers that constitute a polydisperse assembly be can defmed (Aquilina et 
al., 2003). Unfortunately, the system sensitivity was not sufficient to detect the unknown 
Mwt species at the ng level, therefore it may not be sufficient for analysis of the large 
scale fractions. 
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An alternative method involved crosslinking to fix the multimeric conformation 
of the unknown Mwt species, then visualisation of the cross linked species by 
immunoblotting to confirm the size of the complex present (see Section 5.3.3.5). 
(Optimisation of the cross linking process is detailed in Section 5.3.3.4). 
Finally, the rechromatography of fractions containing the unknown Mwt species, 
on the 23 ml Superose 6 ana1ytical SEC column was performed to investigate whether the 
protein would again elute at the end of the separation range or elute in the position of the 
oligomer (see Section 5.3.3.3). This would confirm that the species was a low Mwt 
complex rather than another form of aB-crystallin and strengthen the argument that the 
species is part of the mechanism of chaperone activity. The current theories of chaperone 
activity are supportive of the dissociation and association of aB-crystallin subunits 
between the oligomer and the active pool of active chaperones. Characterisation of the 
chaperone activity may identify the active pool of chaperone function and it could 
potentially be a more effective chaperone than a wild type solution, which is 99.9% 
oligomeric 
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5.3.3.1. Large scale purification of aB-crystaUin 
Preliminary experiments showed that the amount of unknown Mwt species could 
be increased by raising the concentration of the aS-crystallin load material, although the 
relative peak heights of the unknown Mwt species and the oligomer remained constant 
(data not shown). 
The minimum concentration required for chaperone assays is 0.1 mg/ml, 
therefore the SEC was scaled up accordingly in order to recover the unknown Mwt species 
at the required concentration of 0.1 mg/ml. ELISA data for the 26 ml HW55S SEC 
showed a concentration of 247 nglml (total 197 ng) in the unknown Mwt species (see 
Figure 5.5D). Therefore, to achieve a concentration of 0.1 mg/ml, theoretically a 400x 
increase aB-crystaUin load would be sufficien~ which equates to 200 mg. Based on 
previous wild type purifications, a 0.8 L culture resulted in a final SEC pool of 16 mg. 
The efficiency of the lysis has been shown to be less than 100% efficient in the past, 
therefore to increase the yield of wild type a 0.25 mg/ml solution of lysozyme was added 
to the bacterial ceHs of a 6 L culture to aid the release of aS-crystallin from the cells. The 
6 L culture was the maximum volume, which could be processed as one batch. The 
purification is illustrated in Figure 5.6. 
The lEX purification clearly shows the resolution of the wild type from other 
contaminating proteins (see Figure 5.6A-B) and SDS PAGE analysis of the appropriate 
fractions confinns the major peak to be aS-crystallin and subsequently fractions 8-24 
were pooled to give a total of 260 mg aB-crystallin (by A280). Further purification by 
SEC using a 413 ml HW55S column resulted in a single peak (data not shown) and 
subsequent fraction analysis by SDS PAGE identified aS-crystallin enriched :fractions, 
however, two additional proteins were co-eluted in the major peak fractions (pool 1) with 
a further proteins being observed in the tail fractions (pools 2 and 3) (see Figure 5.6D). 
To identify the nature of these additional bands, immunoblotting was performed using the 
2D2B6 purified monoclonal aS-crystallin antibody, and visualisation confirmed that the 
bands identified by SDS PAGE in pool 1 were all positive for aB-crystallin. These 
additional aB-crystallin positive bands are consistent with those observed with wild type 
aB-crystallin SEC pool at I L scale (se Section 3.3.3.1, Figure 3. 7). The band present at 
30 kDa seen in pools 2 and 3 did not test positive for aS-crystallin. Therefore, I decided 
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to only proceed to the characterisation of the unknown aS-crystallin species with pool 1 , 
despite the amount of aB-crystallin I would lose by dismissing pools 2 and 3. 
Concentration determination confirmed that Pool 1 contained 125 mg of aB-crystallin (by 
A280), thus 135 mg aB-crystalJin was lost in pools 2 and 3. Despite requiring 200 mg of 
1oad material for the large scale analytical SEC, I decided to proceed as a 250X scale up 
was still a large enough increase to potentially amplify this unknown Mwt species for 
characterisation. 
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Figure 5.6. Large Scale purification of wild type aS-crystallin. A 6 L culture of BL-21 
cells expressing wild type aS-crystallin were lysed and the lysate purified by lEX 
chromatography using a 68 ml Fractogel TMAE EMD(s) column (13x2.6cm). The 
resulting lEX profile (A) and SDS PAGE analysis of fractions (B) indicate that fractions 
8-24 inclusive were aS-crystallin enriched and were subsequently pooled. The SEC was 
performed on a 413 ml HW55S column using a peristaltic pump and from individual 
fraction analysis three pools were prepared (D) with each pool containing various 
unknown bands (bands 1-4). Immunoblotting of the pools confirmed bands 2 and 4 were 
aB-crystallin, thus pool 1 was entirely aS-crystallin po iti . Pools 2 d 3 contained 
unknown protein at approx 30 k.Da (band 3) and pool3 at approx 60 k.Da (band l)(C). 
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5.3.3.2. Jdentification of unknown aD-crystallin species by UV, immunoblotting 
and ELISA. 
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The 125 mg wild type solution was applied to the 413 ml HW55S SEC column at 
0.6 ml/min and 8 ml fractions were collected and analysed. Figure 5. 7 illustrates the 
relative UV, ELISA and immunoblotting data for this run. As seen previously at the 0.5 
mg scale, the UV data shows a predominant oligomer peak (see Figure 5.7A) with a tail 
that shows some variation in signal (see Figure 5.7 B). This suggests the resolution of 
additional aB-crystalJin species. Immunoblotting confirms the presence of an aS-
crystallin species, in the tail ofthe oligomer and peaks at fraction 26 (see Figure 5.7C). 
The high sensitivity of the ELISA assay illustrates the aB-crystallin peak, which 
shows an increase from 3000-6700 ng in fraction 24. The peak encompasses fractions 23-
25, which contain 12165 ng of aS-crystallin in 24 ml by ELISA giving a concentration of 
0.00051 mg/ml. Fraction 24 was the most concentrated fraction at 0.00084 mg/ml (total 
0.0067 mg). The equivalent fraction from the 0.5 mg run (see Figure 5.5D) was 0.00029 
mglml, which confirms only a 3x increase in concentration of the unknown Mwt species 
was observed by increasing the load by 250x. however the yield of aS-crystallin in this 
frnction increased 58x from l14.8 ng to 6734.7 ng. The resolution of this material was 
greater in the 125 mg run where a significant peak was observed, compared to the 0.5 mg 
run where numerous peaks between 106-122 min where resolved with the peak at 114 min 
being the most concentrated. Fraction 24 from the 125 mg run represents 78% of a 
co}umn volume and fraction 114 from the 0.5 mg run represents 88% of a column volume. 
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Figure 5. 7. Characterisation of tail material from a 31.25mg/ml aS-crystallin load onto a 
HW55S 413ml column. Column was flowed at 7.5cmlhr using a peristaltic pump and 
fractions were collected in 8ml volume. (A) Shows the elution profile for the SEC 
separation, where resolution of any tail material is not evident. (B) Shows a zoomed in 
region of the elution from Fraction 16-35 ( 420-690min) which identifies the resolution of 
additional peaks. Western Blotting (C) and ELISA data (D) confirms that there ts a 
definjte rise in aB-crystallin signal during this region. 
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These runs are swnmarised in Table 5.4. 
Table 5.4. Comparison ofunknown Mwt species between 125 mg and 0.5 mg SEC runs 
Details of unknown Mwt 
species peak 
Large scale (125 mg) Small scale (0.5 mg) 
Concentration ng/ml 841.8 286.9 
Total ng 6734.7 114.8 
%CV 78 88 
%yield 0.0054 0.022 
The aim of the large scale run was to produce a fraction of the aB-crystallin 
species of sufficient concentration to allow characterisation of the species size and its 
chaperone function. It was evident from the ELISA data (see Figure 5.7D) that the 
material in fraction 24 was too dilute to perform any chaperone function assays. 
However, despite the low concentration, there was a sufficient amount for 
rechromatography of fraction 24 using the analytical 23 ml Superose 6 SEC column. The 
position of the resulting peak would determine whether the unknown Mwt species of 
fraction 24 was a low Mwt complex. Fraction 8 containing the oligomer was diluted to 
the same concentration as fraction 24 to act as a control sample for the visualisation of 
oligomer at the diluted concentration. This would allow me to confirm whether any of the 
}ow Mwt complexes had reassociated into the oligomer. 
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5.3.3.3. Characterisatieu of unknown aD-crystallin species by rechromatography 
of fractions 
Rechromatography of fraction 24 was carried out ensuring that the sample 
temperature has remained constant, thus avoiding any potential associations that could 
lead to multirnerisation. The appearance of a peak at the end of the separation range in the 
rechromatography run would confirm the material is a low Mwt species and not another 
form of uB-crystallin oligomer. The control involved analysis of fraction 8, which 
represented the oligomer peak from the 125 mg run and was used to show the levels of 
low Mwt species present in a fraction of the major peak (see Figure 5.8A). Magnification 
of the late peak at 100.7 min clearly shows the resolution of a peak in the oligomer 
fraction of peak height 2.7 mA.U. (see Figure 5.88). 
A 115000 dilution of Fraction 8, equivalent to the concentration of Fraction 24 
lvas also analysed to determine the level of sensitivity of the UV at this dilution. This 
diluted sample showed a late peak at 91.9 min at similar peak height 2.9 mA.U (see Figure 
5.8C), which is a difficult observation to explain. There is also evidence of a small 
oligmner peak even at this level of dilution at 59 min therefore the UV detection is 
sensitive enough to detect potential reassociation of the unknown Mwt species to an 
oligomeric complex in Fraction 24. 
Analysis ofthe neat sample of Fraction 24 resulted in a peak at 96.3 min of0.13 
rnA. U and showed no evidence of an oligomer peak con:finning the uS-crystallin has not 
reassociated into the oligomer at this concentration (see Figure 5.80) and adds support to 
the theory that this is potentially monomeric or dimeric. To amplify this signal and to 
assess the effect of concentration on the potential for reassociation, the fraction was spin 
concentrated 12 fold. However it seems that some loss of material occurred by binding to 
the membrane as suggested by the peak height being lower than the neat sample at 0.03 
mA.U (see Figure 5.8E). There is a slight peak shift to 97.3 min from the 96.3 min 
observed with the neat fraction 24 sample, which is suggestive of a smaller protein. 
Previous issues with the interference of the 93 min peak were evident in the blank 
consistent with Section 5.3.1.1. All the rechromatography samples were blank corrected 
and did not directly interfere with analysis as any low Mwt species observed, ran later at 
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96.3 min, 97.6 and 100.7 (A-B) and earlier at 91.9 min (see Figure 5.8D, E, A-Band C 
respectively). 
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Figure 5.8. Rechromatography of the unknown aB-crystallin. Fraction 24 from the large 
scale analytical SEC was analysed by 26 ml Superose 6 SEC column to determine whether 
this material, which runs at the end of the separation range actually resolves in the 
corresponding position during rechromatography. The fraction representing the oligomer 
peak (Fraction 8) was also analysed as a control to show the levels of low MW species 
present in a fraction of the major peak (A). Magnification of the late peak at 100.7 min 
clearly shows the resolution of a peak in the oligomer fraction (B). A 115000 dilution of 
Fraction 8, equivalent to Fraction 24 shows the late peak at 91.9 min at similar peak height 
2.9 mA.U (C). There is also evidence of a small oligomer peak even at this level of 
dilution at 59 min. Fraction 24 analysis shows a peak at 96.3 min and no evidence of an 
oligomer peak (D). To amplify this signal the fraction was spin concentrated 12 fold, 
however it seems that some loss of material has occurred on the membrane with the peak 
height being lower than the neat sample (E). Previous issues with the interference of the 
93 min peak were evident in the blank with a small peak shown at 93 m~ however all 
samples were blank corrected Any low MW species o I 96.3 min (D) 
97.6 (E) and 100.7 (A-B) and earlier at 91.9 min (C). 
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5.3.3.4. Optimisation of cross-linking conditions for the analysis of aB..crystallin 
unknown Mwt species 
Crosslinking optimisation studies had investigated the efficiency of various cross-
linking agents to achieve intermolecular crosslinking of aS-crystallin. The cross linking 
would analyse the multimerisation of the unknown aS-crystallin species relative to the 
cross linked wild type aB-crystaHin oligomer and may provide some variation indicative 
of a separate species. Optimisation of the cross linking aimed to investigate conditions, 
which would produce a sample at the stage of cross-linking where intermediate complexes 
were present such as dimer and tetramer, and not just the highest level of association, 
being the oligomer. 
Initial crosslinking optimisation investigated the use of the reversible cross linker, 
Dimethyl 3,3'--dithiobispropionimidate-2 HCI (DTBP), which is a homobifunctional, 
dea\•able and membrane permeable cross linker. It contains an amine-reactive imidoester 
at each end of an I I .9 A spacer ann. The imidoesters react with primary amines at pH 
8.0 to form stable amidine bonds. Several primary amines are present in the side chain of 
lysine residues and theN-terminal that are available as targets for imidoester crosslinking. 
The irnidoamide reaction product does not alter the overall charge of the protein, 
potentially retaining the native conformation and activity of the protein (Pierce Instruction 
Manual 0668.1 ). 
A nwnber of conditions were used in order to achieve the optimal cross-linking 
with DTBP however all proved unsuccessful therefore, the non-cleavable analogue of 
DTBP, Dimethyl Suberimidate-2 HCI (DMS) was analysed. DMS has essentially 
identical cross-linking activity towards primary amines and has a similar length spacer 
arm of ll A compared to DTBP, which is 11.9 A. A cross-linking experiment was 
performed at 20°C using 1.0, 0.5 and 0.1 mg/ml DMS with 0.2 mg/mJ aS-crystallin over 
0, 30, 60 and 120 min to gain an initial assessment of the efficiency of DMS as a cross-
linker of aS-crystallin (see Figure 5.9). 
DMS successfully cross-links aS-crystallin resulting in low Mwt complexes with 
predominant complexes migrating to positions indicating dimer, trimer and perhaps 
octomer at 160 kDa There is no evidence of complete e:ross-linking, which would be 
suggested by the presence of a band in the stacking gel, as the oligomer (564 kDa) would 
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be too large to enter the separating gel. Figure 5.9 shows that all the protein has entered 
the separating gel, which suggests that the DMS does not result in complete cross-linking 
of aS-crystallin under these conditions. The full range of cross-linking intermediates are 
necessary to fully understand any potential differences that may be observed in cross-
linked samples of the unknown aB-crystallin species. 
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0 min 30 min 60 min 120 min 
Lanes 1, 4, 7 and 10-0.1 mglml DMS 
Lanes 2, 5, 8 and 11 - 0.5 mglml DMS 
Lanes 3, 6, 9 and 12- 1.0 mglml DMS 
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Figure 5.9. Cross-linked aS-crystallin wild type oligomer by DMS. A range of DMS 
concentrations of 1.0, 0.5 and 0.1 mg/ml were used with a 0.2 mg/ml aB-crystallin at 
20°C over a time course of 120 min. The greater the DMS is in excess the more cross-
linking is observed as evident by looking at the dimer bands in lanes 3, 6, 9 and 12. A 
strong band can be seen at approx 60 kDa indicative of trimer. All proteins have entered 
the separating gel suggesting there is no 560 k.Da oligomer present, thus cross-linking is 
not complete. 
GJuternldehyde (GA) has been used as an efficient reagent in achieving 
intermolecular cross~linking with aB-<:rystallin (Auguste~ 2004). GA is an amine 
reactive bifunctional cross-linker and has a 5 A spacer ann, compared to DTBP ( 11.9 A) 
and DMS ( 11 A), which limits the ability to covalently link molecules that are more 
distant from each other (Krohn et al., 2002). A 0.2 mg/mJ aB-crystallin solution was 
incubated at 20°C with 0.1%, 0.01% and 0.001% GA (v/v) for 0, 60 and 120 min and 
subsequent analysis following precipitation, by SDS PAGE was performed (see Figure 
5.10A). The GA bas successfully produced a range of cross-linked aB-crystallin species. 
At 0.1% (lane 2), even at 0 min there are high Mwt species, wh'ch are too larg to enter 
tbe separating gel thus, indicate the 564 kDa oligomer. Also at 0 min 0.01% and 0.001% 
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(lane 3 and 4 respectively) GA cross-linked samples show signs of dimer at 40 kDa but 
are still predominantly monomer. After 60 min, the 0.1% sample is completely cross-
linked (lane 5) and the 0.01% sample shows the oligomer and also intermediate complexes 
of predominantly dimer and monomer (lane 6). The 0.001% GA cross-linked sample 
looks similar to the 0 min GA cross-linked sample with the introduction of faint bands at 
60 k.Da and 80 kDa indicative of trimer and tetramer (lane 7). After 120 min, the 0.01% 
sample has almost completely cross-linked with a faint presence of monomer remaining 
(1ane 9), however the 0.001% sample was still showing intermediate complexes, which 
suggests this concentration of GA is efficient for the identification of cross-linked dimeric 
complexes (lane 1 0). 
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Figure 5.1 0. Cross-linking of aB-crystaUin wild type oligomer by gluteraldehyde. A 
range of gluteraldehyde concentrations of 0.1, 0.01 and 0.001% (v/v) were used with 0.2 
mg/ml a.B-crystallin solution at 20°C over 0, 60 and 120 min (A). Cross-linking was 
successful and the experiment was repeated to optimise the cross·linking conditions for 
low a.B-crystallin concentrations, representing potential fractions of the unknown a.B· 
crystallin species from the large scale SEC (B). The SDS PAGE shows complete 
crosslinking for 0.1% and 0.01% gluteraldehyde samples and the presence of dimer at 
0.001% (lanes 4, 7 and 10). The presence of other bands of varying MW cannot be 
detected at the level of sensitivity offered by SDS PAGE. The control shows the untreated 
wild type oligomer (control lane). 
In order to investigate the efficiency of cross-linking of a.B-crystallin at levels 
similar to the unknown Mwt species fractions, a range of a.B-crystallin concentrations 
were cross-linked and analysed. Predicted concentrations of the unknown Mwt species 
following scale-up were approx. 0.05-0.1 mg/ml, therefore 0.1, 0.05 and O.Olmg/ml 
solutions ofaB-crystallin were incubated at 20°C with 0.1%, 0.01% and 0.001% GA (v/v) 
for 60 min (see Figure 5.10B). It is evident that at all a.B-crystallin concentrations, a 
0.001% GA solution was sufficient to produce dimer at 40.32 kDa (lanes 4, 7 and 10), 
however only the 0.01% (lanes 3 and 6) and 0.1% (lanes 2 and 5) solutions resulted in 
~omplete cross-linking. The low a.B-crystallin concentrations make it difficult to visualise 
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any pment1al intem1ediate complexes, thus the experiment was repeated and analysis by 
immunoblotting to achieve the higher level of sensitivity required (see Figure 5.11 A). 
A range ofGA concentrations ofO.l, 0.01 and 0.001% (v/v) were used with a 
range of low aB-Cl)'Stallin concentration solutions at 20°C over 60 min including 0.1, 
0.05 and 0.01 mg/ml (see Figure 5.11A). The immunoblotting shows the 0.1% GA results 
in complete cross-linking at aU aB-crystallin concentrations (lanes 1, 4 and 7) as indicated 
in Figure 5.lOB. The 0.01% GA shows intermediate complexes as \Veil as oligomer and 
monomer (lanes 2, 5 and 8). The 0.001% GA results in a range of complexes, however 
shows no evidence of oligomer (lanes 3, 6 and 9). The excess GA in the 0.01 mg/ml 
sample (lane 8) compared with 0.1 mg/ml and 0.05 mg/ml (lanes 2 and 5 respectively) is 
sutlicient to complete the cross linking with the lower concentration of aB-crystallin. The 
'·ariation in concentration is reflected by the intensity of the dimer bands. 
ldeal cross-linking conditions, which will be applied to the unknown Mwt species 
fractions, would show the range of complexes from monomer to dimer through to the 
oligomer for the wild type solution (see Figme 5.11 A, lane 5). 'fl1ese conditions can then 
be used effectively as a standard to compare the relative cross-linking of the unknown 
1\hvt species to assess any variations in multimerisation. 
Tv achieve cross-linking of similar quality to the 0.05 mg/ml with 0.01% GA (sec 
Figme 5.1lB, lane 5), but with the 0.01 mg/ml, a time course for the 0.01 mg/ml aB-
CI) staUin solution was analysed over 0, 60 and 120 min (see Figure 5.11 B). Lane 9 shows 
that even after 120 min the 0.001% GA does not achieve complete cross-linking, whereas 
the 0.1% and 0.01% GA are both complete (lanes 7 and 8 respectively). The intermediate 
complexes can be seen in Lane 5, which represents 0.01% GA after 60 min incubation at 
20°C, although the lower Mwt bands are relatively faint compared with the 0.05 mg/ml 
aB-crystallin sample under the same conditions (see Figure 5.11 B, lane 5). 
n~e data suggest that at aB-crystaiJin concentrations from 0.2 mg/ml (sec 
Figure 5.llA, lane 6) to 0.1, 0.05 and 0.01 mg/ml (see Figure 5.llA, lanes 2, 5 and 8), an 
incubation of 60 min at 20°C with 0.01% GA was sufficient to cross-link aB-crystallin 
rnultimers. From these data, I conclude that crosslinking with GA under the optimised 
conditions \Vill allow me to assess any variations in multimcrisation or complex size in the 
unknown cd3-crystallin spectes relative to the wild type as the protein oligomer can be 
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detected. The unknown aB-crystallin species would be detected if it was present as an 
oligomer and also any variations in multimerisation achieved by crosslinking would be 
evident and signify a aB-crystallin species different to the wild type oligomer. 
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Figure 5.11. ImmUfloblotting of Cross-linked aS-crystallin wild type oligomer by 
gluteraldehyde. A range of gluteraldehyde concentrations of 0.1 , 0.01 and 0.001% (v/v) 
were used with a range of low aB-crystallin concentration solutions at 20°C over 60 min 
(A). The im.munoblotting shows the 0.1% gluteraldehyde results in complete cross-linking 
at all aB-crystallin concentrations (lanes 1, 4 and 7). The 0.01% gluteraldehyde shows 
intermediate complexes as well as oligomer and monomer (lanes 2, 5 and 8). The 0.001% 
gluteraldehyde results in a range of complexes, however shows no evidence of oligomer 
(lanes 3, 6 and 9). The variation in concentration is reflected by the intensity of the dimer 
bands. A time course for the 0.01 mg/ml aB-crystallin solution was analysed over 0, 60 
and 120 min (B). Lane 9 shows that even after 120 min the 0.001% gluteraldehyde does 
not achieve complete cross-linking, where as the 0.1% and 0.01% gluteraldehyde are both 
complete (lanes 7 and 8 respectively). Lane 5 show both oligorn r, dimer and monomer 
under conditions ofO.Ol% (v/v) gluteraldehyde after 60 min. 
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5.3.3.5. Cross-linking analysis of the aB-crystallin unknown Mwt species 
The conditions optimised for cross-linking aB-crystaUin between 0.2 and 0.01 
mglml was applied to fractions encompassing fraction 24, the fraction containing the peak 
of the unknown Mwt species confirmed by ELISA (see Figure 5.7D). Encompassing 
fractions included fractions 18, 23-25 and 29. As with the rechromatography (see Section 
5.3.3.2.2) fraction 8 of the oligomer peak was cross-linked, as a control along with the 
1/5000 dilution of fraction 8 to allow a relative comparison between the resulting cross-
linked species produced from fraction 8 and the unknown Mwt species fractions. 
Tire SEC was run with 0.2M Ammonium Acetate, thus the fractions had to be 
dialysed into PBS for 60 h to ensure there were no residual primary amines present from 
the eluant buffer, which would compete with the cross-linking reaction. Dialysates were 
incubated for 60 min with 0.01% GA (v/v) prior to precipitation for immunoblotting (see 
Figure 5.12). Initial immunoblotting showed no evidence of any higher Mwt bands in the 
fractions, or more interestingly in diluted fraction 8 (consistent with Figure 5.8C), despite 
the neat fraction 8 showing cross-linking consistent with the optimisation studies (see 
Figure 5.12A). The immunoblotting was repeated to enhance the visualisation of any 
potential higher Mwt bands but showed no improvement on the initial blotting (see Figure 
5.12B). The repeat confirmed that fraction 8 shows evidence of efficient cross-linking, 
although large amounts of monomer remain, at time point 0 min with 0.01% GA, 
therefore this level of GA should be sufficient to efficiently cross-link the aS-crystallin 
present in the unknown Mwt species fractions and the diluted fraction 8. 
A 
Dimer-
40.23 kDa 
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Dimer Frl8 Frl8 1'123 1'123 fi'24 fi'24 Fr8dil Dimer Fr8dil M5 Pr'2S Pr29 Pr29 M Fr8 
llllllkcr TP=O ~ TP=O ~ TP=O ~ TP=O mub:r ~ TP=O ~ TP=O ~ TP=O ~ 
B 
Dimer Pr23 Pr23 fi'24 fi'24 Pr'2S Pr'2S 
muter TP=O ~ TP=O ~ TP=O TP=al TP=O 
Figure 5.12. Irnmunoblotting of Cross-linked aB-crystallin unknown Mwt species. 
Cross-linking analysis of unknown Mwt species fractions and oligomer fraction from the 
large scale analytical SEC (A). Fractions encompassing the unknown Mwt species peak 
(Fr 24) and the oligomer peak of similar dilution (Fr 8dil) all show a single band 
corresponding to the monomer at 20.16 kDa following cross-linking with 0.01% GA (v/v) 
for lhr at 20C. (25ul loaded and blotted with purified aB monoclonal 2D2B6 (111000) 
and (HRP 1/1 000). Fr 8 shows higher MW species after 60 min (TP=60) however the 
same fraction diluted 1/5000 looks similar to the unknown Mwt species fractions. To 
detect any higher MW bands a repeat analysis was performed (B) with increased antibody 
and HRP levels (25ulloaded and blotted with purified aB monoclonal2D2B6 (1/100) and 
HRP (11500). Repeat analysis suggested no multimeric species present in the fractions. 
One factor, which could be influential in the efficiency of the cross-linking, is the 
concentration of the unknown Mwt species fractions. Predicting 0.05-0.1 mg/ml, fraction 
24 containing the peak material was actually 0.00084 mg/ml, some 12x lower than the 
optimised cross-linking for all-crystallin at 0.01 mg/ml. This would mean there was an 
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excess of GA in the unknown Mwt species samples, thus complete cross-linking would be 
likely, however Figure 5.12B clearly shows no presence of a oligomeric band. The 
extremely low concentrations combined with limitations of the GA to covalently link 
molecules that are more distant from each due to a spacer of only 5 A increase the 
possibility that the molecules are not cross-linking. The low concentrations make it very 
difficult to categorically state that there are no other Mwt complexes present. 
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5.4. DISCUSSION 
5.4.1. THE POLYDISPERSITY OF THE WILD TYPE aB-CRYSTALLIN 
OLIGOMER IS DEPENDANT UPON CONCENTRATION 
An important feature of aS-crystallin and other sHSPs is the ability to self 
associate and form mono- or polydisperse assemblies through a mechanism of subunit 
dynamics, however the relationship between the subunit dynamics, oligomerisation and 
chaperone activity remain unresolved (Liu et al., 2006). Many factors have been shown to 
influence the subunit dynamics as discussed extensively in the Introduction (see Section 
5 .2), which subsequently has an impact upon the oligomerisation and chaperone function. 
These include temperature (Datta and Rao, 1999; Koretz et al., 1998; Liu et al., 2006; 
Raman and Rao, 1994; Raman and Rao, 1997; Shashidharamurthy et al., 2005; Spinoui et 
a1., 2006), pH (Koretz et al., 1998; Liu et al., 2006; van Rijk and Bloemendal, 2000; Yun 
et aJ., 2002), divalent cation influences (del Vaile et al., 2002; Duncan and Jacob, 1984; 
Ganadu et al., 2004; Marini et al., 1995), ATP (Biswas and Das, 2004; Ghosh et al., 
2006c; Liu et al., 2006; Muchowski and Clark, 1998; Palmisano et al., 1995; Reddy et al., 
1992}, and phosphorylation (Aquilina et al., 2004; Kamei et al., 2001; Kantorow and 
Piatigorsky, 1998; Moroni and Garland, 2001). 
One of the factors important in the rate of reactions is the concentration, which 
determines the frequency of collision of subunits and subsequently the rate of subunit 
exchange and oligomerisation. Bova suggested that for aA-crystallin the association/ 
dissociation rate was independent of concentration, implying that the exchange of subunits 
is ll(}t due to the collision of the oligomers but is most likely a dissociation mechanism 
(Bova et al., 2000). Here I aimed to analyse the effect of protein concentration of aB-
crystallin upon oligomerisation with the aim to further understand the effect external 
factors may have upon subunit dynamics and the mechanism of chaperone function. 
In this study, I have shown that at aS-crystallin concentrations of approx 0.1 
mglml there is an increase in polydispersity with complexes of both increased and reduced 
size. Further dilution to approx 0.01 mg/ml results in a reduction in the oligomeric 
complex size of the main aS-crystallin peak. 
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The investigation of the effect of aB-crystallin concentration upon 
oligomerisation involved recycling of the oligomer peak material under various 
conditions. Initial investigations of the effect of concentration on oligomerisation showed 
that on the third cycle (approx 0.1 mg/ml) there was resolution of additional peaks. At 
20°C there was the introduction of a shoulder on the leading edge of the oligomer peak at 
49.8 min and a species at 27 .6 min. The oligomer peak (57.6 min) was broader and 
appeared less symmetrical to the wild type in cycles 1 and 2 (approx 2.0 and 0.5 mg/ml 
respectively). The presence of these additional peaks and the asymmetry of the oligomer 
peak suggest that the dilution increased the polydispersity of the wild type oligomer. The 
fourth cycle (approx 0.01 mg/ml) resulted in a symmetrical but smaller oligomer peak 
(60.3 min) suggesting that a further fall in aB-crystallin concentration affected the ability 
to form the oligomer observed at higher concentrations. 
At 4°C it was intended that the low temperature would reduce the rate of 
association and dissociation and perhaps amplify the effects of concentration upon 
poJydispersity at 0.1 mg/ml. Similarly to the oligomerisation observed at 20°C, the aB-
crystallin oligomer is consistent through cycles 1 and 2. At the third cycle a change in the 
poJydispersity was evident with additional peaks relatively small in height, being observed 
at 19.2, 39.3 and this time a smaller complex at 73.6 min. The oligomer peak remains 
similar in symmetry to cycle I and 2. At 20°C, dilution of aB-crystallin oligomer to 0.1 
mglml in cycle 3 showed a greater effect upon polydispersity of the oligomer peak where 
at 4°C a smaller complex was resolved at 73.6 min. Under conditions of high ionic 
strength at 20°C, cycle 3 (approx 0.1 mg/ml) however, showed an additional peak 
representing a smaller complex at 81.6 min (see Appendix 4, Figure A4.1 ). 
Further dilution to 0.01 mg/ml at 20°C, 4°C and under conditions of high ionic 
strength, resulted in a smaller broader oligomer peak. Here, the dilution reaches a level, 
which results in an effect upon the size of the oligomer as well as the polydispersity. 
These data suggest that the reduction in concentration to 0.1 mg/ml reduces the 
rate of associations and dissociations, which results in the appearance of additional species 
through increased polydispersity. At even lower concentrations ofO.Ol mg/ml the rate of 
subunit exchange is further reduced and combined with a further fall in the frequency of 
coUisions we observe a negative effect upon the ability of the aB-crystallin to fully 
oligomerise. 
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These data support the theory that there is a critical concentration for a.B-
crystallin oligomerisation. In equilibrium there would be constant exchange of a.B-
crystallin subunits between the oligomer and a pool of a.B-crystallin subunits. This has 
been observed for a.A-crystallin where a study revealed a quaternary structure of a.A 
crystallin consisting of small multimers of a.A crystallin subunits (trimer or tetramer) in a 
dynamic equilibrium with the oligomeric complex (Bova et al., 2000). 
The concentration of a.B-crystallin subunits in the pool, at this equilibrium is 
referred to as the critical concentration, also referred to as the concentration of a.B 
subunits required for oligomer formation (Lewin, 2007). When the total concentration of 
subunits is below the critical concentration only monomer will exist. In contrast, when the 
total concentration of subunits is greater than the critical concentration oligomer will form 
(Lewin, 2007). 
As observed from the data shown, at concentrations above the critical 
concentration the oligomer will form at rates that depend linearly on the concentration of 
subunits in solution, thus resulting in the formation of a range of intermediate complexes 
of varying size. ln its native state, a.B-crystallin consists primarily of oligomers 
containing 24-33 subunits, with a dominant species being composed of 28 subunits 
(consistent with these data where a.B-crystallin has a Mwt of 564 kDa (see Figure 4.3)). 
Additionally, low levels of oligomers as small as a 1 O-rner and as large as a 40-mer were 
observed (Aquilina et al., 2003; Benesch et al., 2006). The formation of sHSPs oligomers 
from plants, yeast and bacteria have been shown to consist of dimeric building blocks, 
which have been proposed as the active unit involved in chaperone activity and to 
contribute towards their monodisperisty (Narberhaus, 2002; van Montfort et al., 2001 b). 
ln wheat sHSP16.5, the IX(IN) motif of the C-terminal interacts with the ~ and (38 
strands of another monomer to form the higher order dodecameric double disk quaternary 
structure observed in the crystal structure (van Montfort et al., 200lb). While a.B-
crystallin contains the same three structural domains found in Mjannaschii ssHSP16.5 
and wheat sHSP16.9, the complex assembly of human a.B-crystallin is larger and more 
polydisperse than the two sHSPs that have been crystallised and cryo-electron microscopy 
studies showed that a.B-crystallin has an asymmetric variable quaternary structure 
consisting of 32 subunits with a central cavity (Feil et al., 2001; Haley et al., 1998). The 
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variable quaternary structure of aS-crystallin is consistent with the polydispersity of the 
oligomer and with the dynamic nature of aS-crystallin (Haley et al., 1998). Aquilina et 
a1. (2003) observed the formation of aS-crystallin oligomers that contained odd and even 
numbers of subunits implying both dimeric and non-dimeric quaternary interactions form 
the basic building block of oligomerisation and that these monomers or dimers may 
constitute the active units of chaperone activity (Aquilina et al., 2003; Aquilina et al., 
2004). 
The data shown here suggests increased polydispersity is associated with a fall in 
aB-crystallin concentration revealing additional oligomers of both higher and lower Mwt 
relative to the 564 kDa oligomer. The nature of aS-crystallin oligomer formation which 
sees a distribution of oligomers from a 1 O-rner up to a 40-mer with the primary oligomers 
consisting of 24-33-mers and a dominant 28-mer species highlights the natural 
polydispersity of aS-crystallin and indicates how the associations of aS-crystallin 
subunits allows the formation of a wide range of oligomeric complexes, which is 
increased under conditions of lowered concentration. Figure 5.13 indicates the many 
possible intermediate aS-crystallin oligomers, which may form as a function of the 
poJydispersity to achieve the distributions observed by Aquilina (Aquilina et al., 2003). 
The temperature and time of incubation also show variations in the polydispersity 
adding support to theory that the oligomer of aB-crystallin is in constant dynamic 
exchange, which can be influenced by external factors (Datta and Rao, 1999; Koretz et al., 
1998; Liu et al., 2006; Raman and Rao, 1994; Raman and Rao, 1997; Shashidharamurthy 
et ai., 2005; Spinozzi et al., 2006). The effect of changes in polydispersity upon the 
function of aS-crystallin as a chaperone remains unclear. The chaperone activity 
improves with a smaller complex size as observed in Chapter 4 with the Q 151 X aD-
crystallin (see Section 4.4.2), suggesting that the polydispersity resulting from a dynamic 
subunit exchange rate may be more important than complex size in regulating the 
chaperone activity of aS-crystallin and sHSPs by regulating the exposure of the 
imeractive sites involved in the binding of client proteins (Datta and Rao, 2000; Lindner et 
al., 2000; Liu et al., 2006; Shashidharamurthy et al., 2005). In the aS-crystallin oligomer, 
the interactive site for chaperone activity and substrate binding is the f:B-fJ8-f39 interface 
(Ghosh et al., 2006a), which may be buried in the oligomer and inaccessible to unfolding 
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proteins. This leads to the hypothesis that dissociation of aD-crystallin complexes is 
required for effective chaperone activity. Changes in the polydispersity may influence 
chaperone activity by increasing or reducing the exposure of this interactive region 
depending on the size of the additional complexes. 
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Figure 5.13. Schematic representation of the possible oligomeric assembly of aD-
crystallin. The potential primary associations that may occur during oligomerisation are 
highlighted to indicate how the distribution of aD-crystallin oligomers may occur to 
achieve a polydisperse molecule. The building block of oligomerisation is believed to be 
the monomer, yet following monomeric associations multimers may associate to form 
larger complexes. The associations of multimeric complexes gives rise to a number of 
possible associations that may occur to achieve 10-mers, 24-33-mers and 40-mers and also 
the additional complexes observed at lowered aD-crystallin protein concentrations. 
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5.4.2. A LOW MWT aD-CRYSTALLIN SPECIES ISOLATED FROM THE aD-
CRYSTALLIN OLIGOMER COULD POTENTIALLY BE THE ACTIVE 
UNIT OF CHAPERONE ACTIVITY 
Preliminary analysis of the aB-crystaJlin oligomer tail identified the presence of 
an additional aS-crystallin species past the separation range of the column, independent 
of the type of column matrix and pump system utilised. Evidence of a dynamic exchange 
resulting in additional species at concentrations lower than 0.1 mg/ml (see Section 5.3.1) 
supports the theory that this aS-crystallin could potentially be a low Mwt complex 
representative of an active pool of subunits that are dissociated as part of the mechanism 
of chaperone activity or present in a dynamic exchange with the oligomer. This isolation 
supports the theory that dissociation of subunits from the oligomer is required for efficient 
chaperone activity and that the oligomer acts as a 'reservoir' of aS-crystallin subunits, 
which are in constant dynamic exchange with the active pool of subunits, under native 
conditions (Horwitz et al., 2004; Liu et al., 2006; Narberhaus, 2002; van Montfort et al., 
2001b). The dynamic exchange is increased under conditions of stress where the demand 
for the chaperone activity is greater resulting in increased subunit exchange. For example, 
heat shock raises the demand for chaperone function and leads to the exposure of 
hydrophobic chaperone sites by subunit exchange (Shashidharamurthy et al., 2005). 
Under acidic conditions, the interaction between aS crystallin subunits increased with a 
higher association rate and a lower dissociation rate (Liu et al., 2006). 
The isolation of this unknown Mwt species allows further characterisation, which 
is required to identify the size of this species 
To fully understand the role of the unknown Mwt aS-crystallin species in subunit 
dynamics and chaperone activity it is important to characterise the size of this species and 
also investigate the relative chaperone activity and its role in oligomerisation. 
The isolation of the potential active unit of chaperone activity aimed to 
investigate the relative chaperone activities of the unknown Mwt species and the wild type 
solution, which contained a mixture of predominantly oligomer with trace amounts of the 
unknown Mwt species. The unknown Mwt species could potentially be a more effective 
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chaperone than the oligomer, thus, the isolation and amplification of this species could 
challenge the wild type as a chaperone. 
Resolution of the unknown Mwt species from a scaled up SEC yielded a protein 
concentration of 0.00084 mg/ml, therefore the chaperone assays could not be performed as 
they required a minimum concentration of unknown Mwt species of approx 0.05-0.1 
mglml. The recovery of the unknown Mwt species can be increased albeit 
disproportionately, however, there is limitation to the potential concentration that can be 
achieved. This suggests that the presence and isolation of the species is a function of the 
low concentration. In section 5.3.1, I discussed how concentrations of aB-crystallin 
below 0.1 mg/ml induced increased polydispersity and a smaller oligomer size. Perhaps a 
higher concentration of the unknown Mwt species would result in a different species 
caused by a change in the subunit dynamics, thus the reassociation of subunits to form 
larger oligomeric complexes. 
Subsequent characterisation of the unknown Mwt species at 0.00084 mg/ml 
concentration involved rechromatography to assess the size of the species. Typically size 
determination could be carried out using Tandem Mass Spectrometry (Aquilina et al., 
2003; Benesch et al., 2006), however the technique required sample material of 
significantly greater concentration. 
A low Mwt species was observed by a peak at 96.3 min and showed no evidence 
of an oligomer peak. The oligomer fraction was diluted to the same concentration as the 
unknown Mwt species resulted in a definite oligomer peak at 58 min. These data 
confurned the aS-crystallin had not reassociated into the oligomer and any oligomer, if 
present in the unknown Mwt fraction, would be detected at this level of sensitivity. This 
data combined with the data showing there is a presence of the unknown Mwt species 
from SEC with various matrices and systems, confirms that the unknown Mwt aS-
crystallin species is of a very low Mwt and is not a product of interactions of denatured or 
active forms of aB-crystallin with the column or denatured proteins attached to the 
column, that may subsequently be displaced by the presence of additional aB-crystallin. 
This adds support to the theory that this low Mwt species of aB-crystallin is potentially 
the monomeric or dimcric active unit of chaperone activity. 
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Further characterisation of the low Mwt aS-crystallin species by cross-linking 
analysis aimed to identify any relative differences in oligomerisation between the wild 
type oligomer and the low Mwt species, which may be significant when considering the 
potential role of the low Mwt species in the chaperone activity. Using optimised cross-
linking conditions, the low Mwt species showed only monomer similar to the diluted 
oligomer control, however, the neat oligomer fraction showed cross-linking consistent 
with optimisation studies. The absence of any Mwt species above monomer in the low 
Mwt species fractions and the diluted oligomer control could be symptomatic of a number 
of conditions. If the monomer was the major cross-linked species, then visualisation at 
such a low protein concentration of any lower intensity oligomer bands of the low Mwt 
species and diluted oligomer control may not be possible. The GA however, was added at 
a concentration that was sufficient to produce predominantly oligomer at aS-crystallin 
solutions of 0.01 mg/rnl, thus the monomer should be the band of lowest intensity and 
higher multimers should greater in intensity and easily visible. The monomers that we see 
representing the cross-linked low Mwt species and diluted oligomer control could be real 
monomers, however, the rechromatography of the diluted oligomer fraction confirmed at 
this low concentration that oligomer was present. Finally, the combination of low 
concentration and the limitations of the 5A spacer arm of GA in forming links with 
distant subunits could have had an inhibitory effect upon the cross-linking efficiency. The 
crosslinking data investigating the relative differences in oligomerisation between the wild 
type oligomer and the low Mwt species was not conclusive due to limitations caused by 
the low protein concentrations being analysed. 
Therefore, the characterisation of the unknown aS-crystallin species suggests that 
it has a very low Mwt and may be monomeric or a small multimer. This supports the 
theory that the species may be the active unit of chaperone activity in constant equilibrium 
and dynamic exchange with the oligomer. However, it has not been possible to 
categorically confirm the size of the species or the efficiency as a chaperone due to the 
limitations provided by a low concentration of the unknown Mwt species yielded from the 
scaled-up SEC. It appears that the presence of this species is a function of the low 
concentration, thus making it very difficult to potentially achieve a concentration that 
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would allow analysis of the chaperone function and complex size determination by mass 
spectrometry. The development of matrix-assisted laser desorption ionization (MALDI) 
mass spectrometry has permitted the determination of the molecular mass of proteins up to 
the 105-Da range with an accuracy of 0.1-0.01 %, requiring only picomoles or sub 
picomoles of material (Beavis and Chait, 1990; Juhasz and Biemann, 1994; Karas, 1987), 
however, the tandem mass spectrometry system specific for the analysis of oligomeric 
complexes (Aquilina et al., 2003; Benesch et al., 2006; Benesch and Robinson, 2006) was 
not sensitive enough to detect the low Mwt aB-crystallin species at the current 
concentration of 0.00084 mg/ml. An alternative method for determining molecular weight 
is Analytical ultracentrifugation. With analytical centrifugation, the sedimentation 
equilibrium is most commonly used for Mwt determinatio~ where the solute particles do 
not peliet at the bottom of the cell. Instead they redistribute over time with increasing 
concentration as the distance from the centre of rotation increases. After an appropriate 
period of time, the process of diffusion equals the process of sedimentation (called the 
sedimentation equilibrium). Measurement of the solute concentration at different time 
points leads to the determination of the molar weight of the sedimenting solute (Ralston, 
1993). For a typical sedimentation equilibrium experiment, 150 ~I of sample with an OD 
at 280 nm of 0.3 is required, which for aB-crystallin is approx 0.4 mg/ml, however with 
less protein available it is suggested that a lower wavelength (e.g. 220 nm) can be used 
(Beckman, Model XL-A Training Guide, Beckman Instruments Inc, CA, USA). 
Analytical centrifugation has been typically performed at protein concentrations of 0.25 
mg/ml or above (Bunkoczi et al., 2007; Chang et al., 1996; Li et al., 2007; Yu et al., 
2004), however concentrations of 0.06mg/ml have also been utilised (Schar et al., 2008). 
Therefore, the Mwt determination of the low Mwt aB-crystallin species at 0.00084 mg/ml 
could potentially be achieved by Analytical ultracentrifugation but will require further 
analysis. 
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5.5. CHAPTER'S CONCLUSIONS 
The aim of this chapter was to investigate the effect of concentration upon the 
oligomerisation of all-crystallin. By the end of this Chapter, I have confirmed that the 
reduction of all-crystallin concentration below 0.1 mg/ml results in increased 
polydispersity and the appearance of additional high and low Mwt species independent of 
temperature. Further reduction in all-crystallin concentration to 0.01 mg/ml shows a 
smaller oligomeric complex size. These studies resulted in the identification of a low 
Mwt all-crystallin species in the late tail region of the oligomer. This low Mwt aB-
c.rystallin could potentially be the active unit of chaperone activity in constant equilibrium 
and dynamic exchange with the oligomer but this will require further analysis. Further 
characterisation was hindered by the disproportionate increase in concentration (3X) 
achieved by scale-up ( 125X) and suggested that the appearance of this species may be a 
function of the low concentration and as Horwitz observed in 2004, under normal 
physiological conditions, it is impossible to isolate significant amount of monomers, 
dimers, or tetramers of a-crystallin (Horwitz et al., 2004). Confirmation of the size of the 
low Mwt all-crystallin remains difficult without a higher concentration, which may be 
slightly improved, albeit disproportionately by further scale up of the SEC process. 
Alternatively, analytical ultracentrifugation may be a successful technique for the Mwt 
determination of this species. Confirmation of the size of the low Mwt aB-crystallin 
would perhaps help understand the mechanism involved in the relationship between 
oJigomerisation, subunit dynamics and chaperone function. 
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CHAPTER6 
CONCLUSION 
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6.1. STUDY SUMMARY 
To date, the role of the C-terminal extension of aS-crystallin upon solubility, 
structure and function and the relationship with disease has not been investigated. In this 
study, the systematic analysis of the role of the C-terminal extension of aS-crystallin 
aimed to investigate the hypothesis that the C-terminal region in aS-crystallin is important 
for solubility, structure and function of the protein. This study also aimed to find a link 
between the role of the C-terminus and the symptoms of disease, thus providing a 
potential explanation of whether the three mutations (450delA, Ql51X and 464delCT) 
cause the various diseases via the loss of chaperone function or perhaps by a different 
mechanism. The nature of the disease mutants is to form aggregates within the lens 
(450delA, E164X) and muscle tissue (464delCT and Q151X) thus, providing a link 
between the effect of a severely altered C-terminal and the solubility of the expressed 
protein. Elucidation of the mechanism of disease may help understand the phenotypic 
variation observed with mutations of aS-crystallin. Further understanding of the 
mechanism of chaperone function with regards to the oligomerisation state and subunit 
dynamics aimed to provide further understanding of the role this plays in efficient 
chaperoning of client proteins. 
The findings of this study showed that the flexible C-terminal extension was 
essential to produce a stable aS-crystallin complex as the sequential removal of the C-
terminal resulted in aggregation of the mutants. . The mutants displayed a varying level of 
insolubility during the refold process as a function of the severity of the alterations to the 
C-terminal extension. The disease mutants 450delA, 464delCT and Ql51X along with the 
post translational modification (PTM) E164X proved the most insoluble and indicated that 
the non flexible region was also influential upon complex solubility through a different 
mechanism involving oligomerisation and chaperone function, suggesting a relationship 
between the role of the C-terminal extension and disease. 
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The C-terminal extension has been shown to be primarily involved in subunit-
subunit interactions required for oligomerisation and was not essential for chaperone 
activity. The C-terminal extension can actually inhibit client substrate binding by 
'capping' the 133-138-139 interface in the a-domain, which is the interactive site for 
substrate binding. The findings in Chapters 3 and 4 suggested that the potential molecular 
mechanism behind the pathology of the disease causing mutants is a function of the 
reduced protein stability and uncontrolled self-aggregation caused by the alterations to the 
C-tenninal extensions and not caused by a loss of chaperone activity as illustrated by the 
efficiency of the Q151X aS-crystallin as a chaperone. The link however, between these 
findings and the mechanism, which causes the variations in phenotypic expression, 
remains unclear and requires further investigation. 
In chapter 5, I identified a potentially low Mwt species of aS-crystallin that 
maybe important for effective chaperone activity. This species may be an active unit of 
chaperone activity, however in this study I was unable to confirm the size of the species 
therefore the implications of this species upon chaperone function remain unresolved. 
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6.2. IMPLICATIONS FOR THE CELLULAR FUNCTIONS OF 
aB-CRYST ALLIN 
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The identified physiological roles of aB-crystallin include regulator of IF 
networks, regulators of apoptosis, transcriptional regulators, genome stability and 
proteosome function. 
The findings of this study propose that the chaperone function of the wild type 
aB-crystallin is inhibited via coaggregation with the destabilised mutants, suggesting 
several possible consequences for cellular function (see Figure 6.1), which are discussed 
below. 
CYTOPLASMIC ABNORMALITIES 
alkrystallln 
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Figure 6.1. Effect of coaggregation upon the physiological function of aB-crystallin. The 
inability for aB-crystallin to perform its cellular functions could cumulatively play a role 
in disease pathogenesis. The loss of aB-crystallin has potential cytoplasmic and nuclear 
consequences including altered nuclear function and genome instability, abnormal 
apoptosis, proteosome inhibition and disruption of the cytoskeletal assembly. 
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6.2.1. CYTOPLASMIC EFFECTS 
aD-crystallin participates in the dynamic assembly, disassembly, reorganisation 
and stabilisation of the filamentous cytoskeleton during cell development and cell 
differentiation (Bennardini et al., 1992; Ghosh et al., 2007; Nicholl and Quinlan, 1994). 
Disruption of the cytoskeletal assembly is one of the early effects of any stress that can 
ultimately lead to cell death thus, maintaining the individuality of IFs by controlling 
filament-filament interactions (Pemg, 1999) and assisting in the formation of IF networks 
in cells (Pemg et al., 2004) by a.B-crystallin is essential for a functioning cytoskeleton. 
The absence of wild type a.B-crystallin, caused by co-aggregation with the disease causing 
mutants, would lead to the disruption of the cytoskeletal assembly via aggregation of IFs, 
as observed for desmin in diseases with muscle phenotype including DRM and MM (see 
Figure 6.1 ). 
aB-crystallin is thought to participate broadly in the regulation of muscle cell 
death by suppressing myogenic differentiation and the activation of caspase-3 (Kamradt et 
al., 2002), which plays a central role in the execution of apoptosis (Cryns and Yuan, 
1998). The induction of caspase-3 during myogenesis might be required for the ablation 
of differentiation-incompetent myoblasts (Ikeda et al., 2006). Loss of a.B-crystallin by co-
aggregation would remove the ability to inhibit caspase-3 activation and myogenic 
differentiation, subsequently leading to excessive apoptosis (see Figure 6.1 ), which has 
been shown to be a feature of various diseases including cancer, autoimmune diseases, 
neurodegenerative diseases muscular atrophy, Parkinson's disease, Alzheimer's and 
ischaemia (Elmore, 2007). Apoptosis has also been associated with human 
cataractogenesis where various factors, which cause cataractogenesis, also trigger lens 
epithelial ceH apoptosis. In fact, death precedes development of lens opacification and 
apoptotic cells are found in human cataractous lenses (Yan et al., 2006). Thus, it is 
evident that an abnormal apoptosis mechanism caused by the expression of an a.B-
crystallin disease causing mutant could contribute towards the pathology observed for the 
450delA, Q151X and 464delCT a.B-crystallin mutations. 
Apoptosis is further linked with a.B-crystallin, albeit indirectly, via its role in the 
proteosome-mediated degradation of selected proteins (den Engelsman et al., 2003; 
Parccllier et al., 2005). The co-aggregation of a.B-crystallin with the mutant a.B-
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crystallins may inhibit proteosome function as it is active in the mechanism that destines 
proteins for ubiquitin-dependant degradation (den Engelsman et al., 2003). The inhibition 
of the proteosome activates the apoptotic pathway dependant on the stress kinase cJUN N-
terminal kinase (JNK) and simultaneously induces synthesis of the protective protein 
HSP72, which suppresses JNK (Meriin et al., 1998). Meriin et al. (1998) suggested the 
balance between these two activities could define whether pro- or anti-apoptotic action of 
the inhibitors would dominate (see Figure 6.1) (Meriin et al., 1998). 
Proteosome inhibitors have been demonstrated to cause complex effects on 
programmed cell death and while inhibition is usually pro-apoptotic (Drexler, 1997; 
Orlowski, 1999; Wojcik, 1999), under certain conditions it prevents apoptosis triggered by 
harmful stimuli (Grimm et al., 1996; Meriin et al., 1998; Sadoul et al., 1996). Proteosome 
inhibition could have clinical therapeutic relevance and has been linked to effective anti-
tumour activity inducing apoptosis by disrupting the regulated degradation of pre-growth 
cell cycle proteins (Adams et al., 1999) and also in pancreatic cancer (Shah et al., 2001), 
nonhodgkin's lymphoma (O'Connor, 2005) and psoriasis (Zollner et al., 2002). Studies 
have also shown that proteosome inhibition protects lens epithelial cells against interferon 
induced apoptosis and correlates with increased expression of sHSPs and implicates 
sHSPs as mediators of the protective effect of proteosome inhibition (Awasthi and 
Wagner, 2005). 
s-IBM (inclusion body mitosis) the most common muscle disease of patients aged 
50 and above, features the accumulation of intra-muscle fiber multi-protein aggregates 
similar to Alzheimer's disease (Askanas and Engel, 2006). The reduction of 26S 
proteosome activity was recently demonstrated within s-IBM muscle fibers (Fratta et al., 
2005) and aB-crystallin was shown immunohistochemically to be abnormally 
accumulated in muscle fibers of s-ISM. It was proposed that increased aS-crystallin 
expression precedes other abnormalities in s-IBM muscle fibers (Banwell and Engel, 
2000). HSP27 and aB-crystallin are increased, phosphorylated and localised in 
aggresomes when proteosome activity is inhibited (Ito et al., 2002). 
There is a link between the accumulation of aS-crystallin within the muscle and 
lens fibers and the activity of both the proteosome and apoptosis, which may be part of a 
mechanism, contributing towards the onset of MM and cataract caused by the 450delA, 
464delCt and Q 151 X all-crystallin mutants. 
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6.2.2. NUCLEAR EFFECTS 
The identification of aS-crystallin as a nuclear speckle component in unstressed 
cells suggests a constitutive function for this chaperone in the nucleus where a role in 
transcription is possible (van den IJssel et al., 2003). Speckles are linked to transcriptional 
activity and are thought to be transit or storage sites for splicing components where 
dynamic protein interactions are important (Bellini and Gall, 1999; Phair and Misteli, 
2000; Sleeman et al., 2001; Sleeman and Lamond, 1999; Yin et al., 2001). Heat stress 
invokes the formation of intranuclear granules comprising protein chaperones (Velazquez 
and Lindquist, 1984) and sHSPs are effective in accelerating the recovery of cells with 
nuclear aggregates (Kampinga et al., 1994). The possible role of aB-crystallin in 
transcription can not be discriminated between a chaperoning role restricted to protein-
protein interactions, a facilitator of protein traffic through the speckle compartment or 
even a direct role in RNA splicing itself, however the role involves unstressed cells 
suggesting it is essential for efficient nuclear function (van den IJssel et al., 2003). The 
mutation Rl20G has been shown to inhibit the accumulation of aS-crystallin into nuclear 
speckles, which could affect the nuclear function of aS-crystallin (van den IJssel et al., 
2003), Similarly the co-aggregation of wild type aS-crystallin with C-terminal mutants 
450de1A, QISIX, 464delCT aB-crystallin may effect the nuclear function and contribute 
towards the development of a muscle phenotype but not cataract as an effect upon nuclear 
function would not implicate the lens fiber cells due removal of the nuclei during 
organogenesis (Harding, 1991). Perhaps a similar mechanism involving nuclear function 
and transcriptional regulation occurs with the R 157H mutant leading to DCM, however 
the effect of the mutation on the structure and function is yet to be elucidated. 
There is mounting evidence that transcription and genomic instability are linked 
processes (Aguilera, 2002; Tini, 2002) and transcription has been proven to be important 
in the maintenance of genome integrity and in the induction of genetic instability and 
diversity (Aguilera, 2002). The maintenance of primary DNA sequence and the 
preservation of chromosomal ploidy and structure are important factors in genome 
stability (Hartwell et al., 1994). The loss of aB-crystallin enhances genome instability 
and hyperproliferation (Andley et al., 2001), and provides a further link suggesting that 
o:B-crystallinregulates cell division (Andley et al., 2001; And1ey et al., 2000; Fujita et al., 
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2004). In fact, all-crystallin is associated with the regulation of actin filament dynamics 
in vivo (Singh et al., 2007) and connections between remodelling of the actin cytoskeleton 
and the control of cell proliferation have been suggested to play a role in a pathway 
through which an aberrant actin cytoskeleton can cause epithelial hyperproliferation in 
corneal cells (Ikeda, 2003). Because lens epithelial cells grow throughout a lifetime and 
the lens is exposed to light induced stress it is likely that mechanisms may be present to 
protect these cells for a lifetime of exposure to metabolic and environmental stress 
(Andley et al., 2000). Genomic instability is a hallmark of many syndromes, which 
include neurodegeneration, cancer, premature aging and immunodeficiency (Andley et al., 
2001). 
The implications of aggregated all-crystallin upon the various cellular functions of 
aB-crystallin reveal the complex mechanisms that can be influenced, and potentially play 
an important role in the generation of the disease phenotype. Consideration of these 
cellular effects can be made in conjunction with other factors to discuss in Section 6.3, the 
unresolved mechanism of phenotypic variation associated with o.B-crystallin C-terminal 
mutations. 
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6.3. POTENTIAL MECHANISMS OF PHENOTYPIC 
HETEROGENEITY ASSOCIATED WITH aD-CRYSTALLIN 
The mechanism of disease associated with C-terminal mutants is influenced by an 
effect upon solubility and chaperone activity, however it is still not possible to draw a link 
between structure and function of the aB-crystallin and its phenotypic heterogeneity. 
The three disease-causing mutations in the C-terminal extension of aB-crystallin 
{Ql51X, 450delA and 464delCT) are restricted in their pathology to either the lens 
(450deiA) (Berry et al., 2001)) or muscle (Ql51X and 464delCT) (Selcen and Engel, 
2003)) and yet aB-crystallin is very highly expressed in both tissues (Kato et al., 1991). 
This is a familiar trend for aB-crystallin mutations and even the most recently published 
mutation (R157H) causes DCM alone (Inagaki et al., 2006) and D140N, causes only lens 
cataract (Liu et al., 2006b). Thus far, R120G aB-crystallin is the only mutation that has 
produced both lens and muscle pathologies (Vicart et al., 1998), although both R120G and 
Dl40N mutations result in similar structure changes (Liu et al., 2006b). This is not to say 
that sub-clinical pathology can be totally excluded for the other mutations, including 
Ql51X, as tissue biopsies from apparently unaffected tissues were not analysed. 
Liu et al. (2006) suggested that perhaps the dominant negative effect of the 
D140N mutation is one of the major mechanisms of the cataract phenotype and that 
mutant aB-crystallin was rapidly degraded in muscles, which have active proteolytic 
systems (Liu et al., 2006b ). It was also suggested that due to the low expression levels 
observed in the muscle compared to the lens, the mutant aB-crystallin may not reach 
levels necessary for inhibiting chaperone activity of wild type aS-crystallin and other 
sHSPs (Liu et al., 2006b ). This proposal does not reflect the findings of this thesis, which 
suggest it is the self aggregation rather than a loss of chaperone function that leads to the 
disease onset (see Chapter 4). 
The 450delA aB-crystallin causes isolated congenital cataract and has no muscle 
phenotype, whereas the Q151X and the 464delCT aB-crystallin cause symptoms 
associated with MM but not cataract. This suggests that perhaps one factor that may be 
influential in the phenotypic expression is the tissue specific associations of uB-crystallin. 
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HSP27 interacts with aA and aD-crystallin in vivo, but to a greater extent with 
aD-crystallin. In non-lenticular tissues HSP27 is expressed with aD-crystallin rather than 
aA-crystallin and may serve to stabilise aD-crystallin in non-lenticular tissues by co-
localisation with aS-crystallin under both normal conditions and in a stressed or diseased 
state (Zantema et al., 1992). 
Perhaps the 450delA mutation causes a dominant negative effect not only on the 
wild type aS-crystallin but also causes co-aggregation of the aA-crystallin oligomer, thus 
causing cataract. If the 450delA mutation caused such an effect then it is likely that a 
muscle phenotype would also be observed, as the stabilising aA-crystallin is not present in 
muscle tissue, however this is not the case. The significantly lower expression levels 
observed in non-lenticular tissues may be such that the tissue specific aS-crystallin 
stabilising partner HSP27 is able to chaperone any aggregating aS-crystallin and prevent 
any pathological effect, alternatively the co-aggregation observed in muscle tissue may be 
the result of a completely different mechanism. The concern, however is if the HSP27 can 
stabilise the 450delA aS-crystallin aggregates then the QlSIX and 464delCT aD-
crystallin in theory should also be stabilised by the HSP27 aggregates, yet a muscle 
phenotype is characteristic of these mutations with no cataract. Perhaps, a combination of 
the concentration in the lens and the size of the 450delA aS-crystallin aggregates are 
responsible for the aggregation of the aA-crystallin and cataract. The MM mutants 
especially the Q 151 X are smaller complexes without an extended C-terminal and perhaps 
the aA -crystallin can efficiently chaperone the aggregated mutants to maintain the 
refractive properties of the lens. The muscle phenotype could be a function of a disrupted 
or abnormal association mechanism between aS-crystallin and HSP27. 
The potential contribution towards the onset of disease caused by the disturbance 
of the other cellular functions of aB-crystallin (see Section 6.2) may help explain the 
mechanism of phenotypic heterogeneity. The potential role of aS-crystallin in the nuclear 
functions such as protein-protein interactions, facilitator of protein traffic through the 
speckle compartment and a direct role in RNA splicing (van den IJssel et al., 2003), 
suggests that loss of aS-crystallin through self aggregation could affect the nuclear 
function of aS-crystallin. The lens fiber cells however, do not contain nuclei due to 
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programmed loss of cellular organelles during differentiation (Harding, 1991) and 
provides a significant variation between lenticular and non-lenticular tissue. Any 
physiological consequence of altered nuclear function caused by aS-crystallin mutation 
would not be observed in the lens fiber cells, thus providing a possible explanation for the 
Ql51X and 464delCT phenotypic expression. 
The disturbance of the apoptosis mechanism has been shown to have specific 
effects on the lens epithelial cells, which eventually result in cataractogenesis (Yan et al., 
2006). First, lens epithelial cell death interrupts the life long growth of human lenses, 
therefore contributing towards the thinness of cataract lenses (Goodman, 1964; Laursen 
and Fledelius, 1979), and the lower density of epithelial cells in the cataract lenses (Karim 
et al., 1987; Konofsky et al., 1987). Secondly, depletion of individual or patches of lens 
epithelial cells will eliminate homeostatic epithelial cell control of the underlying fiber 
ceJls leading to impairment of the integrity and transparency of these of these fiber cells 
(Spector, 1991 ). Thus induction of apoptosis due to the inhibition of the aS-crystallin 
function in the apoptotic mechanism may initiate cataract formation. Subsequently, this 
effect would not affect muscle tissue and perhaps the mutant 450delA aB-crystallins can 
be stabilised by association with HSP27. 
It is important to consider the wider biological context of phenotypic variation and 
the association with disease. Thus far, four sHSPs have been associated with disease and 
include aA-, aS-crystallin, HSP27 and HSP22 (Selcen and Engel, 2003; Tang et al., 
2005a; Tang et al., 2005b; Vicart et al., 1998). Interestingly the mutations of both HSP22 
and HSP27 also display phenotypic variation and lead to the onset of various neuropathies 
and muscle related disorders. Mutations in genes encoding the IF nuclear lamins and 
associated proteins cause a wide spectrum of diseases sometimes called "laminopathies." 
(Pigliucci, 2003; Worman and Bonne, 2007). Recently, 5 missense mutations in HSP27 
have been identified to cause Charcot-Marie-Tooth disease (CMT) type 2F and distal 
hereditary motor neuropathy (dHMN) (Evgrafov et al., 2004; Harding and Thomas, 
1980a; Harding and Thomas, 1980b; Ismailov SM, 2001; Suter and Scherer, 2003; Tang et 
al., 2005a). 
Mutations of the HSP22 gene (HSPB8) co-segregate perfectly with either the CMT 
phenotype (De Jonghe, 1998; Tang et al., 2005b; Timmerman et al., 1992) or the dHMN 
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phenotype (Carra et al., 2005); (Irobi et al., 2004) (Morrow and Tanguay, 2003; Soti and 
Csermely, 2003). Tang suggested that the dysfunction ofHSP22leads to the formation of 
aggregates that may block axonal transport (Tang et al., 2005b ). The different regions, 
such as the anterior hom cells or peripheral nerves, in which the aggregates are deposited 
may be associated with the different phenotypes, i.e., CMT and dHMN (Tang et al., 
2005b). Kasak.ov suggested that mutations in the {35--{:37 loop of HSP22 located on the 
border of an intrinsically disordered region and the {37-strand affect the structure of HSP22 
and its chaperone-like activity. This explains why mutations in this part of different sHSPs 
( aA-, aB-crystallin, HSP27 and HSP22), induce deleterious effects and are associated 
with different congenital diseases (Kasak.ov et al., 2007). 
Phenotypic variation has been studied for many years beginning in 1942, when 
C.H. Waddington proposed a new mechanism of evolutionary change, which he termed 
'"genetic assimilation" (Waddington, 1942; Waddington, 1961). The idea was that certain 
environmental or genetic factors can disrupt the normally canalized (i.e., stable) course of 
development of living organisms. This disruption may then generate phenotypic variation 
that could allow a population to persist in a novel or stressful environment until new 
mutations would eventually let natural selection fix ("assimilate") the advantageous 
phenotypic variants (Pigliucci, 2003). Epigenetic variation is often overlooked as a source 
of phenotypic variation for natural or artificial selection. Strong theoretical arguments in 
favour of the importance of epigenetic mechanisms have been discussed (Cubas et al., 
1999; Hollick et al., 1997; Jablonka, 2002; Jacobsen and Meyerowitz, 1997; Jacobsen et 
a1., 2000; Kermicle et al., 1995; Martienssen et al., 1990; Martienssen and Baron, 1994; 
McClintock, 1951; Pigliucci and Murren, 2003; Soppe et al., 2000; Stokes et al., 2002). 
In recent years, the heat shock response has been suggested to play a role in 
phenotypic evolution, whereby chaperones acting as "capacitors" of morphological 
change, provide a molecular basis for Waddington's genetic assimilation. (Queitsch et al., 
2000; Rutherford and Lindquist, 1998). The malfunctioning of molecular chaperones may 
result in uncovering genetic variation however, the molecular basis of this phenomenon 
remains largely unknown (Bobula et al., 2006; Sangster et al., 2004). In 1998, Rutherford 
et al., provided first evidence for an explicit molecular mechanism, involving the 
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molecular chaperone HSP90, that assists the process of evolutionary change in response to 
the environment (Queitsch et al., 2002; Rutherford et al., 2007a; Rutherford et al., 2007b; 
Rutherford, 2007; Rutherford and Lindquist, 1998; Salathia and Queitsch, 2007). Fully 
functional HSP90 stabilises wild type phenotypes by suppressing underlying genetic and 
epigenetic variation (Salathia and Queitsch, 2007; Samakovli et al., 2007). Further 
discoveries identified a similar role for other chaperones such as HSP70 (which works in 
conjunction with HSP90) and HSP60 in other organisms (Fares et al., 2002). 
Additionally, overexpression of the chaperonin GroEL has been shown to buffer the 
fitness effects of deleterious polymorphisms in E.co/i (Fares et al., 2002) and GroE 
overexpression suppresses many mutations (Fayet et al., 1986; Jenkins et al., 1986). In 
recent years the idea has emerged that not only chaperones but a large number of other 
proteins may also regulate the diversity of the phenotype (Bergman and Siegal, 2003; 
Csermely, 2004; Csermely and Soti, 2006). 
Molecular chaperones can mask the negative effects of mutations but the 
mechanism of such buffering need not be direct. A plausible role of chaperones is to 
stabilise genetic networks, thus making them more tolerant to malfunctioning of their 
constituents. (Hartman et al., 2001; Hermisson and Wagner, 2004; Kirschner and Gerhart, 
1998; Siegal and Bergman, 2002; Wagner, 2005). Thus, the ability to resist genetic 
perturbations results from the ability to cope with environmental challenges (Rutherford 
and Lindquist, 1998). 
The mechanism of phenotypic heterogeneity remams unresolved. Phenotypic 
expression of the C-terminal aB-crystallin mutations ( 450delA, Q 151 X and 464delT) may 
be a function of combined factors including effect upon cellular functions and the 
destabilisation of genetic networks, the effect of the mutation upon tissue specific 
associations and finally the propensity to self-aggregate. Further analysis of the 
mechanism is required to gain understanding ofthe phenotypic variation. 
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6.4. FUTURE WORK 
Several questions remain unresolved and could be answered by further analyses. 
6.4.1. Phenotypic Heterogeneity 
The mechanism of phenotypic variation remains unresolved for C-terminal 
mutations of aB-crystallin. Investigation of this mechanism would involve analysis of the 
relative associations of aA-, aB-crystallin and HSP27 between the C-terminal mutant aB-
crystallins upon the stability and refolding efficiency of the formed complexes. Further 
characterisation of the complexes would initially analyse relative chaperone function, 
thermostability, secondary structure and quaternary structure. 
Analysis of these associations in a mammalian cell environment would provide an 
indication of the relative effects the C-terminal aS-crystallin mutants have upon solubility 
and cellular localisation. These experiments may provide a correlation between altered 
associations, the type of stabilising chaperone present, the mutation and expressed 
phenotype. 
Protein aggregates containing aB-crystallin and desmin are typical features of 
patients with MM. In Chapter 4, I investigated the effect of the C-terminal mutants upon 
desmin filament assembly in vitro, but did not investigate this effect further in a 
mammalian cell environment. Transient co-transfection of the aS-crystallin mutants and 
desmin into MCF7 cells, where there is no endogenous aB-crystallin, may show 
variations in the formation of desmin filaments, which may show a correlation with the 
disease phenotype. Further more, transient transfection of desmin, aA- and aB-crystallin 
using a cell line where 450delA aS-crystallin is endogenous may also help towards 
explaining the phenotypic heterogeneity by analysing the relative effects upon desmin 
stability. 
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6.4.2. Additional congenital aD-crystallin mutant characterisation 
The naturally occurnng mutations of aS-crystallin not analysed in this thesis 
include the P20S (Liu et al., 2006a), R157H (lnagaki et al., 2006) and D140N (Liu et al., 
2006b) point mutations, which cause congenital isolated cataract, dilated cardiomyopathy 
(DCM) and isolated lamellar cataract respectively. All three mutations affect individual 
chaperone sites (see Figure 4.1A), with the Rl57H mutation occurring in the C-terminal 
extension, the Dl40N mutation affecting the a-crystallin domain and the P20S in theN-
terminal. Subsequent characterisation of these mutants would provide further insight 
towards the relationship between the structure and function of aS-crystallin and the 
relationship with disease and phenotypic heterogeneity. These mutants also provide three 
further subjects in investigating the relative associations between mutant aS-crystallins 
and stabilising aA-, aS-crystallin and HSP27 proteins. 
6.4.3. Refolding efficiency 
One of the limitations of characterisation, observed especially for the Q 151 X aS-
crystallin, is the concentration of mutant protein achieved during the refolding. Thus, 
further optimisation of the refolding process would be necessary to improve the current 
yields, which range from 1.4% (Ql51X aS-crystallin) to 12.0% (E164X aS-crystallin) 
(see Table 3.11). Refolding of the 450delA and 464delCT aS-crystallin as homogenous 
protein solutions would provide data directly comparable to the wild type aS-crystallin 
and the other aS-crystallin mutants, which are refolded without the presence of the 
stabilising wild type aS-crystallin. Current refolding protocol utilises a dilution method, 
which reduces both the urea and protein concentration prior to dialysis at l6°C (see 
Section 2.7.3). Further investigation of these parameters may help optimise the refolding 
yield. 
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6.4.4. The effect of aD-crystallin concentration upon oligomerisation and 
polydispersity 
In Chapter 5, the increased polydispersity of wild type aB-crystallin at 
concentrations below 0.1 mg/ml and the appearance of additional oligomeric complexes of 
varying size were observed during SEC at ambient temperature. The separation by SEC 
performed at 4 oc may increase polydispersity, although samples stored intermittently at 
4 oc prior to SEC at ambient temperature showed no additional polydispersity, compared 
to samples stored at ambient temperature. Relative chaperone activities of the various 
oligomeric complexes, resulting from increasing polydispersity, may provide an insight 
into the relationship between efficient chaperone function and complex size. Data of this 
nature would provide evidence for proving or disproving the theories of chaperone activity 
discussed in Chapter 5. This investigation may also extend to the incorporation of other 
factors, which have been shown to affect the oligomerisation characteristics of aS-
crystallin such as low pH, phosphorylation and oxidative stress (see Section 5.2.2.) 
6.4.5. Characterisation of the potential unit of chaperone activity 
Elucidation of the Mwt of the unknown aB-crystallin species, isolated from the 
tail region of an aB-crystallin SEC separation, would help determine its potential as an 
active unit of chaperone activity. Preferably Mass Spectrometry would be utilised to 
determine the nature of the unknown aB-crystallin species, however, the type of 
characterisation method to be utilised is limited due to the very low protein concentration 
of the species recovered from the SEC. It may be that immunoblotting of a native SDS-
PAGE, analysing the tail region of the SEC separation, could provide evidence of the 
monomeric species considering a native SDS-PAGE successfully illustrated the Ql51X 
aS-crystallin mutant, which is predicted to be monomeric (see Figure 4.4). In Section 
5.4.2, I discussed how further scale up would increase the protein concentration, but 
disproportionately, therefore characterisation at the current low protein concentration 
would be preferred. Such characterisation using the technique of analytical 
ultracentrifugation has been utilised at concentrations as low as 0.06 mg/ml, therefore may 
be successful in providing the Mwt data required. Further scale up would be an option if 
Chapter 6-ConcJusion 258 
analytical centrifugation proved unsuccessful. Confirmation of the size of the unknown 
aB-crystallin species would prompt similar analyses of the C-terminal aS-crystallin 
mutants in order to assess the presence of a similar species. 
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Al.l THE PROMOTER AND MULTIPLE CLONING 
SEQUENCES OF VECTORS USED FOR MUTAGENESIS 
AND CLONING 
Figure Al.l. The promoter and multiple cloning sequences of pGEM®-T Easy 
T7 Transcription Start 
I ... 
5' ... TGTAA TACGA CTCAC TATAG GGCGA ATIGG GCCCG ACGTC GCATG CTCCC OOCCG CCATG 
3' ... ACATT ATGCT GAGTG ATATC CCGCT TAACC CGGGC TGCAG CGTAC G~ CCGGC GGTAC 
T7Promoter I II II I I I~ 
Apal Aatll Sphl BetZI Ncol 
SP6 Transcription Start 
• I 
CATAT GGGA GIGCT CCCAA CGCGT TGGAT GCATA GCTTG AGTAT TCTAT AGTGT CACCT AAAT ... 3' 
GTATA CCCT CTCGA GGGTT GCGCA ACCTA CGTAT CGAAC TCATA AGATA TCACA GTGGA TTTA ... 5' 
I I I IL _JI i SP6 Promoter 
Ndel Sad BstXI Nail 
Figure Al.l. The promoter and multiple cloning sequence of the pGEM®-T and 
pGEM®-T Easy Vectors. The top strand of the sequence shown corresponds to the 
RNA synthesized by T7 RNA polymerase. The bottom strand corresponds to the RNA 
synthesized by SP6 RNA polymerase (Taken from Promega Technical Manual TM042, 
Promega, Southampton, UK). 
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Figure Al.2. The promoter and multiple cloning sequences of pET23d( +) 
T7 promoter primer #69348-3 
... 
Bglll T7 promoter ... Xba I rba 
AGA TC TCGA TCCCGCGAAA T T AA T ACGAC TC ACT AT AGGGAGAC CAC AACGGT T TCCC TC T AGAAA T AA TT TTG T T T AAC TT T AAGAAGGAGA 
ET-23 Hlncll Eagl Nde I Nhe I T7•lllg P 0 BamH I EcoR I Sac I Sa/ I Hind Ill ~ Xho I Hls•Tag 
T ATACA T ATGGCT AGCATGACTGGTGGACAGCAAATGGGTCGCGGATCCGAA TTCGAGCTCCGTCGACAAGCTTGCGGCCGCAC TCGAGCACCACCACCACCACCACTGA 
MetAioSerMetThrGiyGiyGinGinMetGiyArgGiySerGiuPheGiuleuArgArgGinAioCysGiyArgThrArgAioProProProProProleu 
pET-23d 
Nco I 
TACCATGGCTAGC. 
MetA loSer ... 
pET-23b 
pET-23c .d 
.. GGTCGGGATCCGAATTCGAGCTCCGTCGACAAGCTTGCGGCCGCACTCGAGCACCACCACCACCACCACTGA 
. G I yArgAspProAsnSerSerSerVal AsplysLeuA I oA I aA I aleuG I uH isH IsH IsH isH isH i sEnd 
... GGTCGGA TCCGAA T TCGAGC TCCGT CGACAAGC TTGCGGCCGCAC TCGAGCACCACCACCAC CACCACTGA 
. .. G I vAro II eArQII eArQA loProSerThrSerleuArQProH i sSerSerThrThrThrThrThrThrG I u 
Bpu11 02 I T7 tennlnator 
261 
GA TCCGGCTGCT AACAAAGC CC GAAAGGAAGCTGAG T TGGC TGC TGCC ACCGCTGAGCAA T AAC T AGC AT AACCCC T TGGGGCC TC T AAACGGGTC TTGAGGGGTT TTTTG 
T7 terminator primer #69337 -3 
Figure Al.2. The maps for pET23b(+), pET23c(+) and pET23d(+) are the same as 
pET23a(+) (shown) with the following exceptions: pET23b(+) is a 3665bp plasmid; 
subtract 1 bp from each site beyond BamHI at 198. pET23c( +) is a 3664bp plasmid; 
subtract 2bp from each site beyond BamHI at 198. pET23d(+) is a 3663bp plasmid; the 
BamHI site is in the same reading frame as in pET23c( + ). An Nco/ site is substituted 
for the Ndel site with a net 1 bp deletion at position 238 of pET23c( + ). As a result, Nco 
I cuts pET23d(+) at 234, and NheJ cuts at 228. For the rest of the sites, subtract 3bp 
from each site beyond position 239 in pET23a(+). Ndel does not cut pET-23d(+). 
Note also that Sty/ is not unique in pET23d(+). (Taken from Novagen Technical 
Bulletin TBOSI, Novagen, WI, USA). 
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Figure Al.3. The promoter and multiple cloning sequences ofpcDNA3.1(-) 
enhancer region (3 · end) 
689 CATTGACGTC AATGGGAGTT TGTTTT GCA CCAAAATCAA CGGGACTTTC CAAAATGTCG 
~ ~ 
749 TAACAACTCC GCCCCATTGA CGCAAATGGG CGGTAGGCGT GTACGGTGGG AGGTCTATAT 
3' end ofhCMV )lo ~ I putative transcriptional start ,----
809 AAGCAGAGCT CTCTGGCTAA CTAGAGAACC CACTGCTTAC TGGCTTATCG AAATTAATAC 
T7 promoter/primer binding site N1e I P"{e I Dra
1 
U Alf I~ I Xho I Noll 
869 GACTCACTAT AGGGAGACCC AAGCTGGCTA GCGTTTAAAC GGGCCCTdA GACTCGAGCG 
BstX I* EcoR V EcoR I BstX l* BamH I 
I I .-' I c:' 
929 GCCGCCACTG TGCTGGATAT CTGCAGAATT CCACCACACT GGACIAGTGG ATCCGAGCTC 
Asp7i81 Kpn I Hind Ill Aflll Pme 1 pcDNA3.1/BGH reverse priming site 
989 GGT ACC"'AAGcTT AAGTh AA ACCGCTGATC AGCCTCGACT GTGCCTrCT A GTTGCCAGCC 
1049 ATCTGTTGTT TGCCCCTCCC CCGTGCCTTC CTTGACCCTG GAAGGTGCCA CTCCCACTGT 
BGH poly (A) site 
1109 CCTTTCC~AA TAAAATGAGG AAATTGCATC 
Figure Al.3. The multiple cloning site for pcDNA3.1(-). Restriction sites are labelled 
to indicate cleavage site. The Xbal site contains an internal stop codon (TGT AGA). 
The multiple cloning site has been confirmed by sequencing and functional testing by 
Invitrogen. (Taken from Invitrogen Technical manual 081401, Invitrogen, Paisley, 
UK). 
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A1.2 ASSEMBLY OF Ql51X aD-CRYSTALLIN CONSTRUCT 
BYSDM 
Initial SDM optimisation followed the manufacturers guidelines utilizing the 
proof reading capabilities of pfu Turbo polymerase. This enzyme failed to generate a 
PCR product of the correct size. Further SDM PCR reactions utilised Taq polymerase 
with primer combinations including T7 promoter/Q151X reverse primer (reaction 1) 
and Q151X forward primer/ T7 terminator (reaction 2). Both combinations produced 
the pET23d(+) vector of required size 4159 bp (see Figure Al.4A). Dpnl digested 
DNA from the Q 151 X forward primer/ T7 terminator reaction was proliferated to 
allow confitmation of the Q151X mutant insert by screening using Nco//Stul digestion. 
From 8 colonies selected of transformants, two constructs showed Ncol/Stul digest 
fragments representing the Q151X insert (see Figure A1.4B, lane 10 and 12; construct 
1 and 2 respectively). Subsequent sequencing and BLAST analysis of the two 
constructs confirmed the presence of the mutant Q151X insert, however, construct 1 
had two random base changes at 413c-t and 430c-t (see Figure Al.5). Clone 2 BLAST 
data (see Figure A1.6) showed a cytosine insertion at 470, however this insertion was 
downstream to the stop codon introduced at codon 151, therefore the plasmid DNA 
was a suitable candidate for use in protein expression. 
A 
pET23d(+) 
plus insert 
(4159bp) 
primers 
1 2 
Dpnl + 
T7 promoter 
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3 4 5 6 
+ 
T7 terminator 
Q 151 X reverse primer Q 151 X forward primer 
B 
pET23d(+) 
plus insert 
(4159bp) 
1 2 
-
pET23d(+) 
+-minus insert 
(3704bp) 
264 
+-Nco 1/Stu I fragment 
(455bp) 
Figure A1.4. SDM PCR for insertion of mutant aB-crystallin into pET23d(+) 
bacterial expression vector. (A) confirms the correctly sized pET23d(+) vector (approx 
4159 bp) produced using Taq polymerase and T7 promoter/ Q151X reverse primer 
(lanes 1 and 2) and vice versa (lanes 5 and 6). Unincorporated primers bands are more 
intense in lanes 1 and 2, suggesting the mutagenesis may be more successful in lanes 5 
and 6. This DNA was proliferated. DNA ladders A Pstl (lane 4, black box- 339, 805, 
4749bp) and 100bp GeneRuler (lane 3, black circle- 500 and 3000bp). (B) Successful 
incorporation of the mutant Q151X insert is confirmed by the presence of Ncol/ Stul 
fragments (455bp) (lane 10 and 11) in DNA purified from the respective 
transformants, with sequencing and BLAST analysis confirming the clone in lane 12 to 
be suitable for protein expression despite an insertion downstream to the mutated stop 
codon. DNA ladders A Pstl (lane 7, white box- 514, 805, 5077bp) and lOObp 
GeneRuler (lane 8, white circle- 500 and 3000bp). 
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Figure Al.S. BLAST data for Q151X insert in pET23d(+) Construct 1 
Stu I in BOLD (AGGCCT) 
Pink - random substituton 
Green - insertion/ deletion 
Red - Wild Type Methionine and wt stop codon 
Blue-SDM mutation 
Underlined -primer sequence 
-24 GACCCCTCAC ACTCACCTAG CCACCATGGA CATCGCCATC CACCACCCCT GGATCCGCCG 
36 CCCCTTCTTT CCTTTCCACT CCCCCAGCCG CCTCTTTGAC CAGTTCTTCG GAGAGCACCT 
96 GTTGGAGTCT GATCTTTTCC CGACGTCTAC TTCCCTGAGT CCCTTCTACC TTCGGCCACC 
156 CTCCTTCCTG CGGGCACCCA GCTGGTTTGA CACTGGACTC TCAGAGATGC GCCTGGAGAA 
216 GGACAGGTTC TCTGTCAACC TGGATGTGAA GCACTTCTCC CCAGAGGAAC TCAAAGTTAA 
276 GGTGTTGGGA GATGTGATTG AGGTGCATGG AAAACATGAA GAGCGCCAGG ATGAACATGG 
336 TTTCATCTCC AGGGAGTTCC ACAGGAAATA CCGGATCCCA GCTGATGTAG ACCCTCTCAC 
396 CATTACTTCA TCCCTGTTAT CTGATGGGGT CCTCATTGTG AATGGACCAA GGAAATAGGC 
456 CTCTGGCCCT GAGCGCACCA TTCCCATCAC CCGTGAAGAG AAGCCTGCTG TCACCGCAGC 
516 CCCCAAGAAA TAGATGCCCT TTCTTGAATT GCATTTTTTA AAACAAGAAA GTTTCCCCAC 
576 CAGTGAATGA AAGTCTTGTG ACTAGTGCTG AAGCTTATTA ATGCTAAGGG CAGGCCCAAA 
636 TTATCAAGCT AATAAAATAT CATTCAGCAA C 
Figure A1.6. BLAST data for QlSlX insert in pET23d(+) Construct 2 
Homo sapiens crystallin, alpha B (CRYAB), mRNA 
Length = 691 
Score= 1025 bits (517), Expect= 0.0 
Identities= 530/533 (99%), Gaps= 1/533 (0%) 
Strand = Plus I Minus 
QUERY: 116 TCTATTTCTTGGGGGCTGCGGTGACAGCAGGCTTCTCTTCACGGGTGATGGGAATGGTGC 
1111111111111111111111111111111111111111111111111111111_11_1_11 
175 
SBJCT: 554 TCTATTTCTTGGGGGCTGCGGTGACAGCAGGCTTCTCTTCACGGGTGATGGGAATGGTGC 495 
QUERY: 176 CGCTCAGGGCCAGAGGCCTATTTCCTTGGTCCATTCACAGTGAGGACCCCATCAGATGAC 235 
11111111111111 Ill I I I I II I I I I I I I II I I I II I I I I I I II I I II II I I I II I 
SBJCT: 494 - GCTCAGGGCCAGAGACCTGTTTCCTTGGTCCATTCACAGTGAGGACCCCATCAGATGAC 436 
QUERY: 236 AGGGATGAAGTAATGGTGAGAGGGTCTACATCAGCTGGGATCCGGTATTTCCTGTGGAAC 295 
I I I I I II II I I I I II II I I I I I I I I I I I I II II I I I I I I I I II II I I I I I II I I I I II II 
SBJCT: 435 AGGGATGAAGTAATGGTGAGAGGGTCTACATCAGCTGGGATCCGGTATTTCCTGTGGAAC 376 
QUERY: 296 TCCCTGGAGATGAAACCATGTTCATCCTGGCGCTCTTCATGTTTTCCATGCACCTCAATC 355 
I I I I II II II II I II I II I I I I I I I I I I I II II I I I I I I I I I II I I I I I I II II I I I I II 
SBJCT: 375 TCCCTGGAGATGAAACCATGTTCATCCTGGCGCTCTTCATGTTTTCCATGCACCTCAATC 316 
QUERY: 356 ACATCTCCCAACACCTTAACTTTGAGTTCCTCTGGGGAGAAGTGCTTCACATCCAGGTTG 415 
111111111111111111111111111111111111111111111111111111111111 
SBJCT: 315 ACATCTCCCAACACCTTAACTTTGAGTTCCTCTGGGGAGAAGTGCTTCACATCCAGGTTG 256 
QUERY: 416 ACAGAGAACCTGTCCTTCTCCAGGCGCATCTCTGAGAGTCCAGTGTCAAACCAGCTGGGT 475 
I I I I II I I I I I I I I I I I I II II II I II II I I II I I I I II I II I I I I I I II I II II I I I I I 
SBJCT: 255 ACAGAGAACCTGTCCTTCTCCAGGCGCATCTCTGAGAGTCCAGTGTCAAACCAGCTGGGT 196 
QUERY: 476 GCCCGCAGGAAGGAGGGTGGCCGAAGGTAGAAGGGACTCAGGGAAGTAGACGTCGGGAAA 535 
111111111111111111111111111111111111111111111111111111111111 
SBJCT: 195 GCCCGCAGGAAGGAGGGTGGCCGAAGGTAGAAGGGACTCAGGGAAGTAGACGTCGGGAAA 136 
QUERY: 536 AGATCAGACTCCAACAGGTGCTCTCCGAAGAACTGGTCAAAGAGGCGGCTGGGGGAGTGG 595 
1111111111111111111111111111111111111 I I II II I I I I I 111111 I II I I I 
SBJCT: 135 AGATCAGACTCCAACAGGTGCTCTCCGAAGAACTGGTCAAAGAGGCGGCTGGGGGAGTGG 76 
QUERY: 596 AAAGGAAAGAAGGGGCGGCGGATCCAGGGGTGGTGGATGGCGATGTCCATGGT 648 
I I I I I II I I I I II II I I II I I I I I I I I II I I I I I I II I I I I I I I I I II II I II 
SBJCT: 75 AAAGGAAAGAAGGGGCGGCGGATCCAGGGGTGGTGGATGGCGATGTCCATGGT 23 
265 
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A1.3 ASSEMBLY OF E165X aD-CRYSTALLIN BY SDM 
The optimisation of the SDM process for the Q151X mutant has shown that 
the Taq polymerase enzyme is successful in generating the mutated PCR product. 
Initial SDM reverted back to the manufacturers guidelines by utilising forward and 
reverse complementary primers to incorporate the E 165X mutation. The PCR resulted 
in a correctly sized pET23d(+) band of 4159bp (see Figure A1.7.A, lane 1), therefore 
this PCR product was Dpnl digested and proliferated in DH5a cells. Purified DNA 
was screened using an Ncol!Hindlll digest to assess the presence of the mutant insert 
of expected size 497bp. The pET23d( +) vector contains a Hindlll site downstream to 
the insert, therefore unsuccessful constructs still containing the wild type aB-crystallin 
insert will also produce a digest fragment of an expected size of 559bp as clarified in 
Figure Al.7.B. The digestion identified 5 constructs, which potentially could be viable 
for protein expression. The constructs were sequenced and compared for fidelity to the 
GenBank data base entry (accession no. NM001885), using BLAST software. This 
revealed that construct 2 and 10 (see Figure A1.7.B, lane 2 and lane 12 respectively) 
although containing a polymorphism point mutation at C474T, the codon remained 
threonine, therefore was viable for protein expression (see Figure A1.8 and A8.9 
respectively). 
A 
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pET23d(+) 
plus insert ___. 
(4159bp) 
Unincorporated 
primers 
B 
pET23d( +) minus 
wt insert (3600bp) 
pET23d( +) minus 
wt insert (559bp) 
E165X insert (497bp) 
1 
Constructs 1-6 
pET23d(+) 
control 
(wt insert) 
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Constructs 7-12 
Figure Al.7. PCR mutagenesis ofE165X mutant construct assembly. PCR conditions 
successful in producing a correctly sized pET23d(+) vector (approx 4159bp lane 1). 
DNA ladders A. Pstl (lane 2, white box- 805, 2838, 5077bp) and lOObp GeneRuler 
(lane 3, white circle- 500 and 3000bp). (B) Restriction enzyme digestion 
(Ncol/Hind!II) of potentially viable E 165X constructs. Screening identified the 
constructs, which contained the E165X aB-crystallin insert (lanes 2 and 11-14) by a 
497bp fragment leaving a pET23d(+) vector of 3662bp. Constructs where SDM failed 
to incorporate the E 165X mutation contain a pET23d( +) vector of 3600bp, and a digest 
fragment of 559bp (lanes 1, 3-6 and 9-10). Construct 7 appears incomplete. DNA 
ladders A. Pstl (lane 8, black box- 514, 805, 2838bp). The overexposure through lane 
12 was a function of the Biorad Gel Doc 2000. 
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Figure A1.8. BLAST data for E165X insert in pET23d(+) Construct 2 
Hind Ill in BOLD (AAGCTT) 
Pink - random substituton 
Green- insertion/ deletion 
Red - Wild Type Methionine and wt stop codon 
Blue-SDM mutation 
Underlined -primer sequence 
*= polymorphism 
Homo sapiens crystallin, alpha B (CRYAB) , mRNA 
Length = 691 
Score= 1025 bits (517), Expect= 0.0 
Identities a 528/532 (99%) 
Strand = Plus I Plus 
Query: 57 ACCATGGACATCGCCATCCACCACCCCTGGATCCGCCGCCCCTTCTTTCCTTTCCACTCC 116 
111111111111111111111111111111111111111111111111111111111111 
SBJCT: 23 ACCATGGACATCGCCATCCACCACCCCTGGATCCGCCGCCCCTTCTTTCCTTTCCACTCC 82 
QUERY: 117 CCCAGCCGCCTCTTTGACCAGTTCTTCGGAGAGCACCTGTTGGAGTCTGATCTTTTCCCG 176 
111111111111111111111111111111111111111111111111111111111111 
SBJCT: 83 CCCAGCCGCCTCTTTGACCAGTTCTTCGGAGAGCACCTGTTGGAGTCTGATCTTTTCCCG 142 
QUERY: 177 ACGTCTACTTCCCTGAGTCCCTTCTACCTTCGGCCACCCTCCTTCCTGCGGGCACCCAGC 236 
111111111111111111111111111111111111111111111111111111111111 
SBJCT: 143 ACGTCTACTTCCCTGAGTCCCTTCTACCTTCGGCCACCCTCCTTCCTGCGGGCACCCAGC 202 
QUERY: 237 
SBJCT: 203 
QUERY : 297 
SBJCT: 263 
QUERY: 357 
SBJCT: 323 
QUERY: 417 
SBJCT: 383 
QUERY: 477 
SBJCT: 443 
QUERY: 537 
SBJCT: 503 
TGGTTTGACACTGGACTCTCAGAGATGCGCCTGGAGAAGGACAGGTTCTCTGTCAACCTG 296 
111111111111111111111111111111111111111111111111111111111111 
TGGTTTGACACTGGACTCTCAGAGATGCGCCTGGAGAAGGACAGGTTCTCTGTCAACCTG 262 
GATGTGAAGCACTTCTCCCCAGAGGAACTCAAAGTTAAGGTGTTGGGAGATGTGATTGAG 356 
111111111111111111111111111111111111111111111111111111111111 
GATGTGAAGCACTTCTCCCCAGAGGAACTCAAAGTTAAGGTGTTGGGAGATGTGATTGAG 322 
GTGCATGGAAAACATGAAGAGCGCCAGGATGAACATGGTTTCATCTCCAGGGAGTTCCAC 416 
111111111111111111111111111111111111111111111111111111111111 
GTGCATGGAAAACATGAAGAGCGCCAGGATGAACATGGTTTCATCTCCAGGGAGTTCCAC 382 
AGGAAATACCGGATCCCAGCTGATGTAGACCCTCTCACCATTACTTCATCCCTGTCATCT 476 
111111111111111111111111111111111111111111111111111111111111 
AGGAAATACCGGATCCCAGCTGATGTAGACCCTCTCACCATTACTTCATCCCTGTCATCT 442 
GATGGGGTCCTCACTGTGAATGGACCAAGGAAACAGGTCTCTGGCCCTGAGCGCACT*~ 536 
I I I II I I I I I I II I I I I I I I I II I I I I I I I I I I I I I I I I I I I I II I II II I I II I I I I I 
GATGGGGTCCTCACTGTGAATGGACCAAGGAAACAGGTCTCTGGCCCTGAGCGCACC*ATT 502 
CCCATCACCCGTGAATAGAAGCTTGCTGTCACCNCAGCCCCCAAGAAATAGA 588 
111111111111111 111111 1111111111 111111111111111111 
CCCATCACCCGTGAAGAGAAGCCTGCTGTCACCGCAGCCCCCAAGAAATAGA 554 
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Figure A1.9. BLAST data for E165X insert in pET23d(+) Construct 10 
Homo sapiens crysta~~in, a~pha B (CRYAB), mRNA 
Length • 691 
Score= 1031 bits (520), Expect= 0.0 
Identities = 529/532 (99%) 
Strand = P~us I P~us 
QUERY: 56 ACCATGGACATCGCCATCCACCACCCCTGGATCCGCCGCCCCTTCTTTCCTTTCCACTCC 115 
111111111111111111111111111111111111111111111111111111111111 
SBJCT: 23 ACCATGGACATCGCCATCCACCACCCCTGGATCCGCCGCCCCTTCTTTCCTTTCCACTCC 82 
QUERY: 116 CCCAGCCGCCTCTTTGACCAGTTCTTCGGAGAGCACCTGTTGGAGTCTGATCTTTTCCCG 175 
111111111111111111111111111111111111111111111111111111111111 
SBJCT: 83 CCCAGCCGCCTCTTTGACCAGTTCTTCGGAGAGCACCTGTTGGAGTCTGATCTTTTCCCG 142 
QUERY: 176 ACGTCTACTTCCCTGAGTCCCTTCTACCTTCGGCCACCCTCCTTCCTGCGGGCACCCAGC 235 
I I I I I I I I I I I I I I I II II IIIII I II II I I I I I I I I I II I I Ill I I I II I I I I I Ill II 
SBJCT: 143 ACGTCTACTTCCCTGAGTCCCTTCTACCTTCGGCCACCCTCCTTCCTGCGGGCACCCAGC 202 
QUERY: 
SBJCT: 
QUERY: 
SBJCT: 
QUERY: 
SBJCT: 
236 
203 
296 
263 
356 
323 
TGGTTTGACACTGGACTCTCAGAGATGCGCCTGGAGAAGGACAGGTTCTCTGTCAACCTG 295 
I I I I I I I I II I II I I I I I I I I Ill I II I I I I I Ill I II I II I I I I II I Ill I I I I I II II 
TGGTTTGACACTGGACTCTCAGAGATGCGCCTGGAGAAGGACAGGTTCTCTGTCAACCTG 262 
GATGTGAAGCACTTCTCCCCAGAGGAACTCAAAGTTAAGGTGTTGGGAGATGTGATTGAG 355 
111111111111111111111111111111111111111111111111111111111111 
GATGTGAAGCACTTCTCCCCAGAGGAACTCAAAGTTAAGGTGTTGGGAGATGTGATTGAG 322 
GTGCATGGAAAACATGAAGAGCGCCAGGATGAACATGGTTTCATCTCCAGGGAGTTCCAC 415 
111111111111111111111111111111111111111111111111111111111111 
GTGCATGGAAAACATGAAGAGCGCCAGGATGAACATGGTTTCATCTCCAGGGAGTTCCAC 382 
QUERY: 416 AGGAAATACCGGATCCCAGCTGATGTAGACCCTCTCACCATTACTTCATCCCTGTCATCT 475 
I I I I I I I I I I I I I I I I I I I I I I II I II I I I I I I I I I I I I II I I I I II I I I I I I I I I I I I I 
SBJCT: 383 AGGAAATACCGGATCCCAGCTGATGTAGACCCTCTCACCATTACTTCATCCCTGTCATCT 442 
QUERY: 476 GATGGGGTCCTCACTGTGAATGGACCAAGGAAACAGGTCTCTGGCCCTGAGCGCACT* ATT 535 
11111111111111111111111111111111111111111111111111111111 -11-1 
SBJCT: 443 GATGGGGTCCTCACTGTGAATGGACCAAGGAAACAGGTCTCTGGCCCTGAGCGCACC* ATT 502 
QUERY: 536 CCCATCACCCGTGAATAGAAGCTTGCTGTCACCGCAGCCCCCAAGAAATAGA 587 
111111111111111 111111 11111111111111111111111111111 
SBJCT: 503 CCCATCACCCGTGAAGAGAAGCCTGCTGTCACCGCAGCCCCCAAGAAATAGA 554 
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A1.4 ASSEMBLY OF 464DELCT aD-CRYSTALLIN 
PCR mutagenesis experiments involved the production of the 464delCT aS-
crystallin mutant insert with 3 'A overhangs for subsequent ligation into the pGEM®-T 
Easy vector (see Figure Al.10.A). The 464delCT mutant does not contain a suitable 
unique restriction site, hence an EcoRI site in the pGEM®-T Easy vector downstream 
from the ligation site was utilised (see Figure Al.1). DNA from selected 
transformants was purified and the presence of the mutation assessed using an 
Ncol/EcoRI digest to screen for fragments of expected size 498bp (see Figure 
A 1.1 O.B). Screening suggested that 11 out of the 12 clones contained the 464delCT 
mutant insert. Subsequent sequencing and BLAST analysis identified constructs 8, 10 
and 11 (shown in lanes 9, 10 and 12 respectively) contained the 464delCTmutant insert 
with no additional mutations incurred when compared to the GenBank data base entry 
(accession no. NM001885) for human aS-crystallin 
Construct 8 (see Figure A 1.11) was subcloned into pET23 d( +) using an 
Ncol/EcoRI digest. The multiple cloning region of pET23d(+) is shown in Figure 
Al.2. The presence of the mutation was assessed using the Ncol/EcoRI digest on 
purified constructs to screen for fragments of expected 464delCT insert size of 498bp 
(see Figure Al.IO.C). Of 11, constructs 1, 2, 3 and 5 indicated the presence of a low 
intensity fragment at 498bp (lanes 1, 2, 3 and 5 respectively, see arrowhead). 
Subsequent sequencing and BLAST analysis of the 4 constructs confirmed the 
464delCT insert had successfully been subcloned into the pET23d(+) vector in 
construct 2 with no unwanted sequence changes, when compared to the GenBank data 
base entry (accession no. NM001885) for human aS-crystallin. Construct 2 was 
viable for protein expression. (see Figure Al.12). 
A 
Excised 
-464deiCT mutant 
insert (492bp) 
c 
pET23d(+) 
minus insert -+ 
(3619bp) 
464delCT i"""n-+ 
(498bp) 
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Figure Al.10. Assembly of 464delCT aB-crystallin construct using pGEM®-T Easy 
vector system. PCR mutagenesis produced a PCR product of 492bp (A) that was 
purified and ligated into using pGEM®-T Easy vector. The efficiency of the ligation 
was assessed using an Nco!!EcoRI digest screen (B), which suggested 11 out of 12 
selected constructs contained the 464delCT insert. Sequencing confirmed constructs 
shown in lanes 9, 10 and 12 contained the 464delCT mutant insert. . DNA ladder A 
Pstl (Figure Al.10.B, lane 7, black circle- 514, 805 , 1159, 1700, 2838 and 4507bp) 
The overexposure through lane 3 was a function of the Biorad Gel Doc 2000. The 
464delCT insert (Figure 3.5 B, lane 9) was subcloned into the pET23d(+) vector. 
Purified DNA was screened (C) using Ncol/EcoRI digestion and suggested the 
464delCT insert was present in constructs shown in lanes 1, 2, 3 and 5 at 498bp (see 
arrowhead). Sequencing confirmed the construct in lane 2 contained the 464delCT 
insert with no additional mutations, therefore was viable for protein expression. DNA 
ladder A Pstl (Figure A1.10.C lane 9, black circle- 514, 1159, 2838 and 4507bp). 
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Figure Al.ll. BLAST data for 464delCT insert in pGEM-T Easy-Construct 8 
Pink - random substituton 
Green - insertion/ deletion 
Red - Wild Type Methionine and wt stop codon 
Blue-SDM mutation 
Underlined -primer sequence 
*= polymorphism 
Homo sapiens crystallin, alpha B (CRY AB), mRNA 
Length=691 Length=691 
Score = 959 bits (484), Expect= 0.0 
Identities= 493/495 (99%), Gaps = 2/495 (0%) 
Strand=Pius!Pius 
Query 52 ACCATGGACATCGCCATCCACCACCCCTGGATCCGCCGCCCCTTCTTTCCTTTCCACTCC 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 23 ACCATGGACATCGCCATCCACCACCCCTGGATCCGCCGCCCCTTCTTTCCTTTCCACTCC 
Query 112 CCCAGCCGCCTCTTTGACCAGTTCTTCGGAGAGCACCTGTTGGAGTCTGATCTTTTCCCG 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 83 CCCAGCCGCCTCTTTGACCAGTTCTTCGGAGAGCACCTGTTGGAGTCTGATCTTTTCCCG 
Query 172 ACGTCTACTTCCCTGAGTCCCTTCTACCTTCGGCCACCCTCCTTCCTGCGGGCACCCAGC 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 143 ACGTCTACTTCCCTGAGTCCCTTCTACCTTCGGCCACCCTCCTTCCTGCGGGCACCCAGC 
Query 232 TGGTTTGACACTGGACTCTCAGAGATGCGCCTGGAGAAGGACAGGTTCTCTGTCAACCTG 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 203 TGGTTTGACACTGGACTCTCAGAGATGCGCCTGGAGAAGGACAGGTTCTCTGTCAACCTG 
Query 292 GATGTGAAGCACTTCTCCCCAGAGGAACTCAAAGTTAAGGTGTTGGGAGATGTGATTGAG 
11111111111111111111111111111111111111111111111111111111111 I 
Sbjct 263 GATGTGAAGCACTTCTCCCCAGAGGAACTCAAAGTTAAGGTGTTGGGAGATGTGATTGAG 
Query 352 GTGCATGGAAAACATGAAGAGCGCCAGGATGAACATGGTTTCATCTCCAGGGAGTTCCAC 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 323 GTGCATGGAAAACATGAAGAGCGCCAGGATGAACATGGTTTCATCTCCAGGGAGTTCCAC 
Query 412 AGGAAATACCGGATCCCAGCTGATGTAGACCCTCTCACCATTACTTCATCCCTGTCATCT 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 383 AGGAAATACCGGATCCCAGCTGATGTAGACCCTCTCACCATTACTTCATCCCTGTCATCT 
Query 472 GATGGGGTCCTCACTGTGAATGGACCAAGGAAACAGGTCTCTGGCC--GAGCGCACCATT 
1111111111111111111111111111111111111111111111 111111111111 
Sbjct 443 GATGGGGTCCTCACTGTGAATGGACCAAGGAAACAGGTCTCTGGCCCTGAGCGCACCATT 
Query 530 CCCATCACCCGTGAA 544 
111111111111111 
sbjct 503 CCCATCACCCGTGAA 517 
272 
111 
82 
171 
142 
231 
202 
291 
262 
351 
322 
411 
382 
471 
442 
529 
502 
_ .. -.~---·----
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Figure A1.12. BLAST data for 464deiCT insert in pET23d(+)-Construct 2 
Homo sapiens crystallin, alpha B (CRYAB), mRNA 
Length=691 
score = 954 bits (481), Expect = 0.0 
Identities= 492/495 (99%), Gaps= 2/495 (0%) 
Strand=Plus/Minus 
Query 115 TTCACGGGTGATGGGAATGGTGCGCTC--GGCCAGAGACCTGTTTCCTTGGTCCATTCAC 
111111111111111111111111111 1111111111111111111111111111111 
Sbjct 517 TTCACGGGTGATGGGAATGGTGCGCTCAGGGCCAGAGACCTGTTTCCTTGGTCCATTCAC 
Query 173 AGTGAGGACCCCATCAGATGACAGGGATGAAGTAATGGTGAGAGGGTCTACATCAGCTGG 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 457 AGTGAGGACCCCATCAGATGACAGGGATGAAGTAATGGTGAGAGGGTCTACATCAGCTGG 
Query 233 GATCCGGTATTTCCTGTGGAACTCCCTGGAGATGAAACCATGTTCATCCTGGCGCTCTTC 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 397 GATCCGGTATTTCCTGTGGAACTCCCTGGAGATGAAACCATGTTCATCCTGGCGCTCTTC 
Query 293 ATGTTTTCCATGCACCTCAATCACATCTCCCAACACCTTAACTTTGAGTTCCTCTGGGGA 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 337 ATGTTTTCCATGCACCTCAATCACATCTCCCAACACCTTAACTTTGAGTTCCTCTGGGGA 
Query 353 GAAGTGCTTCACATCCAGGTTGACAGAGAACCTGTCCTTCTCCAGGCGCATCTCTGAGAG 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 277 GAAGTGCTTCACATCCAGGTTGACAGAGAACCTGTCCTTCTCCAGGCGCATCTCTGAGAG 
Query 413 TCCAGTGTCAAACCAGCTGGGTGCCCGCAGGAAGGAGGGTGGCCGAAGGTAGAAGGGACT 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 217 TCCAGTGTCAAACCAGCTGGGTGCCCGCAGGAAGGAGGGTGGCCGAAGGTAGAAGGGACT 
Query 473 CAGGGAAGTAGACGTCGGGAAAAGATCAGACTCCAACAGGTGCTCTCCGAAGAACTGGTC 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 157 CAGGGAAGTAGACGTCGGGAAAAGATCAGACTCCAACAGGTGCTCTCCGAAGAACTGGTC 
Query 533 AAAGAGGCGGCTGGGGGAGTGGAAAGGAAAGAAGGGGCGGCGGATCCAGGGGTGGTGGAT 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 97 AAAGAGGCGGCTGGGGGAGTGGAAAGGAAAGAAGGGGCGGCGGATCCAGGGGTGGTGGAT 
Query 593 GGCGATGTCCATGGT 607 
111111111111111 
Sbjct 37 GGCGATGTCCATGGT 23 
172 
458 
232 
398 
292 
338 
352 
278 
412 
218 
472 
158 
532 
98 
592 
38 
273 
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A1.5 ASSEMBLY OF E164X aD-CRYSTALLIN 
PCR mutagenesis experiments involved the production of the E164X aB-
crystallin mutant insert with 3 'A overhangs for subsequent ligation into the pGEM®-T 
Easy vector. The E164X mutant contains a unique Pstl restriction site downstream to 
the stop codon. DNA from selected transformants was screened using an Ncol/Pst! 
digest to identify fragments of expected size 506bp (see Figure A1.13.A). Screening 
suggested that 5 out of the 8 clones contained the E164X mutant insert. Subsequent 
sequencing and BLAST analysis confirmed all 5 constructs contained the E164X 
mutant insert. 
Construct 4 (see, Figure Al.l4) was subcloned into pET23d(+) usmg an 
Ncol/EcoRI digest. The presence of the E164X mutation was assessed using the 
Ncol/Pst! digest on purified constructs to screen for fragments of expected E164X 
insert size of 506bp (see Figure A 1.13 .B). Of 6, constructs 1, 2, 3 and 4 indicated the 
presence of a low intensity fragment at 506bp (lanes 1, 2, 3 and 4 respectively). 
Subsequent sequencing and BLAST analysis of the 4 constructs confirmed the E164X 
insert had successfully been subcloned into the pET23d(+) vector in construct 1-3 with 
no unwanted sequence changes, (see, Figure A.l5.). Construct 1 would be used for 
protein expression. 
A 
pGEM-TEasy 
(3037bp) 
non specific / 
digest fragments _. 
I ~ I . 
•••• 
B 
pET23d( +) _. 
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Figure Al.l3. Assembly of E164X aD-crystallin construct using pGEM®-T Easy 
vector system. PCR mutagenesis produced a PCR product of 528bp that was purified 
and ligated into using pGEM®-T Easy vector. The efficiency of the ligation was 
assessed using an Ncol/Pst! digest screen (A), which suggested 5 out of 8 selected 
constructs contained the El64X insert. Sequencing confirmed constructs 2, 3, 4, 5 and 
7 shown in lanes 2, 4, 5, 6 and 8 respectively contained the E164X mutant insert. 
Construct 4 (Figure Al.l3A, lane 5) was subcloned into the pET23d(+) vector. 
Purified DNA was screened (B) using Ncol!Pstl digestion and suggested the El64X 
insert was present in constructs 1-4 shown in lanes 1, 2, 3 and 5 respectively at 506bp. 
Sequencing confinned constructs 1-3 contained the E164X insert with no additional 
mutations, therefore were viable for protein expression. DNA ladder J.... Pst! (Figure 
Al.l3.A lane 3;Figure Al.l3.B, lane 4-black circle- 514, 1159 and 2838bp). The 
overexposure through lane 6 was a function of the Biorad Gel Doc 2000. 
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Figure A1.14. BLAST data for E164X insert in pGEM-T Easy-Construct 4 
Pst I highlighted in bold (CTGCAG) 
Pink - random substituton 
Green - insertion/ deletion 
Red - Wild Type Methionine and wt stop codon 
Blue-SDM mutation 
Underlined -primer sequence 
*= polymorphism 
Homo sapiens crystallin, alpha B (CRYAB), rnRNA 
Length=691 
Score= 1021 bits (515), Expect= 0.0 
Identities= 524/527 (99%), Gaps: 0/527 (0%) 
Strand:Plus/Plus 
Query 51 ACCATGGACATCGCCATCCACCACCCCTGGATCCGCCGCCCCTTCTTTCCTTTCCACTCC 110 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 23 ACCATGGACATCGCCATCCACCACCCCTGGATCCGCCGCCCCTTCTTTCCTTTCCACTCC 82 
Query 111 CCCAGCCGCCTCTTTGACCAGTTCTTCGGAGAGCACCTGTTGGAGTCTGATCTTTTCCCG 170 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 83 CCCAGCCGCCTCTTTGACCAGTTCTTCGGAGAGCACCTGTTGGAGTCTGATCTTTTCCCG 142 
Query 171 ACGTCTACTTCCCTGAGTCCCTTCTACCTTCGGCCACCCTCCTTCCTGCGGGCACCCAGC 230 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 143 ACGTCTACTTCCCTGAGTCCCTTCTACCTTCGGCCACCCTCCTTCCTGCGGGCACCCAGC 202 
Query 231 TGGTTTGACACTGGACTCTCAGAGATGCGCCTGGAGAAGGACAGGTTCTCTGTCAACCTG 290 
111111111111111111111111111111111111111111111111111111111111 
sbjct 203 TGGTTTGACACTGGACTCTCAGAGATGCGCCTGGAGAAGGACAGGTTCTCTGTCAACCTG 262 
Query 291 GATGTGAAGCACTTCTCCCCAGAGGAACTCAAAGTTAAGGTGTTGGGAGATGTGATTGAG 350 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 263 GATGTGAAGCACTTCTCCCCAGAGGAACTCAAAGTTAAGGTGTTGGGAGATGTGATTGAG 322 
Query 351 GTGCATGGAAAACATGAAGAGCGCCAGGATGAACATGGTTTCATCTCCAGGGAGTTCCAC 410 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 323 GTGCATGGAAAACATGAAGAGCGCCAGGATGAACATGGTTTCATCTCCAGGGAGTTCCAC 382 
Query 411 AGGAAATACCGGATCCCAGCTGATGTAGACCCTCTCACCATTACTTCATCCCTGTCATCT 470 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 383 AGGAAATACCGGATCCCAGCTGATGTAGACCCTCTCACCATTACTTCATCCCTGTCATCT 442 
Query 471 GATGGGGTCCTCACTGTGAATGGACCAAGGAAACAGGTCTCTGGCCCTGAGCGCACCATT 
111111111111111111111111111111111111111111111111111111-ll-ll-ll 
530 
Sbjct 443 GATGGGGTCCTCACTGTGAATGGACCAAGGAAACAGGTCTCTGGCCCTGAGCGCACCATT 502 
Query 531 CCCATCACCCGTTAAGAGAAGCCTGCAGTCACCGCAGCTCCCAAGAA 577 
111111111111 1111111111111 11111111111 11111111 
Sbjct 503 CCCATCACCCGTGAAGAGAAGCCTGCTGTCACCGCAGCCCCCAAGAA 549 
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Figure A1.15. BLAST data for E164X insert in pET23d(+)-Construct 1 
Homo sapiens crystallin, alpha B (CRYAB), mRNA 
Length=691 
score= 1021 bits (515), Expect= 0.0 
Identities= 524/527 (99%), Gaps= 0/527 (0%) 
Strand=Plus/Plus 
Query 51 ACCATGGACATCGCCATCCACCACCCCTGGATCCGCCGCCCCTTCTTTCCTTTCCACTCC 110 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 23 ACCATGGACATCGCCATCCACCACCCCTGGATCCGCCGCCCCTTCTTTCCTTTCCACTCC 82 
Query 111 CCCAGCCGCCTCTTTGACCAGTTCTTCGGAGAGCACCTGTTGGAGTCTGATCTTTTCCCG 170 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 83 CCCAGCCGCCTCTTTGACCAGTTCTTCGGAGAGCACCTGTTGGAGTCTGATCTTTTCCCG 142 
Query 171 ACGTCTACTTCCCTGAGTCCCTTCTACCTTCGGCCACCCTCCTTCCTGCGGGCACCCAGC 230 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 143 ACGTCTACTTCCCTGAGTCCCTTCTACCTTCGGCCACCCTCCTTCCTGCGGGCACCCAGC 202 
Query 231 TGGTTTGACACTGGACTCTCAGAGATGCGCCTGGAGAAGGACAGGTTCTCTGTCAACCTG 290 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 203 TGGTTTGACACTGGACTCTCAGAGATGCGCCTGGAGAAGGACAGGTTCTCTGTCAACCTG 262 
Query 291 GATGTGAAGCACTTCTCCCCAGAGGAACTCAAAGTTAAGGTGTTGGGAGATGTGATTGAG 350 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 263 GATGTGAAGCACTTCTCCCCAGAGGAACTCAAAGTTAAGGTGTTGGGAGATGTGATTGAG 322 
Query 351 GTGCATGGAAAACATGAAGAGCGCCAGGATGAACATGGTTTCATCTCCAGGGAGTTCCAC 410 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 323 GTGCATGGAAAACATGAAGAGCGCCAGGATGAACATGGTTTCATCTCCAGGGAGTTCCAC 382 
Query 411 AGGAAATACCGGATCCCAGCTGATGTAGACCCTCTCACCATTACTTCATCCCTGTCATCT 470 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 383 AGGAAATACCGGATCCCAGCTGATGTAGACCCTCTCACCATTACTTCATCCCTGTCATCT 442 
Query 471 GATGGGGTCCTCACTGTGAATGGACCAAGGAAACAGGTCTCTGGCCCTGAGCGCACCATT 530 
111111111111111111111111111111111111111111111111111111-ll-ll-ll 
Sbjct 443 GATGGGGTCCTCACTGTGAATGGACCAAGGAAACAGGTCTCTGGCCCTGAGCGCACCATT 502 
Query 531 CCCATCACCCGTTAAGAGAAGCCTGCAGTCACCGCAGCTCCCAAGAA 577 
111111111111 1111111111111 11111111111 11111111 
Sbjct 503 CCCATCACCCGTGAAGAGAAGCCTGCTGTCACCGCAGCCCCCAAGAA 549 
277 
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Al.6 ASSEMBLY OF A171X aD-CRYSTALLIN 
PCR mutagenesis experiments involved the production of the Al71X aS-
crystallin mutant insert with 3 'A overhangs for subsequent ligation into the pOEM®-T 
Easy vector. The A171X mutant contains a unique Sac! restriction site downstream 
from the stop codon. This site was used to screen DNA from selected transformants 
using an Ncol/Sacl digest to identify fragments of expected size 512bp (see Figure 
A1.16.A). Screening suggested that 7 out ofthe 8 clones contained the A171X mutant 
insert. Subsequent sequencing and BLAST analysis confirmed constructs 2, 3, 4, 6 
and 8 shown in Figure 3.7A, lanes 2, 3, 4, 6 and 9 respectively, contained the A171X 
mutant insert. 
Construct 2 (see Figure Al.17) was subcloned into pET23d(+) usmg an 
Ncol/EcoRI digest. The ligation of the A171X mutant insert was confirmed using the 
Nco!/Sacl digest on purified constructs to screen for fragments of expected A171X 
insert size of 512bp (see Figure A 1.16.8). All 6 constructs indicated the presence of a 
low intensity fragment at 512bp (lanes 1, 2, 3, 5, 6 and 7 respectively). Subsequent 
sequencing and BLAST analysis of constructs 1-5 confirmed the A171X insert had 
successfully been subcloned into the pET23d( +) vector in construct 2 and 3 with no 
unwanted sequence changes, (see Figure Al.18). Construct 2 would be used for 
protein expression. 
A 
Al71X insert 
(512bp) 
B 
A171X insert 
(512bp) 
1 2 
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Figure Al.16. Assembly of A171X aB-crystallin construct using pGEM®-T Easy 
vector system. PCR mutagenesis produced a PCR product of 540bp that was purified 
and ligated into using pGEM®-T Easy vector. The efficiency of the ligation was 
assessed using an Ncol/Sacl digest screen (A), which suggested 7 out of 8 selected 
constructs contained the A171X insert. Sequencing confirmed constructs 2, 3, 4, 6 and 
8 shown in lanes 2, 3, 4, 6 and 9 respectively contained the A171X mutant insert. 
Construct 2 (Figure A 1.16.A, lane 2) was subcloned into the pET23d( +) vector. 
Purified DNA was screened (B) using NcoJ/Sacl digestion and suggested the A171X 
insert was present in constructs 1-6 shown in lanes 1, 2, 3, 5, 6 and 7 respectively at 
512bp. Sequencing confirmed constructs 2 and 3 contained the A171X insert with no 
additional mutations, therefore were viable for protein expression. DNA ladder f... Pstl 
(Figure Al.16.A lane 7; Figure Al.16.B, lane 4-black circle- 514, 1159 and 2838bp). 
Jppendix 1 
Figure A1.17. BLAST data for Al71X insert in pGEM-T Easy-Construct 2 
Sac I highlighted in bold (GAGCTC) 
Pink - random substituton 
Green - insertion/ deletion 
Red - Wild Type Methionine and wt stop codon 
Blue-SDM mutation 
Underlined -primer sequence 
*= polymorphism 
Homo sapiens crystallin, alpha B (CRYAB), mRNA 
Length=691 
Score= 1041 bits (525), Expect 0.0 
Identities= 534/537 (99%), Gaps= 0/537 (0%) 
Strand=Plus/Minus 
Query 60 GGGCATCTATTTCTTGGGAGCTCAGGTGACAGCAGGCTTCTCTTCACGGGTGATGGGAAT 
111111111111111111 Ill 111111111111111111111111111111111111 
Sbjct 559 GGGCATCTATTTCTTGGGGGCTGCGGTGACAGCAGGCTTCTCTTCACGGGTGATGGGAAT 
Query 120 GGTGCGCTCAGGGCCAGAGACCTGTTTCCTTGGTCCATTCACAGTGAGGACCCCATCAGA 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 499 GGTGCGCTCAGGGCCAGAGACCTGTTTCCTTGGTCCATTCACAGTGAGGACCCCATCAGA 
Query 180 TGACAGGGATGAAGTAATGGTGAGAGGGTCTACATCAGCTGGGATCCGGTATTTCCTGTG 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 439 TGACAGGGATGAAGTAATGGTGAGAGGGTCTACATCAGCTGGGATCCGGTATTTCCTGTG 
Query 240 GAACTCCCTGGAGATGAAACCATGTTCATCCTGGCGCTCTTCATGTTTTCCATGCACCTC 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 379 GAACTCCCTGGAGATGAAACCATGTTCATCCTGGCGCTCTTCATGTTTTCCATGCACCTC 
Query 300 AATCACATCTCCCAACACCTTAACTTTGAGTTCCTCTGGGGAGAAGTGCTTCACATCCAG 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 319 AATCACATCTCCCAACACCTTAACTTTGAGTTCCTCTGGGGAGAAGTGCTTCACATCCAG 
Query 360 GTTGACAGAGAACCTGTCCTTCTCCAGGCGCATCTCTGAGAGTCCAGTGTCAAACCAGCT 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 259 GTTGACAGAGAACCTGTCCTTCTCCAGGCGCATCTCTGAGAGTCCAGTGTCAAACCAGCT 
Query 420 GGGTGCCCGCAGGAAGGAGGGTGGCCGAAGGTAGAAGGGACTCAGGGAAGTAGACGTCGG 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 199 GGGTGCCCGCAGGAAGGAGGGTGGCCGAAGGTAGAAGGGACTCAGGGAAGTAGACGTCGG 
Query 480 GAAAAGATCAGACTCCAACAGGTGCTCTCCGAAGAACTGGTCAAAGAGGCGGCTGGGGGA 
111111111111111111111111111111111111111111 111111111111111111 
Sbjct 139 GAAAAGATCAGACTCCAACAGGTGCTCTCCGAAGAACTGGTCAAAGAGGCGGCTGGGGGA 
Query 540 GTGGAAAGGAAAGAAGGGGCGGCGGATCCAGGGGTGGTGGATGGCGATGTCCATGGT 596 
111111111111111111111111111111111111111111111111111111111 
Sbjct 79 GTGGAAAGGAAAGAAGGGGCGGCGGATCCAGGGGTGGTGGATGGCGATGTCCATGGT 23 
119 
500 
179 
440 
239 
380 
299 
320 
359 
260 
419 
200 
479 
140 
539 
80 
280 
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Figure A1.18. BLAST data for Al71X insert in pET23d(+)-Construct 2 
Homo sapiens crystallin, alpha B (CRYAB), mRNA 
Length=691 
Score= 1035 bits (522), Expect= 0.0 
Identities= 533/537 (99%), Gaps= 0/537 (0%) 
Strand=Plus/Minus 
Query 108 GGGCATCTATTTCTTGGGAGCTCAGGTGACAGCAGGCTTCTCTTCACGGGTGATGGGAAT 167 
111111111111111111 Ill 111111111111111111111111111111111111 
Sbjct 559 GGGCATCTATTTCTTGGGGGCTGCGGTGACAGCAGGCTTCTCTTCACGGGTGATGGGAAT 500 
Query 168 GGTGCGCTCAGGGCCAGAGACCTGTTTCCTTGGTCCATTCACAGTGAGGACCCCATCAGA 227 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 499 GGTGCGCTCAGGGCCAGAGACCTGTTTCCTTGGTCCATTCACAGTGAGGACCCCATCAGA 440 
Query 228 TGACAGGGATGAAGTAATGGTGAGAGGGTCTACATCAGCTGGGATCCGGTATTTCCTGTG 287 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 439 TGACAGGGATGAAGTAATGGTGAGAGGGTCTACATCAGCTGGGATCCGGTATTTCCTGTG 380 
Query 288 GAACTCCCTGGAGATGAAACCATGTTCATCCTGGCGCTCTTCATGTTTTCCATGCACCTC 347 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 379 GAACTCCCTGGAGATGAAACCATGTTCATCCTGGCGCTCTTCATGTTTTCCATGCACCTC 320 
Query 348 AATCACATCTCCCAACACCTTAACTTTGAGTTCCTCTGGGGAGAAGTGCTTCACATCCAG 407 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 319 AATCACATCTCCCAACACCTTAACTTTGAGTTCCTCTGGGGAGAAGTGCTTCACATCCAG 260 
Query 408 GTTGACAGAGAACCTGTCCTTCTCCAGGCGCATCTCTGAGAGTCCAGTGTCAAACCAGCT 467 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 259 GTTGACAGAGAACCTGTCCTTCTCCAGGCGCATCTCTGAGAGTCCAGTGTCAAACCAGCT 200 
Query 468 GGGTGCCCGCAGGAAGGAGGGTGGCCGAAGGTAGAAGGGACTCANGGAAGTAGACGTCGG 527 
11111111111111111111111111111111111111111111 111111111111111 
Sbjct 199 GGGTGCCCGCAGGAAGGAGGGTGGCCGAAGGTAGAAGGGACTCAGGGAAGTAGACGTCGG 140 
Query 528 GAAAAGATCAGACTCCAACAGGTGCTCTCCGAAGAACTGGTCAAAGAGGCGGCTGGGGGA 587 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 139 GAAAAGATCAGACTCCAACAGGTGCTCTCCGAAGAACTGGTCAAAGAGGCGGCTGGGGGA 80 
Query 588 GTGGAAAGGAAAGAAGGGGCGGCGGATCCAGGGGTGGTGGATGGCGATGTCCATGGT 644 
111111111111111111111111111111111111111111111111111111111 
Sbjct 79 GTGGAAAGGAAAGAAGGGGCGGCGGATCCAGGGGTGGTGGATGGCGATGTCCATGGT 23 
281 
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A1.7 ASSEMBLY OF K174X aD-CRYSTALLIN 
PCR mutagenesis experiments involved the production of the K174X aS-
crystallin mutant insert with 3' A overhangs for subsequent ligation into the pGEM®-T 
Easy vector. The K174X mutant contains a unique Sac!! restriction site upstream to 
the stop codon. DNA from selected transformants was purified and presence of the 
K174X mutation was assessed using an Ncol/Sac!I digest to screen for fragments of 
expected size 514bp (see Figure Al.19.A). Screening suggested that all 12 constructs 
contained the K174X mutant insert. Subsequent sequencing and BLAST analysis of2, 
3, 4, 5 and 11 confirmed constructs 2 and 5 shown in Figure Al.l9.A, lanes 2 and 5 
respectively, contained the K174X mutant insert. 
Construct 2 (see Figure Al.20) was subcloned into pET23d(+) using an 
Ncol/EcoRI digest. The ligation of the K174X mutant insert was assessed using the 
Ncol/Sacll digest on purified constructs to screen for fragments of expected K174X 
insert size of514bp (see Figure Al.19.B). Constructs 1, 2 and 4 indicated the presence 
of a low intensity fragment at 514bp (lanes 2, 3 and 5 respectively see arrow head). 
Subsequent sequencing and BLAST analysis of constructs 1, 2 and 5 confirmed the 
K174X insert had successfully been subcloned into the pET23d(+) vector in construct 
1 with no unwanted sequence changes, (see Figure Al.21). Construct 1 would be used 
for protein expression and subcloning into pcDNA3 .1 (-) vector for transient expression 
in mammalian cells. 
A 
Kl74X insert 
(514bp) .... 
B 
1 2 
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Figure Al.l9. Assembly of K174X aB-crystallin construct using pGEM®-T Easy 
vector system. PCR mutagenesis produced a PCR product of 528bp that was purified 
and ligated into using pGEM®-T Easy vector. The efficiency of the ligation was 
assessed using an Ncol/Sac!I digest screen (A), which suggested all 12 constructs 
contained the K174X insert. Sequencing confirmed constructs 2, and 5 shown in lanes 
2, and 5 respectively contained the K174X mutant insert. Construct 2 (Figure 
A 1.19 .A, lane 2) was subcloned into the pET23d( +) vector. Purified DNA was 
screened (B) using Nco!/Sac!I digestion and suggested the K174X insert was present 
in constructs 1, 2 and 4 shown in lanes 2, 3, and 5 respectively at 514bp. Sequencing 
confirmed constructs 1 contained the K174X insert with no additional mutations, 
therefore were viable for protein expression. DNA ladder f... Pst! (Figure A1.19.A lane 
7; Figure Al.l9.B, lane 1-white circle- 514, 1159 and 2838bp). The overexposure 
through Figure Al.l9.B lane 3 was a function ofBiorad Gel Doc 2000. 
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Figure A1.20. BLAST data for K174X insert in pGEM-T Easy-Construct 2 
Sac li highlighted in bold (CCGCGG) 
Pink - random substituton 
Green- insertion/ deletion 
Red - Wild Type Methionine and wt stop codon 
Blue-SDM mutation 
Underlined -primer sequence 
*= polymorphism 
Homo sapiens crystallin, alpha B (CRYAB), mRNA 
Length=691 
Score= 1019 bits (514), Expect= 0.0 
Identities= 522/525 (99%), Gaps= 0/525 (0%) 
Strand=Plus/Minus 
Query 48 TTCTAGGGGGCCGCGGTGACAGCAGGCTTCTCTTCACGGGTGATGGGAATGGTGCGCTCA 107 
1111 111111 111111111111111111111111111111111111111111111111 
Sbjct 549 TTCTTGGGGGCTGCGGTGACAGCAGGCTTCTCTTCACGGGTGATGGGAATGGTGCGCTCA 490 
Query 108 GGGCCAGAGACCTGTTTCCTTGGTCCATTCACAGTGAGGACCCCATCNGATGACAGGGAT 167 
II I I II I I II II II I I I II I I II II II I II I II II II I I II II I II I I I I I II I II I I I 
Sbjct 489 GGGCCAGAGACCTGTTTCCTTGGTCCATTCACAGTGAGGACCCCATCAGATGACAGGGAT 430 
Query 168 GAAGTAATGGTGAGAGGGTCTACATCAGCTGGGATCCGGTATTTCCTGTGGAACTCCCTG 227 
11111111111111111111111111111111111111 II 11111111111111111111 
Sbjct 429 GAAGTAATGGTGAGAGGGTCTACATCAGCTGGGATCCGGTATTTCCTGTGGAACTCCCTG 370 
Query 228 GAGATGAAACCATGTTCATCCTGGCGCTCTTCATGTTTTCCATGCACCTCAATCACATCT 287 
I I I I I II I I II II II I II II I I I I I I II I II II I I I II II II I I II II II II I II II I II 
Sbjct 369 GAGATGAAACCATGTTCATCCTGGCGCTCTTCATGTTTTCCATGCACCTCAATCACATCT 310 
Query 288 CCCAACACCTTAACTTTGAGTTCCTCTGGGGAGAAGTGCTTCACATCCAGGTTGACAGAG 347 
11111111111111111111111111111111111111111111111111111 II IIIII 
Sbjct 309 CCCAACACCTTAACTTTGAGTTCCTCTGGGGAGAAGTGCTTCACATCCAGGTTGACAGAG 250 
Query 348 AACCTGTCCTTCTCCAGGCGCATCTCTGAGAGTCCAGTGTCAAACCAGCTGGGTGCCCGC 407 
I I I I I I I I I I II II I I I I I I I I I I I I I I I II I I I I I I I I I I I I I I II I II I II I I II II I 
Sbjct 249 AACCTGTCCTTCTCCAGGCGCATCTCTGAGAGTCCAGTGTCAAACCAGCTGGGTGCCCGC 190 
Query 408 AGGAAGGAGGGTGGCCGAAGGTAGAAGGGACTCAGGGAAGTAGACGTCGGGAAAAGATCA 467 
I I I I I I I I I II II I I I I II I II I II I I I I I I I I I I I I II II II I I I I I I I I I I I II I II I 
Sbjct 189 AGGAAGGAGGGTGGCCGAAGGTAGAAGGGACTCAGGGAAGTAGACGTCGGGAAAAGATCA 130 
Query 468 GACTCCAACAGGTGCTCTCCGAAGAACTGGTCAAAGAGGCGGCTGGGGGAGTGGAAAGGA 527 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 129 GACTCCAACAGGTGCTCTCCGAAGAACTGGTCAAAGAGGCGGCTGGGGGAGTGGAAAGGA 70 
Query 528 AAGAAGGGGCGGCGGATCCAGGGGTGGTGGATGGCGATGTCCATG 572 
II I I I I I I I I II I II I II I II I I I I II I I I I I I I I I I I II II I I I 
Sbjct 69 AAGAAGGGGCGGCGGATCCAGGGGTGGTGGATGGCGATGTCCATG 25 
284 
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Figure A1.21. BLAST data for K174X insert in pET23d(+)-Construct 1 
Homo sapiens crystallin, alpha B (CRYAB), mRNA 
Length=691 
Score= 1029 bits (519), Expect 0.0 
Identities= 525/527 (99%), Gaps 0/527 (0%) 
Strand=P1us/Minus 
Query 113 TTCTAGGGGGCCGCGGTGACAGCAGGCTTCTCTTCACGGGTGATGGGAATGGTGCGCTCA 
II II 111111 111111111111111111111111111111111111111111111111 
Sbjct 549 TTCTTGGGGGCTGCGGTGACAGCAGGCTTCTCTTCACGGGTGATGGGAATGGTGCGCTCA 
Query 173 GGGCCAGAGACCTGTTTCCTTGGTCCATTCACAGTGAGGACCCCATCAGATGACAGGGAT 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 489 GGGCCAGAGACCTGTTTCCTTGGTCCATTCACAGTGAGGACCCCATCAGATGACAGGGAT 
Query 233 GAAGTAATGGTGAGAGGGTCTACATCAGCTGGGATCCGGTATTTCCTGTGGAACTCCCTG 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 429 GAAGTAATGGTGAGAGGGTCTACATCAGCTGGGATCCGGTATTTCCTGTGGAACTCCCTG 
Query 293 GAGATGAAACCATGTTCATCCTGGCGCTCTTCATGTTTTCCATGCACCTCAATCACATCT 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 369 GAGATGAAACCATGTTCATCCTGGCGCTCTTCATGTTTTCCATGCACCTCAATCACATCT 
Query 353 CCCAACACCTTAACTTTGAGTTCCTCTGGGGAGAAGTGCTTCACATCCAGGTTGACAGAG 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 309 CCCAACACCTTAACTTTGAGTTCCTCTGGGGAGAAGTGCTTCACATCCAGGTTGACAGAG 
Query 413 AACCTGTCCTTCTCCAGGCGCATCTCTGAGAGTCCAGTGTCAAACCAGCTGGGTGCCCGC 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 249 AACCTGTCCTTCTCCAGGCGCATCTCTGAGAGTCCAGTGTCAAACCAGCTGGGTGCCCGC 
Query 473 AGGAAGGAGGGTGGCCGAAGGTAGAAGGGACTCAGGGAAGTAGACGTCGGGAAAAGATCA 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 189 AGGAAGGAGGGTGGCCGAAGGTAGAAGGGACTCAGGGAAGTAGACGTCGGGAAAAGATCA 
Query 533 GACTCCAACAGGTGCTCTCCGAAGAACTGGTCAAAGAGGCGGCTGGGGGAGTGGAAAGGA 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 129 GACTCCAACAGGTGCTCTCCGAAGAACTGGTCAAAGAGGCGGCTGGGGGAGTGGAAAGGA 
Query 593 AAGAAGGGGCGGCGGATCCAGGGGTGGTGGATGGCGATGTCCATGGT 639 
11111111111111111111111111111111111111111111111 
Sbjct 69 AAGAAGGGGCGGCGGATCCAGGGGTGGTGGATGGCGATGTCCATGGT 23 
-------
--------~-------
172 
490 
232 
430 
292 
370 
352 
310 
412 
250 
472 
190 
532 
130 
592 
70 
285 
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A1.8 SUBCLONING aD-CRYSTALLIN CONSTRUCTS INTO 
THE MAMMALIAN EXPRESSION VECTOR PCDNA3.1(-) 
In order to express the aS-crystallin mutants in mammalian cells by transient 
transfection, the inserts were subcloned from the pET23d(+) bacterial expression 
vector into pcDNA3.1(-) using an Xbal/Hindlll digest. Subsequent screening utilised 
an ApaUHindlll digest, where Apal is unique to the pcDNA3.1(-) vector, thus 
confirming the efficient ligation of the mutant insert, but also the presence of the target 
vector pcDNA3 .1 (-). The multiple cloning region of pcDNA3 .1 (-) is shown in Figure 
A1.3. The screening process for the ligations of each aS-crystallin mutant is shown in 
Figure Al.22. 
The 464delCT screen suggested constructs 1. 2, 4 and 5 (see Figure Al.22.A, 
lanes 1, 2, 5 and 6 respectively) contained the correct mutant insert. Sequencing and 
BLAST analysis of constructs 2, 4 and 5 confirmed that all three constructs contained 
the correct insert with no unwanted sequences when compared for fidelity to the 
GenBank data base entry (accession no. NM001885) for human aS-crystallin. The 
BLAST sequence for construct 2 is shown in Figure Al.23. 
The 450delA screen suggested constructs 1, 3, 4, 5 and 6 (see Figure A1.22.B, 
lanes 1, 3, 5, 6 and 7 respectively) contained the correct mutant insert. Sequencing and 
BLAST analysis of constructs 3 and 4 confirmed that both constructs contained the 
correct insert with no unwanted sequences. The BLAST sequence for construct 3 is 
shown in Figure Al.24. 
The K174X screen suggested constructs 1- 6 (see Figure Al.22.C, lanes 1-3 
and 5-7 respectively) contained the correct mutant insert. Sequencing and BLAST 
analysis of constructs 1-3 confirmed that all constructs contained the correct insert 
with unwanted sequences. The BLAST sequence for construct 1 is shown in Figure 
Al.25. 
The Q151X screen, suggested constructs 1- 6 (see Figure A1.22.D, lanes 1-3 
and 5-7 respectively) contained the correct mutant insert. Sequencing and BLAST 
analysis of constructs 1-3 confirmed that all constructs contained the correct insert 
with no unwanted sequences. The BLAST sequence for construct 1 is shown in Figure 
A 1.26. (The Q151 X mutant insert contains a guanine insertion downstream from the 
stop codon, seen previously in Figure A 1.6, which does not affect the viability of the 
mutant DNA). 
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The E164X screen, suggested constructs 1- 12 (see Figure A1.22.E, lanes 1-3, 
5-10 and 12-14 respectively) contained the correct mutant insert. Sequencing and 
BLAST analysis of constructs 4, 5, 10 and 11 confirmed that all four constructs 
contained the correct insert with no unwanted sequences .. The BLAST sequence for 
construct 4 is shown in Figure A1.27. 
The A171X screen, suggested constructs 2, 3, 4, 7, 10 and 11 (see Figure 
Al.22.F, lanes 2, 3, 5, 8, 12 and 13 respectively) contained the correct mutant insert. 
Sequencing and BLAST analysis of constructs 2, 7, 10 and 11 confirmed that 
constructs 2, 7 and 1 0 contained the correct insert with unwanted sequences. . The 
BLAST sequence for construct 2 is shown in Figure A1.28. 
Finally, the E165X screen, suggested constructs 1-10 and 12 (see Figure 
Al.22.G, lanes 1-6, 8-11 and 13 respectively) contained the correct mutant insert. 
Sequencing and BLAST analysis of constructs 1-5 confirmed that all five constructs 
contained the correct insert with no unwanted sequences. . The BLAST sequence for 
construct 1 is shown in Figure Al.29. 
B 
E 
pcDNA3.1(-) 
(5346bp)-+ 
El64X insert-+ 
(594bp) 
F 
pcDNA3.1(-) 
(5346bpj-+ 
Al71X insert-+ 
(606bp) 
G 
pcDNA3.1(-)-+ 
(5346bp) 
El65X inse~-+ 
(600bp) 
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Figure Al.22. Subcloning of aS-crystallin constructs from pET23d(+) into the vector 
pcDNA3.1(-). Mutant inserts were ligated into pcDNA3.1(-) from pET23d(+) using 
XbaUHind!II restriction digestion. Screening was performed with ApaUHind!II 
digestion where the A pal is specific to pcDNA3 .1 (-). Sequencing identified the 
constructs for each mutant that contained the correct insert with no additional 
mutations, therefore were viable for expression in mammalian cells. DNA ladder J.. 
Pstl -black circle- 514 and 5077bp. 
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Figure A1.23. BLAST data for 464deiCT insert in pcDNA3.1(-)- Construct 2 
Pink - random substituton 
Green - insertion/ deletion 
Red - Wild Type Methionine and wt stop codon 
Blue-SDM mutation 
Underlined -primer sequence 
*= polymorphism 
Homo sapiens crystallin, alpha B (CRYAB), mRNA 
Length=691 
Score= 959 bits (484), Expect= 0.0 
Identities= 493/495 (99~), Gaps= 2/495 (0%) 
Strand=Plus/Plus 
Query 71 ACCATGGACATCGCCATCCACCACCCCTGGATCCGCCGCCCCTTCTTTCCTTTCCACTCC 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 23 ACCATGGACATCGCCATCCACCACCCCTGGATCCGCCGCCCCTTCTTTCCTTTCCACTCC 
Query 131 CCCAGCCGCCTCTTTGACCAGTTCTTCGGAGAGCACCTGTTGGAGTCTGATCTTTTCCCG 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 83 CCCAGCCGCCTCTTTGACCAGTTCTTCGGAGAGCACCTGTTGGAGTCTGATCTTTTCCCG 
Query 191 ACGTCTACTTCCCTGAGTCCCTTCTACCTTCGGCCACCCTCCTTCCTGCGGGCACCCAGC 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 143 ACGTCTACTTCCCTGAGTCCCTTCTACCTTCGGCCACCCTCCTTCCTGCGGGCACCCAGC 
Query 251 TGGTTTGACACTGGACTCTCAGAGATGCGCCTGGAGAAGGACAGGTTCTCTGTCAACCTG 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 203 TGGTTTGACACTGGACTCTCAGAGATGCGCCTGGAGAAGGACAGGTTCTCTGTCAACCTG 
Query 311 GATGTGAAGCACTTCTCCCCAGAGGAACTCAAAGTTAAGGTGTTGGGAGATGTGATTGAG 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 263 GATGTGAAGCACTTCTCCCCAGAGGAACTCAAAGTTAAGGTGTTGGGAGATGTGATTGAG 
Query 371 GTGCATGGAAAACATGAAGAGCGCCAGGATGAACATGGTTTCATCTCCAGGGAGTTCCAC 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 323 GTGCATGGAAAACATGAAGAGCGCCAGGATGAACATGGTTTCATCTCCAGGGAGTTCCAC 
Query 431 AGGAAATACCGGATCCCAGCTGATGTAGACCCTCTCACCATTACTTCATCCCTGTCATCT 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 383 AGGAAATACCGGATCCCAGCTGATGTAGACCCTCTCACCATTACTTCATCCCTGTCATCT 
Query 491 GATGGGGTCCTCACTGTGAATGGACCAAGGAAACAGGTCTCTGGCC--GAGCGCACCATT 
1111111111111111111111111111111111111111111111 111111111111 
Sbjct 443 GATGGGGTCCTCACTGTGAATGGACCAAGGAAACAGGTCTCTGGCCCTGAGCGCACCATT 
Query 549 CCCATCACCCGTGAA 563 
111111111111111 
Sbjct 503 CCCATCACCCGTGAA 517 
130 
82 
190 
142 
250 
202 
310 
262 
370 
322 
430 
382 
490 
442 
548 
502 
289 
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Figure Al.24. BLAST data for 450delA insert in pcDNA3.1(-)- Construct 3 
Homo sapiens crystallin, alpha B (CRYAB), mRNA 
Length=691 
Score= 1203 bits (607), Expect= 0.0 
Identities= 614/615 (99%), Gaps= 1/615 (0%) 
Strand=Plus/Plus 
Query 70 ACCATGGACATCGCCATCCACCACCCCTGGATCCGCCGCCCCTTCTTTCCTTTCCACTCC 129 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 23 ACCATGGACATCGCCATCCACCACCCCTGGATCCGCCGCCCCTTCTTTCCTTTCCACTCC 82 
Query 130 CCCAGCCGCCTCTTTGACCAGTTCTTCGGAGAGCACCTGTTGGAGTCTGATCTTTTCCCG 189 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 83 CCCAGCCGCCTCTTTGACCAGTTCTTCGGAGAGCACCTGTTGGAGTCTGATCTTTTCCCG 142 
Query 190 ACGTCTACTTCCCTGAGTCCCTTCTACCTTCGGCCACCCTCCTTCCTGCGGGCACCCAGC 249 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 143 ACGTCTACTTCCCTGAGTCCCTTCTACCTTCGGCCACCCTCCTTCCTGCGGGCACCCAGC 202 
Query 250 TGGTTTGACACTGGACTCTCAGAGATGCGCCTGGAGAAGGACAGGTTCTCTGTCAACCTG 309 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 203 TGGTTTGACACTGGACTCTCAGAGATGCGCCTGGAGAAGGACAGGTTCTCTGTCAACCTG 262 
Query 310 GATGTGAAGCACTTCTCCCCAGAGGAACTCAAAGTTAAGGTGTTGGGAGATGTGATTGAG 369 
111111111111111111111111111111111111111111111111111 111 111111 
Sbjct 263 GATGTGAAGCACTTCTCCCCAGAGGAACTCAAAGTTAAGGTGTTGGGAGATGTGATTGAG 322 
Query 370 GTGCATGGAAAACATGAAGAGCGCCAGGATGAACATGGTTTCATCTCCAGGGAGTTCCAC 429 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 323 GTGCATGGAAAACATGAAGAGCGCCAGGATGAACATGGTTTCATCTCCAGGGAGTTCCAC 382 
Query 430 AGGAAATACCGGATCCCAGCTGATGTAGACCCTCTCACCATTACTTCATCCCTGTCATCT 489 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 383 AGGAAATACCGGATCCCAGCTGATGTAGACCCTCTCACCATTACTTCATCCCTGTCATCT 442 
Query 490 GATGGGGTCCTCACTGTGAATGGACCAAGG- AACAGGTCTCTGGCCCTGAGCGCACCATT 548 
111111111111111111111111111111 11111111111111111111111111111 
Sbjct 443 GATGGGGTCCTCACTGTGAATGGACCAAGGAAACAGGTCTCTGGCCCTGAGCGCACCATT 502 
Query 549 CCCATCACCCGTGAAGAGAAGCCTGCTGTCACCGCAGCCCCCAAGAAATAGATGCCCTTT 608 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 503 CCCATCACCCGTGAAGAGAAGCCTGCTGTCACCGCAGCCCCCAAGAAATAGATGCCCTTT 562 
Query 609 CTTGAATTGCATTTTTTAAAACAAGAAAGTTTCCCCACCAGTGAATGAAAGTCTTGTGAC 668 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 563 CTTGAATTGCATTTTTTAAAACAAGAAAGTTTCCCCACCAGTGAATGAAAGTCTTGTGAC 622 
Query 669 TAGTGCTGAAGCTTA 683 
111111111111111 
Sbjct 623 TAGTGCTGAAGCTTA 637 
TAA = new stop codon caused by a frameshift due to the 450delA 
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Figure A1.25. BLAST data for K174X insert in pcDNA3.1(-)- Construct 1 
Sac II highlighted in bold (CCGCGG) 
Homo sapiens crystallin, alpha B (CRYAB), mRNA 
Length=691 
score= 1029 bits (519), Expect= 0.0 
Identities= 525/527 (99%), Gaps= 0/527 (0%) 
Strand=Plus/Plus 
Query 71 ACCATGGACATCGCCATCCACCACCCCTGGATCCGCCGCCCCTTCTTTCCTTTCCACTCC 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 23 ACCATGGACATCGCCATCCACCACCCCTGGATCCGCCGCCCCTTCTTTCCTTTCCACTCC 
Query 131 CCCAGCCGCCTCTTTGACCAGTTCTTCGGAGAGCACCTGTTGGAGTCTGATCTTTTCCCG 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 83 CCCAGCCGCCTCTTTGACCAGTTCTTCGGAGAGCACCTGTTGGAGTCTGATCTTTTCCCG 
Query 191 ACGTCTACTTCCCTGAGTCCCTTCTACCTTCGGCCACCCTCCTTCCTGCGGGCACCCAGC 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 143 ACGTCTACTTCCCTGAGTCCCTTCTACCTTCGGCCACCCTCCTTCCTGCGGGCACCCAGC 
Query 251 TGGTTTGACACTGGACTCTCAGAGATGCGCCTGGAGAAGGACAGGTTCTCTGTCAACCTG 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 203 TGGTTTGACACTGGACTCTCAGAGATGCGCCTGGAGAAGGACAGGTTCTCTGTCAACCTG 
Query 311 GATGTGAAGCACTTCTCCCCAGAGGAACTCAAAGTTAAGGTGTTGGGAGATGTGATTGAG 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 263 GATGTGAAGCACTTCTCCCCAGAGGAACTCAAAGTTAAGGTGTTGGGAGATGTGATTGAG 
Query 371 GTGCATGGAAAACATGAAGAGCGCCAGGATGAACATGGTTTCATCTCCAGGGAGTTCCAC 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 323 GTGCATGGAAAACATGAAGAGCGCCAGGATGAACATGGTTTCATCTCCAGGGAGTTCCAC 
Query 431 AGGAAATACCGGATCCCAGCTGATGTAGACCCTCTCACCATTACTTCATCCCTGTCATCT 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 383 AGGAAATACCGGATCCCAGCTGATGTAGACCCTCTCACCATTACTTCATCCCTGTCATCT 
Query 491 GATGGGGTCCTCACTGTGAATGGACCAAGGAAACAGGTCTCTGGCCCTGAGCGCACCATT 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 443 GATGGGGTCCTCACTGTGAATGGACCAAGGAAACAGGTCTCTGGCCCTGAGCGCACCATT 
Query 551 CCCATCACCCGTGAAGAGAAGCCTGCTGTCACCGCGGCCCCCTAGAA 597 
11111111111111111111111111111111111 111111 II II 
Sbjct 503 CCCATCACCCGTGAAGAGAAGCCTGCTGTCACCGCAGCCCCCAAGAA 549 
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Figure A1.26. BLAST data for Q151X insert in pcDNA3.1(-)- Construct 1 
Stu I highlighted in BOLD (AAGCCT) 
Homo sapiens crystallin, alpha B (CRYAB), mRNA 
Length:691 
Score= 1025 bits (517), Expect 0.0 
Identities= 530/533 (99%), Gaps= 1/533 (0%) 
Strand=Plus/Plus 
Query 70 ACCATGGACATCGCCATCCACCACCCCTGGATCCGCCGCCCCTTCTTTCCTTTCCACTCC 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 23 ACCATGGACATCGCCATCCACCACCCCTGGATCCGCCGCCCCTTCTTTCCTTTCCACTCC 
Query 130 CCCAGCCGCCTCTTTGACCAGTTCTTCGGAGAGCACCTGTTGGAGTCTGATCTTTTCCCG 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 83 CCCAGCCGCCTCTTTGACCAGTTCTTCGGAGAGCACCTGTTGGAGTCTGATCTTTTCCCG 
Query 190 ACGTCTACTTCCCTGAGTCCCTTCTACCTTCGGCCACCCTCCTTCCTGCGGGCACCCAGC 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 143 ACGTCTACTTCCCTGAGTCCCTTCTACCTTCGGCCACCCTCCTTCCTGCGGGCACCCAGC 
Query 250 TGGTTTGACACTGGACTCTCAGAGATGCGCCTGGAGAAGGACAGGTTCTCTGTCAACCTG 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 203 TGGTTTGACACTGGACTCTCAGAGATGCGCCTGGAGAAGGACAGGTTCTCTGTCAACCTG 
Query 310 GATGTGAAGCACTTCTCCCCAGAGGAACTCAAAGTTAAGGTGTTGGGAGATGTGATTGAG 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 263 GATGTGAAGCACTTCTCCCCAGAGGAACTCAAAGTTAAGGTGTTGGGAGATGTGATTGAG 
Query 370 GTGCATGGAAAACATGAAGAGCGCCAGGATGAACATGGTTTCATCTCCAGGGAGTTCCAC 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 323 GTGCATGGAAAACATGAAGAGCGCCAGGATGAACATGGTTTCATCTCCAGGGAGTTCCAC 
Query 430 AGGAAATACCGGATCCCAGCTGATGTAGACCCTCTCACCATTACTTCATCCCTGTCATCT 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 383 AGGAAATACCGGATCCCAGCTGATGTAGACCCTCTCACCATTACTTCATCCCTGTCATCT 
Query 490 GATGGGGTCCTCACTGTGAATGGACCAAGGAAATAGGCCTCTGGCCCTGAGCGGCACCAT 
111111111111111111111111111111111 Ill 11111111111111 1111111 
Sbjct 443 GATGGGGTCCTCACTGTGAATGGACCAAGGAAACAGGTCTCTGGCCCTGAGC - GCACCAT 
Query 550 TCCCATCACCCGTGAAGAGAAGCCTGCTGTCACCGCAGCCCCCAAGAAATAGA 602 
11111111111111111111111111111111111111111111111111111 
Sbjct 502 TCCCATCACCCGTGAAGAGAAGCCTGCTGTCACCGCAGCCCCCAAGAAATAGA 554 
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Figure A1.27. BLAST data for E164X insert in pcDNA3.1(-)- Construct 4 
Pst I highlighted in bold (CTGCAG) 
Homo sapiens crystallin, alpha B (CRYAB), mRNA 
Length=691 
Score= 1021 bits (515), Expect = 0.0 
Identities= 524/527 (99%), Gaps= 0/527 (0%) 
Strand=Plus/Plus 
Query 62 ACCATGGACATCGCCATCCACCACCCCTGGATCCGCCGCCCCTTCTTTCCTTTCCACTCC 121 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 23 ACCATGGACATCGCCATCCACCACCCCTGGATCCGCCGCCCCTTCTTTCCTTTCCACTCC 82 
Query 122 CCCAGCCGCCTCTTTGACCAGTTCTTCGGAGAGCACCTGTTGGAGTCTGATCTTTTCCCG 181 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 83 CCCAGCCGCCTCTTTGACCAGTTCTTCGGAGAGCACCTGTTGGAGTCTGATCTTTTCCCG 142 
Query 182 ACGTCTACTTCCCTGAGTCCCTTCTACCTTCGGCCACCCTCCTTCCTGCGGGCACCCAGC 241 
11111111111111111111111111 111111 1111111111111111111111111111 
Sbjct 143 ACGTCTACTTCCCTGAGTCCCTTCTACCTTCGGCCACCCTCCTTCCTGCGGGCACCCAGC 202 
Query 242 TGGTTTGACACTGGACTCTCAGAGATGCGCCTGGAGAAGGACAGGTTCTCTGTCAACCTG 301 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 203 TGGTTTGACACTGGACTCTCAGAGATGCGCCTGGAGAAGGACAGGTTCTCTGTCAACCTG 262 
Query 302 GATGTGAAGCACTTCTCCCCAGAGGAACTCAAAGTTAAGGTGTTGGGAGATGTGATTGAG 361 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 263 GATGTGAAGCACTTCTCCCCAGAGGAACTCAAAGTTAAGGTGTTGGGAGATGTGATTGAG 322 
Query 362 GTGCATGGAAAACATGAAGAGCGCCAGGATGAACATGGTTTCATCTCCAGGGAGTTCCAC 421 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 323 GTGCATGGAAAACATGAAGAGCGCCAGGATGAACATGGTTTCATCTCCAGGGAGTTCCAC 382 
Query 422 AGGAAATACCGGATCCCAGCTGATGTAGACCCTCTCACCATTACTTCATCCCTGTCATCT 481 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 383 AGGAAATACCGGATCCCAGCTGATGTAGACCCTCTCACCATTACTTCATCCCTGTCATCT 442 
482 GATGGGGTCCTCACTGTGAATGGACCAAGGAAACAGGTCTCTGGCCCTGAGCGCACCATT 541 
111111111111111111111111111111111111111111111111111111-ll-ll-ll 
Query 
Sbjct 443 GATGGGGTCCTCACTGTGAATGGACCAAGGAAACAGGTCTCTGGCCCTGAGCGCACCATT 502 
Query 542 CCCATCACCCGTTAAGAGAAGCCTGCAGTCACCGCAGCTCCCAAGAA 588 
111111111111 1111111111111 11111111111 11111111 
Sbjct 503 CCCATCACCCGTGAAGAGAAGCCTGCTGTCACCGCAGCCCCCAAGAA 549 
293 
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Figure A1.28. BLAST data for Al71X insert in pcDNA3.1(-)- Construct 2 
Sac I highlighted in bold (GAGCTC) 
Homo sapiens crystallin, alpha B (CRYAB), mRNA 
Length=691 
Score= 1041 bits (525), Expect= 0.0 
Identities= 534/537 (99%), Gaps= 0/537 (0%) 
Strand=Plus/Plus 
Query 63 ACCATGGACATCGCCATCCACCACCCCTGGATCCGCCGCCCCTTCTTTCCTTTCCACTCC 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 23 ACCATGGACATCGCCATCCACCACCCCTGGATCCGCCGCCCCTTCTTTCCTTTCCACTCC 
Query 123 CCCAGCCGCCTCTTTGACCAGTTCTTCGGAGAGCACCTGTTGGAGTCTGATCTTTTCCCG 
111111111111111111111111111111111111111111111111111111111111 
sbjct 83 CCCAGCCGCCTCTTTGACCAGTTCTTCGGAGAGCACCTGTTGGAGTCTGATCTTTTCCCG 
Query 183 ACGTCTACTTCCCTGAGTCCCTTCTACCTTCGGCCACCCTCCTTCCTGCGGGCACCCAGC 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 143 ACGTCTACTTCCCTGAGTCCCTTCTACCTTCGGCCACCCTCCTTCCTGCGGGCACCCAGC 
Query 243 TGGTTTGACACTGGACTCTCAGAGATGCGCCTGGAGAAGGACAGGTTCTCTGTCAACCTG 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 203 TGGTTTGACACTGGACTCTCAGAGATGCGCCTGGAGAAGGACAGGTTCTCTGTCAACCTG 
Query 303 GATGTGAAGCACTTCTCCCCAGAGGAACTCAAAGTTAAGGTGTTGGGAGATGTGATTGAG 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 263 GATGTGAAGCACTTCTCCCCAGAGGAACTCAAAGTTAAGGTGTTGGGAGATGTGATTGAG 
Query 363 GTGCATGGAAAACATGAAGAGCGCCAGGATGAACATGGTTTCATCTCCAGGGAGTTCCAC 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 323 GTGCATGGAAAACATGAAGAGCGCCAGGATGAACATGGTTTCATCTCCAGGGAGTTCCAC 
Query 423 AGGAAATACCGGATCCCAGCTGATGTAGACCCTCTCACCATTACTTCATCCCTGTCATCT 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 383 AGGAAATACCGGATCCCAGCTGATGTAGACCCTCTCACCATTACTTCATCCCTGTCATCT 
Query 483 GATGGGGTCCTCACTGTGAATGGACCAAGGAAACAGGTCTCTGGCCCTGAGCGCACCATT 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 443 GATGGGGTCCTCACTGTGAATGGACCAAGGAAACAGGTCTCTGGCCCTGAGCGCACCATT 
Query 543 CCCATCACCCGTGAAGAGAAGCCTGCTGTCACCTGAGCTCCCAAGAAATAGATGCCC 599 
111111111111111111111111111111111 Ill 111111111111111111 
Sbjct 503 CCCATCACCCGTGAAGAGAAGCCTGCTGTCACCGCAGCCCCCAAGAAATAGATGCCC 559 
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Figure A1.29. BLAST data for E165X insert in pcDNA3.1(-)- Construct 1 
Hind Ill is highighted in BOLD (AAGCTT) 
Homo sapiens crystallin, alpha B (CRYAB), mRNA 
Length=691 
Score= 979 bits (494), Expect= 0.0 
Identities= 500/502 (99%), Gaps= 0/502 (0%) 
Strand=Plus/Plus 
Query 17 ACCATGGACATCGCCATCCACCACCCCTGGATCCGCCGCCCCTTCTTTCCTTTCCACTCC 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 23 ACCATGGACATCGCCATCCACCACCCCTGGATCCGCCGCCCCTTCTTTCCTTTCCACTCC 
Query 77 CCCAGCCGCCTCTTTGACCAGTTCTTCGGAGAGCACCTGTTGGAGTCTGATCTTTTCCCG 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 83 CCCAGCCGCCTCTTTGACCAGTTCTTCGGAGAGCACCTGTTGGAGTCTGATCTTTTCCCG 
Query 137 ACGTCTACTTCCCTGAGTCCCTTCTACCTTCGGCCACCCTCCTTCCTGCGGGCACCCAGC 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 143 ACGTCTACTTCCCTGAGTCCCTTCTACCTTCGGCCACCCTCCTTCCTGCGGGCACCCAGC 
Query 197 TGGTTTGACACTGGACTCTCAGAGATGCGCCTGGAGAAGGACAGGTTCTCTGTCAACCTG 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 203 TGGTTTGACACTGGACTCTCAGAGATGCGCCTGGAGAAGGACAGGTTCTCTGTCAACCTG 
Query 257 GATGTGAAGCACTTCTCCCCAGAGGAACTCAAAGTTAAGGTGTTGGGAGATGTGATTGAG 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 263 GATGTGAAGCACTTCTCCCCAGAGGAACTCAAAGTTAAGGTGTTGGGAGATGTGATTGAG 
Query 317 GTGCATGGAAAACATGAAGAGCGCCAGGATGAACATGGTTTCATCTCCAGGGAGTTCCAC 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 323 GTGCATGGAAAACATGAAGAGCGCCAGGATGAACATGGTTTCATCTCCAGGGAGTTCCAC 
Query 377 AGGAAATACCGGATCCCAGCTGATGTAGACCCTCTCACCATTACTTCATCCCTGTCATCT 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 383 AGGAAATACCGGATCCCAGCTGATGTAGACCCTCTCACCATTACTTCATCCCTGTCATCT 
Query 437 GATGGGGTCCTCACTGTGAATGGACCAAGGAAACAGGTCTCTGGCCCTGAGCGCACT*ATT 
11111111111111111111111111111111111111111111111111111111 -Ill 
Sbjct 443 GATGGGGTCCTCACTGTGAATGGACCAAGGAAACAGGTCTCTGGCCCTGAGCGCACC*ATT 
Query 497 CCCATCACCCGTGAA~AGAAGC 518 
111111111111111 111111 
Sbjct 503 CCCATCACCCGTGAAGAGAAGC 524 
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APPENDIX2 
CALIBRATION OF ANALYTICAL SEC COLUMN AND 
MOLECULAR WEIGHT DETERMINATION OF 
aB-CRYSTALLIN MUTANTS FOR CHAPTER 4 
(SECTION 4.3.1). 
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A2.1 CALIBRATION OF SUPEROSE 6 ANALYTICAL SEC 
COLUMN 
The SEC calibrator profiles are shown in Figure A2.1 (A-H). The retention 
times were used to generate a calibration curve (see Figure A2.2), from which the Mwt of 
each aB-crystallin mutant was calculated, (see Chapter 4.3. 1, Table 4.2). 
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Figure A2.1 The SEC calibrator profiles for calibration of the analytical SEC column. A 
range of calibrators, from the low Mwt Cytochrome C at 12 kDa (B), to the high Mwt 
Thyroglobulin at 669 kDa (G). The void volume of the SE column was determined 
using Dextran at 2000 k.Da (A) . The separation range of the column was determined using 
ATP (H). 
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A2.2 MOLECULAR WEIGHT DETERMINATION OF aB-CRYSTALLIN 
MUTANTS 
A calibration curve of Kav versus log molecular weight was prepared using the 
data from Figure A2.1 and the following equation: 
Kav Ye- Y0 
= 
Where Ye =elution volume as retention time, Y0 =column void volume, Yc =geometric 
column volume. 
Separate calibration curves of low Mwt ca librators (see Figure A2.2.A) and high 
Mwt calibrators (see Figure A2.2.B) were prepared to allow accurate Mwt determination 
for aB-crystallin mutants with retention times at both the low and high range of 
calibration. 
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Figure A2.2. SEC calibration curves for Mwt determination. The calibration curves of 
low Mwt calibrators (A) and high Mwt calibrators (B) are shown with a linear trendline. 
The equations required for calculations of unknown Mwt aB-crystallin mutants at both the 
low range (A) and high range (B) are shown. 
The aB-crystallin mutants Mwt were calculated, using the appropriate curve for the 
resulting retention time. For example. for mutants with retention times between 30-72 
min the high Mwt calibration curve was used and retention times between 72- 93 min the 
low Mwt calibration curve was used (see Chapter 4, Section 4.3.1). 
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APPENDIX3 
CHAPERONE ASSAY DATA SETS FOR CHAPTER 4 
(SECTION 4.3.4) 
302 
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A3.1 CITRATE SYNTHASE ASSAY TRIPLICATE DATA SETS 
FOR FIGURE 4.7 
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Figure A3.1. Triplicate data set of Citrate synthase assays. The three data sets were 
averaged to produce Figure 4.7 A and B 
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Table A3.1. Inhibition data for the Citrate Synthase assay. The percentage inhibition for 
assays A, B and C from Figure A3.1 A, B and C respectively, are detailed with the 
subsequent average and standard deviations used in Figure 4.7B. 
Inhibition (%) Standard Average 
aB-crystall in Deviation Inhibition Assa~ A Assa):: B Assa~ C {%} 
Wild Type 100% 100% 100% 0% 100% 
450delA/ Wild Type 525% 719% 632% 97% 625% 
464delCT/ Wild Type 113% 347% 188% 119% 216% 
QISIX/ Wild Type 1181% 1437% 1172% 150% 1263% 
Q151X 641% 924% 702% 149% 755% 
E164X -11% -86% -75% 40% -57% 
E165X 178% 418% 342% 123% 313% 
K174X 327% 717% 423% 203% 489% 
A171X 416% 678% 501% 134% 532% 
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A3.2 INSULIN ASSAY TRIPLICATE DATA SETS FOR FIGURE 
4.8 
A fl6 
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Figure A3.2. Triplicate data set of Insulin assays. The three data sets were averaged to 
produce Figure 4.8A and B. 
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Table A3.2. Inhibition data for the Insulin assay. The percentage inhibition for assays A, 
B and C from Figure A3.2 A, B and C respectively, are detailed with the subsequent 
average and standard deviations used in Figure 4.8B. 
Inhibition(%) Standard Average 
aB-crystall in Deviation Inhibition Assa~ A Assa~ B Assa~ C {%} 
Wild Type 100% 100% 100% 0% 100% 
450de!A/ Wild Type 62% 71% 70% 5% 68% 
464delCT/ Wild Type 81% 76% 76% 2% 78% 
Ql51X/ Wild Type 42% 43% 56% 8% 47% 
QI51X -57% -44% -34% 11% -45% 
EI64X -131% -154% -130% 14% -138% 
E165X -10% -12% -1% 6% -8% 
K174X 93% 92% 94% 1% 93% 
A171X 95% 92% 92% 2% 93% 
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APPENDIX4 
CHARACTERISATION OF THE NATURE OF THE 93 MIN 
PEAK RESOLVED DURING ANALYTICAL SEC OF 
aD-CRYSTALLIN FOR CHAPTER 6 (SECTION 6.3.1). 
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A4.1 THE NATURE OF THE 93 MIN PEAK MATERIAL 
The investigation of the effect of aS-crystallin concentration upon 
oligomerisation involved the use of a Superose 6 SEC column with a Merck Hitachi 
HPLC system with injection valve. Initial experiments identified a peak, which appeared 
consistently at the end of the 93.3 min separation range of the column but showed 
variations in peak heights. Blank runs with various buffers including Tris, ammonium 
acetate and sodium phosphate all identified the 93 min peak, confirming it was not caused 
by a buffer component. 
The potential interaction of aS-crystallin with the column matrix was assessed 
by using the SEC protocol shown in Figure 5.1 under conditions of 1M NaCl (see Figure 
A4.1 ). This involved SEC analysis of 500~g wild type aS-crystallin at 2 mg/ml to isolate 
the oligomeric species, which was then reinjected onto the SEC for subsequent analysis. 
This was repeated for a total of four cycles to allow the identification of any 93 min peak 
material. This data also provided a comparable data set for the effect of aS-crystallin 
concentration upon oligomerisation shown in Figure 5.1. 
Figure A4. I confirms that the high ionic strength does not prevent the presence of 
the 93 min peak, which is present in all four cycles of SEC. The oligomer peak in cycle 4 
shifted slightly indicated by a larger retention time similar to the shift shown in Figure 5.1. 
The wild type aS-crystallin also appears more polydisperse in cycle 3 (approx 0.1 mg/ml) 
(see Figure A4.1 C), which is similar to the polydispersity shown in Figure 5.1 C. 
The peak height of the 93 min peak is variable and is not proportional to the 
amount of aS-crystallin applied as the 93 min peak in cycle 4 (approx 0.01 mg/ml) has a 
height of 0.524 mA.U compared to 0.296 mA.U. observed in cycle 2 (approx 0.5 mg/ml) 
(see Table A4.1). 
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Figure A4.1. The effect of decreasing concentration upon the oligomerisation of wild type 
aB-crystallin under conditions of 1M NaCI. Wild type aB-crystallin at 2 mg/ml was 
analysed by analytical SEC (A) and the fraction collected between 55-60 min was 
recycled over the SEC column for a further 3 cycles (B-C) in order to see the effect of 
dilution upon the oligomerisation characteristics. The SEC were performed in 1M NaCl 
in order to determine whether the presence of the 93 min peak was a product of 
hydrophobic interactions with the column matrix. 
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Table A4.1. Integration data for Figure A4.1. 
Cycle Time (min) Height (rnA. U) Peak Area (%) 
Cycle! 57.331 271.505 99.68 
93.678 0.734 0.22 
105.894 0.299 0.1 
Cycle 2 58.222 49.503 99.57 
93.966 0.296 0.43 
Cycle3 58.909 9.754 84.91 
81.565 0.505 7.64 
92.771 0.39 4.21 
103.513 0.305 3.24 
Cycle4 59.38 1.683 31.74 
93.907 0.524 15.85 
123.911 0.519 52.41 
With the consistent appearance of the 93 min peak, the question still remaining 
was whether the 93 min peak was in fact aD-crystallin and was due to increased subunit 
dynamics induced by decreasing aD-crystallin concentration. 
The presence of the 93 min peak in blank runs of the aS-crystallin solvent 
(lOmM Tris-HCI, lmM EGTA, 5mM EDTA, 150mM NaCl, pH7.5 and in blank runs of 
0.2M ammonium acetate and IOmM sodium phosphate, pH7.0 suggest that it is not caused 
by buffer components, therefore could it be due to aS-crystallin carry over in between 
runs. 
In order to determine the nature of the 93 min peak, the SEC column was 
sanitised and underwent extensive equilibration for 72 h, after which 5 consecutive blank 
runs were performed prior to separation of the wild type aD-crystallin (2 mg/ml) (pre aB-
crystallin blanks). Following separation a further blank was performed (post aS-crystallin 
blank) and the appropriate fractions encompassing the 93 min peak were probed for aD-
crystallin (see Figure A4.2). The first blank shows the greatest peak height of 2.5 mA.U 
(see Figure A4.2A, Table A4.2) following the equilibration, and declines to a consistent 
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height of approx 0.15 mA.U for blanks 2-5 (see Figure A4.2S-E, Table A4.2). On 
application of wild type aS-crystallin (see Figure A4.2F) the peak height is 2.2 rnA. U and 
there is an additional peak resolved at I 00.6 min, which is similar to blank 5 which also 
showed a peak of retention time of 103.5 min. The post wild type blank (see Figure 
A4.2G) also shows the two peaks and the 93 min peak has a peak height of 0.2 mA.U. 
TI1e 93 min peak fractions from all the blanks and the wild type SEC were probed for the 
presence of aS-crystallin, along with the oligomer peak produced in Figure A4.2F. 
Figure A4.2H (lanes 2-6) showed that there was no aS-crystallin in the 93 min peak 
material for blanks 1-5 (see Figure A4.2A-E). The aB-crystallin present in the oligomer 
peak was represented by a strong band in lane 7, and fractions encompassing 90-105 min 
(lanes 8-1 0 respectively) clearly indicate the presence of aS-crystallin as do 90-1 05 min 
fractions for the post wild type blank (lanes 11-13 respectively). The interesting point is 
that although blank 1 has a greater peak height of2.5 mA.U compared to 2.2 mA.U for the 
wild type 93min peak, there is no aS-crystallin signal. The post wild type blank (lanes 
11-13) with a peak height of 0.2 mA.U (see Figure A4.2G), despite being a tenth of the 
size of the 93 min peak in blank 1 shows a weak aB-crystallin signal. Therefore, it seems 
that the 93 min peak is not representative of protein, as it is consistently in blanks where 
there is no protein present in the system. The size of the 93 min peak also shows random 
variability in peak height independent to the type of mobile phase in use, therefore suggest 
that it is a function of the instrument and not biological in nature. The presence of aB-
crystallin in fractions 90-105 min (see Figure A4.3H, lanes 8-1 0) confirms that there is the 
presence of a low molecular weight aB-crystallin complex past the separation range of the 
column, however it is not represented by the 93 min peak resulting from the Absorbance 
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data. The calibrated SEC column gives a retention time of 87.2 min for 12 kDa 
Cytochrome C (see Appendix 2). 
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Figure A4.2. Analysis of the 93 min peak of the Superose 6 SEC analytical column. A 
total of 5 blanks runs (A-E) were performed prior to analysis of the wild type aB-
crystallin (F) using lOmM Tris-HCl, lmM EGTA, 5mM EDTA, 150mM NaCl, pH7.5. A 
post wild type blank was performed (G). Appropriate fractions were probed for aB-
crystallin (H). 
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Table A4.2. Relative peak heights of93 min peaks from Figure A4.2 
Run Peak height (mA.U) 
Blank 1 2.50 
Blank 2 0.22 
Blank 3 0.15 
Blank4 0.16 
Blank 5 0.15 
Wild type aS-crystallin 2.20 
Post wild type Blank 1 0.20 
The 93 min peak appears to be a function of the HPLC instrument, and the point 
at which irregularities could most likely be introduced would be the injection valve. 
Therefore, the effect of the injection valve upon the presence of the peak was investigated 
(see Figure A4.3). A blank run was performed with and without physical injection of 
buffer (see Figure A4.3A and B respectively). The blank run without injection showed a 
steady decline of A280 over the 120 min time course, however once the injection was 
introduced the 93 min peak was again evident. There was no aS-crystallin present in the 
93 min peak ofthe blank (see Figure A4.3D, lanes 4-6) as confirmed by immunoblotting, 
but was obvious in the equivalent fractions for the wild type aS-crystallin (see Figure 
A4.3D, lanes 8-1 0). This result was reproducible for alternative injection valves. 
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Figure A4.3. The effect ofthe injection upon the presence ofthe 93 min peak. A blank 
run was performed without injection (A) by turning of the valve and a second blank was 
injected (B). The wild type aS-crystallin was analysed (C) and fractions from the runs A-
C were probed for aS-crystallin (D). Both blanks show no evidence of aS-crystallin 
despite the peak height of the 93 min peak for run B being above the level of sensitivity 
required for immunoblotting detection. The presence of aS-crystallin in 90-105 min 
fractions is evident in lanes 8-10 (D). 
Therefore, I can conclude that the 93 min peak is an artefact introduced by 
injection of sample into the injection valve and interferes with the UV detection because 
of the level of sensitivity at which the experiments are performed. The immunoblotting of 
SEC fractions of wild type aS-crystallin show that there was resolution of an unknown 
aS-crystallin species past the separation range of the column. 
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APPENDIX5 
DEVELOPMENT OF AN aB-CRYST ALLIN ELISA ASSAY 
FOR THE DETECTION AND QUANTITATION OF SEC 
FRACTIONS FROM CHAPTER 5 
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A5.1 DEVELOPMENT OF AN a.B-CRYSTALLIN ELISA 
The development of this assay was carried with the help and support of 
ImmunoDiagnostics Limited. The development aimed to produce a sandwich assay rather 
than a competitive assay, where two antibodies bind to epitopes that do not overlap on the 
antigen. This can be accomplished with either two monoclonal antibodies that recognise 
discrete sites or one batch of affinity purified poly clonal antibodies or one monoclonal and 
one polyclonal antibody for the same antigen. 
The capture antibody is bound to the solid phase, after which the antigen is added 
and allowed to complex with the bound antibody. The detection antibody, conjugated to 
an enzyme completes the sandwich and the assay is quantitated by measuring the amount 
of labelled detection antibody bound to the matrix through the use of a colourimetric 
substrate. 
The major advantage of this format is that the antigen does not require prior 
purification and the assays are very specific, however not all antibodies can be used. 
Monoclonal antibody combinations must be qualified as matched pairs meaning they can 
recognise separate epitopes on the antigen so they do not hinder each other's binding. 
(Chemicon Technical information-Introduction to Antibodies-ELISA 
http://www.chemicon.com/resource/ANT101/a2C.asp). The assay format is illustrated in 
Figure AS. I. 
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Sandwich ELISA 
Figure A5.1. A typical sandwich ELISA assay. The capture antibody is bound to the 
microtitre plate well and complexed with the antigen. The antigen is quantitated using a 
second antibody labelled with enzyme for detection using a colourimetric substrate. 
(Figure taken from Chemicon Technical information-Introduction to Antibodies - ELISA 
http://www.chemicon.com/resource/ANT101/a2C.asp) 
In order to develop a highly sensitive and reliably accurate ELISA, a series of 
optimisation experiments were performed looking at a number of criteria. These 
conditions can be separated into five categories: 
(I) Assay type, including the simultaneous assay, where the antigen and 
conjugate are simultaneously placed in contact with the antibody. The 
second assay was the split assay, which typically is of greater sensitivity 
as the antigen is incubated with the antibody prior to addition of the 
conjugate and both components are present in twice the volume as those 
seen in the simultaneous assay simply due to the limitations of well size. 
(II) Coating antibody, Both the aB-crystallin Mab and Pab were coated onto 
96-well plates to allow analysis of both combinations 
(III) Conjugated antibody, Both the aB-crystallin Mab and Pab were 
conjugated to analyse the quality of aB-crystallin detection with both 
combinations 
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(IV) Type of conjugate, Both Biotinylation and HRP conjugation were carried 
out with both the Mab and the Pab to investigate the best assay 
combinations. 
(V) Concentration of plate coat antibody, two sets of plates for each antibody 
were prepared at 2 and 5 mg/L to optimise the sensitivity of the assay. 
Optimisation of the assay conditions and of the combinations of the different 
assay components were aiming to produce a high quality reliable and sensitive a.B-
crystallin ELISA. 
AS.l.l Purification and conjugation of aB-crystallin Mab and Pab 
The culture and harvest of Hybridoma cells, expressing a.B-crystallin Mab 2D2B6 
clone of a.B-crystallin produced 180 ml of cell supernatant, which was subsequently 
purified on a PROSEP® G Mfinity chromatography column (10 x lOOmm Omnifit). The 
amount of purified Mab recovered was 20.1 mg (determined by A280), however losses 
occurred following the spin concentration to 1 mg/ml, resulting in a final yield of 14.5 mg. 
The a.B-crystallin Pab was a rabbit polyclonal antibody, clone 3148 generated to 
the C-terminal decapeptide KP A VT AAPKK. A I ml aliquot was purified by ammonium 
sulphate precipitation and PD-1 0 purification resulting in 6.6 mg at a stock concentration 
of 1 mg/ml. 
For ELISA development, both Biotin and HRP conjugates of the Mab were to be 
prepared. Biotinylated and HRP conjugated Mab were produced at a stock concentration 
of 25 !!g/ml. 
Appendix 5 319 
A5.1.2 Titration of aD-crystallin Mab and Pab HRP conjugates 
In order to find the optimal conditions for aB-crystallin detection and quantitation 
a titration of aB-crystallin Mab and Pab HRP conjugates from 125ng/ml to lOOOng/ml 
was performed. The antigen used was purified aB-crystallin wild type, which was used to 
produce a calibration curve ranging from 0-100 ng/ml. Other variables used are the 
concentration of antibody coated on the plate, (2mg/L and 5mg/L) and the type of capture 
antibody (Mab or Pab aB-crystallin). The final variable was the type of ELISA utilised, 
(Split or simultaneous assay). 
In order to investigate the success of the assay under all the conditions, 8 assays 
were carried out and included: 
Assay 1: Simultaneous assay - Mab capture (2 g/L )-Pab:HRP detection 
Assay 2: Simultaneous assay- Mab capture (5 giL)- Pab:HRP detection 
Assay 3: Split assay - Mab capture (2 giL)- Pab:HRP detection 
Assay 4: Split assay - Mab capture (5 giL)- Pab:HRP detection 
Assay 5: Simultaneous assay - Pab capture (2 giL)- Mab:HRP detection 
Assay 6: Simultaneous assay- Pab capture (5 giL)- Mab:HRP detection 
Assay 7: Split assay - Pab capture (2 giL)- Mab:HRP detection 
Assay 8: Split assay - Pab capture (5 g/L)- Mab:HRP detection 
The results for the Pab HRP detection are shown in Figure A5.2 and for Mab HRP 
detection in Figure A5.3. 
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Figure A5.2. Titration Pab HRP conjugates on plates wjth 0-100 ng/ml aB-crystallin. 
Assay 1 and 2 (A and B respectively) are simultaneous assays using Mab capture and Pab: 
HRP detection with 2 g/L (A) or 5 giL (B) capture antibody. Assay 3 and 4 (C and D 
respectively) are split with 2 giL (C) or 5 giL (D) capture antibody. 
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Figure A5.3. Titration ofMab HRP conjugates on plates with 0-100 ng/rnl aB-crystallin. 
Assay 5 and 6 (A and B respectively) are simultaneous assays using Pab capture and Mab: 
HRP detection wjth 2 giL (A) or 5 giL (B) capture antibody. Assay 7 and 8 ( and D 
respectively) are split with 2 giL (C) or 5 giL (D) capture antibody. 
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The relative signal achieved using the 2 mg/L and 5 mg/L capture antibody 
concentration is comparable for assays using the same conjugate. Figures A5.3A and Cat 
2 g/L compared with Figure A5.2 S and D at 5 giL, illustrate the similarities in signal 
between the split and simultaneous assay where the 1000 ng/ml Poly HRP achieves an 
A.U value of approx 0.75 A.U. This pattern is also observed for the Mab HRP titration 
(see Figure A5.3), however, the 1000 ng/ml Mab HRP achieves a signal of approx 4.0 
A. U suggesting that using the Pab as a capture antibody produces an assay of significantly 
greater sensitivity than the Mab capture antibody. Utilising the split assay can increase 
the sensitivity of the Mab capture assay from 0.75 A.U to approx 2.0 A.U (see Figure 
A5.2 C and D), however still remains significantly lower in sensitivity to the Pab capture 
assay (see Figures A5.3C and D). Additionally, the Mab capture also results in a 
relatively higher level of non-specific binding confirmed by similar A.U values for the 0 
nglml and 1 ng/ml aS-crystallin. 
So far the optimisation had identified the 2 giL Pab capture as the most sensitive 
assays for the aS-crystallin detection (see Figures A5.3 A and C). Assays 5 and 7 suggest 
the optimal level of Mab: HRP conjugate is 250 ng/ml in the simultaneous assay. This 
combination produces a signal range up to 2.0 A.U for detection of 100 ng/ml aS-
crystallin. Any signal above 2.0 A.U cannot be considered as reliable data. The 125 
ng/mi of Mab :HRP although providing a detection range under 2.0 A.U only achieves 1.0 
AU in the simultaneous assay (see Figure A5.3A) and 1.50 A.U in the split assay (see 
Figure A5.3C), thus not maximising the potential detection range. The simultaneous 
assay appears to be the optimal assay format, compared with the split assay where, a 250 
nglml Mab: HRP signal achieves an output of 2.60 A.U for 100 ng/ml aS-crystallin 
detection thus is out of range. The split assay also shows a lower level of sensitivity for 
the detection of low concentrations of aS-crystallin between 1-10 ng/ml (see Figure 
A5.3C). 
The optimised assay conditions for the detection of aB-crystallin at levels between 
1 OOng/ml - 1.27ng/ml utilises a 2 mg/L Poly capture with a 250 ng/ml Mab: HRP 
conjugate detection in a Simultaneous assay. 
A5.1.2.1 
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Initial assessment of relative sensitivity between Mab: HRP and 
Mab:Biotin detection of aB-crystallin 
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An initial assay was performed to assess the relative difference in sensitivity of the 
Mab: HRP and Mab: Biotin assays, by varying the Mab: Biotin concentrations whilst 
looking at various A vi din: HRP concentrations. This was aiming to give an initial 
assessment of the sensitivity achieved using biotinylated Mab (see Figure A5.4). 
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Figure A5.4. The specific signal of a Poly capture assay with titrated Mab Biotin and Av-
HRP levels. To assess the relative sensitivity of Biotin conjugated Mab and HRP, this 
assay analysed 500 ng/ml-2000 ng/ml Mab Biotin at two levels of Av-HRP, 125 ng/ml 
and 250 ng/ml. 
The Assay utilised a 2 mg!L Poly coated plate with the simultaneous assay 
method. The absorbance readings shown in Figure A5.4 are above 2.0 A.U suggesting the 
Mab: Biotin levels used are too high resulting in an assay with greater sensitivity than is 
required for detection of aB-crystallin. The variation of A vidin-HRP concentration does 
not significantly affect the signal achieved. Reduction of the Mab: Biotin concentration 
and utilisation of a 250 ng/ml Av-HRP solution where 50% is unlabelled Avidin to 50% 
labelled Avidin HRP should result in a lower sensitivity ofthe assay. 
This initial assessment of the Biotin sensitivity allowed the comparison of 
absorbance achieved with 500 ng/ml Mab Biotin (see Figure A5.4) and Mab HRP (see 
Figure A5.3A for lOng/ml of aB-crystallin is 0.896A.U and 3.697A.U respectively. This 
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revealed that the Mab: Biotin assay has a four fold higher sensitivity than the Mab: HRP 
assay and would allow detection of analyte at levels below 1 Ong/ml. Further optimisation 
was required to test this hypothesis. 
A5.1.2.2 Optimisation of Mab: Biotin concentration and aD-crystallin standard 
curve 
Section 6.3.3 confirmed that the Mab: Biotin detection method results in a four 
fold increase in sensitivity for aB-crystallin relative to the Mab: HRP. Figure A5.4 
showed that a 500 ng/ml Mab: Biotin concentration combined with 125 ng/ml Av-HRP 
produced a signal in strength that was greatly above the detection limit. 
Therefore, further optimisation of the Mab: Biotin assay included titration of 
Mab: Biotin from 125ng/ml to 500ng/ml and also increased the standard range from 
lOOng/ml-1.27 ng/ml to 100 ng/ml-0.1 pg/ml in order to identify the lower limits of 
sensitivity of the Mab: Biotin assay. A compromise for the level of Avidin required for 
optimal aB-crystallin detection is a solution of 50% HRP labelled Avidin and 50% 
unlabelled Avidin to a final concentration of 250 ng/ml. These data are shown in Figure 
A5.5. 
Figure A5.5A suggests that the Mab: Biotin assay is too sensitive for the detection 
of aB-crystallin at concentrations above 1 Ong/ml regardless of the Mab: Biotin 
concentration and above 6 ng/ml the 250 ng/ml Mab: biotin produces a signal greater than 
2.0 A.U (see Figure A5.5B). At aB-crystallin concentrations below 1.0 ng/ml an 
appropriate calibration curve is evident (see Figure A5.5C). 
The 500 ng/ml concentration of Mab: Biotin has a limiting affect on the assay 
resulting in a relatively low signal compared to the 125 ng/ml and the 250 ng/ml Mab: 
Biotin. The 250ng/ml Mab: Biotin achieves the optimal standard curve and allows 
detection of aB-crystallin in the range 6.0-0.10 ng/ml at 250ng/ml Mab: Biotin, (see 
Figure A5.5B and C). 
The optimised assay conditions for the detection of aB-crystallin at levels 
between 6.0 ng/ml-0.1 ng/ml utilises a 2 mg/L Poly capture with a 250 ng/ml Mab: Biotin 
conjugate in association with Av/Av-HRP (50% labelled) detection of 250 ng/ml in a 
simultaneous assay. 
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Figure A5.5. Optimisation of the aS-crystallin Mab Biotin Simultaneous ELISA. The 
Mab:Biotin concentrations of 125, 250 and 500 ng/ml were used with 250 ng/ml Av-HRP 
to assess the relative sensitivities of aS-crystallin detection. The lower limit of aS-
crystallin that could be detected was investigated and the detected signal from 0.1-100 
ng/ml (A), 0.1~10 ng/ml (B) and 0.1 -1.0 ng/ml (C) showed that aS-crystallin at the pg 
level was accurately detected. 
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A5.1.3 The use of ELISA for potential quantification aD-crystallin protein isolated 
in SEC fractions 
One of the aims of this chapter was to be able to develop a working aB-crystallin 
ELISA of greater sensitivity than immunoblotting to allow quantification of low level aB-
crystallin in SEC fractions. Here I tested the ability of the ELISA to accurately quantifY 
the presence of aS-crystallin in SEC fractions from a typical 500 !-tg load on the 26 ml 
Superose 6 SEC column. I also investigated the appropriate dilutions for each stage of the 
SEC elution and subsequently depending on the sensitivity required, which Mab: 
conjugate was required. 
A5.1.3.1 Quantification aD-crystallin in SEC fractions using Mab: HRP 
A typical elution will result in the major oligomeric species at 57 min followed 
by an unknown low Mwt multimeric/monomeric species at approx as shown in Figure 
A5.6. Thus the dilutions required and most appropriate Mab: conjugate will reflect the 
relative peak areas. 
Initial analysis investigated the efficiency of the less sensitive Mab: HRP assay. 
This assay optimised conditions for the detection of aB-crystallin at levels between 
1 OOng/ml - 1.27ng/ml utilising a 2 mg/L Poly capture with a 250 ng/ml Mab: HRP 
conjugate detection in a Simultaneous assay. The samples analysed included 2 fractions 
encompassing the major oligomeric peak (oligomer I and 2) and three fractions 
encompassing the low Mwt species (low Mwt 1, 2 and 3). These fractions provide a 
typical range of aB-crystallin concnetrations that would require quantitation. 
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Figure A5.6. A typical 500 !lg SEC elution profile. The range of a.B-crystallin 
concentrations resulting in this SEC are evident by the absorbance data for specific 
regions. The oligomer peak (A) is some 250x greater in peak height than the low Mwt 
species highlighted in B. 
The fractions were assayed at a range of dilutions aiming to produce a signal 
within the central region of the standard curve and the resulting quantitation data is shown 
in Table A5.1. Oligomer fraction 1 encompasses 55-60 min of the elution, whilst 
Oligomer fraction 2 encompasses 60-65 min. the low Mwt fractions encompass 90-95 
min (fraction 1), 95-100 min (fraction 2) and 100-105 min (fraction 3) (see Figure A5.6). 
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Table A5.1. Quantitation of Oligomer and 93min peak material from 500~-tg aB-crystallin 
lo d . M b HRP a usmg a : 
Peak and Fraction Dilution Observed Total Mean total Mean 
ng/ml ng/ml ng/ml total 
~-tg/ml 
Oligomeric fraction 1 5000 59.3 296500 305750 306 Oligomeric fraction 1 50000 6.3 315000 
Oligomeric fraction 2 5000 35 175000 175000 175 Oligomeric fraction 2 50000 3.5 175000 
Low Mwt fraction 1 10 11.0 110 
Low Mwt fraction 1 100 3.8 380 245 0.25 
Low Mwt fraction 1 1000 <1.27 <1.27 
Low Mwt fraction 2 10 5.5 55 
Low Mwt fraction 2 100 1.6 160 108 0.11 
Low Mwt fraction 2 1000 <1.27 <1.27 
Low Mwt fraction 3 10 4.5 45 
Low Mwt fraction 3 100 1.4 140 93 0.10 
Low Mwt fraction 3 1000 <1.27 <1.27 
Table A5.1 details the quantitation achieved and shows that the dilutions for the 
oligomeric fractions especially the 5000x, results in observed ng/ml values of aB-
crystallin within the standard curve. The 50000x dilution results in ng/ml values at the 
low limits of the curve therefore an optimal dilution series for these samples would be 
1 :5000 and 1 :25000. 
The low Mwt fraction analysis indicates that a 1 OOOx dilution is too large for aB-
crystallin concentrations at this level of sensitivity and thus the absorbance readings were 
lower than the lower limits of the standard curve ( < 1.2 7 ng/ml. The 1 OOx dilution is just 
above this limit whereas the 1 Ox dilution produces values that are more reliable. Based on 
these observations it is evident that a 2x and 1 Ox dilution would provide data which could 
be reliably and accurately converted to aB-crystallin concentrations in these low Mwt 
fractions. These assays were repeated for fractions from a 125 ~-tg, 25 ~-tg and 2.5 ~-tg SEC 
load however, the assay was not of sufficient sensitivity to be able to accurately quantify 
the low Mwt fractions. It was however feasible method of quantitation for the oligomeric 
fractions and the data is shown in Table A5.2. 
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Table A5.2. Quantitation of Oligomer and 93min peak material from 125~g aB-crystallin 
ld. MbHRP oa usmg a 
Peak and Load Dilution Observed Total Mean total Mean total Fraction (~g) ng/ml ng/ml ng/ml ~g/ml 
Oligomeric 125 500 93.9 46950 fraction 1 61975 62.0 Oligomeric 125 5000 15.4 77000 fraction 1 
Oligomeric 125 500 32.3 16150 fraction 2 
-- 17825 18.0 Oligomeric 125 5000 3.9 19500 fraction 2 
Oligomeric 25 50 89.6 4480 fraction 1 5820 5.8 Oligomeric 25 500 26.8 13400 fraction 1 
Oligomeric 25 50 69.9 3495 fraction 2 3323 3.3 Oligomeric 25 500 6.3 3150 fraction 2 
Oligomeric 2.5 10 10.1 101 fraction 1 101 0.10 Oligomeric 2.5 100 1.0 < 1.27 fraction 1 
Oligomeric 2.5 10 3.4 34 fraction 2 34 0.03 Oligomeric 2.5 100 0.2 < 1.27 fraction 2 
Table A5.2 details the quantitation achieved and shows that the dilutions for the 
oligomeric fractions results in observed ng/ml values for aB-crystallin within the standard 
curve. The 2.5 ~g SEC resulted in observed ng/ml values for aB-crystallin at the low 
limits of the standard curve when using a 1 OOx dilution, however valid data is produced 
with a 1 Ox dilution and perhaps a 2x dilution would be an appropriate second dilution for 
these tractions. 
As we have seen previously in section 11.1.2.2, the Mab: Biotin conjugate 
achieves a four fold increase in sensitivity allowing quantification aB-crystallin protein at 
5ng/ml -1 OOpg/ml concentrations, thus the experiment was repeated to assess how the 
sensitivity observed during optimisation transferred to the quantitation of aB-crystallin 
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fractions and if the quantitation of the oligomer and especially the low Mwt fractions is 
enhanced using the Mab: Biotin. 
Development of an ELISA for the analysis of aB-crystallin in SEC fractions of a 
wide range of protein concentrations has been successful. However, further optimisation 
is required using the Mab: Biotin assay in order to quantify those fractions with low Mwt 
species of aB-crystallin. 
A5.1.3.2 Quantification aD-crystallin in SEC fractions using Mab: Biotin 
The Mab: HRP assay provides an assay of appropriate sensitivity for the 
quantitation of the oligomeric fractions, which avoids excessive dilutions of fraction 
samples to provide a signal within the calibration curve. However, the low Mwt fractions 
require an assay of increased sensitivity and we know the Mab: Biotin can provide this. I 
also wanted to assess the level of dilution required to quantify the oligomeric fractions in 
this assay (see Table A5.3). 
Table A5.3. Quantitation of Oligomer and 93min peak material from 500!-lg aB-crystallin 
I d M b B' t" oa usmg a : lOin. 
Peak and Fraction Dilution Observed Total Mean Mean 
pg/ml Ng/ml total total 
ng/ml f..lg/ml 
Oligomeric fraction 1 1000000 184.1 184100 184100 184.1 Oligomeric fraction 1 5000000 42.9 <128 pg/ml 
Oligomeric fraction 2 1000000 121.3 <128~ml 121300 121.3 Oligomeric fraction 2 5000000 16.4 <128 pg/ml 
Low Mwt fraction 1 100 934.1 93.4 85.1 0.09 Low Mwt fraction 1 500 153.3 76.7 
Low Mwt fraction 2 10 4362.1 43.6 
Low Mwt fraction 2 100 406.3 40.6 42.1 0.04 
Low Mwt fraction 2 500 56.0 <128~ml 
Low Mwt fraction 3 10 3648.6 36.5 
Low Mwt fraction 3 100 336.5 33.7 35.1 0.04 
Low Mwt fraction 3 500 85.7 <128 pg/ml 
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Table A5.3 details the quantitation achieved and shows that the dilutions for the 
low Mwt species fractions results in observed pg/ml for aB-crystallin within the standard 
curve. An optimal dilution series for these samples appears to be I: I 0 and 1: I 00. The 
oligomeric fractions were assayed at a substantial dilution of Ixl06 and 5xi06, which 
proved too excessive and only produced a signal within the calibration curve for fraction 
1. 
This signal was itself towards the lower limit of the calibration range. It appears 
that dilutions of 5xl05 and Sxi 04 would be sufficient to provide viable absorbance data 
for quantification, some I Ox greater than dilutions required with the Mab: HRP. It is 
evident that both Mab conjugates can be used for quantification of aB-crystallin in the 
oligomer fractions and choice would depend perhaps on the available sample volume 
required to achieve the respective dilutions. The quantification of the low Mwt fractions 
with the Mab: Biotin proves to be an effective method for assay of 500 1-lg SEC fractions. 
The assay is sensitive between 5000-128 pg/ml, therefore the quantification ofthe 125, 25 
and 2.5 ~-tg SEC fractions was investigated. At the 2.5 1-lg SEC level it was interesting to 
analyse the oligomeric fractions along with the low Mwt fractions. 
Table A5.4 details the quantitation achieved and suggests the optimal dilutions fro 
quantitation of aB-crystallin at the varying levels of SEC load. The I25 1-lg SEC low M wt 
fractions require a neat and 3x dilution; the 25 1-lg SEC fractions require a neat and 2x 
dilution. Interestingly, the 2.5 ~-tg SEC fractions appear to require a larger dilution relative 
to the 25 ~-tg SEC fractions, of 2.5x and 5x. The oligomeric fractions of the 2.5 ~-tg SEC 
show viable absorbance data with this Mab: Biotin assay. The variations observed 
between the 2.5 ~-tg and 25 ~-tg SEC quantification highlights the dynamic characteristics of 
aB-crystallin with decreasing concentration as discussed in Chapter 5. 
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Table A5.4. Quantitation of 93min peak material from 125~g aB-crystallin load using 
Mab: Biotin. 
Mean 
Load Observed Total 
Peak and fraction Dilution total 
(~g) pg/ml ng/ml 
ng/ml 
-
--- ---
Low Mwt fraction 1 125 233.7 3 0.7 
0.7 
Low Mwt fraction 1 125 95.2 10 < 128 pg/ml 
Low Mwt fraction 2 125 451.2 3 1.4 
2.9 
Low Mwt fraction 2 125 429.9 10 4.3 
Low Mwt fraction 3 125 115.4 3 < 128 pg/ml 
1.3 
Low Mwt fraction 3 125 133.2 10 1.3 
Low Mwt fraction 1 25 129.6 3 0.4 
0.4 
Low Mwt fraction 1 25 36.9 10 < 128 pg/ml 
Low Mwt fraction 2 25 223.1 3 0.7 
0.7 
Low Mwt fraction 2 25 26.1 10 < 128 pg/ml 
Low Mwt fraction 3 25 41.7 3 < 128 pg/ml 
N/a 
Low Mwt fraction 3 25 15.2 10 < 128 pg/ml 
Oligomer fraction 1 2.5 2119.3 10 21.2 
27 
Oligomer fraction 1 2.5 1090 30 32.7 
Oligomer fraction 2 2.5 133.2 10 1.3 
1.3 
Oligomer fraction 2 2.5 103.6 30 < 128 pg/ml 
Low Mwt fraction 1 2.5 210.1 2.5 0.5 
2.1 
Low Mwt fraction 1 2.5 731.2 5 3.7 
Low Mwt fraction 2 2.5 644.4 2.5 1.6 
2.3 
Low Mwt fraction 2 2.5 569.6 5 2.9 
Low Mwt fraction 3 2.5 156.9 2.5 0.4 
2.0 
Low Mwt fraction 3 2.5 728.8 5 3.6 
Investigating the feasibility of using the aB-crystallin ELISA for the analysis and 
quantitation of aB-crystallin present in SEC fractions with a wide range of concentrations 
resulted in the identification of appropriate dilutions for optimal detection in the Mab: 
Biotin and Mab: HRP assays. 
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The development of an ELISA assay for the detection and quantitation of aS-
crystallin has resulted in 2 assays optimised for varying levels of sensitivity. The 
simultaneous Mab: HRP assay is optimised to the 5-l OOng/mllevel, for oligomer samples 
from runs 500~-tg, 125~-tg and 25~-tg and low Mwt samples from 500~-tg, and 125~-tg runs. 
For fractions of lower aS-crystallin concentration, the Mab: Biotin assay is preferred with 
sensitivity from 5ng/ml - 128 pg/ml. Although this work has identified appropriate 
dilutions it is not always possible to assume the aS-concentration of particular fractions 
and selected dilutions may not produce absorbance data sufficiently within the calibration 
range, therefore re-assaying with amended dilutions may be required. However, this work 
has also shown that the aB-crystallin ELISA is a feasible means of quantifying aS-
crystallin at any level of sensitivity. 
The Mab: Biotin detection system is a powerful tool for the analysis of the tail 
material of aS-crystallin analytical SEC elutions, to determine the presence of additional 
aS-crystallin species of low Mwt as discussed in Chapter 5 (see Section 5.3.2-5.3.3). The 
Mab: Biotin ELISA produced repeatable, reliable and accurate quantification of aS-
crystallin in the SEC fractions to aid the investigation of the subunit dynamics of aB-
crystallin, which was supported by immunoblotting and Absorbance data performed in 
conjunction with the ELISA. 
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Here we investigate the effects of a myopathy-causing muta-
tion in aD-crystallin, Ql51X, upon its structure and function. 
This mutation removes the C-terminal domain of aD-crystallin, 
which is expected to compromise both its oligomerization and 
chaperone activity. We compared this to two other aD-crystallin 
mutants (450delA, 464delCT) and also to a series of C-terminal 
, truncations (El64X, El65X, Kl74X, and Al71X). We find that 
the effects of the Ql51X mutation were not always as predicted. 
Specifically, we have found that although the Ql51X mutation 
decreased oligomerization of aD-crystallin and even increased 
some chaperone activities, it also significantly destabilized 
aD-crystallin causing it to self-aggregate. This conclusion was 
supported by our analyses of both the other disease-causing 
mutants and the series of C-terminal truncation constructs of 
aD-crystallin. The 450delA and 464delCT mutants could only 
be refolded and assayed as a complex with wild type aD-crystal-
. , which was not the case for Ql51X aD-crystallin. From these 
dies, we conclude that all three disease-causing mutations 
(450delA, 464delCT, and Ql51X) in the C-terminal extension 
destabilize aD-crystallin and increase its tendency to self-aggre-
te. We propose that it is this, rather than a catastrophic loss of 
haperone activity, which is a major factor in the development of 
e reported diseases for the three disease-causing mutations 
died here. In support of this hypothesis, we show that Ql51X 
D-crystallin is found mainly in the insoluble fraction of ceO 
xtracts from transient transfected cells, due to the formation of 
plasmic aggregates. 
The crystallins were first identified as the major proteins of 
e eye lens and their subsequent classification into a-, 13-. and 
-crystallins (1) allowed different functional properties to be 
signed to the a- and /3-y-crystallin groups (2). The a-crystal-
ins are two distinct proteins derived from two separate genes, 
- and aD-crystallin (2). Whereas aA-crystallin is almost 
ntirely lens specific (3), aS-crystallin is expressed widely in 
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other tissues, most notably astrocytes (4) and muscle (5). In the 
early 1980s, pioneering work from Klemenz and co-workers (6) 
and Horwitz (7) laboratories established that aD-crystallin was 
a protein chaperone and a member of the small heat shock 
protein (sHSPf family, that is now known to comprise 10 dif-
ferent human proteins (8). 
When the first mutation (R120G) in aD-crystallin was 
reported, it was found to cause both cataract and desmin-re-
lated myopathy in the affected patients (9). Characteristic his-
topathological aggregates of the muscle intermediate filament 
protein desmin were observed (9), strongly suggesting that 
there is an important functional interaction between interme-
diate filaments and aD-crystallin. Subsequent analyses showed 
that the R120G aD-crystallin mutation induced increased bind-
ing for desmin intermediate filaments (10), providing an expla-
nation for the formation of the desmin aggregates in the mus-
cles of the affected individuals. Coincidentally, mutations in 
desmin also induced filament aggregation (11, 12) and these 
aggregates also contained aD-crystallin (12). Collectively, these 
data suggest that one of the functions of aD-crystallin is to 
chaperone intermediate filaments and their networks in cells 
(10, 13, 14). 
Subsequently, three other mutations in the C-terminal 
extension were reported for aD-crystallin, but in contrast to the 
R120G mutation, none caused both cataract and myopathy. 
The first of these was the 450delA mutation that is associated 
only with cataract and resulted in a 184-residue product where 
the coding sequence of the C-terminal extension was altered 
from residue 150 onwards (15). This region is distal to the 
/3-strand 9 and proximal to the conserved hydrophobic IX(IN) 
motif (16) that forms part of /3-strand 10 in the crystal structure 
of the archaeal HSP16.5 (17). Two other mutations were then 
reported (Q151X and 464delCT) that cause myopathy and not 
cataract (18) that either truncated (Q151X) or substituted the 
C-terminal extension from residue 155 (464delCT). The fact 
that all three mutations delete a known substrate interaction 
site (157-164) (19) and a region important in the oligomeriza-
tion of aS-crystallin itself (155-166) (20) support the hypothe-
sis that this region in aD-crystallin is important to both the 
structure and function of the protein. Very recently, a C-termi-
- llill point mutation (R157H) (21) was reported, lending further 
2 The abbreviations used are: sHSP, small heat shock protein; bis-ANS, 4,4'-
dianilino-1, 1 '-binaphthyl-5,5 '-disulfonic acid; MWCO, molecular weight 
cut off; SEC, size exclusion chromatography. 
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Removal of C-terminal Extension Induces aS-Crystallin Aggregation 
TABLE1 
Oligonucleotide primer sequence details used for introduction of the a8-crystallin mutations 
The unique restriction enzyme sites incorporated into the primer design are highlighted in bold text Ql51X and El65X were introduced using site-directed mutagenesis 
(SDM) requiring complementary forward (5' -3') and reverse (3' -5) primers. The 464delcr, Kl74X, Al71X, and El64X mutant mRNA were amplified using a forward 
primer overlapping the pET23d insertion site and the 5' end of the template wild type aS-crystallin. Reverse primers were complementary to the 3' end of the template wild 
type alk:rystallinand incorporated the mutation and unique restriction sites to assist screening. using the available software (DNA_Analysis_Frame). A suitable restriction 
enzyme site was not available for the 464de1Cf mutation. 
Mutant aS-crystallin Restriction enzyme site 
Ql51X Stul 
El65X Hindlll 
464detcr NA4 
Kl74X Sa ell 
Al71X Sad 
El64X Pstl 
a NA, not applicable. 
support to this conclusion. Thus far, the effect of such extensive 
deletions (Q151X) combined with altered C-terminal 
equences (450delA and 464CT) upon aS-crystallin structure 
d function have not been investigated. 
In other sHSPs, the C-terminal domain has been shown to be 
ery important to both oligomerization and chaperone func-
. on and therefore the expectation is that the C-terminal exten-
ion mutations would similarly affect aS-crystallin. Removal of 
e 17 most C-terminal residues of aA-crystallin reduced its 
haperone activity and induced the formation of larger oli-
omers (22). In two crystal structures of sHSPs (HSP16.5 (17) 
d HSP16.9 (23)), the C-terminal extension makes contact 
'th a hydrophobic patch on neighboring protein subunits, 
trengthening the dimer-dimer interaction in the oligomer 
23). The sequence between f:J-strands 9 and 10 of the C-termi-
al extension contains a hinge that likely contributes to the size 
olydispersity of the different sHSPs by allowing packinggeom-
tries to vary while maintaining common interaction surfaces 
23). Some naturally occurring sHSPs lack a C-terminal exten-
ion and in such cases the oligomerization is restricted, as seen 
or Tsp36 from the tapeworm Taenia saginata, which forms 
· ers and tetramers, but is functional as a chaperone (24). 
ikewise, removal of the short C-terminal extension from 
ethanococcus janaschii HSP16.5 resulted in reduced oli-
omerization, but the retention of chaperone activity (25). This 
quite contrary to the closely related lens chaperone aA-crys-
·n that naturally co-oligomerizes with aS-crystallin in the 
ns. Stepwise removal of C-terminal sequences from aA -crys-
in, including th REEK motif, not only reduced oligomeriza-
on, but also resulted in the sequential loss of chaperone activ-
(26), despite the fact that the IX(IN) motif was retained in 
e mutants investigated. Mutations oflysine and glutamic acid 
sidues in the C-terminal extension can improve chaperone 
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Primer sequence (5' -3') 
Forward primer: 
gtgaatggaccaaggaaataggcctctggccctgagcgcacc 
Reverse primer: 
ggtgcgctcagggccagaggcctatttccttggtccattcac 
Forward primer: 
attcccatcacccgtgaatagaagcttgctgtcaccgcagccccc 
Reverse primer: 
gggggctgcggtgacagcaagcttctattcacgggtgatgggaat 
Forward primer: 
taccatggacatcgccatccaccacc 
Reverse primer: 
tcacgggtgatgggaatggtgcgctcggccagagacctgtttcc 
Forward primer: 
taccatggacatcgccatccaccacc 
Reverse primer: 
ctagggggccgcggtgacagcaggcttc 
Forward primer: 
taccatggacatcgccatccaccacc 
Reverse primer: 
gggcatctatttcttgggagctcaggtgacagcaggcttctc 
Forward primer: 
taccatggacatcgccatccaccacc 
Reverse primer: 
cttgggagctgcggtgactgcaggcttctcttaacgggtgatgggaatggt 
activity against amyloid fibril formation providing a potential 
application of aS-crystallin in the treatment of amyloid-related 
diseases (27). In aS-crystallin, there has not been any system-
atic analysis of the role of the C-terminal extension and there-
fore no potential explanation of whether the three mutations 
(450delA, Q151X, and 464delCT) cause the various diseases via 
the loss of chaperone function or perhaps by a different 
mechanism. 
In this study, we have analyzed the effects of the Q151X, 
464delCT, and 450delA upon the oligomerization and chaper-
one activity of aS-crystallin. For comparison, we have also 
assessed the activity of a series of aS-crystallin constructs trun-
cated at residues Lys174, Ala17l, Glu165, and Glu164 to sequen-
tially remove important regions of the C-terminal extension 
and therefore help us understand the effect of the Q151X muta-
tion. With respect to the role of the C-terminal extension in 
oligomerization, our data show similar results to those obtained 
for aA-crystallin (28). Interestingly, the chaperone function of 
Q151X is actually increased in some in vitro chaperone assays. 
The ability of Q151X aS-crystallin to resist self-aggregation is, 
however, very greatly diminished, a trend that is further 
enhanced by the 464delCT and 450delA mutations, which are 
only stable in the presence of wild type aS-crystallin. These 
data show that like other sHSPs, the C-terminal extension is 
important for oligomerization. Its removal increases the tend-
ency of aS-crystallin to self-aggregate. 
EXPERIMENTAL PROCEDURES 
Construction of aB-Crystallln Mutants 
Primers (Table 1; Sigma Genosys, UK) were designed based 
on the rnRNA sequence for wild type human aS-crystallin 
(DDS}/EMSL/GenBank entry NM_001885) and were used to 
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Removal of C-terminal Extension Induces aS-Crystallin Aggregation 
generate the mutants listed, using wild type aB-crystallin as a 
template for PCR mutagenesis. With the exception of the 
Q151X and E165X mutations, the amplified products were 
cloned into the vector pGEM®-T Easy (Promega). After verifi-
cation of the sequences, the mutant aB-crystallin constructs 
were subdoned into the Ncoi and EcoRI sites of the expression 
vector pET23d (Invitrogen). The Q151X and E165X mutations 
were introduced into pET23d by site-directed mutagenesis 
(Stratagene) using complementary primers (see Table 1). Con-
structs were sequenced and compared for fidelity to the Gen-
Bank™ data base (accession number NM001885). 
Protein Expression and Purification of aS-Crystallin Mutants 
Proteins were recombinantly expressed in Escherichia coli 
strain BL21 (pLysS). The wild type aB-crystallin, K174X and 
A171X proteins were prepared essentially as described (29), but 
adding polyethyleneimine (final concentration 0.1% (w/v)) to 
remove contaminating DNA (10, 30) before purification by ion 
exchange chromatography on a Fractogel TMAE column. Peak 
fractions were pooled and then dialyzed into 20 mM Tris-HCl, 
100 mM NaCl, pH 7.4, in preparation for size exclusion chro-
matography on a Fractogel EMD BioSEC Superformance col-
umn (60 X 1.6 em; VWR, UK). 
All other mutant aB-crystallins formed inclusion bodies, and 
were purified essentially as described (31). These were dis-
solved in 10 mM Tris-HCl, 6 M urea, 1 mM EDTA, pH 8.0, 0.2 mM 
phenylmethylsulfonyl fluoride, 1 mM dithiothreitol and then 
purified by ion exchange chromatography (29) on a Fractogel 
TMAE column. 
Fractions containing aB-crystallin were pooled and some-
imes concentrated using an Amicon Ultra Centrifugal filter 
evice 10K MWCO (Millipore, Bedford, MA). Concentrations 
f the purified proteins were determined using BCA Protein 
ssay reagent kit (Pierce) unless otherwise stated. 
efoldlng of aS-crystallin Mutants following Inclusion Body 
urlficatlon 
In the Presence of Wild Type aS-crystallin 
The 450delA, 464delCT, and Q151X were refolded in the 
resence of wild type aS-crystallin. Wild type aS-crystallin was 
"alyzed for 16 hat 4 ·c into 10 mM Tris-Hd, 6 M urea, 1 mM 
DT A, pH 8.0, 1 mM dithiothreitol. Protein concentration of 
e wild type and mutant aS-crystallin were determined by 
D280 (extinction coefficients were determined using the 
mboss Pepstats program) and then mixed in a 1:1 ratio. 
Diluted Refold Protocol (450deiA/WIId Type, QJSJX/WIId 
ype, EJ64X, and QJSJXJ 
The protein mixture was diluted to 0.25 mg/ml in 10 mM 
ris-Hd, 6 M urea, 1 mM EDTA, pH 8.0, 1 mM dithiothreitol 
_llowed by an additional 6-fold dilution to 1 M urea in refold 
Uffer (10 mM Tris-HCl, 5 mM EDTA, 1 mM EGTA, 150 mM 
_ aQ,.pH-7.5)priorto dialysisagainsHhe same buffer fur·4-h at-
6 ·c. The dialysate was partially concentrated using Arnicon 
tra Centrifugal filter device 10K MWCO (Millipore) and cen-
ifuged for 2 h at 4 ·c at 250,000 X gin the Beckman Optima 
Ultracentrifuge MLA-80 rotor (Beckman Instruments 
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Inc., Fullerton, CA). The supernatant was further concentrated 
to a suitable volume. 
Undiluted Refolding Protocol (464deiCT/WIId Type, EJ65X} 
The protein mixture was dialyzed into refold buffer for 4 h at 
16 ·c. The dialysate was centrifuged for 2 h at 4 ·c at 250,000 X 
gin the Beckman Optima MAX Ultracentrifuge MLA-80 rotor 
(Beckman Instruments Inc.) and the supernatant concentrated 
to give the desired protein concentration. 
Characterization of aS-crystallin Mutants 
Analytical Size Exclusion Chromatography (SEC} 
Purified aS-crystallin proteins were analyzed using a Super-
ose 6 column (290 X 10 mm) at a flow rate of 0.2 ml/rnin at 
room temperature using a Merck-Hitachi Biochromatography 
system. The data were analyzed using Chromeleon 6.30 soft-
ware (Sunnyvale, CA). 
Mass Spectrometry for Molecular Weight Determination 
Purified proteins were loaded onto a MassPREP desalting 
cartridge (Waters, Elstree, Herts, UK) to remove buffer con-
taminants. The protein was eluted with 70% (v/v) acetonitrile, 
0.5% (v/v) formic acid at 0.2 ml/min and introduced into a 
Waters Q-TOF Premier mass spectrometer operating in posi-
tive electrospray mode, with a cone voltage of 40 V. Spectra 
were externally calibrated using sodium formate, then cor-
rected for drift using a leucine enkephalin lockspray. Multiply 
charged protein ions were deconvoluted using the manufactur-
er-supplied MaxEntl software, to determine protein mass. 
CD Spectroscopy 
Far UV CD spectra of wild type and mutant aS-crystallin 
were recorded in a cuvette with 0.1-cm path length at room 
temperature using a Jasco J-810 spectropolarimeter. Samples 
were at a concentration of0.2-0.3 mg/ml, with the exception of 
Q151X, assayed at 0.1 mglml due to the low yield of soluble 
protein. Samples were assayed in 10 mM Tris, 150 mM Nad, 5 
mM EDT A, 1 mM EGTA, pH 7.5. Four data sets were collected 
for each sample and averaged, by continuous scanning at 100 
nm/min, between wavelengths 190 and 250 nm. The UV CD 
spectra were baseline corrected using spectra of the buffer. The 
CD spectra were normalized and expressed as molar ellipticity. 
Thermal Stability Assay 
Absorbance at 360 nm over a temperature gradient of 
25-86 ·cat 1 ·ctmin ramp rate was continuously monitored 
using the Beckman DU640 spectrophotometer. Samples were 
assayed at 0.1 mglml. 
In Vitro Protein Chaperone Assays 
Citrate Synthase-A 200-,.U volume of citrate synthase from 
porcine heart (Sigma) was dialyzed for 16 hat 4 ·c againstS_!) 
mMTrls=HCl; 2-mM EDTA, pK8:o, ancfdlluted to0.49-mglml. 
The assay mixture contained citrate synthase and aS-crystallin 
at a 4:1 ratio of substrate:chaperone in 220 ~Jl. Time-dependant 
light scattering was measured at 360 nm every 15 s over 30 min 
at 42 ·c using a Beckman DU640 spectrophotometer. 
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Insulin Assay-A 20-mg aliquot of insulin from bovine pan-
creas (Sigma) was reconstituted in 100 OlM NaS041 20 IOM 
NaP041 pH 6.9 (Insulin buffer), and solubilized by the addition 
of30% (v/v) acetic acid and gentle mixing for 15 min. The insu-
lin solution was dialyzed for 16 h at 4 ·c against the insulin 
buffer and the dialysate was centrifuged for 1 min at 13,000 X g 
in an Eppendorf bench top centrifuge (5417R; Eppendorf, 
Hamburg, Germany). The insulin concentration was deter-
mined from the measured OD280 using its extinction coefficient 
((A28015840) X 5600 = mg/ml). Insulin was mixed with aS-crys-
tallin at a 4:1 ratio and the change in light scattering was meas-
ured at 360 om every 15 s over a period of 15 min at 37 ·c using 
a Beckman DU640 spectrophotometer. 
Bis-ANS Fluorescence Measurements 
aS-Crystallin variant proteins were incubated in 10 IOM Tris, 
150 IOM Nad, 5 IOM EDTA, 1 IOM EGTA, pH 7.5, at a protein 
concentration of 1 IJ.M and in the presence of a 10-fold molar 
excess of bis-ANS (4,4' -dianilino-1,1 '-binaphthyl-5,5' -disulfo-
nic acid, purchased from Invitrogen). Samples were allowed to 
equilibrate for 1 hat room temperature prior to the acquisition 
of fluorescence spectra on a Varian Cary Eclipse fluorescence 
spectrophotometer. The excitation wavelength was 410 om and 
emission was collected between 420 and 700 om with excitation 
and emission slit widths of 5 om and a scan speed of 600 
om/min. All spectra are the average of 10 individual scans. 
In Vitro Desmin Filament Assembly and Cased/mentation 
Assay 
er's protocol. Cells were allowed to recover for 24 h before proc-
essing for immunofluorescence microscopy, cell fractionation, 
and immunoblotting. 
Cell Fractionation, SD5-PAGE, and lmmunoblotting 
Cells grown on 10-cm dishes were washed twice with phos-
phate-buffered saline before being lysed with 1 ml of extraction 
buffer (phosphate-buffered saline, 0.5% (v/v) Triton X-100} by 
repeatedly passing through a 25-gauge needle. Following incu-
bation on ice for 15 min, the lysates were clarified by centrifu-
gation 18,000 X g for 10 min at 4 ·c. The resulting supernatant 
and pellet fractions were solubilized in equal volumes of Lae-
mmli sample buffer before SDS-PAGE and immunoblotting 
analysis as described (10). Membranes were probed with a 
panel of purified mouse monoclonal anti-aS-crystallin 2D2B6 
and monoclonal anti-HSP27 antibody, ER-D5, as described 
(10). Antibody labeling was detected by enhanced chemilumi-
nescence using a luminescent image analyzer (LAS-1000plus; 
Fuji Photo Film (UK), London, United Kingdom). 
Immunofluorescence Microscopy 
Cells were processed as described previously (10). The pri-
mary antibodies used in this study were rabbit polyclonal anti-
aS-crystallin, a synthetic peptide corresponding to human 
aS-crystallin residues 1-10 (MDWHHPWI) conjugated to 
hemocyanin (1:200; Chemicon Ab1546) and monoclonal 
mouse anti-keratin LE41 (1:1; CRUK). Samples were analyzed 
using an Axioplan fluorescence microscope (Carl Zeiss, Jena, 
Germany). Images were obtained using a confocal Axiovert 
200M microscope and LSM 510 META software (both Zeiss, 
Germany). Optical sections were set to ~ 1.0 IJ.m. Images were 
processed and prepared for figures using Adobe Photoshop 8.0 
(Adobe Systems). Quantitation of the aS-crystallin phenotypes 
was by visual assessment of the cells. 
In vitro assembly and cosedimentation assays were carried 
out essentially as described (10}. Recombinant human desmin 
was a kind gift from Dr. Ming Der Perng (Durham, UK). Wild 
type or mutant aS-crystallin was mixed with desmin in low 
ionic strength buffer at a 1:1 mass ratio at 0.1 mg!ml. After 
filament assembly, samples were separated into pellet and 
supernatant fractions by high speed centrifugation (80,000 X g RESULTS 
for 30 min at 20 ·c in a Beckman TLS-55 rotor (Beckman Expression and Purification of the C-terminal Extension 
Instruments Inc., Fullerton, CA)) as described (10} to pellet aB-Crystallin Mutants-An overview of the C-terminal exten-
assembled desmin filament and the associated aS-crystallin. sion mutants in comparison to wild type aS-crystallin is pre-
o investigate the ability of the three aS-crystallin mutants and sen ted (Fig. IA). It shows the relationship of the various muta-
e other C-terminal truncation constructs to prevent fila- tions and truncations to the structural features of the 
ent-filament interactions in vitro, an additional low-speed C-terminal extension and also summarizes the consequences of 
entrifugation assay was used (2500 X g for 15 min in a bench the two frameshift mutations, 450delA and 464delCT, that 
op centrifuge) as described previously (10). The pellet and cause inherited cataract (15) and myofibrillar myopathy (18}, 
upernatant fractions were analyzed by 12% (w /v) SDS-P AGE respectively. In addition to the three disease-causing mutations 
32} and protein bands visualized by Coomassie Blue staining. (Q151X, 450delA, and 464delCT}, a series of C-terminal exten-
he amount of protein in the supernatant and pellet fractions sion truncation constructs were also expressed and purified 
ere analyzed by a luminescent image analyzer (LAS-1000plus; (Fig. 1B). All the mutants except A171X and K174X were puri-
uji Film, Tokyo, Japan) and quantified using the Image Gauge fled from inclusion bodies. The predicted mass of each of the 
oftware (version 4.0; Fuji Film). expressed proteins was confirmed by mass spectrometry meas-
urements (Fig. 1C}. Whereas Q151X, E164X, and E165X could 
ell Cultures and Transient Transfectlon Assays be refolded successfully without the addition of wild type 
MCF7 cells were maintained as described previously (10}. aS-crystallin, both 450delA and ~elCT coul<!_()J!}y__l>e_ 
~il~-=-type.and=mutant-aB-crystallin-were subcloned-into the - refolde-dinits piesence.'Wnen refold eo withan -eqUimolar ratio 
ammalian expression vector pcDNA3.1 (Invitrogen) from the of aS-crystallin, ~7% of 450delA and 10% of 464delCT 
acterial expression vector pET23d, using Xbal and Hindiii. remained soluble (Fig. 1D). Although Q151X aS-crystallin 
ransient transfection of these cells was achieved using Gene- could be refolded in the absence of wild type aS-crystallin, the 
uice transfection reagent (Novagen) according to manufactur- yield could be increased some 7 -fold when the wild type protein 
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decrease in oligomer size (Fig. 2A). 
The shortest construct Q151X 
aS-crystallin produces a peak with 
very significantly increased elution 
volume (Fig. 2B) and represents the 
most dramatic reduction in oli-
gomerization observed for all the 
constructs studied. This effect on 
Q151X oligomerization is obvious 
when the negative stained electron 
micrographs of wild type and 
Q151X aS-crystallin are compared 
(Fig. 2, C and D, respectively). 
Notice the absence of particles in 
the Q151X sample (Fig. 2D) relative 
to the wild type (Fig. 2C). 
C) I SIX 
.. 
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FIGURE 1. Details of the aB-aystallln mutants and their charaderizatlon by SDS-PAGE. Structural align-
ment of the C -terminal extensions of aS-crystallin mutants (A) Includes the C -terminal extension from residue 
149 (24), and ~sheets and the IX(IM motif are indicated as black boxes. The {37 sequence spans residues 
118- 123 (FHRKYR), {38 sequence spans residues 134-138 (TSSLS), and {39 sequence spans residues 142-148 
(VL lVNGP). The highly conserved IX(IM motif includes residues 159-161 (I PI). The ( -terminal extension con-
sists of residues 149-175 (RKQVSGPERTIPITREEKPAVfMPKK). 8, characterization ofthe bacterially expressed 
and purified mutants used in this stucly by SDS-PAGE. The 450deiA (arrow) and 464deiCT (arrowhead) mutants 
could not be produced as individual soluble proteins and therefore were refolded in the presence of wild type 
aS-crystallin. Molecular weight markers (track M) are indicated (e) in order of increasing relative mobility (40, 
33, 24, and 17 kDa). The relative molecular weights of the wild type and mutant aB-crystallins (Q were con-
firmed by mass spectrometry and compared with values calculated from the amino acid sequences using the 
Emboss Pepstats program. D, refolding yields for aS-crystallin truncation constructs and mutants purified from 
inclusion bodies. 
Deletion of the two C-terminal 
lysines (K174X) did not alter signifi-
cantly the oligomerization of 
aS-crystallin, as previously reported 
(33). Removal of 5 C-terminal resi-
dues, however, reduced the apparent 
size of the main peak, as did the 
removal of both 11 (E165X) and 12 
(E164X) residues. In the case of the 
latter two truncation mutants, there is 
evidence of increased polydispersity 
as indicated by the very noticeable 
shoulder on the main peak for the 
E165X construct and the presence of 
was included. These data show the disease-causing mutations 
seriously affect the solubility of aS-crystallin. 
The K174X construct removes the two most C-terminal 
lysine residues and would be expected to retain the secondary 
structural characteristics and oligomerization characteristics of 
aS-crystallin (33). The electrophoretic mobility of this K174X 
mutant was increased relative to the wild type aS-crystallin 
(Fig. lB) and is in agreement with previous observations for 
-terminal-deleted forms of aS-crystallin (34 -37}. Removal of 
e 5 most C-terminal residues generated the A171X mutant 
nd is equivalent to the truncated form of aS-crystallin found 
· normal rat lenses (38}, bovine lenses (39}, and in rat models of 
iabetic cataracts (40). Another C-terminal-truncated form of 
-crystallin (E164X) has 12 residues removed from the C ter-
inus and this has been detected in normal rat lenses (41). This 
uncation deletes the pair of glutamic acid residues at positions 
64 and 165 that are part of the REEK motif in aA-crystallin 
at have been shown to be important in oligomerization (26}. 
t is also equivalent to the 10-residue C-terminal-truncated 
orm of aA-crystallin (40). 
Truncation of the C-terminal Extension Reduces aB-Crystal-
in Oligomerization-Wild type aS-crystallin formed oli-
omers that were equivalent to 564 kDa, as calculated from the 
ize exclusion chromatography data, agreeing with pr viously 
ublished data (42}. The oligomer population was consistent 
etween different preparations as shown by dynamic light scat-
ering (supplementary data Fig. S1}. The sequential truncation 
f the C-terminal extension of aS-crystallin produces a steady 
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an additional peak at the void volume of the column for the E164X 
construct The elution volume of the main peak is increased, sug-
gestive of reduced mean size for aS-crystallin oligomers. These 
data suggest that residues Glu164-Glu165 also contribute to 
aS-crystallin oligomerization. 
The two frameshift mutants 450de!A and 464delCT 
remained insoluble unless they were refolded in the presence of 
wild type aS-crystallin. As seen from the elution proftles in Fig. 
2A, the presence of these mutant proteins decreased the oli-
gomer size of the wild type aS-crystallin. SDS-PAGE analysis 
(Fig. lB) revealed that the wild type aS-crystallin is present in 
excess compared with 450de!A aS-crystallin, yet this excess 
was not sufficient to retain the elution characteristics of the 
wild type protein. In fact, this proved to be the maximum ratio 
~ompatible with protein solubility for the 450de!A-wild type 
aS-crystallin complex and is in stark contrast to 464delCT 
aS-crystallin, where a 1:1 mixture with wild type aS-crystallin 
was entirely soluble. The presence of the 450de!A aS-crystallin 
also increased the polydispersity of the main peak, as seen by 
the shoulder and the additional small peak with a predicted 
molecular weight equivalent to aS-crystallin dimers. 
The 450de!A mutation introduces a unique 33-residue 
polypeptide completely unrelated to the C-terminal extension 
of wild type aS-crystallin (Fig. lA) and quite clearly this frame-
shift sequence has a significant effect upon the oligomerization 
of aS-crystallin. It is, however, the Q151X mutation that has 
the most dramatic effect, with the complete removal of the 
single peak equivalent to the 564-kDa oligomer and the appear-
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B aB-<:rystallin 
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4SOdc:W Wild Type 
464deiCT/ Wild Type 
Ql51X/ Wild Type 
Ql51X 
E164X 
EI65X 
K174X 
AI71 X 
Retention time (min) 
58.7 :1: 0.15 
61.1 :1: 0.21 
63.0 :1: 0.73 
62.7 :1: 0.38 
85.0 :1: 0.16 
63.7 :1: 0.24 
62.3 :1: 0.79 
57.3 :1: 0.75 
59.0 ± 0.66 
120 
FIGURE 2. Effect of the Q151X mutation upon the oligomerization of aS-crystallin. The elution profiles of 
the various aB-crystallins were determined on a 290 x 10-mm Superose 6 column (A). The elution character-
istics of the various mutants are plotted relative to those obtained for wild type aS-crystallin (wild type), as 
highlighted by the vertical line indicating the retention time of the oligomeric complex, which is the major and 
only peak resolved in the wild type aS-crystallin sample. Additional minor species seen in E164X and 450deiN 
wild type are highlighted. A summary of the retention times (8) is shown for the major peak resolved during SEC 
of the wild type aS-crystallin and other constructs. The retention times of minor peaks are included in the figure 
as appropriate. The retention times (~S.D.) were calculated from the average of three cycles of SEC. Negative 
stained images of wild type (C) and 0151 X aS-crystallin (D) were obtained by transmission electron microscopy 
and illustrate the absence of characteristic particles in the Q 1 51 X sample, in agreement with the SEC data. Bar, 
SOOnm. 
Of the other mutants studied, the 
E164X and El65X mutants were 
intermediate in their effects upon 
negative ellipticity as compared 
with the Q151X mutant. This inter-
mediate effect is likely associated 
with the extent of the C-terminal 
truncations of E164X, E165X rela-
tive to Q151X, and suggests a less 
significant loss of secondary struc-
ture. Interestingly, the E164X 
mutant showed a red shift in the 
minimum indicating that the dele-
tion of the second of the two glu-
tamic acid residues in the REEK 
motif does introduce a detectable 
change in secondary structure. A 
recent study showed an R163X 
mutant with significantly altered 
secondary structure compared with 
the wild type (27). The frameshift 
mutation, 464d.elCT, introduced a 
small blue shift of the minimum to 
208 nm and the appearance of a 
shoulder at - 223 nm, both of which 
are indicative of increased helicity. 
This increase may be the result of 
helix formation by the novel C-ter-
minal sequence. Both the K174X 
and A171X truncation mutants and 
the 450de!A frameshift mutant have 
far UV CD spectra very similar to 
the wild type aS-crystallin. 
Loss in Heat Stability of aB-Crys-
tailin Correlates with Changes in 
Secondary Structure-To probe the 
consequences of the altered second-
ary sequence characteristics of the 
ance of a peak with elution characteristics predicted to be 
quivalent to a monomer. Non-denaturing gel electrophoresis 
so confirmed that the Q151X mutation dramatically altered 
•ts electrophoretic mobility under non-denaturing conditions 
·n line with significantly altered oligomerization (supplemen-
data Fig. 2). 
Effect of the C-terminal Mutations upon the Secondary Struc-
re and Oligomerization of aB-Crystallin-CD spectroscopy 
f wild type aS-crystallin showed a single, broad minima, 
etween 208 and 217 nm, indicative of a protein rich in {3 sheet 
Fig. 3), which is consistent with previously reported data (42-
). The Q151X mutation had the most significant effect upon 
he far UV CD characteristics of aS-crystallin (Fig. 3), due to a 
ery significant red shift of the minima to 217 nm and a - 50% 
eduction in magnitude, suggestive of a significant loss of sec-
ndary structure. Similar shift pattern hav been s en for 
-terminal truncation mutants of aA-crystallin (26). A 1:1 
olar mixture of Q151X with aS-crystallin wild type produced 
spectrum that was clearly biased toward the Q151X, indica-
ive of the dominant nature of this mutation. 
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aS-crystallin C-terminal extension mutants, their heat stability 
was determined (Fig. 4). These data show that the two most 
unstable mutants are E164X and E165X because both the onset 
and optical signal was very significantly increased compared 
with wild type aS-crystallin for these two mutants. The E164X 
mutant began to aggregate at 46 ·c, some 30 ·c lower than the 
wild type protein. The E165X mutant was notable for the rapid-
ity of aggregation when initiated at 57 •c, whereas the Q151X 
mutant was notable in its failure to develop a strong OD360 
signal, despite the very significant decrease in stability indicated 
by the increased turbidity at 53 ·c. This signal reached a maxi-
mum at 55 ·c and remained constant until the conclusion of the 
assay. The two shorter C-terminal truncations (K174X and 
A171X), showed decreased stability, but were the most stable of 
the constructs studied. 
These data suggest a correlation between altered secondary 
structure and decreased heat stability. This trend is also seen for 
the two frameshift mutants ( 450de!A/wild type and 464d.elCT I 
wild type) that were more stable than the three shortest con-
structs, but less stable than either the A171X or K174X trunca-
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FIGURE 3. Orcular dichroism of wild type aS-crystallin and the C-tenninal extension mutants. Far UV CD 
spectra (205-250 nm) for each protein were the average of four spectra The far UV CD signal was converted to 
molar ellipticity expressed as degree/cmfdmol - 1 to normalize for slight differences in molecular mass 
between the wild type and the other aS-crystallin constructs. The far UV CD spectra of wild type, A 171 X, and 
K174X are similar In shape and magnitude and contained broad minima between 208 and 217 nm. The 
450de1Nwild type and 464deiCT/wlld type mixtures show increased negative ellipticity and a shift in minima 
to 208 nm. Truncation of the (-terminal extension results in the loss of secondary structure reflected by a 
decrease in negative ellipticity and a shift in wavelength minima (E164X, E165X, Q151X,and Q151X/wild type), 
with the most dramatic effects seen for 0151 X. 
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IGURE 4. Thei'I'INII stability of wild type and C-terminal extension mutants of aS-crystallin. The effect of 
he (-terminal extension mutations on the heat-induced aggregation of aS-crystallin was measured at 360 nm 
ver the temperature range 25-86 •c. The temperature was increased at a 1 •Cfmin over 1 h. Wild type and 
utant aS-crystallins were assayed at 0.1 mg/ml. Notice the signifiCantly reduced stability of the E164X, 
151X, and E165X aS-crystallin mutants. 
bind more bis-ANS relative to the 
wild type till-crystallin, except for 
the Q151X mutant, which binds 
substantially less. As all the mutants 
except Q151X till-crystallin form 
oligomers (Fig. 2), we infer from 
these data that the increase in 
exposed hydrophobic surfaces arise 
from changes within their respec-
tive oligomeric structures. The rea-
son why Q151X aS-crystallin binds 
so little bis-ANS is probably due the 
combined effects of decreased oli-
gomerization and loss of secondary 
structure. We tested this by examin-
ing the bis-ANS binding properties 
of the wild type protein under 
mildly denaturing conditions (2 M 
guanidinium hydrochloride), which 
have been shown previously to eject 
aS-crystallin from native a-crystal-
lin oligomers and to cause a signifi-
cant loss of secondary structure 
(47).lndeed the presence of the gua-
nidinium hydrochloride greatly 
reduced the bis-ANS binding to 
wild type till-crystallin, with the flu-
orescence intensity dropping 
almost as low as that obtained for 
Q151X aS-crystallin alone. 
Effect of C-terminal Extemion 
Mutatiom; upon aB-Crystallin 
Chaperone Activity-Citrate syn-
thase (Fig. 6A) and insulin (Fig. 6C) 
chaperone assays were used to 
determine the effects of the 
aS-crystallin C-terminal extension 
mutations. Our expectation was 
that the observed chaperone activity 
would correlate with the effects of 
the mutations on protein secondary 
structure and heat stability. We pre-
dicted that El64X, E165X, and 
Q151X would exhibit the least 
activity in this assay. The chaperone 
activity achieved by these mutants 
in a citrate synthase aggregation 
assay (Fig. 6B) showed that whereas 
E164X was indeed the worst of all 
ion constructs. These data correlate with more conservative 
hanges in secondary structure as detected by far UV CD spec-
oscopy for the two frameshift mutants (Fig. 3) and the largely 
nchanged spectra for the A171X and K174X mutants. 
Effect of C-terminal Extension Mutants upon Exposed 
ydrophobicity-The probe, bis-ANS, has a low fluorescence 
uantum yield in aqueous solution, however, this increases dra-
atically upon binding to surface-exposed hydrophobic 
the aS-crystallin constructs (-57% inhibition) none of the 
other C-terminal extension constructs performed worse that 
the wild type protein (100% inhibition). Indeed, the E165X 
(313%) was slightly better than the wild type protein and Ql51X 
(755%) was one of the best. In fact, the combination of Q151X 
and wild type aS-crystallin was the best chaperone in the citrate 
synthase assay (1263% inhibition). 
egions. As can be seen in Fig. 5, all the aS-crystallin mutants 
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Another surprise from the citrate synthase chaperone assay 
was the relative performance of the two frameshift mutants, 
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The assay takes advantage of the 
fact that intermediate ffiaments 
interact with each other in solution 
(10, 48) and this can be measured by 
sedimentation assay. The presence 
of a mutant protein that interacts 
with desmin filaments, for ex-
ample, R120G aB-crystallin,activity 
FIGURE 5. Bis-ANSfluorescence binding properties of aB<rystaWn mutants. The effect of the (-terminal muta-
tions upon the relative exposed hydrophobicity was performed using bis-ANS to bind to surface-exposed hydro-
phobic regions on the mutant and wild type aS-crystallin. Each protein was analyzed at 1 IJ.M in the presence of a 
1Q-fold molar excess of bis-ANS. The excitation wavelength was 410 nm and emission spectra were collected 
between 420 and 700 nm. All spectra are the average of 10 individual scans. The resulting exposed hydrophobicity 
is increased for all mutants relative to the wild type aS-crystallin, with the exception ofthe Ql 51 X mutant 
encourages more filament-filament 
associations and therefore increases 
the proportion of pelletable desmin. 
Both Q151X and 464delCT aB-
crystallin when mixed with wild 
type displayed desmin filament 
associations similar to wild type 
alone, whereas the 450delA/wild 
type protein mixture was signifi-
cantly more effective than R120G 
aB-crystallin in inducing this fila-
ment association, highlighting the 
dominant effect of the 450delA 
mutation over the wild type 
aB-crystallin (Fig. 7). 
450delA and 464delCT, both of which performed better in 
combination with wild type aB-crystallin than the wild type 
aB-crystallin alone {625 and 216% inhibition, respectively). 
These data show that the disease-causing mutations in 
aB-crystallin {Q151X, 450delA, and 464delCT) all retain signif-
icant chaperone activity, surpassing the potential of the wild 
type protein alone for this client protein in this particular chap-
erone assay. 
In contrast to the results with citrate synthase, all the C-ter-
minal extension mutants performed worse than the wild type 
aB-crystallin in the insulin-based chaperone assay {Fig. 6Cj. In 
this assay, the three most heat-sensitive aB-crystallin mutants, 
164X, E165X, and Q151X, increased protein aggregation 
ompared with wild type aB-crystallin ( -138, -8, and -45% 
"bition, respectively (Fig. 6D)). An equimolar mixture of 
151X and wild type aB-crystallin {47% inhibition) retained 
ignificant chaperone activity of Q151X, but it was still one of 
e poorer chaperones in this assay. The K174X (93%) and 
171X {93%) mutants had chaperone activities that most 
losely resembled the wild type aB-crystallin (100%) and even 
e two frameshlft mutants, 450delA and 464delCT, in their 
espective combinations with wild type aB-crystallin, still pos-
essed credible activities (68 and 78% inhibition, respectively). 
Ability of the Disease-causing aB-Crystallin Mutants to 
nhibit Desmin Filament Aggregation-One of the characteris-
ic histopathological features of the human myopathies caused 
y some of the mutations in aB-crystallin under investigation 
n this study is the presence of aggregates of desmin filaments 
9, 12). It was r fi r d cid d to analyze th billty of the 
B-crystallin mutants in this study to prevent desmin filament-
ament associations (Fig. 7), using an assay developed to inves-
igate the cell biological effects of the R120G mutation in 
B-crystallin {10). 
PRIL 18, 2008 •VOLUME 283·NUMBER 16 
In stark contrast to these results, 
the Q151X aB-crystallin was the 
most effective chaperone of all the disease-causing mutants and 
was also better than wild type aB-crystallin in reducing the 
proportion of pelletable desmin (Fig. 7 A). Most of the Q151X 
mutant co-sedimented with desmin in the pellet fraction (cf. 
Fig. 7, Band Cj. Mixing Q151X with wild type aB-crystallin in 
an equimolar ratio reduced this binding to desmin filaments (cf. 
Fig. 7, Band C) and restored the levels of pelletable desmin to 
those obtained in the presence of wild type aB-crystallin (Fig. 
7 A). In contrast, the 450delA mutant was clearly dominant over 
the wild type aS-crystallin as there was not only increased bind-
ing to the filaments (cf. Fig. 7, B and Cj, but also a significant 
increase in the proportion of pelletable desmin {Fig. 7A). We 
interpret these data to indicate that the increased binding of 
450delA aB-crystallin induces more filament-filament interac-
tions resulting in more desmin in the pellet. Interestingly all the 
mutant aB-crystallins exhibited elevated binding to desmin fil-
aments (Fig. 7Cj, but under these assay conditions (0.1 mg/ml 
desmin at 37 ·q, the Q151X and 450delA aB-crystallin had 
opposite effects upon the promotion of filament-filament 
interactions. 
To show that the effects of Q151X aB-crystallin were not due 
to an inhibition of desmin filament assembly per se, negatively 
stained samples were analyzed by electron microscopy (Fig. 7 E) 
and the presence of abundant 10-nm filaments confirmed. 
When compared with des min assembled in the presence of wild 
type aB-crystallin (Fig. 7D), the absence of aB-crystallin parti-
cles in the Q151X containing sample was also immediately 
apparent, confirming independently the data in Fig. 2, A and D. 
Cytoplasmic Aggregate Formation of Selected aB-Crystallin 
Mutants in MCF7 Cells-The in vitro assays show that the 
Q151X mutant increased some chaperone activities, but also 
significantly destabilized the protein causing it to aggregate. 
We then decided to investigate the behavior ofQ151X aB-crys-
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FIGURE 6. Aggregation of citrate synthase and Insulin in the presence of wild type and mutant alkrystalllns. The effect of wild type and mutant alkrystallin 
n the thermal aggregation of citrate synthase CA and 8), over a 3Q-mln period at 42 "C, and reduction-induced aggregation of insulin (C and D), over a 15-min period 
t 37 "C was measured using 00360 (00360). A 4:1 molar ratio of substrate:chaperone was used. The relative inhibition of citrate synthase (8) and insulin (D) aggrega-
ion by the (-terminal extension mutants was calculated as a percentage of the level of inhibition achieved by wild type alkrystallin alone (1 00% inhibition). These 
ata represented the average (:!:S.D.) of three independent experiments (see supplementary data Figs. S3 and S4 for the complete data sets). 
allin when transiently transfected into tissue culture cells (Fig. 
), using MCF7 cells as established in previous studies investi-
ating desmin {49) and aB-crystallin {10) mutations. MCF7 
ells have high endogenous levels of HSP27, a small heat shock 
rotein chaperone that is known to form heterogeneous oli-
omers with aB-crystallin (50). The cell line also has little or no 
ndogenous aB-crystallin (10, 14), thus avoiding the need to tag 
e protein for subsequent detection. Cells expressing wild type 
B-crystallin (Fig. SA, green channel), showed a homogeneous 
ytoplasmic distribution. In contrast, cells expressing the 
151X mutant aB-crystallin were obvious by the presence of 
oplasmic aggregates that were immunopositive for aB-crys-
in (Fig. 8B). A similar result was also obtained for two other 
B-crystallin constructs, the mutant 464delCT and the C-ter-
. al-truncated aB crystallin E164X (Fig. 8, C and D). Our 
revious data (Figs. 2 and 4) suggest that like Q151X, both were 
estabilized and prone to self-aggregation and the fact that 
oth also form cytoplasmic aggregates supports this conclu-
ion. Our data also complement a paper published as our manu-
0508 JOURNAL OF BIOLOGICAL CHEMISTRY 
script was being reviewed, which found that both Q151X and 
464delCT aB-crystallin formed aggregates in transfected cells 
(51). To provide an assessment of the solubility of the different 
aB-crystallin constructs in populations of transiently trans-
fected MCF7 cells, cell extracts were produced and fractionated 
into supernatant and pellet fractions by centrifugation prior to 
analysis by SDS-PAGE and immunoblotting with antibodies to 
HSP27 and aB-crystallin (Fig. 8£). Transfected wild type 
aB-crystallin was found almost entirely in the soluble fraction 
(Fig. 8£, lane 1). Transfected Q151X, 464delCT, and E164X, 
however, were detected almost entirely in the pellet fractions 
(Fig. 8E, lanes 4, 6, and 8, respectively) with only a small pro-
portion left in the supernatant fractions (Fig. 8£, lanes 3, 5, and 
7, respectively). The endogenous HSP27 was unable to prevent 
the formation of aggregates by the mutant aB-crystallins and 
the presence of these aggregates did not cause a significant shift 
in the solubility of the endogenous HSP27 to the pellet fraction. 
These data support our hypothesis that the loss of the C-terrni-
nal domain, as occurs in the Q151X mutation, dramatically 
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he ability of the 0151 X aD-crystallin to prevent des min filament aggregation. Images obtained by electron microscopy of negatively stained samples of the 
mbled filaments fordesmin assembled in the presence of wild type (E) and 0151 X (F) aEk:rystallin are shown to show that the addition of both chaperones has not 
ramatkally altered filament morphology or length. Notice the lack of crystallin partkles In the 0151 X sample. Bar, 100 nm. 5, supernatant; P, pellet. 
creases the tendency of aB-crystallin to self-aggregate, even 
a cellular environment. 
Removal of the C-terminal Extension Reduces a.B-Crystallin 
ligomerization, but Not Chaperone Activity-The consensus 
'ew that has emerged from recent studies on mammalian 
PRIL 18, 2008•VOLUME 283 · NUMBER 16 
sHSPs is that the C-terminal extension is important for oli-
gomerization and chaperone function {19, 22, 26, 28). The 
study presented here is the first to investigate the effects of 
sequentially truncating this domain (Lys174, Ala171 , Glu165, and 
Glu164) upon both aspects for aB-crystallin. It shows that dele-
tion of the last 5 residues can improve chaperone activity in the 
citrate synthase assay without dramatically changing the sec-
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FIGURE 8. Decreased solubility and Increased aggregation potential of 
Q151X aS-crystallin is revealed by transient transfectlon Into MCF7 
cells. A-D, MCF7 cells transiently transfected with wild type (A), 0151 X (8), 
464deiG (Q, or E164X (D) aS-crystallin were fixed at 24 h post-transfection 
and processed for immunofluorescence microscopy. The subcellular distribu-
tion of aS-crystallin and keratin were visualized by double labeling with 
monoclonal anti-keratin (red channe/) and polyclonal anti-aS-crystallin anti-
bodies (green channe/). A-D are merged images, showing the superimposi-
tion of the green, red, and blue (4' ,6-diamidino-2-phenylindole staining) chan-
nels. Images are individual optical sections acquired using a confocal laser 
scanning microscope (Zeiss 510). Cells expressing wild type aS-crystallin (A) 
showed the expected cytoplasmic distribution of aS-crysta llin. In contrast, 
cells expressing mutant aS-crystallin resulted in the formation of cytoplasmic 
aggregates of aS-crystallin (8-D). Notice that 464deiG aggregates are scat-
tered throughout the cytoplasm, whereas the 0151X and E164X aggregates 
locate to the perinuclear region of the cell. Bars, 10 J.lftl. lmmunoblotting 
·analysis (E) of aS-crystallin transiently transfected in MCF7 cells shows a shift 
in solubility for the mutant aS-crystallins. At 24 h post-transfection, cells were 
extracted with detergent buffer followed by centrifugation at 18,000 x g for 
10 min at 4 •c. The resulting supernatant (5) and pellet {PJ fractions were 
analyzed by 5DS.PAGE followed by immunoblotting analysis using anti-H5P 
27 (loading control) and aS-crystallin antibodies. The blot was developed 
using enhanced chemiluminescence. Whereas wild type aS-crystallin was 
almost entirely soluble (f, lane 7, labeled 5), 0151 X (lane 4), 464deiG (lane6), 
and E 164X (lane 8) were found mostly in the pellet fractions (labeled P) of cell 
extracts. The relative electrophoretic mobility of mutant aS-crystallins is 
denoted by the arrowhead ( .... ). Uke wild type aS-crystallin, HSP27 was also 
largely present in the supernatant fractions (E, lanes 2, 4, and 6, labeled P). 
ese data are representative of three experiments. 
ndary structure or oligomerization of aS-crystallin. Trunca-
·ons (E164X, E165X) in the conserved REEK motif (26) 
ecreased chaperone activity and oligomerization, although 
is coincided with more polydispersity for the oligomer as 
udged by size exclusion chromatography (Fig. 2). The removal 
fthe C-terminal extension by the Q151X mutation produced a 
onstruct with the best chaperone activity profile of all the indi-
. dual protein clients investigated (Figs. 6 and 7) despite the 
ost significant changes in secondary structure (Fig. 3), his-
S binding (Fig. 5), and altered oligomerization (Fig. 2). 
Whereas these r ults are in bro d gr rn nt with the con-
ens us for other mammalian sHSPs, they demonstrate that the 
emoval of the C-terminal extension from residue 151 prevents 
ligomerization (at concentrations less than 0.1 mg/rnl), but 
ot at the expense of chaperone function for aS-crystallin. 
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Indeed the citroconylation of full-length aS-crystallin achieves 
similar results and together with these data strongly support 
the conclusion that oligomerization is not required for aS-crys-
tallin chaperone activity (42). 
Deletion of the C-terminal Extension by the QJSJX Mutation 
Increases Chaperone Activity for Some Client Proteins-The 
somewhat surprising observation is that the Q151X mutation 
actually improved chaperone activity for some client proteins 
(desmin and citrate synthase), in stark contrast to the effect of 
removing a similar region from aA-crystallin where chaperone 
activity was lost (22, 28). 
The C-terminal extension deleted by the Q151X mutation 
includes the IX(I/V) motif (16), which is part of f3-strand 10 (17, 
23), that has been shown to be both part of a client protein 
binding site (19) and an oligomerization sequence (20) in 
aS-crystallin. This is removed by all three disease-causing 
mutations, including Q151X, but retained in the other trunca-
tion constructs (Fig. 1). Glycine substitutions in the IX(I/V) 
motif not only increased oligomerization and polydispersity of 
aS-crystallin, but also significantly increased chaperone activ-
ity (52). The data we have presented for Q151X aS-crystallin 
and the other truncation constructs suggest that the client pro-
tein binding site that embraces the IX(I/V) motif (19, 53) is not 
only dispensable for activity, but that it could actually inhibit 
chaperone function as its removal actually increased activity 
(citrate synthase, ~7.5-fold; desmin, -2-fold). 
A three-dimensional model of aS-crystallin has suggested 
that the C-terminal extension potentially acts as a "cap" on an 
important oligomerization and client protein binding site, 
namely the {33-{38-{39 interface (46). This region also interacts 
with the {34 strand, which is important in sHSP oligomerization 
as seen from the crystal structure of HSP16.9 (23), but it is also 
critical for chaperone activity (46). In fact reducing aS-crystal-
lin to just its a-crystallin domain spanning residues 57-157, 
which still includes the {33-{38-{39 surface, retained chaperone 
activity, but this construct only formed dimers and could not 
oligomerize (54). It is easy to explain these observations and 
also our data on the Q151X aS-crystallin mutant, in terms of 
how the removal of this C-terminal extension cap as proposed 
in the model ( 46) could allow substrate to bind more readily and 
thus enhance chaperone function while also decreasing oli-
gomer size. The data we have presented here support this 
model and also add an interesting dimension. Our data also 
suggest that the C-terminal extension actually limits the full 
potential of aS-crystallin chaperone activity for some client 
proteins. 
Aggregation of aB-Crystallin Encouraged by the Removal of 
the C-terminal Extension-The strong tendency of Q151X to 
aggregate at protein concentrations greater than 0.1 mglml and 
its very low refolding yield (Fig. ill}, suggests another potential 
role played by the C-terminal extension in preventing the 
uncontrolled self-aggregation of aS-crystallin (55). From the 
available sHSP crystal structures (17, 23), the C-terminal exten-
sion l solvent exposed and contributes to the higher order 
assembly of the oligomer (23, 56 -58). In HSP16.9, the IX(I/V) 
motif from one subunit lays in a hydrophobic groove between 
{34 and {38 strands of the other interacting monomer. Although 
aB-crystallin has similar structural features, including the con-
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served IX(IIV) motif in its C-terminal extension (Fig. lA), the 
oligomers it forms are more polydisperse (55, 59, 60) compared 
with either HSP16.5 or HSP16.9, suggesting that the precise 
detail for the interactions of the C-terminal extension in 
aB-crystallin will vary, not least due to the different hinge 
sequences between 13-strands 9 and 10 (23). The strong tend-
ency of Q151X aB-crystallin to aggregate suggests that the 
C-terminal extension actually prevents such potential errant 
associations to favor instead oligomerization. 
Reduced Protein Stability and Uncontrolled Self-aggregation 
Underlies the Molecular Basis of the Q151X, 450delA, and 
464delCT Mutations-The loss of the C-terminal extension 
due to the Q151X mutation in aB-crystallin dramatically 
altered the secondary {Fig. 3) and tertiary structure of the pro-
tein (Fig. 2). This mutant was significantly destabilized as seen 
from the heat stability assay (Fig. 4) and showed a dramatic 
increase in the tendency to self-aggregate in vitro (Fig. 1) and in 
vivo (Fig. 8). Only a small proportion of Q151X aB-crystallin 
( ~ 1%, Fig. 1D) remained soluble after refolding. Even in the 
presence of equimolar wild type aB-crystallin, the mixture had 
significantly altered secondary structure (Fig. 2), which affected 
aB-crystallin oligomerization (Fig. 3) and reduced refold yields 
(Fig. 1D). The Q151X mutation was dominant over the wild 
type protein in its effects upon heat stability, solubility, and 
secondary structure. These data suggest that the str~ng tend-
ency to self-aggregate as a result of reduced stability is poten-
tially an important factor in disease development. 
Our data for both 450delA and 464delCT also suggest that it 
is a similar loss in protein stability that causes cataract and 
myofibrillar myopathy, respectively. Both mutants can only be 
refolded in the presence of wild type aB-crystallin and even 
en the temperature stabilities of the mixtures are reduced by 
orne 20 ·c compared with the wild type protein alone. Both the 
50delA and 464delCT mutations introduced novel C-terminal 
eptides that have no homology to the existing C-terminal 
xtension of aS-crystallin (Fig. lA). Both mutations changed 
e oligomerization of wild type aB-crystallin and neither 
utant/wild type mixture was an effective chaperone in either 
e desmin (Fig. 7) or insulin (Fig. 6, C and D) assays. Indeed, the 
50delA mutation actively promoted filament-filament inter-
ctions for desmin, as reported previously for R120G aB-crys-
in (10) and, under the assay conditions here, 450delA was 
ore efficient than R120G in this activity. Therefore the loss of 
haperone activity coupled with sequestration by client pro-
eins could both contribute to the development of disease in the 
ase of these two mutants. We suggest, however, that the aggre-
ation of aB-crystallin is a key feature that offers potential for 
ain of function via its amyloidogenic potential (61). 
The most difficult observation to explain regarding the 
151X mutation is its muscle-specific effect, which restricts 
e pathology to myofibillar myopathy (18). In fact all three 
isease-causing mutations in the C-terminal extension of 
B-crystallin (Q151X, 450delA, and 464delCT) are restricted in 
_ eir,pathology _to-either- the-lens-(450delA -(16)) or-muscle 
151X, 464delCT; (18)) and yet aB-crystallin is very highly 
xpressed in both tissues (5). This is a familiar trend for 
B-crystallin mutations and even the most recently published 
utation, D140N, causes only lens cataract (62). Thus far, 
PRIL 18, 2008•VOLUME 283·NUMBER 16 
R120G aB-crystallin is the only mutation that has produced 
both lens and muscle pathologies (9), but this is not to say that 
subclinical pathology can be totally excluded for the other 
mutations, including Q151X, as tissue biopsies from apparently 
unaffected tissues were not analyzed. Aggregation is a key his-
topathological feature of the Q151X mutation (18) concurring 
with our transient transfection and cell fractionation studies 
(Fig. 8) and so, this provides a plausible mechanism to support 
a potential dominant negative effect of the mutation by inhib-
iting the chaperone function of wild type aB-crystallin via coag-
gregation with mutant Q151X as implicated from our in vitro 
studies (Fig. 1). 
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Supplementary Figure 1. Dynamic Light Scattering analyses of aB-crystallin wild type. The data shown 
represents the average of 3 runs, each of which consisted of 5 data accumulations. Supplementary Figure 
LA shows the 3 data sets overlayed and confirms that the wild type oligomer accounts for 100% of the 
protein in the SEC pool. Figure IB shows the corresponding histogram and (C) represents the intensity or 
level of light scattering produced by the aB-crystallin wild type. 
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Supplementary Figure 2. Native gel electrophoresis of the Q 151 X aB-crystallin oligomer. Analysis of 
Q151X aB-crystallin oligomer size, relative to wild type and Q15IX/ wild type aB-crystallin . High and 
low Mwt calibrators are shown in lanes 4-7. All lanes represent a 20 Jlg loading with the exception of the 
Ql51X aB-crystallin (1.0 I•&) wh re the nature of the Ql5lX aB crystallin refolding limits the available 
level of protein for analysis. 
1.0 
0.9 
0.8 
a 0.7 
0.6 
M 
~ 0.5 
~ 
-e 0.4 
~ 
~ 0.3 
0.2 
0.1 
-+- Citrate Synthase control 
~Wild Type 
"""'*"- 450deW Wlld Type 
--- 464delCf/ Wild Type 
---1- Ql51X/ Wild Type 
-+- Ql51X 
-B-El64X 
-&-El65X 
....,._ Kl74X 
-Al71X 
400 
200 400 
600 
600 
Appendix 6 
800 1000 1200 1400 
Tune (sec) 
800 1000 1200 1400 
Time (sec) 
800 1000 1200 1400 
Time (sec) 
Supplementary Figure 3. Triplicate data set of Citrate synthase assays. 
348 
1600 1800 
1600 1800 
1600 1800 
Appendix 6 349 
References 350 
REFERENCES 
References 351 
Adams, J.M., Huang, D.C., Puthalakath, H., Bouillet, P., Vairo, G., Moriishi, K., 
Hausmann, G., O'Reilly, L., Newton, K., Ogilvy, S., Bath, M.L., Print, C.G., 
Harris, A.W., Strasser, A. and Cory, S. (1999) Control of apoptosis in 
hematopoietic cells by the Bcl-2 family of proteins. Cold Spring Harb Symp Quant 
Bioi, 64, 351-358. a. 
Aguilera, A. (2002) The connection between transcription and genomic instability. EMBO 
J., 21, 195-201. 
Andley, U.P., Mathur, S., Griest, T.A. and Petrash, J.M. (1996) Cloning, expression, and 
chaperone-like activity of human a.A-crystallin. J Bioi Chem, 271,31973-31980. 
Andley, U.P., Patel, H.C. and Xi, J.H. (2002) The Rll6C mutation in a.A-crystallin 
diminishes its protective ability against stress-induced lens epithelial cell 
apoptosis. J Bioi Chem, 277, 10178-10186. 
Andley, U.P., Song, Z., Wawrousek, E.F., Brady, J.P., Bassnett, S. and Fleming, T.P. 
(2001) Lens epithelial cells derived from a.B-crystallin knockout mice demonstrate 
hyperproliferation and genomic instability. Faseb J, 15, 221-229. 
Andley, U.P., Song, Z., Wawrousek, E.F., Fleming, T.P. and Bassnett, S. (2000) 
Differential protective activity of a.A- and a.B-crystallin in lens epithelial cells. J 
Bioi Chem, 215,36823-36831. 
Apple, D.J., Peng, Q., Visessook, N., Werner, L., Pandey, S.K., Escobar-Gomez, M., 
Ram, J., Whiteside, S.B., Schoderbeck, R., Ready, E.L. and Guindi, A. (2000) 
Surgical prevention of posterior capsule opacification. Part 1: Progress in 
eliminating this complication of cataract surgery. J Cataract Refract Surg, 26, 180-
187. 
Aquilina, J.A. (2005) Subunit Exchange of Polydisperse Proteins. The Journal of 
Biological Chemistry, 280, 14485-14491. 
Aquilina, J.A., Benesch, J.L., Bateman, O.A., Slingsby, C. and Robinson, C.V. (2003) 
Polydispersity of a mammalian chaperone: mass spectrometry reveals the 
population of oligomers in a.B-crystallin. Proc Nat/ A cad Sci U S A, I 00, 10611-
10616. 
Aquilina, J.A., Benesch, J.L., Ding, L.L., Yaron, 0., Horwitz, J. and Robinson, C.V. 
(2004) Phosphorylation of a.B-crystallin alters chaperone function through loss of 
dimeric substructure. J Bioi Chem, 279, 28675-28680. 
Arai, H. and Atomi, Y. (1997) Chaperone activity of a.B-crystallin suppresses tubulin 
aggregation through complex formation. Cell Struct Funct, 22, 539-544. 
Askanas, V. and Engel, W.K. (2006) Inclusion-body myositis: a myodegenerative 
conformational disorder associated with Afl, protein misfolding, and proteasome 
inhibition. Neurology, 66, 839-48. 
Augusteyn, R.C. (2004a) a.-crystallin: a review of its structure and function. Clin Exp 
Optom, 87, 356-366. 
Augusteyn, R.C. (2004b) Dissociation is not required for a.-crystallin's chaperone 
function. Exp Eye Res, 19,781-784. 
Augusteyn, R.C., Stevens, A. (1998) Macromolecular Structure of the Eye lens. Progress 
in Polymer Science, 23, 375-413. 
Avilov, S.V., Aleksandrov, N.A. and Demchenko, A.P. (2004) Quaternary structure of a.-
crystallin is necessary for the binding of unfolded proteins: a surface plasmon 
resonance study. Protein Pept Lett, 11,41-48. 
References 352 
Awasthi, N. and Wagner, B.J. (2005) Upregulation of heat shock protein expression by 
proteasome inhibition: an antiapoptotic mechanism in the lens. Invest Ophthalmol 
Vis Sci, 46, 2082-2091. 
Aziz, A., Santhoshkumar, P., Sharma, K.K. and Abraham, E.C. (2007) Cleavage of the C-
terminal serine of human aA-crystallin produces aA1-172 with increased 
chaperone activity and oligomeric size. Biochemistry, 46, 2510-2519. 
Bardwell, J.C. and Craig, E.A. (1988) Ancient heat shock gene is dispensable. J Bacteriol, 
170, 2977-2983. 
Barral, J.M., Broadley, S.A., Schaffar, G. and Hartl, F.U. (2004) Roles of molecular 
chaperones in protein misfolding diseases. Semin Cell Dev Bioi, 15, 17-29. 
Beavis, R.C. and Chait, B.T. (1990) High-accuracy molecular mass determination of 
proteins using matrix-assisted laser desorption mass spectrometry. Anal Chem, 62, 
1836-1840. 
Bellini, M. and Gall, J.G. (1999) Coilin shuttles between the nucleus and cytoplasm in 
Xenopus oocytes. Mol Bioi Cell, 10, 3425-3434. 
Benesch, J.L., Aquilina, J.A., Ruotolo, B.T., Sobott, F. and Robinson, C.V. (2006) 
Tandem mass spectrometry reveals the quaternary organization of macromolecular 
assemblies. Chem Bioi, 13, 597-605. 
Benesch, J.L. and Robinson, C.V. (2006) Mass spectrometry of macromolecular 
assemblies: preservation and dissociation. Curr Opin Struct Bioi, 16,245-251. 
Bennardini, F., Wrzosek, A. and Chiesi, M. (1992) aB-crystallin in cardiac tissue. 
Association with actin and desmin filaments. Circ Res, 71,288-294. 
Bergman, A. and Siegal, M.L. (2003) Evolutionary capacitance as a general feature of 
complex gene networks. Nature, 424, 549-552. 
Berry, V., Francis, P., Kaushal, S., Moore, A. and Bhattacharya, S. (2000) Missense 
mutations in MIP underlie autosomal dominant 'polymorphic' and lamellar 
cataracts linked to 12q. Nat Genet, 25, 15-17. 
Berry, V., Francis, P., Reddy, M.A., Collyer, D., Vithana, E., MacKay, I., Dawson, G., 
Carey, A.H., Moore, A., Bhattacharya, S.S. and Quinlan, R.A. (2001) aB crystallin 
gene (CRY AB) mutation causes dominant congenital posterior polar cataract in 
humans. Am J Hum Genet, 69, 1141-1145. 
Bhat, S.P. and Nagineni, C.N. (1989) aB subunit of lens-specific protein a-crystallin is 
present in other ocular and non-ocular tissues. Biochem Biophys Res Commun, 
158, 319-325. 
Bhattacharyya, J., Padmanabha Udupa, E.G., Wang, J. and Sharma, K.K. (2006) Mini-aB-
crystallin: a functional element of aB-crystallin with chaperone-like activity. 
Biochemistry, 45, 3069-3076. 
Billingsley, G., Santhiya, S.T., Paterson, A.D., Ogata, K., Wodak, S., Hosseini, S.M., 
Manisastry, S.M., Vijayalakshmi, P., Gopinath, P.M., Graw, J. and Heon, E. 
(2006) CRYBA4, a novel human cataract gene, is also involved in 
microphthalmia. Am J Hum Genet, 79, 702-709. 
Biswas, A. and Das, K.P. (2004) Role of ATP on the interaction of a-crystallin with its 
substrates and its implications for the molecular chaperone function. J Bioi Chem, 
279, 42648-42657. 
Bloemendal, H., de Jong, W., Jaenicke, R., Lubsen, N.H., Slingsby, C. and Tardieu, A. 
(2004) Ageing and vision: structure, stability and function of lens crystallins. Prog 
Biophys Mol Bioi, 86, 107-485. 
References 353 
Bloemendal, H. and de Jong, W.W. (1991) Lens proteins and their genes. Prog Nucleic 
Acid Res Mol Bioi, 41, 259-281. 
Boelens, W.C., Croes, Y., de Ruwe, M., de Reu, L. and de Jong, W. W. (1998) Negative 
charges in the C-terminal domain stabilize the aS-crystallin complex. J Bioi 
Chem, 273, 28085-28090. 
Bobula, J., Tomala, K., Jez, E., Wloch, D.M., Borts, R.H. and Korona, R. (2006) Why 
molecular chaperones buffer mutational damage: a case study with a yeast 
Hsp40/70 system. Genetics, 174, 937-944. 
Bousquet, 0., Ma, L., Yamada, S., Gu, C., Idei, T., Takahashi, K., Wirtz, D. and 
Coulombe, P .A. (200 1) The nonhelical tail domain of keratin 14 promotes filament 
bundling and enhances the mechanical properties of keratin intermediate filaments 
in vitro. JCe/1 Bioi, 155,747-754. 
Bova, M.P., Ding, L.L., Horwitz, J. and Fung, B.K. (1997) Subunit exchange of aA-
crystallin. J Bioi Chem, 272, 29511-29517. 
Bova, M.P., McHaourab, H.S., Han, Y. and Fung, B.K. (2000) Subunit exchange of small 
heat shock proteins. Analysis of oligomer formation of aA-crystallin and Hsp27 
by fluorescence resonance energy transfer and site-directed truncations. J Bioi 
Chem, 275, 1035-1042. 
Bova, M.P., Yaron, 0., Huang, Q., Ding, L., Haley, D.A., Stewart, P.L. and Horwitz, J. 
(1999) Mutation R120G in aS-crystallin, which is linked to a desmin-related 
myopathy, results in an irregular structure and defective chaperone-like function. 
Proc Nat/ Acad Sci US A, 96, 6137-6142. 
Bradley, R.H., Ireland, M.E. and Maisel, H. (1979) Age changes in the skeleton of the 
human lens. Acta Ophtha/mol (Copenh), 57,461-469. 
Bron, A.J., Vrensen, G.F., Koretz, J., Maraini, G. and Harding, J.J. (2000) The ageing 
lens. Ophthalmologica, 214, 86-104. 
Bu, L., Jin, Y., Shi, Y., Chu, R., Ban, A., Eiberg, H., Andres, L., Jiang, H., Zheng, G., 
Qian, M., Cui, B., Xia, Y., Liu, J., Hu, L., Zhao, G., Hayden, M.R. and Kong, X. 
(2002) Mutant DNA-binding domain of HSF4 is associated with autosomal 
dominant lamellar and Marner cataract. Nat Genet, 31,276-278. 
Bullard, B., Ferguson, C., Minajeva, A., Leake, M.C., Gautel, M., Labeit, D., Ding, L., 
Labeit, S., Horwitz, J., Leonard, K.R. and Linke, W.A. (2004) Association of the 
chaperone aS-crystallin with titin in heart muscle. J Bioi Chem, 279, 7917-7924. 
Bunkoczi, G., Salah, E., Filippakopoulos, P., Fedorov, 0., Muller, S., Sobott, F., Parker, 
S.A., Zhang, H., Min, W., Turk, B.E. and Knapp, S. (2007) Structural and 
functional characterization of the human protein kinase ASKl. Structure, 15, 
1215-1226. 
Carra, S., Sivilotti, M., Chavez Zobel, A.T., Lambert, H. and Landry, J. (2005) HspB8, a 
small heat shock protein mutated in human neuromuscular disorders, has in vivo 
chaperone activity in cultured cells. Hum Mol Genet, 14, 1659-1669. 
Carver, J.A. (1999) Probing the structure and interactions of crystallin proteins by NMR 
spectroscopy. Prog Retin Eye Res, 18,431-462. 
Carver, J.A., Aquilina, J.A., Truscott, R.J. and Ralston, G.B. (1992) Identification by 1H 
NMR spectroscopy of flexible C-terminal extensions in bovine lens a-crystallin. 
FEBS Lett, 311, 143-149. 
Carver, J.A., Guerreiro, N., Nicholls, K.A. and Truscott, R.J. (1995) On the interaction of 
a-crysta_llin with_ unfo~ded proteins. Biochim Biophys Acta_, 1252, 25 !~60. 
References 354 
Carver, J.A. and Lindner, R.A. (1998) NMR spectroscopy of a-crystallin. Insights into the 
structure, interactions and chaperone action of small heat-shock proteins. Int J Bioi 
Macromol, 22, 197-209. 
Carver, J.A., Nicholls, K.A., Aquilina, J.A. and Truscott, R.J. (1996) Age-related changes 
in bovine a-crystallin and high-molecular-weight protein. Exp Eye Res, 63, 639-
647. 
Caspers, G.J., Leunissen, J.A. and de Jong, W.W. (1995) The expanding small heat-shock 
protein family, and structure predictions of the conserved "a-crystallin domain". J 
Mol Evol, 40, 238-248. 
Cenciarelli, C., Chiaur, D.S., Guardavaccaro, D., Parks, W., Vidal, M. and Pagano, M. 
(1999) Identification of a family of human F-box proteins. Curr Bioi, 9, 1177-
1179. 
Chang, Z., Primm, T.P., Jakana, J., Lee, I.H., Serysheva, 1., Chiu, W., Gilbert, H.F. and 
Quiocho, F.A. (1996) Mycobacterium tuberculosis 16-kDa antigen (Hsp16.3) 
functions as an oligomeric structure in vitro to suppress thermal aggregation. J 
Bioi Chem, 271, 7218-7223. 
Chavez Zobel, A.T., Loranger, A., Marceau, N., Theriault, J.R., Lambert, H. and Landry, 
J. (2003) Distinct chaperone mechanisms can delay the formation of aggresomes 
by the myopathy-causing R120G aD-crystallin mutant. Hum Mol Genet, 12, 1609-
1620. 
Cheng, C.Y., Yen, M.Y., Chen, S.J., Kao, S.C., Hsu, W.M. and Liu, J.H. (2001) Visual 
acuity and contrast sensitivity in different types of posterior capsule opacification. 
J Cataract Refract Surg, 27, 1055-1060. 
Chiesi, M., Longoni, S. and Limbruno, U. (1990) Cardiac a-crystallin. III. Involvement 
during heart ischemia. Mol Cell Biochem, 97, 129-136. 
Christen, W.G., Glynn, R.J., Chew, E.Y. and Buring, J.E. (2007) Vitamin E and Age-
Related Cataract in a Randomized Trial of Women. Ophthalmology. 
Ciechanover, A. (1998) The ubiquitin-proteasome pathway: on protein death and cell life. 
Embo J, 17, 7151-7160. 
Ciechanover, A. (2001) Linking ubiquitin, parkin and synphilin-1. Nat Med, 7, 1108-1109. 
Cobb, B.A. and Petrash, J.M. (2002) a-Crystallin chaperone-like activity and membrane 
binding in age-related cataracts. Biochemistry, 41, 483-490. 
Colvis, C.M., Duglas-Tabor, Y., Werth, K.B., Vieira, N.E., Kowalak, J.A., Janjani, A., 
Yergey, A.L. and Garland, D.L. (2000) Tracking pathology with proteomics: 
identification of in vivo degradation products of aD-crystallin. Electrophoresis, 21, 
2219-2227. 
Conley, Y.P., Erturk, D., Keverline, A., Mah, T.S., Keravala, A., Barnes, L.R., Bruchis, 
A., Hess, J.F., FitzGerald, P.G., Weeks, D.E., Ferrell, R.E. and Gorin, M.B. (2000) 
A juvenile-onset, progressive cataract locus on chromosome 3q21-q22 is 
associated with a missense mutation in the beaded filament structural protein-2. 
Am J Hum Genet, 66, 1426-1431. 
Cryns, V. and Yuan, J. (1998) Proteases to die for. Genes Dev, 12, 1551-1570. 
Csermely, P. (2004) Strong links are important, but weak links stabilize them. Trends 
Biochem Sci, 29, 331-334. 
Csermely, P. and Soti, C. (2006) Cellular networks and the aging process. Arch Physiol 
Biochem, 112, 60-64. 
Cubas, P., Vincent, C. and Coen, E. (1999) An epigenetic mutatio!l resiJonsible for natural 
- vanatiori-m flonifsymmetry. Nature, 401~157-161. -
References 355 
Cvekl, A. and Piatigorsky, J. (1996) Lens development and crystallin gene expression: 
many roles for Pax-6. Bioessays, 18, 621-630. 
Dahlman, J.M., Margot, K.L., Ding, L., Horwitz, J. and Posner, M. (2005) Zebrafish a-
crystallins: protein structure and chaperone-like activity compared to their 
mammalian orthologs. Mol Vis, 11, 88-96. 
Datta, S.A. and Rao, C.M. (1999) Differential temperature-dependent chaperone-like 
activity of aA- and aS-crystallin homoaggregates. J Bioi Chern, 274, 34773-
34778. 
Datta, S.A. and Rao, C.M. (2000) Packing-induced conformational and functional changes 
in the subunits of a-crystallin. J Bioi Chern, 275,41004-41010. 
de Jong, W. W., Caspers, G.J. and Leunissen, J.A. (1998) Genealogy of the a-crystallin--
small heat-shock protein superfamily. Int J Bioi Macrornol, 22, 151-162. 
de Jong, W.W., Leunissen, J.A., Leenen, P.J., Zweers, A. and Versteeg, M. (1988) 
Dogfish a-crystallin sequences. Comparison with small heat shock proteins and 
Schistosoma egg antigen. J Bioi Chern, 263, 5141-5149. 
De Jonghe, P., Timmerman, V., Van Broeckhoven, C. (1998) 2nd Workshop of the 
European CMT Consortium: 53rd ENMC International Workshop on 
Classification and Diagnostic Guidelines for Charcot-Marie-Tooth Type 2 (CMT2-
HMSN II) and Distal Hereditary Motor Neuropathy (distal HMN-Spinal CMT) 26-
28 September 1997, Naarden, The Netherlands. Neurornuscul Disord, 8, 426-431. 
De Rijk, E.P., Van Rijk, A.F., Van Esch, E., De Jong, W.W., Wesseling, P. and 
Bloemendal, H. (2000) Demyelination and axonal dystrophy in aA-crystallin 
transgenic mice. Int J Exp Pathol, 81,271-282. 
del Valle, L.J., Escribano, C., Perez, J.J. and Garriga, P. (2002) Calcium-induced decrease 
of the thermal stability and chaperone activity of a-crystallin. Biochirn Biophys 
Acta, 1601, 100-109. 
Delcourt, C., Dupuy, A.M., Carriere, 1., Lacroux, A. and Cristo!, J.P. (2005) Albumin and 
transthyretin as risk factors for cataract: the POLA study. Arch Ophthalrnol, 123, 
225-232. 
den Engelsman, J., Keijsers, V., de Jong, W.W. and Boelens, W.C. (2003) The small heat-
shock protein aS-crystallin promotes FBX4-dependent ubiquitination. J Bioi 
Chern, 278, 4699-4 704. 
Deretic, D., Aebersold, R.H., Morrison, H.D. and Papermaster, D.S. (1994) aA- and aS-
crystallin in the retina. Association with the post-Golgi compartment of frog retinal 
photoreceptors. J Bioi Chern, 269, 16853-16861. 
Derham, B.K. and Harding, J.J. (1999) a-crystallin as a molecular chaperone. Prog Retin 
Eye Res, 18,463-509. 
Dickerson, J.E., Jr., Dotzel, E. and Clark, A.F. (1997) Steroid-induced cataract: new 
perspective from in vitro and lens culture studies. Exp Eye Res, 65, 507-516. 
Doss-Pepe, E.W., Carew, E.L. and Koretz, J.F. (1998) Studies of the denaturation patterns 
of bovine a-crystallin using an ionic denaturant, guanidine hydrochloride and a 
non-ionic denaturant, urea. Exp Eye Res, 67, 657-679. 
Drexler, H.C. (1997) Activation of the cell death program by inhibition of proteasome 
function. Proc Nat/ Acad Sci US A, 94, 855-860. 
Dubin, R.A., Wawrousek, E.F. and Piatigorsky, J. (1989) Expression of the murine aB~ 
crystallin gene is not restricted to the lens. Mol Cell Bioi, 9, 1083-1091. 
Duncan,_ G._and_Jacob,_T.J,_(1984)-Calcium-and the-physiology-of-cataract. Giba Found -
Syrnp, 106, 132-152. 
;s.---- - --
References 356 
Durrant, A. (1962) The environmental induction of heritable change in Linum. Heredity, 
17, 27-61. 
Ehrnsperger, M., Lilie, H., Gaestel, M. and Buchner, J. (1999) The dynamics of Hsp25 
quaternary structure. Structure and function of different oligomeric species. J Bioi 
Chern, 274, 14867-14874. 
Ellis, R.J. and Minton, A.P. (2003) Cell biology: join the crowd. Nature, 425, 27-28. 
Elmore, S. (2007) Apoptosis: a review of programmed cell death. Toxicol Patho/, 35, 495-
516. 
Evgrafov, O.V., Mersiyanova, I., Irobi, J., Van Den Bosch, L., Dierick, I., Leung, C.L., 
Schagina, 0., Verpoorten, N., Van lmpe, K., Fedotov, V., Dadali, E., Auer-
Grumbach, M., Windpassinger, C., Wagner, K., Mitrovic, Z., Hilton-Jones, D., 
Talbot, K., Martin, J.J., Vasserman, N., Tverskaya, S., Polyakov, A., Liem, R.K., 
Gettemans, J., Robberecht, W., De Jonghe, P. and Timmerman, V. (2004) Mutant 
small heat-shock protein 27 causes axonal Charcot-Marie-Tooth disease and distal 
hereditary motor neuropathy. Nat Genet, 36, 602-606. 
Fain, 0. (2004) [Vitamin C deficiency]. Rev Med Interne, 25, 872-880. 
Fares, M.A., Ruiz-Gonzalez, M.X., Moya, A., Elena, S.F. and Barrio, E. (2002) 
Endosymbiotic bacteria: groEL buffers against deleterious mutations. Nature, 417, 
398. 
Fayet, 0., Louam, J.M. and Georgopoulos, C. (1986) Suppression of the Escherichia coli 
dnaA46 mutation by amplification of the groES and groEL genes. Mol Gen Genet, 
202, 435-445. 
Feil, I.K., Malfois, M., Hendle, J., van Der Zandt, H. and Svergun, D.l. (2001) A novel 
quaternary structure of the dimeric a-crystallin domain with chaperone-like 
activity. J Bioi Chern, 276, 12024-12029. 
Fernando, P., Heikkila, J.J. (2000) Functional characterisation of Xenopus small heat 
shock protein, Hsp3-C: the carboxyl end is required for stability and chaperone 
activity. Cell Stress & Chaperones, 5, 148-159. 
Francis, P.J., Berry, V., Bhattacharya, S.S. and Moore, A.T. (2000) The genetics of 
childhood cataract. J Med Genet, 37,481-488. 
Francis, P.J., Berry, V., Moore, A.T. and Bhattacharya, S. (1999) Lens biology: 
development and human cataractogenesis. Trends Genet, 15, 191-196. 
Fratta, P., Engel, W.K., McFerrin, J., Davies, K.J., Lin, S.W. and Askanas, V. (2005) 
Proteasome inhibition and aggresome formation in sporadic inclusion-body 
myositis and in amyloid-beta precursor protein-overexpressing cultured human 
muscle fibers. Am J Pathol, 167, 517-526. 
Fujita, Y., Ohto, E., Katayama, E. and Atomi, Y. (2004) aB-Crystallin-coated MAP 
microtubule resists nocodazole and calcium-induced disassembly. J Cell Sci, 117, 
1719-1726. 
Ganadu, M.L., Aru, M., Mura, G.M., Coi, A., Mlynarz, P. and Kozlowski, H. (2004) 
Effects of divalent metal ions on the a.B-crystallin chaperone-like activity: 
spectroscopic evidence for a complex between copper(ll) and protein. J Inorg 
Biochem, 98, 1103-1109. 
Geisler, N. and Weber, K. (1981) Comparison of the proteins of two immunologically 
distinct intermediate-sized filaments by amino acid sequence analysis: desmin and 
vimentin. Proc Nat/ Acad Sci US A, 78,4120-4123. 
Georgopoulos, C. (2004) In vivo analysis of the overlapping functions of DnaK and 
trigger-factor~EMBO-Rep, 5, 195:;;200:- --- - ----
References 357 
Ghosh, J.G. and Clark, J.I. (2005a) Insights into the domains required for dimerization and 
assembly ofhuman aB crystallin. Protein Sci, 14, 684-695. 
Ghosh, J.G., Estrada, M.R. and Clark, J.l. (2005b) Interactive domains for chaperone 
activity in the small heat shock protein, human aB crystallin. Biochemistry, 44, 
14854-14869. 
Ghosh, J.G., Estrada, M.R. and Clark, J.l. (2006a) Structure-based analysis of the betaS 
interactive sequence of human aB crystallin. Biochemistry, 45, 9878-9886. 
Ghosh, J.G., Estrada, M.R., Houck, S.A. and Clark, J.I. (2006b) The function of the fB 
interactive domain in the small heat shock protein and molecular chaperone, 
human aB crystallin. Cell Stress Chaperones, 11, 187-197. 
Ghosh, J.G., Houck, S.A. and Clark, J.l. (2007) Interactive sequences in the stress protein 
and molecular chaperone human aB crystallin recognize and modulate the 
assembly of filaments. Int J Biochem Cell Bioi, 39, 1804-1815. 
Ghosh, J.G., Houck, S.A., Doneanu, C.E. and Clark, J.I. (2006c) The fl4-fl8 Groove Is an 
ATP-interactive Site in the a-Crystallin Core Domain of the Small Heat Shock 
Protein, Human aB Crystallin. J Mol Bioi, 364, 364-375. 
Ghosh, J.G., Shenoy, A.K., Jr. and Clark, J.I. (2006d) N- and C-Tenninal Motifs in 
Human aB Crystallin Play an Important Role in the Recognition, Selection, and 
Solubilization of Substrates. Biochemistry, 45, 13847-13854. 
Glass, C.K. and Rosenfeld, M.G. (2000) The coregulator exchange in transcriptional 
functions of nuclear receptors. Genes Dev, 14, 121-141. 
Goodman, H. (1964) Senile changes of the lens and the vitreous. Am J Ophthalmol, 57, 1-
13. 
Gounari, F., Merdes, A., Quinlan, R., Hess, J., FitzGerald, P.G., Ouzounis, C.A. and 
Georgatos, S.D. (1993) Bovine filensin possesses primary and secondary structure 
similarity to intermediate filament proteins. J Cell Bioi, 121, 847-853. 
Grainger, R.M. (1992) Embryonic lens induction: shedding light on vertebrate tissue 
determination. Trends Genet, 8, 349-355. 
Granzier, H.L. and Labeit, S. (2004) The giant protein titin: a major player in myocardial 
mechanics, signaling, and disease. Circ Res, 94, 284-295. 
Graw, J. (2003) The genetic and molecular basis of congenital eye defects. Nat Rev Genet, 
4, 876-888. 
Grimm, L.M., Goldberg, A.L., Poirier, G.G., Schwartz, L.M. and Osborne, B.A. (1996) 
Proteasomes play an essential role in thymocyte apoptosis. Embo J, 15, 3835-
3844. 
Groenen, P.J., Merck, K.B., de Jong, W.W. and Bloemendal, H. (1994) Structure and 
modifications of the junior chaperone a-crystallin. From lens transparency to 
molecular pathology. Eur J Biochem, 225, 1-19. 
Gupta, R. and Srivastava, O.P. (2004) Deamidation affects structural and functional 
properties of human aA-crystallin and its oligomerization with aS-crystallin. J 
Bioi Chern, 279, 44258-44269. 
Guruprasad, K. and Kumari, K. (2003) Three-dimensional models corresponding to the C-
terminal domain of human aA- and aB-crystallins based on the crystal structure of 
the small heat-shock protein HSP16.9 from wheat. lnt J Bioi Macromol, 33, 107-
112. 
References 358 
Haley, D.A., Bova, M.P., Huang, Q.L., McHaourab, H.S. and Stewart, P.L. (2000) Small 
heat-shock protein structures reveal a continuum from symmetric to variable 
assemblies. J Mol Bioi, 298, 261-272. 
Haley, D.A., Horwitz, J. and Stewart, P.L. (1998) The small heat-shock protein, aS-
crystallin, has a variable quaternary structure. J Mol Bioi, 277, 27-35. 
Hamamichi, S., Kosano, H., Nakai, S., Ogihara-Umeda, I. and Nishigori, H. (2003) 
Involvement of hepatic glucocorticoid receptor-mediated functions in steroid-
induced cataract formation. Exp Eye Res, 77, 575-580. 
Harding, J.J. (1991) Post-translational modification of lens proteins in cataract. Lens Eye 
Toxic Res, 8, 245-250. 
Harding, A.E. and Thomas, P.K. (1980a) The clinical features of hereditary motor and 
sensory neuropathy types I and II. Brain, 103, 259-280. 
Harding, A.E. and Thomas, P.K. (1980b) Hereditary distal spinal muscular atrophy. A 
report on 34 cases and a review of the literature. J Neuro/ Sci, 45, 337-348. 
Harrington, V., McCall, S., Huynh, S., Srivastava, K. and Srivastava, O.P. (2004) 
Crystallins in water soluble-high molecular weight protein fractions and water 
insoluble protein fractions in aging and cataractous human lenses. Mol Vis, 10, 
476-489. 
Hartman, J.L.t., Garvik, B. and Hartwell, L. (2001) Principles for the buffering of genetic 
variation. Science, 291, 1001-1004. 
Hartwell, L., Weinert, T., Kadyk, L. and Garvik, B. (1994) Cell cycle checkpoints, 
genomic integrity, and cancer. Cold Spring Barb Symp Quant Bioi, 59,259-263. 
Hasan, A., Smith, D.L. and Smith, J.B. (2002) a-crystallin regions affected by adenosine 
5'-triphosphate identified by hydrogen-deuterium exchange. Biochemistry, 41, 
15876-15882. 
Haslbeck, M., Walke, S., Stromer, T., Ehrnsperger, M., White, H.E., Chen, S., Saibil, H.R. 
and Buchner, J. (1999) Hsp26: a temperature-regulated chaperone. Embo J, 18, 
6744-6751. 
Hayashi, L.C. (1998) Ultraviolet radiation and cataract: A review. Asia Pac J Public 
Health. 
Head, M.W., Corbin, E. and Goldman, J.E. (1993) Overexpression and abnormal 
modification of the stress proteins aS-crystallin and HSP27 in Alexander disease. 
Am J Patho/, 143, 1743-1753. 
Head, M.W. and Goldman, J.E. (2000) Small heat shock proteins, the cytoskeleton, and 
inclusion body formation. Neuropathol App/ Neurobiol, 26, 304-312. 
Heon, E., Priston, M., Schorderet, D.F., Billingsley, G.D., Girard, P.O., Lubsen, N. and 
Munier, F.L. (1999) The gamma-crystallins and human cataracts: a puzzle made 
clearer. Am J Hum Genet, 65, 1261-1267. 
Hermisson, J. and Wagner, G.P. (2004) The population genetic theory of hidden variation 
and genetic robustness. Genetics, 168, 2271-2284. 
Hess, J.F., Casselman, J.T. and FitzGerald, P.G. (1993) eDNA analysis of the 49 kDa lens 
fiber cell cytoskeletal protein: a new, lens-specific member of the intermediate 
filament family? Curr Eye Res, 12, 77-88. 
Hess, J.F., Casselman, J.T. and FitzGerald, P.G. (1996) Gene structure and eDNA 
sequence identify the beaded filament protein CP49 as a highly divergent type I 
intermediate filament protein. J Bioi Chem, 271,6729-6735. 
Hess, J.F., Casselman, J.T., Kong, A.P. and FitzGerald, P.G. (1998) Primary sequence, 
secondru-y-structure;-gl~nestrucfute~ ana-assenioly -propertie-s suggests-lliatthe ·lens-
References 359 
specific cytoskeletal protein filensin represents a novel class of intermediate 
filament protein. Exp Eye Res, 66, 625-644. 
Hiller, R., Sperduto, R.D., Podgor, M.J., Wilson, P.W., Ferris, F.L., 3rd, Colton, T., 
D'Agostino, R.B., Roseman, M.J., Stockman, M.E. and Milton, R.C. (1997) 
Cigarette smoking and the risk of development of lens opacities. The Framingham 
studies. Arch Ophtha/mo/, 115, 1113-1118. 
Hollick, J.B., Dorweiler, J.E. and Chandler, V.L. (1997) Paramutation and related allelic 
interactions. Trends Genet, 13, 302-308. 
Horwitz, J. (1992) a-crystallin can function as a molecular chaperone. Proc Nat/ Acad Sci 
US A, 89, 10449-10453. 
Horwitz, J. (1993) Proctor Lecture. The function of a~crystallin. Invest Ophthalmol Vis 
Sci, 34, 10-22. 
Horwitz, J. (2003) a-crystallin. Exp Eye Res, 76, 145~153. 
Horwitz, J., Emmons, T. and Takemoto, L. (1992) The ability of lens a-crystallin to 
protect against heat-induced aggregation is age-dependent. Curr Eye Res, 11, 817~ 
822. 
Horwitz, J., Huang, Q. and Ding, L. (2004) The native oligomeric organization of a-
crystallin, is it necessary for its chaperone function? Exp Eye Res, 79, 817-821. 
Ikeda, R., Yoshida, K., Ushiyama, M., Yamaguchi, T., !washita, K., Futagawa, T., 
Shibayama, Y., Oiso, S., Takeda, Y., Kariyazono, H., Furukawa, T., Nakamura, 
K., Akiyama, S., Inoue, I. and Yamada, K. (2006) The small heat shock protein 
aB~crystallin inhibits differentiation-induced caspase 3 activation and myogenic 
differentiation. Bioi Pharm Bull, 29, 1815-1819. 
Inagaki, N., Hayashi, T., Arimura, T., Koga, Y., Takahashi, M., Shibata, H., Teraoka, K., 
Chikamori, T., Yamashina, A. and Kimura, A. (2006) aB~crystallin mutation in 
dilated cardiomyopathy. Biochem Biophys Res Commun, 342,379-386. 
Inaguma, Y., Hasegawa, K., Goto, S., Ito, H. and Kato, K. (1995) Induction of the 
synthesis of hsp27 and aB crystallin in tissues of heat-stressed rats and its 
suppression by ethanol or an at-adrenergic antagonist. J Biochem, 117, 1238-
1243. 
Ingolia, T.D. and Craig, E.A. (1982) Four small Drosophila heat shock proteins are related 
to each other and to mammalian a-crystallin. Proc Nat/ Acad Sci US A, 79,2360-
2364. 
Inoue, A., Takahashi, M., Hatta, Y., Okamoto, H. (1994) Developmental regulation of 
Islet-1 mRNA expression during neuronal differentiation in embryonic zebrafish. 
Dev. Dyn, 199, 1-11. 
Ionasescu, V., Searby, C., Sheffield, V.C., Roklina, T., Nishimura, D. and Ionasescu, R. 
(1996) Autosomal dominant Charcot-Marie~Tooth axonal neuropathy mapped on 
chromosome 7p (CMT2D). Hum Mol Genet, 5, 1373-1375. 
Irobi, J., Van Impe, K., Seeman, P., Jordanova, A., Dierick, I., Verpoorten, N., Michalik, 
A., De Vriendt, E., Jacobs, A., Van Gerwen, V., Vennekens, K., Mazanec, R., 
Tournev, I., Hilton-Jones, D., Talbot, K., Kremensky, I., Van Den Bosch, L., 
Robberecht, W., Van Vandekerckhove, J., Van Broeckhoven, C., Gettemans, J., 
De Jonghe, P. and Timmerman, V. (2004) Hot-spot residue in small heat-shock 
protein 22 causes distal motor neuropathy. Nat Genet, 36, 597-601. 
Ismailov SM, F.V., Dadali EL. (2001) A new locus for autosomal dominant Charcot-
Marie-To_oth_disease type_2_(CMT2E)_maps to chromosome7qll .. q21. Eu1' J-Hum 
Genet., 9, 646-650. 
~----
References 360 
Ito, H., Kamei, K., Iwamoto, 1., Inaguma, Y., Garcia-Mata, R., Sztul, E. and Kato, K. 
(2002) Inhibition of proteasomes induces accumulation, phosphorylation, and 
recruitment ofHSP27 and aS-crystallin to aggresomes. J Biochem, 131,593-603. 
Ito, H., Kamei, K., Iwamoto, 1., Inaguma, Y., Nohara, D. and Kato, K. (2001) 
Phosphorylation-induced change of the oligomerization state of aS-crystallin. J 
Bioi Chern, 276, 5346-5352. 
Itoh-Satoh, M., Hayashi, T., Nishi, H., Koga, Y., Arimura, T., Koyanagi, T., Takahashi, 
M., Hohda, S., Ueda, K., Nouchi, T., Hiroe, M., Marumo, F., lmaizumi, T., 
Y asunami, M. and Kimura, A. (2002) Titin mutations as the molecular basis for 
dilated cardiomyopathy. Biochem Biophys Res Commun, 291,385-393. 
lwaki, T., Kume-Iwaki, A., Liem, R.K. and Goldman, J.E. (1989) aS-crystallin is 
expressed in non-lenticular tissues and accumulates in Alexander's disease brain. 
Cell, 57, 71-78. 
Iwamoto, T., Kagawa, Y., Naito, Y., Kuzuhara, S. and Kojima, M. (2004) Steroid-induced 
diabetes mellitus and related risk factors in patients with neurologic diseases. 
Pharmacotherapy, 24, 508-514. 
Jablonka, E., Matzke, M., Thieffry, D., Speybroeck, L.V. (2002) the genome in context: 
Biologists and philosophers on epigenetics. Bioessays, 24, 392-394. 
Jacob, R.F., Cenedella, R.J. and Preston Mason, R. (2000) Determination of human eye 
lens membrane structure by xray diffraction analysis. The Rigaku Journal, 17. 
Jacob, T.J. (1999) The relationship between cataract, cell swelling and volume regulation. 
Prog Retin Eye Res, 18, 223-233. 
Jacobsen, S.E. and Meyerowitz, E.M. ( 1997) Hypermethylated SUPERMAN epigenetic 
alleles in arabidopsis. Science, 277, 1100-1103. 
Jacobsen, S.E., Sakai, H., Finnegan, E.J., Cao, X. and Meyerowitz, E.M. (2000) Ectopic 
hypermethylation of flower-specific genes in Arabi do psis. Curr Bioi, 10, 179-186. 
Jamieson, R.V., Perveen, R., Kerr, B., Carette, M., Yardley, J., Heon, E., Wirth, M.G., van 
Heyningen, V., Donnai, D., Munier, F. and Black, G.C. (2002) Domain disruption 
and mutation of the bZIP transcription factor, MAF, associated with cataract, 
ocular anterior segment dysgenesis and coloboma. Hum Mol Genet, 11, 33-42. 
Jenkins, A.J., March, J.B., Oliver, I.R. and Masters, M. (1986) A DNA fragment 
containing the groE genes can suppress mutations in the Escherichia coli dnaA 
gene. Mol Gen Genet, 202, 446-454. 
Jimenez-Asensio, J., Colvis, C.M., Kowalak, J.A., Duglas-Tabor, Y., Datiles, M.B., 
Moroni, M., Mura, U., Rao, C.M., Balasubramanian, D., Janjani, A. and Garland, 
D. (1999) An atypical form of aS-crystallin is present in high concentration in 
some human cataractous lenses. Identification and characterization of aberrant N-
and C-terminal processing. J Bioi Chern, 274, 32287-32294. 
Johnson, A.B. and Bettica, A. (1989) On-grid immunogold labeling of glial intermediate 
filaments in epoxy-embedded tissue. Am J Anat, 185, 335-341. 
Juhasz, P. and Biemann, K. (1994) Mass spectrometric molecular-weight determination of 
highly acidic compounds of biological significance via their complexes with basic 
polypeptides. Proc Nat/ Acad Sci US A, 91, 4333-4337. 
Kamei, A., Hamaguchi, T., Matsuura, N. and Masuda, K. (2001) Does post-translational 
modification influence chaperone-like activity of a-crystallin? I. Study on 
phosphorylation. Bioi Pharm Bull, 24, 96-99. 
Kamei, A. and Matsuura, N. (2002) Analysis of crystallin-crystallin interactions by 
siirtace plasmon resonance. BTol Pharm Bull, 25, 611-615. -
References 361 
Kampinga, H.H., Brunsting, J.F., Stege, G.J., Konings, A.W. and Landry, J. (1994) Cells 
overexpressing Hsp27 show accelerated recovery from heat-induced nuclear 
protein aggregation. Biochem Biophys Res Commun, 204, 1170-1177. 
Kamradt, M.C., Chen, F., Sam, S. and Cryns, V.L. (2002) The small heat shock protein a 
B-crystallin negatively regulates apoptosis during myogenic differentiation by 
inhibiting caspase-3 activation. J Bioi Chern, 277, 38731-38736. 
Kannabiran, C., Wawrousek, E.; Sergeev, Y.; Rao, G. N.; Kaiser-Kupfer, M.; Hejtmancik, 
J. F. (1999) Mutation of beta A3/A1 crystallin gene in autosomal dominant zonular 
cataract with sutural opacities results in a protein with single globular domain. 
Ophthal. Vis. Sci., 40. 
Kantorow, M. and Piatigorsky, J. (1998) Phosphorylations of aA- and aB-crystallin. Int J 
Bioi Macromol, 22,307-314. 
Karas, M., Bachmann, D., Bahr, U. & Hillenkamp, F. (1987) Matrix-Assisted Ultraviolet 
Laser Desorption of Non-Volatile Compounds. International Journal of Mass 
spectrometry Ion Processes, 78, 53-68. 
Karim, A.K., Jacob, T.J. and Thompson, G.M. (1987) The human anterior lens capsule: 
cell density, morphology and mitotic index in normal and cataractous lenses. Exp 
Eye Res, 45, 865-874. 
Kasakov, A.S., Bukach, O.V., Seit-Nebi, A.S., Marston, S.B. and Gusev, N.B. (2007) 
Effect of mutations in the f35-f37 loop on the structure and properties of human 
small heat shock protein HSP22 (HspB8, Hl1 ). Febs J, 274, 5628-5642. 
Kato, K., Inaguma, Y., Ito, H., lida, K., Iwamoto, I., Kamei, K., Ochi, N., Ohta, H. and 
Kishikawa, M. (2001) Ser-59 is the major phosphorylation site in aB-crystallin 
accumulated in the brains of patients with Alexander's disease. J Neurochem, 76, 
730-736. 
Kato, K., Ito, H., Kamei, K., Inaguma, Y., Iwamoto, I. and Saga, S. (1998) 
Phosphorylation of aS-crystallin in mitotic cells and identification of enzymatic 
activities responsible for phosphorylation. J Bioi Chern, 273, 28346-28354. 
Kato, K., Shinohara, H., Goto, S., Inaguma, Y., Morishita, R. and Asano, T. (1992) 
Copurification of small heat shock protein with aB crystallin from human skeletal 
muscle. J Bioi Chern, 267, 7718-7725. 
Kato, K., Shinohara, H., Kurobe, N., Goto, S., Inaguma, Y. and Ohshima, K. (1991) 
Immunoreactive aA crystallin in rat non-lenticular tissues detected with a sensitive 
immunoassay method. Biochim Biophys Acta, 1080, 173-180. 
Kelly, S.P., Thornton, J., Edwards, R., Sahu, A. and Harrison, R. (2005) Smoking and 
cataract: review of causal association. J Cataract Refract Surg, 31, 2395-2404. 
Kermicle, J.L., Eggleston, W.B. and Alleman, M. (1995) Organization of 
paramutagenicity in R-stippled maize. Genetics, 141, 361-372. 
Krohn, N.M., Yanagisawa, S. and Grasser, K.D. (2002) Specificity of the stimulatory 
interaction between chromosomal HMGB proteins and the transcription factor 
Dof2 and its negative regulation by protein kinase CK2-mediated phosphorylation. 
J Bioi Chern, 277, 32438-32444. 
Kim, K.K., Kim, R. and Kim, S.H. (1998a) Crystal structure of a small heat-shock protein. 
Nature, 394, 595-599. 
Kim, R., Kim, K.K., Yokota, H. and Kim, S.H. (1998b) Small heat shock protein of 
Methanococcus jannaschii, a hyperthermophile. Proc Nat/ Acad Sci US A, 95, 
9129-9133. 
References 362 
Kim, R., Lai, L., Lee, H.H., Cheong, G.W., Kim, K.K., Wu, Z., Yokota, H., Marqusee, S. 
and Kim, S.H. (2003) On the mechanism of chaperone activity of the small heat-
shock protein of Methanococcus jannaschii. Proc Nat/ A cad Sci US A, 100, 8151-
8155. 
King, R.J., Finley, J.R., Coffer, A.I., Millis, R.R. and Rubens, R.D. (1987) 
Characterization and biological relevance of a 29-kDa, oestrogen receptor-related 
protein. J Steroid Biochem, 27, 471-475. 
Kirkwood, T.B. and Austad, S.N. (2000) Why do we age? Nature, 408, 233-238. 
Kirschner, M. and Gerhart, J. (1998) Evolvability. Proc Nat/ Acad Sci US A, 95, 8420-
8427. 
Klein, B.E., Klein, R., Linton, K.L. and Franke, T. (1993) Cigarette smoking and lens 
opacities: the Beaver Dam Eye Study. Am J Prev Med, 9, 27-30. 
Klein, R., Klein, B.E., Wong, T.Y., Tomany, S.C. and Cruickshanks, K.J. (2002) The 
association of cataract and cataract surgery with the long-term incidence of age-
related maculopathy: the Beaver Dam eye study. Arch Ophthalmol, 120, 1551-
1558. 
Klemenz, R., Frohli, E., Steiger, R.H., Schafer, R. and Aoyama, A. (1991) aS-crystallin is 
a small heat shock protein. Proc Nat/ Acad Sci US A, 88, 3652-3656. 
Kojima, M., Shui, Y.B., Murano, H., Nagata, M., Hockwin, 0., Sasaki, K. and Takahashi, 
N. (2002) Low vitamin E level as a subliminal risk factor in a rat model of 
prednisolone-induced cataract. Invest Ophthalmol Vis Sci, 43, 1116-1120. 
Konofsky, K., Naumann, G.O. and Guggenmoos-Holzmann, I. (1987) Cell density and 
sex chromatin in lens epithelium of human cataracts. Quantitative studies in flat 
preparation. Ophthalmology, 94, 875-880. 
Koretz, J.F., Doss, E.W. and LaButti, J.N. (1998) Environmental factors influencing the 
chaperone-like activity of a-crystallin. Int J Bioi Macromol, 22, 283-294. 
Krishnaiah, S., Vilas, K., Shamanna, B.R., Rao, G.N., Thomas, R. and Balasubramanian, 
D. (2005) Smoking and its association with cataract: results of the Andhra Pradesh 
eye disease study from India. Invest Ophthalmol Vis Sci, 46, 58-65. 
Kyhse-Andersen, J. (1984) Electroblotting of multiple gels: a simple apparatus without 
buffer tank for rapid transfer of proteins from polyacrylamide to nitrocellulose. J 
Biochem Biophys Methods, 10,203-209. 
Laemmli, U.K. (1970) Cleavage of structural proteins during the assembly of the head of 
bacteriophage T4. Nature, 227, 680-685. 
Launay, N., Goudeau, B., Kato, K., Vicart, P. and Lilienbaum, A. (2006) Cell signaling 
pathways to aS-crystallin following stresses of the cytoskeleton. Exp Cell Res, 
312, 3570-3584. 
Laursen, A.B. and Fledelius, H. (1979) Variations of lens thickness in relation to 
biomicroscopic types of human senile cataract. Acta Ophthalmol (Copenh}, 57, 1-
13. 
Leroux, M.R., Ma, B.J., Batelier, G., Melki, R. and Candido, E.P. (1997) Unique 
structural features of a novel class of small heat shock proteins. J Bioi Chern, 272, 
12847-12853. 
Lewin, B. (2007) Cells. Jones and Bartlett. 
Lewis, G.P., Erickson, P.A., Kaska, D.D. and Fisher, S.K. (1988) An 
immunocytochemical comparison of Muller cells and astrocytes in the cat retina. 
Exp Eye Res, 47, 839-853. 
References 363 
Li, Y., Chirgadze, D.Y., Bolanos-Garcia, V.M., Sibanda, B.L., Davies, O.R., Ahnesorg, 
P., Jackson, S.P. and Blundell, T.L. (2007) Crystal structure of human 
XLF /Cernunnos reveals unexpected differences from XRCC4 with implications 
for NHEJ. Embo J. 
Liang, J.J. (2000) Interaction between beta-amyloid and lens aS-crystallin. FEBS Lett, 
484, 98-101. 
Liao, J.H., Lee, J.S. and Chiou, S.H. (2002) C-terminal lysine truncation increases 
thermostability and enhances chaperone-like function of porcine aS-crystallin. 
Biochem Biophys Res Commun, 297,309-316. 
Lin, P., Smith, D.L. and Smith, J.B. (1997) In vivo modification of the C-terminallysine 
of human lens aS-crystallin. Exp Eye Res, 65, 673-680. 
Lindblad, B.E., Hakansson, N., Philipson, B. and Wolk, A. (2007) Alcohol consumption 
and risk of cataract extraction: a prospective cohort study of women. 
Ophthalmology, 114, 680-685. 
Lindner, R.A., Carver, J.A., Ehrnsperger, M., Buchner, J., Esposito, G., Behlke, J., Lutsch, 
G., Kotlyarov, A. and Gaestel, M. (2000) Mouse Hsp25, a small shock protein. 
The role of its C-terminal extension in oligomerization and chaperone action. Eur 
J Biochem, 267, 1923-1932. 
Litt, M., Carrero-Valenzuela, R., LaMorticella, D.M., Schultz, D.W., Mitchell, T.N., 
Kramer, P. and Maumenee, I.H. (1997) Autosomal dominant cerulean cataract is 
associated with a chain termination mutation in the human f3-crystallin gene 
CRYBB2. Hum Mol Genet, 6, 665-668. 
Litt, M., Kramer, P., LaMorticella, D.M., Murphey, W., Lovrien, E.W. and Weleber, R.G. 
(1998) Autosomal dominant congenital cataract associated with a missense 
mutation in the human a-crystallin gene CRYAA. Hum Mol Genet, 7, 471-474. 
Liu, M., Ke, T., Wang, Z., Yang, Q., Chang, W., Jiang, F., Tang, Z., Li, H., Ren, X., 
Wang, X., Wang, T., Li, Q., Yang, J., Liu, J. and Wang, Q.K. (2006a) 
Identification of a CRY AB mutation associated with autosomal dominant posterior 
polar cataract in a Chinese family. Invest Ophthalmol Vis Sci, 47, 3461-3466. 
Liu, Y., Zhang, X., Luo, L., Wu, M., Zeng, R., Cheng, G., Hu, B., Liu, B., Liang, J.J. and 
Shang, F. (2006b) A novel aS-crystallin mutation associated with autosomal 
dominant congenital lamellar cataract. Invest Ophthalmol Vis Sci, 47, 1069-1075. 
Liu, L., Ghosh, J.G., Clark, J.I. and Jiang, S. (2006c) Studies of aB crystallin subunit 
dynamics by surface plasmon resonance. Anal Biochem, 350, 186-195. 
Lois, N., Dawson, R., McKinnon, A.D. and Forrester, J.V. (2003) A new model of 
posterior capsule opacification in rodents. Invest Ophthalmol Vis Sci, 44, 3450-
3457. 
Ma, Z., Hanson, S.R., Lampi, K.J., David, L.L., Smith, D.L. and Smith, J.B. (1998) Age-
related changes in human lens crystallins identified by HPLC and mass 
spectrometry. Exp Eye Res, 67, 21-30. 
Mackay, D., Ionides, A., Kibar, Z., Rouleau, G., Berry, V., Moore, A., Shiels, A. and 
Bhattacharya, S. (1999) Connexin46 mutations in autosomal dominant congenital 
cataract. Am J Hum Genet, 64, 1357-1364. 
Mackay, D.S., Boskovska, O.B., Knopf, H.L., Lampi, K.J. and Shiels, A. (2002) A 
nonsense mutation in CR YBB 1 associated with autosomal dominant cataract 
linked to human chromosome 22q. Am J Hum Genet, 71, 1216-1221. 
Maisel, H. ( 1985) The Ocula_r L~_fl§_. Marcel Dekk.er, New York_. _ _ _ 
References 364 
Maisel, H. and Perry, M.M. (1972) Electron microscope observations on some structural 
proteins of the chick lens. Exp Eye Res, 14, 7-12. 
Mangan, S. and Alon, U. (2003) Structure and function of the feed-forward loop network 
motif. Proc Nat/ Acad Sci US A, 100, 11980-11985. 
Mao, J.J., Katayama, S., Watanabe, C., Harada, Y., Noda, K., Yamamura, Y. and 
Nakamura, S. (200 1) The relationship between aS-crystallin and neurofibrillary 
tangles in Alzheimer's disease. Neuropatho/ Appl Neurobio/, 27, 180-188. 
Marini, I., Bucchioni, L., Voltarelli, M., Del Corso, A. and Mura, U. (1995) a-crystallin-
like molecular chaperone against the thermal denaturation of lens aldose reductase: 
the effect of divalent metal ions. Biochem Biophys Res Commun, 212, 413-420. 
Martienssen, R., Barkan, A., Taylor, W.C. and Freeling, M. (1990) Somatically heritable 
switches in the DNA modification of Mu transposable elements monitored with a 
suppressible mutant in maize. Genes Dev, 4, 331-343. 
Martienssen, R. and Baron, A. ( 1994) Coordinate suppression of mutations caused by 
Robertson's mutator transposons in maize. Genetics, 136, 1157-1170. 
Masaki, S. and Watanabe, T. (1992) eDNA sequence analysis ofCP94: mt lens fiber cell 
beaded-filament structural protein shows homology to cytokeratins. Biochem 
Biophys Res Commun, 186, 190-198. 
McCarty, C. and Taylor, H. (2002) A Review of the Epidemiologic Evidence Linking 
Ultraviolet Radiation and Cataracts. 
McClintock, B. ( 1951) Chromosome organization and genic expression. Cold Spring 
Harb Symp Quant Bioi, 16, 13-47. 
McLaren, A.J., Marshall, S.E., Haldar, N.A., Mullighan, C.G., Fuggle, S.V., Morris, P.J. 
and Welsh, K.I. (1999) Adhesion molecule polymorphisms in chronic renal 
allograft failure. Kidney Int, 55, 1977-1982. 
Medawar, P. (1952) An unsolved problem in biology. 
Meehan, S., Knowles, T.P., Baldwin, A.J., Smith, J.F., Squires, A.M., Clements, P., 
Treweek, T.M., Ecroyd, H., Tartaglia, G.G., Vendruscolo, M., Macphee, C.E., 
Dobson, C.M. and Carver, J .A. (2007) Characterisation of amyloid fibril formation 
by small heat-shock chaperone proteins human aA-, aB- and R120G aB-
crystallins. J Mol Bioi, 372,470-484. 
Merlin, A.B., Gabai, V.L., Yaglom, J., Shifrin, V.I. and Sherman, M.Y. (1998) 
Proteasome inhibitors activate stress kinases and induce Hsp72. Diverse effects on 
apoptosis. J Bioi Chern, 273, 6373-6379. 
Miesbauer, L.R., Zhou, X., Yang, Z., Yang, Z., Sun, Y., Smith, D.L. and Smith, J.B. 
(1994) Post-translational modifications of water-soluble human lens crystallins 
from young adults. J Bioi Chern, 269, 12494-12502. 
Mignot, C., Delarasse, C., Escaich, S., Della Gaspera, B., Noe, E., Colucci-Guyon, E., 
Babinet, C., Pekny, M., Vicart, P., Boespflug-Tanguy, 0., Dautigny, A., 
Rodriguez, D. and Pham-Dinh, D. (2007) Dynamics of mutated GF AP aggregates 
revealed by real-time imaging of an astrocyte model of Alexander disease. Exp 
Cell Res, 313, 2766-2779. 
Minassian, D.C., Mehra, V. and Jones, B.R. (1984) Dehydrational crises from severe 
diarrhoea or heatstroke and risk of cataract. Lancet, 1, 751-753. 
Miyake, K., Ota, 1., Miyake, S. and Horiguchi, M. (1998) Liquefied aftercataract: a 
complication of continuous curvilinear capsulorhexis and intraocular lens 
implantation in the lens capsule. Am J Ophthalmo/, 125, 429-435. 
References 365 
Moroni, M. and Garland, D. (2001) In vitro dephosphorylation of a-crystallin is 
dependent on the state of oligomerization. Biochim Biophys Acta, 1546, 282-290. 
Morrow, G. and Tanguay, R.M. (2003) Heat shock proteins and aging in Drosophila 
melanogaster. Semin Cell Dev Bioi, 14, 291-299. 
Moscona, A.A., Fox, L., Smith, J. and Degenstein, L. (1985) Antiserum to lens antigens 
immunostains Muller glia cells in the neural retina. Proc Nat/ Acad Sci US A, 82, 
5570-5573. 
Muchowski, P.J. and Clark, J.I. (1998) ATP-enhanced molecular chaperone functions of 
the small heat shock protein human aB crystallin. Proc Nat/ Acad Sci US A, 95, 
1004-1009. 
Muchowski, P.J., Hays, L.G., Yates, J.R., 3rd and Clark, J.I. (1999) ATP and the core "a-
Crystallin" domain of the small heat-shock protein aD-crystallin. J Bioi Chern, 
274,30190-30195. 
Momer, C. (1894) Z physiol. Chemie, 18,61-106. 
Nakamura, T., Sasaki, H., Nagai, K., Fujisawa, K., Sasaki, K., Suzuki, K. and Tsugawa, 
R. (2003) Influence of cyclosporin on steroid-induced cataracts after renal 
transplantation. Jpn J Ophthalmol, 47, 254-259. 
Narberhaus, F. (2002) a-crystallin-type heat shock proteins: socializing mini chaperones in 
the context of a multichaperone network. Microbiol Mol Bioi Rev, 66, 64-93; table 
of contents. 
Naze, P., Vuillaume, 1., Destee, A., Pasquier, F. and Sablonniere, B. (2002) Mutation 
analysis and association studies of the ubiquitin carboxy-terminal hydrolase L1 
gene in Huntington's disease. Neurosci Lett, 328, 1-4. 
Nene, V., Dunne, D.W., Johnson, K.S., Taylor, D.W. and Cordingley, J.S. (1986) 
Sequence and expression of a major egg antigen from Schistosoma mansoni. 
Homologies to heat shock proteins and a-crystallins. Mol Biochem Parasitol, 21, 
179-188. 
Nicholl, I.D. and Quinlan, R.A. (1994) Chaperone activity of a-crystallins modulates 
intermediate filament assembly. Embo J, 13, 945-953. 
O'Connor, O.A. (2005) Targeting histones and proteasomes: new strategies for the 
treatment of lymphoma. J Clin Oncol, 23, 6429-6436. 
Orii, H., Agata, K., Sawada, K., Eguchi, G. and Maisel, H. (1993) Evidence that the chick 
lens cytoskeletal protein CP 49 belongs to the family of intermediate filament 
proteins. Curr Eye Res, 12, 583-588. 
Orlowski, R.Z. (1999) The role of the ubiquitin-proteasome pathway in apoptosis. Cell 
Death Differ, 6, 303-313. 
Palmisano, D.V., Groth-Vasselli, B., Farnsworth, P.N. and Reddy, M.C. (1995) 
Interaction of ATP and lens a-crystallin characterized by equilibrium binding 
studies and intrinsic tryptophan fluorescence spectroscopy. Biochim Biophys Acta, 
1246, 91-97. 
Pan, S., Wu, K., Liang, S. and Li, S. (1993) [Relations between opacification of lens 
protein and pH]. YanKe Xue Bao, 9, 179-182. 
Parcellier, A., Schmitt, E., Brunet, M., Hammann, A., Solary, E. and Garrido, C. (2005) 
Small heat shock proteins HSP27 and aB-crystallin: cytoprotective and oncogenic 
functions. Antioxid Redox Signal, 7, 404-413. 
Pasta, S.Y., Raman, B., Ramakrishna, T. and Rao Ch, M. (2002) Role of the C-terminal 
~]{tensions_ of a-crystlllli11~·- Sw!ipp_it}g the C-termtll_al extension of a-crystallin t<> 
~·- ---
References 366 
aB-crystallin results in enhanced chaperone activity. J Bioi Chern, 277, 45821-
45828. 
Pasta, S.Y., Raman, B., Ramakrishna, T. and Rao Ch, M. (2003) Role of the conserved 
SRLFDQFFG region of a-crystallin, a small heat shock protein. Effect on 
oligomeric size, subunit exchange, and chaperone-like activity. J Bioi Chern, 278, 
51159-51166. 
Pasta, S.Y., Raman, B., Ramakrishna, T. and Rao Ch, M. (2004) The IXIN motif in the 
C-terminal extension of a-crystallins: alternative interactions and oligomeric 
assemblies. Mol Vis, 10, 655-662. 
Pastor-Valero, M., Fletcher, A.E., De Stavola, B.L. and Chaques-Alepuz, V. (2007) Years 
of sunlight exposure and cataract: a case-control study in a Mediterranean 
population. BMC Ophthalrnol, 7, 18. 
Patteau, F., Bourcier, T., Naacke, H., Allahdadi, H., Borderie, V. and Laroche, L. (2003) 
[Posterior subcapsular cataract in a case of ulcerative colitis treated with 
corticosteroid enema]. J Fr Ophtalrnol, 26, 834-836. 
Pemg, M.D., Zhang, Q. and Quinlan, R.A. (2007) Insights into the beaded filament of the 
eye lens. Exp Cell Res, 313,2180-2188. 
Pemg, M.D., Cairns, L., van den Issei, P., Prescott, A.M., Hutcheson, C., Quinlan, R.A. 
(1999) Intermediate filament interactions can be altered by HSP27 and a B-
crystallin. J. Cell. Sci, 112, 2099-2122. 
Pemg, M.D., Muchowski, P.J., van den IJssel, P.R., Wu, G.J.S., Hutcheson, A.M., Clark, 
J.l. and Quinlan, R.A. (1999) The Cardiomyopathy and Lens Cataract Mutation in 
aB-crystallin alters its Protein Structure, chaperone activity and interaction with 
intermediate filaments in Vitro. J Bioi Chern, 274, 33235-33243. 
Pemg, M.D. and Quinlan, R.A. (2005) Seeing is believing! The optical properties of the 
eye lens are dependent upon a functional intermediate filament cytoskeleton. Exp 
Cell Res, 305, 1-9. 
Pemg, M.D., Wen, S.F., van den, J.P., Prescott, A.R. and Quinlan, R.A. (2004) Desmin 
aggregate formation by R120G aB-crystallin is caused by altered filament 
interactions and is dependent upon network status in cells. Mol Bioi Cell, 15, 2335-
2346. 
Peterson, J.J., Young, M.M. and Takemoto, L.J. (2004) Probing a-crystallin structure 
using chemical cross-linkers and mass spectrometry. Mol Vis, 10, 857-866. 
Phair, R.D. and Misteli, T. (2000) High mobility of proteins in the mammalian cell 
nucleus. Nature, 404, 604-609. 
Piatigorsky, J. (1981) Lens differentiation in vertebrates. A review of cellular and 
molecular features. Difforentiation, 19, 134-153. 
Pigliucci, M. (2003) Epigenetics is back! Hsp90 and phenotypic variation. Cell Cycle, 2, 
34-35. 
Pigliucci, M. and Murren, C.J. (2003) Perspective: Genetic assimilation and a possible 
evolutionary paradox: can macroevolution sometimes be so fast as to pass us by? 
Evolution Int J Org Evolution, 57, 1455-1464. 
Plater, M.L., Goode, D. and Crabbe, M.J. (1996) Effects of site-directed mutations on the 
chaperone-like activity ofaB-crystallin. J Bioi Chern, 271,28558-28566. 
Pras, E., Frydman, M., Levy-Nissenbaum, E., Bakhan, T., Raz, J., Assia, E.I. and 
Goldman, B. (2000) A nonsense mutation (W9X) in CRYAA causes autosomal 
re£_~ssive cataract in an inbred Jewish Persiat!_ family. Irz_vest Ophthalrnol fis Sci, 
41, 3511-3515. 
References 367 
Queitsch, C., Hong, S.W., Vierling, E. and Lindquist, S. (2000) Heat shock protein 101 
plays a crucial role in thermotolerance in Arabidopsis. Plant Cell, 12, 479-492. 
Queitsch, C., Sangster, T.A. and Lindquist, S. (2002) Hsp90 as a capacitor of phenotypic 
variation. Nature, 417, 618-624. 
Rafferty, N.S. (1985) The Ocular Lens. Marcel Dekker, New York. 
Rajan, S., Chandrashekar, R., Aziz, A. and Abraham, E.C. (2006) Role of Arginine-163 
and the (163)REEK(l66) Motif in the Oligomerization of Truncated aA-
Crystallins. Biochemistry, 45, 15684-15691. 
Raju, P., George, R., Ve Ramesh, S., Arvind, H., Baskaran, M. and Vijaya, L. (2006) 
Influence of tobacco use on cataract development. Br J Ophthalmol, 90, 1374-
1377. 
Ralston, G.B. (1993) Analytical Ultracentrifugation Volume 1 Beckman Instruments, Inc, 
California. 
Ramaekers, F.C., Dunia, 1., Dodemont, H.J., Benedetti, E.L. and Bloemendal, H. (1982) 
Lenticular intermediate-sized filaments: biosynthesis and interaction with plasma 
membrane. Proc Nat/ Acad Sci US A, 19, 3208-3212. 
Ramaekers, F.C., Osborn, M., Schimid, E., Weber, K., Bloemendal, H. and Franke, W.W. 
(1980) Identification of the cytoskeletal proteins in lens-forming cells, a special 
epitheloid cell type. Exp Cell Res, 127, 309-327. 
Raman, B. and Rao, C.M. (1994) Chaperone-like activity and quaternary structure of a-
crystallin. J Bioi Chern, 269, 27264-27268. 
Raman, B. and Rao, C.M. (1997) Chaperone-like activity and temperature-induced 
structural changes of a-crystallin. J Bioi Chern, 272, 23559-23564. 
Raso, S.W., King, J. (2000) Protein Folding and Human Disease. Oxford University 
Press. 
Reddy, G.B., Reddy, P.Y., Vijayalakshmi, A., Kumar, M.S., Suryanarayana, P. and 
Sesikeran, B. (2002) Effect of long-term dietary manipulation on the aggregation 
of rat lens crystallins: role of a-crystallin chaperone function. Mol Vis, 8, 298-305. 
Reddy, M.C., Palmisano, D.V., Groth-Vasselli, B. and Farnsworth, P.N. (1992) 31P NMR 
studies of the A TP/a-crystallin complex: functional implications. Biochem 
Biophys Res Commun, 189, 1578-1584. 
Richardson, P .J. (1996) Assessment of myocardial damage in dilated cardiomyopathy. Eur 
Heart J, 17,489-490. 
Rideout, H.J., Larsen, K.E., Sulzer, D. and Stefanis, L. (2001) Proteasomal inhibition 
leads to formation of ubiquitin/a-synuclein-immunoreactive inclusions in PC12 
cells. J Neurochem, 78, 899-908. 
Rutherford, S., Hirate, Y. and Swalla, B.J. (2007a) The Hsp90 capacitor, developmental 
remodeling, and evolution: the robustness of gene networks and the curious 
evolvability of metamorphosis. Crit Rev Biochem Mol Bioi, 42, 355-372. 
Rutherford, S., Knapp, J.R. and Csermely, P. (2007b) Hsp90 and developmental networks. 
Adv ExpMed Bioi, 594, 190-197. 
Rutherford, S., Knapp, J.R., Csermely, P. (2007) Molecular Aspects of the 
StressResponse; Chaperones, Membranes and Networks. Springer, New York. 
Rutherford, S.L. (2003) Between genotype and phenotype: protein chaperones and 
evolvability. Nat Rev Genet, 4, 263-274. 
Rutherford, S.L. and Lindquist, S. (1998) Hsp90 as a capacitor for morphological 
evolution. Nature, 396, 336-342. 
References 368 
Sadoul, R., Fernandez, P.A., Quiquerez, A.L., Martinou, 1., Maki, M., Schroter, M., 
Becherer, J.D., Irmler, M., Tschopp, J. and Martinou, J.C. (1996) Involvement of 
the proteasome in the programmed cell death of NGF -deprived sympathetic 
neurons. Embo J, 15, 3845-3852. 
Salathia, N. and Queitsch, C. (2007) Molecular mechanisms of canalization: Hsp90 and 
beyond. J Biosci, 32, 457-463. 
Samakovli, D., Thanou, A., Valmas, C. and Hatzopoulos, P. (2007) Hsp90 canalizes 
developmental perturbation. J Exp Bot, 58, 3513-3524. 
Sandilands, A. (1995) Characterisation of the intermediate filament proteins filensin and 
CP49 within the eye lens. University ofDundee, Dundee, Vol. Ph.D. 
Sandilands, A., Prescott, A.R., Carter, J.M., Hutcheson, A.M., Quinlan, R.A., Richards, J. 
and FitzGerald, P.G. (1995) Vimentin and CP49/filensin form distinct networks in 
the lens which are independently modulated during lens fibre cell differentiation. J 
Cell Sci, 108 (Pt 4), 1397-1406. 
Sandilands, A., Prescott, A.R., Wegener, A., Zoltoski, R.K., Hutcheson, A.M., Masaki, S., 
Kuszak, J .R. and Quinlan, R.A. (2003) Knockout of the intermediate filament 
protein CP49 destabilises the lens fibre cell cytoskeleton and decreases lens optical 
quality, but does not induce cataract. Exp Eye Res, 76, 385-391. 
Sangster, T.A., Lindquist, S. and Queitsch, C. (2004) Under cover: causes, effects and 
implications ofHsp90-mediated genetic capacitance. Bioessays, 26, 348-362. 
Sangster, T.A. and Queitsch, C. (2005) The HSP90 chaperone complex, an emerging force 
in plant development and phenotypic plasticity. Curr Opin Plant Bioi, 8, 86-92. 
Sawada, K., Agata, K., Yoshiki, A. and Eguchi, G. (1993) A set of anti-crystallin 
monoclonal antibodies for detecting lens specificities: f3-crystallin as a specific 
marker for detecting lentoidogenesis in cultures of chicken lens epithelial cells. 
Jpn J Ophthalmol, 37, 355-368. 
Schar, C.R., Blouse, G.E., Minor, K.H. and Peterson, C.B. (2008) A deletion mutant of 
vitronectin lacking the somatomedin B domain exhibits residual pai-l-binding 
activity. J Bioi Chem. 
Schroder, R., Vrabie, A. and Goebel, H.H. (2007) Primary desminopathies. J Cell Mol 
Med, 11, 416-426. 
Selcen, D. and Engel, A.G. (2003) Myofibrillar myopathy caused by novel dominant 
negative aS-crystallin mutations. Ann Neuro/, 54, 804-810. 
Selcen, D., Ohno, K. and Engel, A.G. (2004) Myofibrillar myopathy: clinical, 
morphological and genetic studies in 63 patients. Brain, 127,439-451. 
Selkoe, D.J. (2003a) Aging, amyloid, and Alzheimer's disease: a perspective in honor of 
Carl Cotman. Neurochem Res, 28, 1705-1713. 
Selkoe, D.J. (2003b) Folding proteins in fatal ways. Nature, 426, 900-904. 
Semina, E.V., Ferrell, R.E., Mintz-Hittner, H.A., Bitoun, P., Alward, W.L., Reiter, R.S., 
Funkhauser, C., Daack-Hirsch, S. and Murray, J.C. (1998) A novel homeobox 
gene PITX3 is mutated in families with autosomal-dominant cataracts and ASMD. 
NatGenet, 19,167-170. 
Shah, S.A., Potter, M.W., McDade, T.P., Ricciardi, R., Perugini, R.A., Elliott, P.J., 
Adams, J. and Callery, M.P. (2001) 26S proteasome inhibition induces apoptosis 
and limits growth of human pancreatic cancer. J Cell Biochem, 82, 11 0-122. 
Shah, S.P., Dineen, B., Jadoon, Z., Bourne, R., Khan, M.A., Johnson, G.J., De Stavola, B., 
Gilbert, C. and Khan, M.D. (2007) Lens opacities in adults in pakistan: prevalence 
and-risk factors. Ophtluilmic-Epidemfol, 14; 381~389: 
References 369 
Shalini, V.K., Luthra, M., Srinivas, L., Rao, S.H., Basti, S., Reddy, M. and 
Balasubramanian, D. (1994) Oxidative damage to the eye lens caused by cigarette 
smoke and fuel smoke condensates. Indian J Biochem Biophys, 31,261-266. 
Sharma, K.K. and Ortwerth, B.J. (1995) Effect of cross-linking on the chaperone-like 
function of a-crystallin. Exp Eye Res, 61,413-421. 
Shashidharamurthy, R., Koteiche, H.A., Dong, J. and McHaourab, H.S. (2005) 
Mechanism of chaperone function in small heat shock proteins: dissociation of the 
HSP27 oligomer is required for recognition and binding of destabilized T4 
lysozyme. J Bioi Chern, 280, 5281-5289. 
Shibata, S., Natori, Y., Nishihara, T., Tomisaka, K., Matsumoto, K., Sansawa, H. and 
Nguyen, V.C. (2003) Antioxidant and anti-cataract effects of Chlorella on rats with 
streptozotocin-induced diabetes. J Nutr Sci Vitaminol (Tokyo), 49, 334-339. 
Shiels, A., Bennett, T.M., Knopf, H.L., Yamada, K., Yoshiura, K., Niikawa, N., Shim, S. 
and Hanson, P.I. (2007) CHMP4B, a novel gene for autosomal dominant cataracts 
linked to chromosome 20q. Am J Hum Genet, 81, 596-606. 
Shiels, A., Mackay, D., Ionides, A., Berry, V., Moore, A. and Bhattacharya, S. (1998) A 
missense mutation in the human connexin50 gene (GJA8) underlies autosomal 
dominant "zonular pulverulent" cataract, on chromosome 1q. Am J Hum Genet, 62, 
526-532. 
Shinohara, T., White, H., Mulhern, M.L. and Maisel, H. (2007) Cataract: window for 
systemic disorders. Med Hypotheses, 69, 669-677. 
Shroff, N.P., Cherian-Shaw, M., Bera, S. and Abraham, E.C. (2000) Mutation of R116C 
results in highly oligomerized aA-crystallin with modified structure and defective 
chaperone-like function. Biochemistry, 39, 1420-1426. 
Siegal, M.L. and Bergman, A. (2002) Waddington's canalization revisited: developmental 
stability and evolution. Proc Nat/ A cad Sci US A, 99, 10528-10532. 
Siezen, R.J., Bindels, J.G. and Hoenders, H.J. (1978) The quaternary structure of bovine 
a-crystallin. Size and charge microheterogeneity: more than 1000 different 
hybrids? Eur J Biochem, 91, 387-396. 
Simon, S., Fontaine, J.M., Martin, J.L., Sun, X., Hoppe, A.D., Welsh, M.J., Benndorf, R. 
and Vicart, P. (2007a) Myopathy-associated aS-crystallin Mutants: Abnormal 
Phosphorylation, intracellular location and Interactions with other small heat shock 
proteins. J Bioi Chem, 282, 34276-34287. 
Simon, S., Michie!, M., Skouri-Panet, F., Lechaire, J.P., Vicart, P. and Tardieu, A. 
(2007b) Residue R120 is essential for the quaternary structure and functional 
integrity of human aS-crystallin. Biochemistry, 46, 9605-9614. 
Singh, B.N., Rao, K.S., Ramakrishna, T., Rangaraj, N. and Rao Ch, M. (2007) Association 
of aS-crystallin, a small heat shock protein, with actin: role in modulating actin 
filament dynamics in vivo. J Mol Bioi, 366, 756-767. 
Sleeman, J.E., Ajuh, P. and Lamond, A.I. (2001) snRNP protein expression enhances the 
formation of Cajal bodies containing p80-coilin and SMN. J Cell Sci, 114, 4407-
4419. 
Sleeman, J.E. and Lamond, A.l. (1999) Newly assembled snRNPs associate with coiled 
bodies before speckles, suggesting a nuclear snRNP maturation pathway. Curr 
Bioi, 9, 1065-1074. 
Smulders, R., Carver, J.A., Lindner, R.A., van Boeke!, M.A., Bloemendal, H. and de Jong, 
_W.YY:._(l996) Immobilization. of !!le C-tennh!~l exteQsioJl'- '![ bovin~ ~A_..crystallin 
reduces chaperone-like activity. J Bioi Chem, 271, 29060-29066. 
References 370 
Soppe, W.J., Jacobsen, S.E., Alonso-Blanco, C., Jackson, J.P., Kakutani, T., Koornneef, 
M. and Peeters, A.J. (2000) The late flowering phenotype offwa mutants is caused 
by gain-of-function epigenetic alleles of a homeodomain gene. Mol Cell, 6, 791-
802. 
Soti, C. and Csermely, P. (2003) Aging and molecular chaperones. Exp Gerontal, 38, 
1037-1040. 
Spector, A. (1991) The lens and oxidative stress, London. 
Spinozzi, F., Mariani, P., Rustichelli, F., Amenitsch, H., Bennardini, F., Mura, G.M., Coi, 
A. and Ganadu, M.L. (2006) Temperature dependence of chaperone-like activity 
and oligomeric state of aS-crystallin. Biochim Biophys Acta, 1764, 677-687. 
Sreelakshmi, Y., Santhoshkumar, P., Bhattacharyya, J. and Sharma, K.K. (2004) aA-
crystallin interacting regions in the small heat shock protein, aS-crystallin. 
Biochemistry, 43, 15785-15795. 
Sreelakshmi, Y. and Sharma, K.K. (2005) Recognition sequence 2 (residues 60-71) plays 
a role in oligomerization and exchange dynamics of aS-crystallin. Biochemistry, 
44, 12245-12252. 
Sreelakshmi, Y. and Sharma, K.K. (2006) The interaction between aA- and aS-crystallin 
is sequence-specific. Mol Vis, 12, 581-587. 
Stamler, R., Kappe, G., Boelens, W. and Slingsby, C. (2005) Wrapping the a-crystallin 
domain fold in a chaperone assembly. J Mol Bioi, 353, 68-79. 
Stark, A., Brennecke, J., Bushati, N., Russell, R.B. and Cohen, S.M. (2005) Animal 
MicroRNAs confer robustness to gene expression and have a significant impact on 
3'UTR evolution. Cell, 123, 1133-1146. 
Stege, G.J., Renkawek, K., Overkamp, P.S., Verschuure, P., van Rijk, A.F., Reijnen-
Aalbers, A., Boelens, W.C., Bosman, G.J. and de Jong, W.W. (1999) The 
molecular chaperone aS-crystallin enhances amyloid beta neurotoxicity. Biochem 
Biophys Res Commun, 262, 152-156. 
Stephan, D.A., Gillanders, E., Vanderveen, D., Freas-Lutz, D., Wistow, G., Baxevanis, 
A.D., Robbins, C.M., VanAuken, A., Quesenberry, M.l., Bailey-Wilson, J., Juo, 
S.H., Trent, J.M., Smith, L. and Brownstein, M.J. (1999) Progressive juvenile-
onset punctate cataracts caused by mutation of the gammaD-crystallin gene. Proc 
Nat/ A cad Sci US A, 96, 1008-1012. 
Stoevring, B., Frederiksen, J.L. and Christiansen, M. (2007) CRY AB promoter 
polymorphisms: influence on multiple sclerosis susceptibility and clinical 
presentation. Clin Chim Acta, 375, 57-62. 
Stokes, T.L., Kunkel, B.N. and Richards, E.J. (2002) Epigenetic variation in Arabidopsis 
disease resistance. Genes Dev, 16, 171-182. 
Studer, S. and Narberhaus, F. (2000) Chaperone activity and homo- and hetero-oligomer 
formation of bacterial small heat shock proteins. J Bioi Chem, 275, 37212-37218. 
Sulochana, K.N., Punitham, R. and Ramakrishnan, S. (2002) Effect of cigarette smoking 
on cataract: Antioxidant enzymes and constituent minerals in the lens and blood of 
humans. Indian Journal of Pharmacology 2002, 34, 428-431. 
Sun, H., Ma, Z., Li, Y., Liu, B., Li, Z., Ding, X., Gao, Y., Ma, W., Tang, X., Li, X. and 
Shen, Y. (2005) Gamma-S crystallin gene (CRYGS) mutation causes dominant 
progressive cortical cataract in humans. J Med Genet, 42, 706-710. 
Sun, T.X., Akhtar, N. and Liang, J.J. (1998) Conformational change of human lens 
insoluble_a .. ccystallin. J Emtein Chem,J7, 6_19-6_8_4._ 
References 371 
Suter, U. and Scherer, S.S. (2003) Disease mechanisms in inherited neuropathies. Nat Rev 
Neurosci, 4, 714-726. 
Takemoto, L., Horwitz, J. and Emmons, T. (1992) Oxidation of theN-terminal methionine 
oflens a-A crystallin. Curr Eye Res, 11, 651-655. 
Tamaoka, A., Mizusawa, H., Mori, H. and Shoji, S. (1995) Ubiquitinated aS-crystallin in 
glial cytoplasmic inclusions from the brain of a patient with multiple system 
atrophy. J Neuro/ Sci, 129, 192-198. 
Tang, B., Liu, X., Zhao, G., Luo, W., Xia, K., Pan, Q., Cai, F., Hu, Z., Zhang, C., Chen, 
B., Zhang, F., Shen, L., Zhang, R. and Jiang, H. (2005a) Mutation analysis of the 
small heat shock protein 27 gene in chinese patients with Charcot-Marie-Tooth 
disease. Arch Neurol, 62, 1201-1207. 
Tang, B.S., Zhao, G.H., Luo, W., Xia, K., Cai, F., Pan, Q., Zhang, R.X., Zhang, F.F., Liu, 
X.M., Chen, B., Zhang, C., Shen, L., Jiang, H., Long, Z.G. and Dai, H.P. (2005b) 
Small heat-shock protein 22 mutated in autosomal dominant Charcot-Marie-Tooth 
disease type 2L. Hum Genet, 116, 222-224. 
Taylor, A., Zuliani, A.M., Hopkins, R.E., Dallal, G.E., Treglia, P., Kuck, J.F. and Kuck, 
K. (1989) Moderate caloric restriction delays cataract formation in the Emory 
mouse. Faseb J, 3, 1741-1746. 
Thampi, P. and Abraham, E.C. (2003) Influence of the C-terminal residues on 
oligomerization of aA-crystallin. Biochemistry, 42, 11857-11863. 
Thampi, P., Hassan, A., Smith, J.B. and Abraham, E.C. (2002) Enhanced C-terminal 
truncation of aA- and aB-crystallins in diabetic lenses. Invest Ophthalmol Vis Sci, 
43, 3265-3272. 
Timmerman, V., Raeymaekers, P., Nelis, E., De Jonghe, P., Muylle, L., Ceuterick, C., 
Martin, J.J. and Van Broeckhoven, C. (1992) Linkage analysis of distal hereditary 
motor neuropathy type II (distal HMN II) in a single pedigree. J Neurol Sci, 109, 
41-48. 
Tomokane, N., Iwaki, T., Tateishi, J., lwaki, A. and Goldman, J.E. (1991) Rosenthal 
fibers share epitopes with aS-crystallin, glial fibrillary acidic protein, and 
ubiquitin, but not with vimentin. Immunoelectron microscopy with colloidal gold. 
Am J Patho/, 138, 875-885. 
Treweek, T.M., Ecroyd, H., Williams, D.M., Meehan, S., Carver, J.A. and Walker, M.J. 
(2007) Site-Directed Mutations in the C-Terminal Extension of Human aS-
Crystallin Affect Chaperone Function and Block Amyloid Fibril Formation. PLoS 
ONE, 2, e1046. 
Treweek, T.M., Rekas, A., Lindner, R.A., Walker, M.J., Aquilina, J.A., Robinson, C.V., 
Horwitz, J., Pemg, M.D., Quinlan, R.A. and Carver, J.A. (2005) R120G aS-
crystallin promotes the unfolding of reduced a.-lactalbumin and is inherently 
unstable. Febs J, 272,711-724. 
Ueda, Y., Duncan, M.K. and David, L.L. (2002a) Lens proteomics: the accumulation of 
crystallin modifications in the mouse lens with age. Invest Ophthalmol Vis Sci, 43, 
205-215. 
Ueda, Y., Fukiage, C., Shih, M., Shearer, T.R. and David, L.L. (2002b) Mass 
measurements of C-terminally truncated a-crystallins from two-dimensional gels 
identify Lp82 as a major endopeptidase in rat lens. Mol Cell Proteomics, 1, 357-
365. 
References 372 
Valero, M.P., Fletcher, A.E., De Stavola, S.L., Vioque, J. and Alepuz, V.C. (2002) 
Vitamin C is associated with reduced risk of cataract in a Mediterranean 
population. J Nutr, 132, 1299-1306. 
van den IJssel, P., Wheelock, R., Prescott, A., Russell, P. and Quinlan, R.A. (2003) 
Nuclear speckle localisation of the small heat shock protein aS-crystallin and its 
inhibition by the Rl20G cardiomyopathy-linked mutation. Exp Cell Res, 287, 249-
261. 
Van Den Oetelaar, P., Van Somerenm PFHM., Thomson, JA., Siezen, RJ. & Hoenders, 
HJ. (1990) A dynamic quaternary structure of bovine a-crystallin as indicated 
from intermolecular exchange of subunits. Biochemistry, 29, 3488-3493. 
Van Montfort, R., Slingsby, C. and Vierling, E. (2001a) Structure and function of the 
small heat shock protein/a-crystallin family of molecular chaperones. Adv Protein 
Chern, 59, 105-156. 
van Montfort, R.L., Sasha, E., Friedrich, K.L., Slingsby, C. and Vierling, E. (2001b) 
Crystal structure and assembly of a eukaryotic small heat shock protein. Nat Struct 
Bioi, 8, 1025-1030. 
van Noort, J.M., van Sechel, A.C., van Stipdonk, M.J. and Sajramovic, J.J. (1998) The 
small heat shock protein aS-crystallin as key autoantigen in multiple sclerosis. 
Prog Brain Res, 117, 435-452. 
van Rijk, A.F. and Sloemendal, H. {2000) aS-crystallin in neuropathology. 
Ophthalmo/ogica, 214, 7-12. 
Van Rijk, A.F., Sweers, M.A., Merkx, G.F., Lammens, M. and Sloemendal, H. (2003) 
Pathogenesis of axonal dystrophy and demyelination in aA-crystallin-expressing 
transgenic mice. Int J Exp Pathol, 84, 91-99. 
Velazquez, J.M. and Lindquist, S. (1984) hsp70: nuclear concentration during 
environmental stress and cytoplasmic storage during recovery. Cell, 36, 655-662. 
Vicart, A., Lefebvre, T., Imbert, J., Fernandez, A. and Kahn-Perles, B. (2006) Increased 
chromatin association of Sp1 in interphase cells by PP2A-mediated 
dephosphorylations. J Mol Bioi, 364, 897-908. 
Vicart, P., Caron, A., Guicheney, P., Li, Z., Prevost, M.C., Faure, A., Chateau, D., 
Chapon, F., Tome, F., Dupret, J.M., Paulin, D. and Fardeau, M. (1998) A missense 
mutation in the aS-crystallin chaperone gene causes a desmin-related myopathy. 
Nat Genet, 20, 92-95. 
Virgolici, B. and Popescu, L. (2006) [Risk factors in cataract]. Oftalmo/ogia, 50, 3-9. 
Waddington, C.H. (1942) Canalization of development and the inheritance of acquired 
characteristics. Nature, 150, 563-565. 
Waddington, C.H. (1952) Genetic assimilation of an acquired character. Evolution, 7, 118-
126. 
Waddington, C.H. (1961) Genetic Assimilation. Advances in Genetics, 10, 257-290. 
Wagner, A. (2005) Robustness, evolvability, and neutrality. FEBS Lett, 579, 1772-1778. 
Walker, M.J., Feather, K.D., Davis, P.D. and Hines, K.K. (1995) A new enhanced 
chemilluminescent substrate for the development of the horseradish peroxidase 
label in Western blotting applications. Journal of NIH research. 
West, S.K. and Valmadrid, C.T. {1995) Epidemiology of risk factors for age-related 
cataract. Surv Ophthalmol, 39, 323-334. 
Wojcik, C. (1999) Inhibition of the proteasome as a therapeutic approach. Drug Discov 
· - Today,-4, 188 ... 189 ... 
References 373 
Worman, H.J. and Bonne, G. (2007) "Laminopathies": a wide spectrum of human 
diseases. Exp Cell Res, 313,2121-2133. 
Xi, J., Farjo, R., Yoshida, S., Kern, T.S., Swaroop, A. and Andley, U.P. (2003) A 
comprehensive analysis of the expression of crystallins in mouse retina. Mol Vis, 
9, 410-419. 
Yan, Q., Liu, J.P. and Li, D.W. (2006) Apoptosis in lens development and pathology. 
Differentiation, 74, 195-211. 
Yin, X., Landay, M.F., Han, W., Levitan, E.S., Watkins, S.C., Levenson, R.M., Farkas, 
D.L. and Prochownik, E.V. (2001) Dynamic in vivo interactions among Myc 
network members. Oncogene, 20, 4650-4664. 
Yu, C.M., Chang, G.G., Chang, H.C. and Chiou, S.H. (2004) Cloning and characterization 
of a thermostable catfish aS-crystallin with chaperone-like activity at high 
temperatures. Exp Eye Res, 79, 249-261. 
Yun, S.J., Hahm, D.H. and Lee, E.H. (2002) Immobilization stress induces the expression 
of aS-crystallin in rat hippocampus: implications of glial activation in stress-
mediated hippocampal degeneration. Neurosci Lett, 324,45-48. 
Zantema, A., Verlaan-De Vries, M., Maasdam, D., Bol, S. and van der Eb, A. (1992) Heat 
shock protein 27 and aS-crystallin can form a complex, which dissociates by heat 
shock. J Bioi Chern, 267, 12936-12941. 
Zhang, L.Y., Yam, G.H., Fan, D.S., Tam, P.O., Lam, D.S. and Pang, C.P. (2007) A novel 
deletion variant of gammaD-crystallin responsible for congenital nuclear cataract. 
Mol Vis, 13, 2096-2104. 
Zodpey, S.P., Ughade, S.N., Khanolkar, V.A. and Shrikhande, S.N. (1999) Dehydrational 
crisis from severe diarrhoea and risk of age-related cataract. J Indian Med Assoc, 
97, 13-15, 24. 
Zollner, T.M., Podda, M., Pien, C., Elliott, P.J., Kaufmann, R. and Boehncke, W.H. 
(2002) Proteasome inhibition reduces superantigen-mediated T cell activation and 
the severity of psoriasis in a SCID-hu model. J Clin Invest, 109, 671-679. 
4. APPENDIX 4-CHARACTERISATION OF THE NATURE OF THE 93 MIN 
PEAK RESOLVED DURING ANALYTICAL SEC OF aB-CRYST ALLIN FOR 
CHAPTER 6 (SECTION 6.3.1) ............................................................................... 307 
A4.1 THE NATURE OF THE 93 MIN PEAK MA TERIAL. ............................................... 308 
5. APPENDIX 5-DEVELOPMENT OF AN aB-CRYST ALLIN ELISA ASSAY 
FOR THE DETECTION AND QUANTITATION OF SEC FRACTIONS FROM 
CHAPTER 5 ............................................................................................................. 31 S 
A5.1 DEVELOPMENT OF AN aS-CRYSTALLIN ELISA ............................................... 316 
A5.1.1 Purification and conjugation of aS-crystallin Mab and Pab ....................... 318 
A5 .1.2 Titration of aS-crystallin Mab and Pab HRP conjugates ........................... .319 
A5.1.3 The use of ELISA for potential quantification aS-crystallin protein 
isolated in SEC fractions .............................................................................. 325 
6. APPENDIX 6-PUBLICATIONS .....................................•.................•...•........ 333 
REFERENCES ................................................................................................................. 350 
-~'-
4. APPENDIX 4-CHARACTERISATION OF THE NATURE OF THE 93 MIN 
PEAK RESOLVED DURING ANALYTICAL SEC OF aB-CRYST ALLIN FOR 
CHAPTER 6 (SECTION 6.3.1) ............................................................................... 307 
A4.1 THE NATURE OF THE 93 MIN PEAK MA TERIAL ................................................ 308 
5. APPENDIX 5-DEVELOPMENT OF AN aD-CRYSTALLIN ELISA ASSAY 
FOR THE DETECTION AND QUANTITATION OF SEC FRACTIONS FROM 
CHAPTER 5 ............................................................................................................ .315 
AS.l DEVELOPMENT OF AN aB-CRYSTALLIN ELISA .............................................. .316 
AS .1.1 Purification and conjugation of aS-crystallin Mab and Pab ...................... .318 
AS.1.2 Titration of aS-crystallin Mab and Pab HRP conjugates ........................... .319 
AS .1.3 The use of ELISA for potential quantification aS-crystallin protein 
isolated in SEC fractions .............................................................................. 32S 
6. APPENDIX 6-PUBLICATIONS .....................................•........•...................•. 333 
REFERENCES ................................................................................................................. 350 
_.~c....---- -
4. APPENDIX 4-CHARACTERISATION OF THE NATURE OF THE 93 MIN 
PEAK RESOLVED DURING ANALYTICAL SEC OF aD-CRYSTALLIN FOR 
CHAPTER 6 (SECTION 6.3.1) ............................................................................... 307 
A4.1 THE NATURE OF THE 93 MIN PEAK MA TERIAL. ............................................... 308 
5. APPENDIX 5-DEVELOPMENT OF AN aD-CRYSTALLIN ELISA ASSAY 
FOR THE DETECTION AND QUANTITATION OF SEC FRACTIONS FROM 
CHAPTER 5 ............................................................................................................. 31 5 
A5.1 DEVELOPMENT OF AN aS-CRYSTALLIN ELISA .............................................. .316 
A5.1.1 Purification and conjugation ofaB-crystallin Mab and Pab ....................... 318 
AS .1.2 Titration of aB-crystallin Mab and Pab HRP conjugates ........................... .319 
A5.1.3 The use of ELISA for potential quantification aB-crystallin protein 
isolated in SEC fractions .............................................................................. 325 
6. APPENDIX 6-PUBLICATIONS ...............................•............................•....... 333 
REFERENCES ................................................................................................................. 350 
